Вы находитесь на странице: 1из 98

Physiol Rev 84: 13811478, 2004; 10.1152/physrev.00047.2003.

Role of Oxidative Modications in Atherosclerosis

ROLAND STOCKER AND JOHN F. KEANEY, JR. Centre for Vascular Research, University of New South Wales, and Department of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia; and Whitaker Cardiovascular Institute, Evans Memorial Department of Medicine, Boston University Medical Center, Boston, Massachusetts

I. Introduction A. Atherosclerosis and its relationship to coronary artery disease B. Hypotheses of atherogenesis II. Redox Reactions in the Vasculature A. Oxidative stress: a definition B. Oxidants and markers of oxidant events C. Sources of oxidants and markers of oxidative events D. Antioxidant defenses E. Redox reactions in cell signaling F. ROS and Cell Proliferation G. Redox reactions in cell death H. Redox reactions in platelet function III. Oxidative Modification Hypothesis of Atherosclerosis A. Original hypothesis B. Evidence in support of the LDL oxidation hypothesis C. LDL Oxidation D. Antioxidant status in atherosclerotic lesions E. Inhibition of LDL oxidation F. Problems with the oxidative modification hypothesis IV. Role of Oxidative Modifications Other Than Low-Density Lipoprotein Oxidation and Clinical Manifestations of Coronary Artery Disease A. Concept of disease activity B. Plaque disruption C. Vasomotor function D. Adhesion molecules V. Reconciling Available Data on Oxidative Events and Atherosclerosis A. Oxidative events and atherosclerosis are not causally linked B. Incomplete knowledge of oxidants involved in atherosclerosis C. The oxidative response to inflammation hypothesis of atherosclerosis D. Conclusions

1382 1382 1385 1389 1389 1389 1391 1396 1405 1411 1412 1413 1414 1414 1414 1419 1426 1429 1430 1436 1436 1438 1440 1443 1444 1445 1445 1446 1448

Stocker, Roland, and John F. Keaney, Jr. Role of Oxidative Modications in Atherosclerosis. Physiol Rev 84: 13811478, 2004; 10.1152/physrev.00047.2003.This review focuses on the role of oxidative processes in atherosclerosis and its resultant cardiovascular events. There is now a consensus that atherosclerosis represents a state of heightened oxidative stress characterized by lipid and protein oxidation in the vascular wall. The oxidative modication hypothesis of atherosclerosis predicts that low-density lipoprotein (LDL) oxidation is an early event in atherosclerosis and that oxidized LDL contributes to atherogenesis. In support of this hypothesis, oxidized LDL can support foam cell formation in vitro, the lipid in human lesions is substantially oxidized, there is evidence for the presence of oxidized LDL in vivo, oxidized LDL has a number of potentially proatherogenic activities, and several structurally unrelated antioxidants inhibit atherosclerosis in animals. An emerging consensus also underscores the importance in vascular disease of oxidative events in addition to LDL oxidation. These include the production of reactive oxygen and nitrogen species by vascular cells, as well as oxidative modications contributing to important clinical manifestations of coronary artery disease such as endothelial dysfunction and plaque disruption. Despite these abundant data however, fundamental problems remain with implicating oxidative modication as a (requisite) pathophysiologically important cause for atherosclerosis. These include the poor performance of antioxidant strategies in limiting either atherosclerosis or cardiovascular events from atherosclerosis, and observations in
www.prv.org 0031-9333/04 $15.00 Copyright 2004 the American Physiological Society 1381



animals that suggest dissociation between atherosclerosis and lipoprotein oxidation. Indeed, it remains to be established that oxidative events are a cause rather than an injurious response to atherogenesis. In this context, inammation needs to be considered as a primary process of atherosclerosis, and oxidative stress as a secondary event. To address this issue, we have proposed an oxidative response to inammation model as a means of reconciling the response-to-injury and oxidative modication hypotheses of atherosclerosis.

I. INTRODUCTION A. Atherosclerosis and Its Relationship to Coronary Artery Disease Atherosclerosis is the major source of morbidity and mortality in the developed world. The magnitude of this problem is profound, as atherosclerosis claims more lives than all types of cancer combined and the economic costs are considerable. Although currently a problem of the developed world, the World Health Organization predicts that global economic prosperity could lead to an epidemic of atherosclerosis as developing countries acquire Western habits. Atherosclerosis is characterized by the accumulation of cholesterol deposits in macrophages in large- and medium-sized arteries. This deposition leads to a proliferation of certain cell types within the arterial wall that gradually impinge on the vessel lumen and impede blood ow. This process may be quite insidious lasting for decades until an atherosclerotic lesion, through physical forces from blood ow, becomes disrupted and deep arterial wall components are exposed to owing blood, leading to thrombosis and compromised oxygen supply to target organs such as the heart and brain. The loss of heart and brain function as a result of reduced blood ow is termed heart attack and stroke, respectively, and these two clinical manifestations of atherosclerosis are often referred to as coronary artery disease and cerebrovascular disease. To simplify any discussion of the underlying pathology in these clinical syndromes, coronary artery disease and cerebrovascular disease are commonly referred to by the collective term cardiovascular disease. With respect to the underlying pathology of atherosclerosis, there are a number of environmental and genetic cardiovascular risk factors that warrant consideration. 1. Epidemiology and risk factors Over the last 40 years, a number of clinical and laboratory variables have proven predictive of the incidence of cardiovascular disease and thus qualify as cardiovascular disease risk factors. In the following, we will restrict our discussion to those traits that are strongly and consistently associated with cardiovascular disease in a manner that is independent of other traits. A) AGE. Although it is not subject to modication, age is among the most important risk factors for predicting
Physiol Rev VOL

incident cardiovascular disease. This concept is, perhaps, best illustrated if one considers the risk of developing cardiovascular disease over a 10-year period. Based on experience in the United States, the average risk of developing cardiovascular disease for a 30- to 34-year-old male is 3% (1040). This number rises some sevenfold to 21% for a comparable individual aged 60 64 yr. Prediction of coronary heart disease uses risk factor categories (1040). The exact magnitude of age-related risk compared with other cardiovascular disease risk factors is illustrated by work from the Framingham Heart Study that has resulted in a 14-point scoring system to predict incident 10-yr cardiovascular disease. In this system, increasing risk is characterized by a higher score, and up to 7 points can be attributed to age alone. Thus age is an overriding risk factor for incident cardiovascular disease. B) GENDER. Numerous observational studies have indicated that males exhibit excess risk for cardiovascular disease compared with age-matched women (40). There has been considerable speculation that estrogens offer a protective effect to women, as cardiovascular disease accelerates in women after menopause. However, this speculation has been difcult to substantiate, as the treatment with estrogen has not reduced the incidence of cardiovascular disease of postmenopausal women (419). Alternatively, some of this apparent protection could be due to the fact that women exhibit relatively higher concentrations of high-density lipoprotein (HDL) cholesterol than do age-matched men. Nevertheless, incident cardiovascular disease is less common in premenopausal women than their age-matched male counterparts. C) OBESITY. There is now a growing appreciation that obesity, dened as an excess body weight with an abnormal high preponderance of body fat, is a condition that increases the incident risk of cardiovascular disease. The exact mechanism(s) to explain this phenomenon, however, are controversial. A number of other risk factors for cardiovascular disease, such as hypertension, low HDL cholesterol, and diabetes mellitus, often coexist with obesity (1041). This relation between obesity and cardiovascular disease has become of considerable concern as the prevalence of obesity in the developed world is increasing at an alarming rate. D) CIGARETTE SMOKING. The notion that cigarette smoking is linked to heart disease dates back to a series of studies that unequivocally linked smoking and the incidence of myocardial infarction (208, 231, 355). More recently, the Surgeon Generals report estimates that smoking inwww.prv.org

84 OCTOBER 2004



creases atherosclerotic disease by 50% and doubles the incidence of coronary artery disease (962a). There is now considerable condence that smoking is causally related to coronary artery disease, as smoking cessation is quite effective in lowering the future risk of the disease. In fact, the risk of heart attack in ex-smokers approaches that of nonsmokers in only 2 years (296). E) HYPERTENSION. Hypertension is dened as a systolic blood pressure in excess of 140 mmHg or a diastolic blood pressure above 90 mmHg (734). The current estimates indicate that the elderly are particularly predisposed to hypertension, with up to 75% of people over 75 years of age qualifying for this diagnosis (734). There appears to be an approximately linear relation between blood pressure elevation and the increased incidence of atherosclerotic vascular disease (573). The causal nature of this association is supported by numerous studies demonstrating that both heart attack and stroke are signicantly reduced in hypertensive patients with the institution of antihypertensive therapy (380). F) DIABETES MELLITUS. Approximately 17 million people in the United States, or 6.2% of the population, carry the diagnosis of diabetes mellitus (165). In patients with diabetes, the risk of coronary atherosclerosis is three- to vefold greater than in nondiabetics despite controlling for other risk factors (60, 739). A number of other known risk factors for coronary disease such as hypertension and abnormal lipids are also more common in diabetics than the general population (60), but despite this association, no more than 25% of the excess coronary atherosclerosis risk from diabetes can be attributed to these known risk factors (670). Thus diabetes represents a major contributing factor to atherosclerosis. G) SERUM CHOLESTEROL. The association between LDL cholesterol and atherosclerosis has been established based, in part, on an experiment of nature. Familial hypercholesterolemia is an autosomal dominant disorder that affects 1 in 500 persons from the general population. Heterozygotes for this disease manifest a two- to vefold elevation in plasma LDL cholesterol that is due to a functional impairment of the LDL receptor, resulting in a defect in LDL clearance. Homozygotes for this disorder demonstrate a four- to sixfold elevation in plasma cholesterol that produces precocious atherosclerosis. In heterozygotes, 85% of individuals have experienced a myocardial infarction by the age of 60, and this age is reduced to 15 yr in patients homozygous for the disease (325). In the general population, the cardiovascular disease risk from increased LDL cholesterol is supported by observations that cholesterol-lowering therapy greatly diminishes the clinical manifestations of atherosclerosis, particularly since the advent of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (i.e., statins) that profoundly lower LDL cholesterol (326).
Physiol Rev VOL

In contrast to the situation with LDL cholesterol, the relation between HDL cholesterol and atherosclerosis is an inverse one (320). The causal nature of this association is also supported by an experiment of nature, Tangier disease (682). This autosomal codominant condition is characterized by the essential absence of HDL cholesterol levels due to a defect in the ATP binding cassette transporter-1 (69, 584, 790) that impairs cholesterol efux from cells (525). Tangier patients demonstrate a tissue cholesterol-loading syndrome, characterized by large tonsils, neuropathy, and premature coronary artery disease in some kindreds (682). Thus considerable evidence supports the inverse relation between coronary artery disease and serum levels of HDL cholesterol. 2. Morphological features of atherosclerosis
A) THE NORMAL ARTERY. The arterial wall normally consists of three well-dened concentric layers that surround the arterial lumen, each of which has a distinctive composition of cells and extracellular matrix. The layer immediately adjacent to the lumen is called the intima, the middle layer is known as the media, and the outermost layer comprises the arterial adventitia. These three layers are demarcated by concentric layers of elastin, known as the internal elastic lamina that separates the intima from the media, and the external elastic lamina that separates the media from the adventitia. A single contiguous layer of endothelial cells lines the luminal surface of arteries. These cells sit on a basement membrane of extracellular matrix and proteoglycans that is bordered by the internal elastic lamina. Although smooth muscle cells are occasionally found in the intima, endothelial cells are the principal cellular component of this anatomic layer and form a physical and functional barrier between owing blood and the stroma of the arterial wall. Endothelial cells regulate a wide array of processes including thrombosis, vascular tone, and leukocyte trafcking among others. Progressing outwards from the internal elastic lamina, the media consists principally of smooth muscle cells arranged in layers, the number of layers depending on the arterial size. An extracellular matrix consisting largely of elastic bers and collagen with a lesser content of proteoglycan holds the smooth muscle cells together. An increasing content of elastin is typical of larger arteries that need to provide for considerable elastic recoil during diastole, the time period between ejections of blood from the heart. The adventitia is the outermost layer of the artery and typically consists of a loose matrix of elastin, smooth muscle cells, broblasts, and collagen. Most of the neural input into blood vessels also traverses through the adventitia. At one time, the adventitia was considered inactive with respect to vascular homeostasis; however, recently it

84 OCTOBER 2004




has become clear that the adventitia, through the production of reactive oxygen species (ROS), may play an important role in controlling vascular remodeling and nitric oxide (NO) bioactivity (766). B) GROSS MORPHOLOGY OF ATHEROSCLEROTIC LESIONS. Atherosclerosis manifests itself histological as arterial lesions known as plaques that have been extensively characterized (878 880) into six major types of lesions that reect the early, developing, and mature stages of the disease (Fig. 1). In lesion-prone arterial sites, adaptive thickening of the intima is among the earliest histological changes. As macrophages accumulate lipid, type II lesions form as nodular areas of lipid deposition that are also known as fatty streaks, and these represent lipid-lled macrophages (i.e., foam cells). Continued foam cell formation and macrophage necrosis can produce type III lesions that contain small extracellular pools of lipid. Types II and III lesions are readily apparent through the use of fat-soluble dyes that stain cholesterol esters accumulated

FIG. 1. Varying stages of atherosclerosis as outlined by Stary et al. (879). The progression of atherosclerosis is depicted from the earliest stages (top left) to the most advanced (bottom right) culminating in plaque rupture and associated thrombosis. [From Stary et al. (879).]

in macrophages and the extracellular space. These early lesions are often evident by age 10 (877) and can occupy as much as one-third of the aortic surface by the third decade. Developing lesions represent the next two types of lesions and, as shown in Figure 1, are characterized by signicant areas of extracellular lipid that represents the core of the atherosclerotic lesion. Type IV lesions are dened by a relatively thin tissue separation of the lipid core from the arterial lumen, whereas type V lesions exhibit brous thickening of this structure, also known as the lesion cap. These type IV and V lesions can be found initially in areas of the coronary arteries, abdominal aorta, and some aspects of the carotid arteries in the third to fourth decade of life. Mature type VI lesions exhibit architecture that is more complicated and characterized by calcied brous areas with visible ulceration. These types of lesions are often associated with symptoms or arterial embolization. It was once thought that end-organ damage and infarction were due to gradual advancement of these lesions, but we now know the processes involved in precipitating heart attack and stroke are considerably more complex. As a consequence, we direct our attention to the histology of an atherosclerotic plaque. C) PLAQUE MORPHOLOGY. The light microscopic appearance of a prototypical atherosclerotic plaque is depicted in Figure 2. Plaques contain a central lipid core that is most often hypocellular and may even include crystals of cholesterol that have formed in the aftermath of necrotic foam cells. In this late stage of lesion development, residual foam cells may be difcult to see but have often left the core with an abundant quantity of tissue factor (1033), an important activator of the clotting cascade. This lipid core is separated from the arterial lumen by a brous cap and myeloproliferative tissue that consists of extracellular matrix and smooth muscle cells. The junction between the cap and the morphologically more normal area of artery is known as the shoulder region of the atherosclerotic plaque. This area is typically more cellular than other areas of the plaque and may contain a variable composition of smooth muscle cells, macrophages, and even T cells. The shoulder region is most prone to rupture and, as shown in Figure 2, may even contain evidence of previously healed ssures. D) PLAQUE RUPTURE. Early concepts of atherosclerosis involved progressive luminal narrowing until the blood ow was compromised to the point that organ metabolic needs could no longer be met, producing ischemia and infarction of the subtended tissue such as the heart or the brain. Over the last 15 years, this concept has changed dramatically to include the notion of plaque rupture as both a precipitant of clinical events but also a component of plaque progression in atherosclerosis. Using perfusion xation techniques, Davies and Thomas (188) published a seminal study demonstrating

Physiol Rev VOL

84 OCTOBER 2004



FIG. 2. Light micrograph of a brofatty plaque in the coronary artery. The lumen is eccentric and separated from the brous cap (FC) by myeloproliferative (MP) tissue. Under the brous cap are calcied (C) areas of the plaque indicative of advanced lesions. The brous cap is separated from the more normal area of the artery by the shoulder region that, in this plaque, demonstrates evidence of a healed ssure (F). The adventitia (A) is the outermost area of the artery, and its border with the media is dened by the external elastic lamina (*). [From Gravanis MB. Histopathology of atherosclerosis. In: Atlas of Atherosclerosis: Risk Factors and Treatment, edited by Wilson PWF. Philadelphia, PA: Current Medicine, 2002.]

blood. This contention is supported by experimental data linking an increased content of macrophages in lesions to structural weakness (539). In summary, atherosclerosis is a major source of morbidity and mortality in the developed world that is characterized by LDL deposition in the arterial wall, a process that is stimulated by environmental and genetic factors such as tobacco use, diabetes, and hypertension. This LDL deposition occurs primarily within macrophages and ultimately begets the formation of well-dened lesions in the arterial intima. Such lesions then develop and are prone to rupture and, as a consequence, can precipitate the clinical events such as heart attack and stroke. Given the public health implications of this disease, it is not surprising that considerable effort has been devoted to understanding the molecular mechanisms of atherosclerosis and the factors that predispose individuals to clinical events. Thus we now turn our attention to contemporary theories of atherogenesis. B. Hypotheses of Atherogenesis Over the past 150 years, there have been numerous efforts to explain the complex events associated with the development of atherosclerosis. In this endeavor, three distinct hypotheses have emerged that are currently under active investigation. These hypotheses of atherosclerosis are not mutually exclusive but rather emphasize different concepts as the necessary and sufcient events to support the development of atherosclerotic lesions. For the purposes of this review, we refer to these paradigms as follows: 1) the response-to-injury, 2) the response-to-retention, and 3) oxidative modication. 1. The response-to-injury hypothesis Early hypotheses of atherosclerosis included the incrustation hypothesis of Rokitansky (778), suggesting that intimal thickening was due to arterial brin deposition, and the lipid transudation hypothesis of Virchow (995) according to which lipid complexes with mucopolysaccharides caused atherosclerosis. A common theme to these early hypotheses was their dependence on passive deposition rather than an active cellular component. Ross and Glomset (782) offered a radical departure from this thinking by proposing the response-to-injury hypothesis of atherosclerosis. In this hypothesis, the proposed initial step in atherogenesis is endothelial denudation leading to a number of compensatory responses that alter the normal vascular homeostatic properties. For example, injury enhances endothelial adhesiveness for leukocytes and platelets and alters the local vascular anticoagulant milieu to a procoagulant one. Recruited leukocytes and platelets then release cytokines, vasoactive agents, and growth factors that promote an inammatory response that is

that acute myocardial infarction and crescendo angina, two cardinal manifestations of atherosclerosis, were associated with atherosclerotic plaque rupture and ssuring in the artery with compromised blood ow. These observations suggested that clinical events were the consequence of an abrupt, catastrophic change in plaque morphology rather than a gradual narrowing of the lumen. Evidence for plaque rupture can also be found in patients dying from noncardiac causes (186), suggesting that plaque rupture is part of atherosclerotic lesion progression rather than a unique feature of clinical events from atherosclerosis. Given that plaque rupture is implicated as a precipitating event in the clinical manifestations of atherosclerosis, a considerable effort has been directed at understanding the events involved in this process. Mature atherosclerotic plaques can be categorized as either stable or vulnerable to rupture. Stable plaques tend to be characterized by a smaller lipid core, a thick brous cap, and shoulder regions with few inammatory cells, whereas vulnerable plaques contain considerable lipid in their core, a thin brous cap, and a robust population of macrophages and T cells in their shoulder regions. These differences in morphology suggest that vulnerable plaques may be weaker structurally and more likely to rupture in response to the physical forces of owing
Physiol Rev VOL

84 OCTOBER 2004



characterized by migration of smooth muscle cells into the intima and their proliferation to form an intermediate lesion. Another component of the inammatory response is the recruitment of macrophages into the arterial wall. These macrophages take up deposited LDL lipid to form lipid-laden foam cells, the hallmark of an early atherosclerotic lesion. The process of lipid accumulation and foam cell formation perpetuates an inammatory response that perpetuates macrophage and lymphocyte recruitment (454, 981). Continued inammation allows for cellular necrosis, with a concomitant release of cytokines, growth factors, and proteolytic enzymes that sets the stage for autocatalytic expansion of the lesion to form a space-occupying collection in the intima not unlike an abscess that would form in other tissues. As the lesion enlarges it begins to encroach upon the lumen and, ultimately, blood ow is impaired. This response-to-injury hypothesis was originally based on the notion of endothelium desquamation as a principal event initiating atherosclerosis (783, 784). More recently, it has become clear that endothelial desquamation is not common and that an intact endothelial cell layer covers developing atherosclerotic lesions. These facts, among others, promoted renement of the initial hypothesis such that endothelial dysfunction is sufcient to initiate atherogenesis through increased endothelial permeability to atherogenic lipoproteins (781) (Fig. 3). This contention is not without its problems, however, as even normal artery segments exhibit rates of LDL entry that exceed the rate of LDL accumulation (124), suggesting that atherogenic lipoprotein entry into the arterial wall may not depend on endothelial dysfunction. In fact, the rate of LDL entry into the arterial wall is rather uniform, but the accumulation of atherogenic lipoproteins is concentrated in areas that are predisposed to future lesion development (820, 821). Such lesion-prone sites tend rather to demonstrate an enhanced retention of atherogenic apolipoprotein B-containing lipoproteins (238, 820, 821). Such observations have prompted alternative hypotheses for the initiation of atherosclerosis. 2. The response-to-retention hypothesis This hypothesis submits that the lipoprotein retention is the inciting event for atherosclerosis (Fig. 4). Within 2 h of injecting LDL into rabbits, arterial retention of LDL and its microaggregates can be observed (667). The underlying mechanisms involved in this process are just now coming to light. It is estimated that 85% of subendothelial lipoprotein delivery is the result of transcytosis, and this process is restricted to particles 70 nm in diameter (852). This size restriction is important as it suggests that lipoprotein lipase activity is needed for triPhysiol Rev VOL

FIG. 3. Response-to-injury hypothesis of atherosclerosis as proposed by Ross (781). In this hypothesis atherosclerosis begins with endothelial injury or dysfunction (A) that is characterized by enhanced endothelial permeability and low-density lipoprotein (LDL) deposition in the subendothelial space. This is followed by leukocyte adhesion and transmigration across the endothelium. In intermediate stages (B), atherosclerosis is characterized by foam cell formation and an inammatory response including T-cell activation, the adherence and aggregation of platelets, and further entry of leukocytes into the arterial wall along with migration of smooth muscle cells into the intima. Finally, advanced atherosclerosis (C) is characterized by continued macrophage accumulation, brous cap formation, and necrosis in the core of the lesion. [From Ross (781), copyright 1999 Massachusetts Medical Society.]

84 OCTOBER 2004




FIG. 4. Response-to-retention hypothesis of atherosclerosis. According to the original hypothesis (1036), mild to moderate hyperlipidemia causes lesion development only in specic sites within the arterial tree characterized by local synthesis of apolipoprotein B-retentive molecules such as biglycan and decorin. The cartoon shows the initial stages of arterial lipoprotein delivery, retention, and efux (15). Accumulation (5) is thought to result from both apolipoprotein B-100 motifs that mediate proteoglycan binding and arterial factors such as secretory sphingomyelinase that facilitate lipoprotein aggregation (reviewed in Ref. 1037). The accumulation of apolipoprotein B-100-containing lipoproteins within the arterial wall is thought to further trigger a proinammatory cascade (6 13). Lipoprotein oxidation (not shown) may or may not be part of these responses. Similar to LDL, apolipoprotein B-48-containing chylomicron remnants may also bind to proteoglycans via residues 8494 of the apolipoprotein (250) and hence be retained within the arterial wall (not shown). [Modied from Proctor et al. (736).]

acylgycerol-rich lipoproteins to reach the subendothelial space (1110). The retention of lipoproteins within the arterial wall, however, appears tightly linked to components of the extracellular matrix. Apolipoprotein B-100, the single protein associated with LDL, is retained within the arterial wall in close association with arterial proteoglycans (118, 1091). This interaction is mediated by specic residues (3359 3369) (71) that, when mutated, protect experimental animals against the development of atherosclerosis (71, 857). Apolipoprotein B-48, which appears to be equally atherogenic as apolipoprotein B-100 in mice (990), also binds avidly to proteoglycans, and this interaction is mediated by residues 84 94 of apolipoprotein B-48 (250). Thus these data support an important role for proteoglycan binding in the retention of apolipoprotein B-containing lipoproteins in the early stages of atherosclerosis. In addition to proteoglycan binding, lipolytic and lysosomal enzymes in the extracellular matrix also appear to play a role. For example, lipoprotein lipase enhances the adherence of LDL in vitro (1035), and this effect is independent of enzymatic activity (1034). Once retained within the arterial wall, LDL can form microaggregates (667, 931), perhaps through the action of secretory sphingomyelinase (1074), an enzyme that also generates ceramides that mediate apoptosis and mitogenesis (357, 455), as well as lysosomal enzymes such as cathepsin D and lysosomal acid lipase (350). Most importantly, aggregated LDL is avidly taken up by macrophages and smooth muscle cells (440) and thus can support foam cell formation (991). Thus many features of atherosclerosis can be atPhysiol Rev VOL

tributed to enhanced retention of LDL within the arterial wall and its association with proteoglycans. 3. The oxidative modication hypothesis The oxidative modication hypothesis, discussed in more detail in section III, focuses on the concept that LDL in its native state is not atherogenic. However, LDL modied chemically is readily internalized by macrophages through a so-called scavenger receptor pathway (317). Exposure to vascular cells in medium that contains transition metals also results in modication of LDL such that it serves as a ligand for the scavenger receptor pathway (395). It is now clear that one mechanism whereby cells in vitro render LDL a substrate for the scavenger receptor pathway is via oxidation of LDL lipids and the resulting modication of apolipoprotein B-100 (886). These observations form the basis for the oxidative modication hypothesis of atherosclerosis (Fig. 5), in which LDL traverses the subendothelial space of lesion-prone arterial sites. During this process, LDL lipids are subject to oxidation and, as a consequence, apolipoprotein B-100 lysine groups are modied so that the net negative charge of the lipoprotein particle increases (347). This modication of apolipoprotein B-100 renders LDL susceptible to macrophage uptake via a number of scavenger receptor pathways producing cholesterol ester-laden foam cells (349). It is this accumulation of foam cells that forms the nidus of a developing atherosclerotic lesion. The process of LDL oxidation is associated with a number of other potentially proatherogenic events. For example, during the initial stages of in vitro LDL oxidawww.prv.org

84 OCTOBER 2004



FIG. 5. Oxidative modication hypothesis of atherosclerosis. LDL becomes entrapped in the subendothelial space where it is subject to oxidative modication by resident vascular cells such as smooth muscle cells, endothelial cells, and macrophages. Oxidized LDL stimulates monocyte chemotaxis (A), prevents monocyte egress (B), and supports foam cell formation (C). Once formed, oxidized LDL also results in endothelial dysfunction and injury (D), and foam cells become necrotic due to the accumulation of oxidized LDL (E). (From Diaz M, Frei B, Vita JA, and Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 337: 408 416, 1997, copyright Massachusetts Medical Society.)

tion, modication of LDL lipids can occur in the absence of any changes to apolipoprotein B-100. Such modied LDL has been termed minimally modied LDL and shown in vitro to induce the synthesis of monocyte chemotactic protein-1 in both smooth muscle and endothelial cells (171, 754), resulting in the recruitment of inammatory cells (659). This particular step appears critical as mice lacking the receptor for monocyte chemotactic protein-1 are resistant to atherosclerosis (72, 323). More heavily in vitro oxidized LDL, commonly termed oxLDL, is chemotactic for monocytes (742) and T lymphocytes (611), perhaps as the result of lysophosphatidylcholine formed during oxidation (886). Oxidized LDL has also been shown to stimulate the proliferation of smooth muscle cells (890) and to be immunogenic by eliciting the production of autoantibodies (710, 795) and the formation of immune complexes that can also facilitate macrophage internalization of LDL (334, 492). The recruitment of inammatory cells may result in the continued oxidation of LDL, setting the stage for catalytic expansion of the atherosclerotic lesion and the full-blown spectrum of atherosclerosis. In summary, the aforementioned hypotheses of atherosclerosis have each attempted to explain the complex
Physiol Rev VOL

cellular events of atherosclerosis along a common theme. The response-to-injury hypothesis focuses on vascular injury as the inciting event in atherosclerosis with the entire spectrum of the disease representing an attempt to heal an ongoing vascular insult. In contrast, the responseto-retention hypothesis uses lipoprotein-matrix interactions as the critical event in early atherosclerosis, whereas the oxidative modication hypothesis requires oxidation of LDL lipids. Although each hypothesis points to its own critical initiating event, there are many common features among these competing hypotheses. For example, each involves a signicant component of inammation, a known feature of atherosclerosis (556). Each hypothesis also includes LDL as a central element, an important point as reduction in LDL cholesterol is among the most effective means of treating atherosclerosis. Perhaps the most unique, however, is the oxidative modication hypothesis as it alone proposes a particular importance of oxidative events and redox reactions in the genesis of vascular disease. The concept of oxidative events in atherosclerosis has changed considerably since the early days of the oxidative modication hypothesis, and it is this subject that will form the basis for the remainder of this review.

84 OCTOBER 2004



II. REDOX REACTIONS IN THE VASCULATURE A. Oxidative Stress: A Denition The notion of oxidative stress in biological systems goes back to the early period of research on oxygen activation with an initial focus on oxygen toxicity and X-irradiation (300). Much of the relevant early literature was reviewed in 1979 by Chance et al. (143) in an article on hydroperoxide metabolism in mammalian organs. In the following, the concept of oxidative stress was developed primarily by Sies (847 849), with synonymous terms such as oxidant stress and pro-oxidant stress, or the related term reductive stress receiving comparatively less emphasis. Sies described oxidative stress as a disturbance in the pro-oxidant/antioxidant balance in favor of the former (847). This original denotation has been modied since to the more rened denition of imbalance between oxidants and antioxidants in favor of the oxidants, potentially leading to damage (848). This more careful denition accounts for some important operational considerations. For example, an oxidative challenge or a loss of antioxidants alone does not constitute oxidative stress. However, if increased formation of oxidant(s) is accompanied by a loss of antioxidant(s) and/or accumulation of oxidized forms of the antioxidant(s), oxidative stress is approached. The rened denition also conceptually distinguishes oxidative stress from oxidative damage. Thus even a severe oxidative assault that is accompanied by a loss of antioxidants may not necessarily result in oxidative damage (848). For example, biological systems are characterized by adaptive responses that may compensate, and perhaps even overcompensate, the oxidative stress that may manifest itself as a situation of increased redox environment (898). The rened denition of oxidative stress and its underlying redox chemistry involving reduction-oxidation

reactions implies that any form of tipping the balance causes an imbalance. This has led to the concept of reductive stress to describe a situation where the balance is altered in favor of reductants (1027). Reductive stress can be intimately linked to oxidative stress. For example, an overproduction of reducing equivalents such as NAD(P)H may result in increased redox cycling of substances that can undergo repetitive rounds of oxidation/ reduction, ultimately leading to the increased generation of superoxide anion radical (O2 ) and secondary oxidants. This has been implicated in the formation of ROS by hypoxia-like metabolic imbalances (951). With the increased appreciation of interplay between ROS and reactive nitrogen species (RNS), including their responses in cells, the term nitrosative stress has also been introduced (364). Nitrosative stress, dened as increase in S-nitrosated compounds associated with a decrease in intracellular thiols, may be associated with a number of biological responses, some of which are of particular interest to vascular physiology and pathophysiology (1044, 1112). B. Oxidants and Markers of Oxidant Events 1. Free radicals or 1e-oxidants A free radical can be dened as any species capable of independent existence that contains one or more unpaired electrons (353). In biological systems, a variety of radicals can be generated (Table 1) with their reactivity depending on their nature and the molecule(s) encountered. If two radicals meet, they can join their unpaired electrons to form a covalent bond in reactions that are often kinetically fast and that lead to nonradical products. An example relevant to the vessel wall is the very fast reaction of O2 with NO to form peroxynitrite (ONOO ) (reaction 1): O2 NO 3 ONOO (1)


Examples of free radicals in biological systems

Name Formula Comments

Carbon-centered radical

Superoxide anion and hydroperoxyl radical Peroxyl and alkoxyl radical

P OC P O2 , HO2 RO2 , RO OH NO, NO2 RS , RSS Fe, Cu, etc.

These radicals with the unpaired electron residing on carbon, usually react rapidly with O2 to make peroxyl radicals. The primary oxygen-centered radicals in its anionic and protonated form. Oxygen-centered radicals that can be formed from reaction of carbon-centered radicals with O2 (RO2 ), or from the breakdown of organic peroxides, such as LOOH (RO2 , RO ). Highly reactive, oxygen-centered radical that reacts with all biomolecules. Nitric oxide is formed from L-arginine, and nitrogen dioxide from reaction of NO with O2. A group of radicals with the unpaired electrons residing on sulfur. Ability to change oxidation numbers by one, allowing them to accept/donate single electrons; hence, they can be catalysts of free radical reactions.

Hydroxyl radical Nitric oxide (nitrogen monoxide) and nitrogen dioxide Thiyl and perthiyl radical Transition-metal ions

[Adapted from information provided in Halliwell and Gutteridge (353).] Physiol Rev VOL
84 OCTOBER 2004




Alternatively, a radical may add to a nonradical molecule or abstract a hydrogen atom from a C-H, O-H, or S-H bond of nonradical molecules. These types of radical reactions are common in biological systems where most molecules are nonradical species. The molecules potentially affected include low-molecular-weight compounds like antioxidants and cofactors of enzymes, lipids, proteins, nucleic acids, and sugars. In this case, a new radical is generated, and this can set up a chain reaction. A typical example of such a chain reaction is the process of lipid peroxidation that may be initiated by, for example, a hydroxyl radical ( OH) abstracting a hydrogen atom from a fatty acid side chain (LH) containing carbon atoms with bisallylic hydrogens ( ) (reaction 2). The resulting, carbon-centered radical (L ) adds rapidly to O2 to generate a lipid peroxyl radical (LOO ) (reaction 3) that itself can propagate the chain by reacting with a neighboring lipid molecule to generate another L and lipid hydroperoxide (LOOH) (reaction 4). In this fashion, many molecules of LOOH may be generated for each initiating radical. LH L LOO OH 3 L O2 3 LOO LH 3 L LOOH H2O (2) (3) (4)

contained in -tocopherol ( -TOH). In this case, the -tocopheroxyl radical ( -TO ) is produced and, for LOO , a molecule of LOOH (reaction 5): LOO -TOH 3 LOOH -TO (5)

A radical may be an oxidizing agent, accepting a single electron from a nonradical, or a reducing agent, donating a single electron to a nonradical. As implied above and like other reactions, free radical reactions are governed by thermodynamic and kinetic principles. A thermodynamic parameter commonly applied in free radical chemistry is the reduction potential that determines the feasibility of a compound X to chemically reduce compound Y. Buettner (104) has compiled a useful list of biologically relevant standard reduction potentials that predict the direction of reactions. Accordingly, the ascorbate/ascorbyl radical system is, for example, capable of reducing the -TO , H / -TOH system (reaction 6) that has a more positive standard reduction potential. H ascorbate -TO 3 -TOH ascorbyl radical 2. 2e-Oxidants In addition to radicals, several nonradical oxidants are important when considering oxidative modications in the vessel wall (Table 2). Arguably, the most abundant of these is hydrogen peroxide (H2O2) derived from the action of oxidases such as glucose oxidase on O2, or from the dismutation of O2 (reaction 7): (6)

Whereas the highly reactive OH abstracts H atoms almost without discrimination, less reactive radicals, such as LOO preferentially abstract H atoms from molecules with weaker bonds, such as the chromanol O-H bond 2.


Examples of nonradical oxidants of potential relevance to oxidative stress in the vasculature

Name Formula Comments

Hydrogen peroxide

H2O2 OCl, HOCl

Hypochlorite, hypochlorous acid

Ozone Singlet oxygen



Oxoperoxonitrate (1 ) or peroxynitrite, peroxynitrous acid


Alkylperoxynitrites, dinitrogen trioxide, nitryl chloride, and nitronium (nitryl) ion Nitrosothiols

ROONO, N2O3, NO2Cl, and NO2 RSNO

A diffusible oxidant that is only a weak oxidizing agent and is generally poorly reactive. It may participate in cellular signaling and, in the presence of available transition metals, can give rise to OH. Weak acid (pKa 7.5) but strong oxidant. Reacts with Fe S clusters, metal ions held in proteins by thiolate ligands, heme, amino acid residues (methionine, cysteine) of proteins, and GSH. Can give rise to secondary, reactive species including chloramines and amino acidderived aldehydes. Strong oxidant that attacks protein and lipids including cholesterol. Singlet oxygen may be formed as a by-product. Reacts with other molecules chemically or by transfer of its excitation energy. Reaction with carbon-carbon double bonds is best known. The relevance of 1 gO2 in the vasculature is unknown. Can be formed via reaction of O2 with NO with k 1010 M 1 s 1 (488). The protonated form is highly reactive (498). A major reaction of ONOO is that with CO2 that gives rise to nitrating, nitrosating, and oxidizing species. Additional reactive nitrogen species. N2O3 is a major nitrosating species. Formed via reaction of RS with NO, or thiols with higher oxides of nitrogen. Nitrosothiols are weak oxidants.

[Adapted from information provided in Halliwell and Gutteridge (353).] Physiol Rev VOL
84 OCTOBER 2004





2H 3 H2O2



As is the case for radicals, the reactivity of the different nonradical species varies. Hydrogen peroxide is generally a weak oxidant, although it can directly oxidize thiol (-SH) groups, for example, at the active site of enzymes like glyceraldehyde-3-phosphate dehydrogenase. Hydrogen peroxide can also react with certain heme proteins (e.g., myoglobin and cytochrome c), and this can result in release of iron and/or the formation of ferryl heme plus amino acid radicals that can propagate oxidation reactions, e.g., via radical chemistry. However, transition metal-catalyzed decomposition with the resulting formation of OH is generally considered the basis of most oxidative damage resulting from H2O2. Like H2O2, ONOO is also a relatively weak oxidant at alkaline pH. However, its protonated form, peroxynitrous acid (ONOOH), is extremely reactive, even more so than hypochlorite/hypochlorous acid ( OCl/HOCl). As the pKa value of ONOOH is 7.5 (488), in biological systems the formation of ONOO likely results in a powerfully oxidizing environment, comparable to that resulting from generation of OH. Nonradical oxidants like ONOOH (947) and HOCl (371373) appear to react preferentially with proteins rather than lipids (998). Cysteine and methionine residues are the preferred targets, followed by tyrosine, tryptophan, and phenylalanine residues; lysine residues can also be oxidized and, due to their relative abundance, may account for a majority of the ONOOH or HOCl that reacts with proteins (714, 1046). This preference for a reaction with proteins differentiates nonradical from radical oxidants, the latter commonly initiating lipid peroxidation (see above). In the case of methionine residues, methionine sulfoxide is produced as the predominant species. In comparison, thiol oxidation by HOCl gives rise to a complex array of products, including disuldes (RSSR), sulfenic (RSOH), sulnic (RSO2H), and sulfonic acids (RSO3H), as well as intra- and intermolecular sulfenamides (RSN-), sulnamides [RS(O)N-], and sulfonamides [RS(O2)N-] (279, 750, 1047). The reaction with aromatic amino acid residues is studied best for tyrosine, with 3-chloro- and 3-nitrotyrosine being chemically characteristic oxidation products of HOCl and ONOOH, respectively (46, 377), although aldehydes can also be formed (see sect. IIC4). An example of formation of 3-nitrotyrosine is the specic nitration of tyrosine residue 430 of bovine prostacyclin synthase by ONOO that results in a decrease in enzymatic activity (814). The local environment also governs the likelihood with which 2e-oxidants react with amino acids in protein side chains. For example, vicinal thiol and methionine residues are particularly sensitive to oxidation, as exemPhysiol Rev VOL

plied by H2O2-mediated oxidation of the carboxy-terminal vicinal methionine residues in calmodulin (1083). Similarly, a local environment that promotes ionization of the thiol (Cys-SH) group a cysteine residue, even at neutral pH, to the thiolate anion (Cys-S ) enhances its susceptibility to oxidation. This may be achieved via neighboring amino acids to lower the pKa value of cysteine residues, or via complex formation with metal ions. Examples of the latter relevant to oxidative stress in the vessel wall are the zinc thiolate (ZnS4) cluster of endothelial nitric oxide synthase (eNOS) (757) and the cysteine-switch domain of prometalloproteinases (984) that are sensitive to ONOOH (1112) and HOCl, respectively (278). Two-electron oxidants like HOCl and ONOOH avidly react with certain prosthetic groups, such as heme and iron sulfur centers of proteins (8), often in preference to reaction with amino acid side chains, as in the case of ONOO -induced inactivation of inducible NOS in the presence of calmodulin (418). As mentioned, lipids are poor targets compared with proteins, although chlorinated species have been characterized as products upon reaction with HOCl (978, 1049). A major biological target for ONOO is carbon dioxide (CO2) (reviewed in Ref. 869). The reaction of ONOO with carbon dioxide is complex and produces metastable species that promote nitration (i.e., addition of a nitro group -NO2), nitrosation (addition of a nitrogen monoxide group -NO), and oxidation reaction. This probably occurs via the intermediate nitrosoperoxycarbonate (ONOOCO2 ) that homolyzes to form a pair of caged radicals (CO3 NO2) that can then diffuse apart to become free radicals. Alternatively, the radicals may combine to nitrocarbonate (O2NOCO2) that then decomposes to nitrite and CO2. Therefore, in the presence of carbon dioxide, the redox chemistry of ONOO is mediated largely by NO2 and CO3 ; in the absence of carbon dioxide it is mediated by NO2 and OH (487). Nitrogen dioxide ( NO2) is a strongly oxidizing radical that can initiate a variety of oxidative pathways (486). For example, NO2 initiates and promotes lipid peroxidation including that of LDL (115), and it gives rise to nitrotyrosine formation (327, 486). However, NO2 is not only derived from ONOO , as other sources, including enzymatic ones, have been identied (see sect. IIC4). Therefore, systems that simultaneously generate NO and O2 have the potential to generate ONOO and a complex mixture of oxidants including the radical oxidant NO2 that can readily oxidize a number of targets in the vessel wall, including LDL. C. Sources of Oxidants and Markers of Oxidative Events Several lines of evidence implicate ROS and RNS in atherogenesis. The advent of gene targeting to predictably modify genes has generated valuable animal models and

84 OCTOBER 2004



allowed a genetic approach to gain information on which oxidants affect disease. The development of sensitive analytical methods also enables researchers to obtain direct chemical evidence for specic reaction pathways that promote oxidative events and lesion formation in vivo, and to relate the accumulation of specic oxidized lipid and protein to different stages of atherosclerosis. Understanding the processes that lead to the different oxidative events is important in developing strategies to effectively inhibit such processes and hence potentially atherosclerosis. Within the vessel wall, the different oxidants can originate principally from cellular and extracellular sources, and from enzymatic and nonenzymatic paths that are reviewed briey in the following sections. The primary consideration given here will be on oxidants of plausible physiological relevance, noting those with the strongest support. 1. NAD(P)H oxidases It has long been known that phagocytes, including neutrophils, monocytes, and macrophages, contain a plasma membrane-bound, multicomponent oxidase that utilizes electrons derived from NADPH to reduce molecular oxygen to O2 in a reaction that is insensitive to the mitochondrial poison KCN. While O2 is principally a reducing agent, it can give rise to secondary products that include strong oxidants. The phagocyte NADPH oxidase (Nox) consists of four major units: p22phox (CYBA gene product) and gp91phox (CYBB gene product), the two subunits of the membrane-spanning cytochrome b558, and two cytosolic components, p47phox (NOXO2 gene product) and p67phox (NOXA2 gene product) (25). Other proteins associate or copurify with the oxidase and/or participate in its assembly/activation or inactivation. Phagocyte NADPH oxidase needs to be activated to produce O2 , a process that begins with the phosphorylation of p47phox leading to its association with cytochrome b558 (25). Translocation of the G protein Rac to cytochrome b558 is also involved (706) but independent of both p47phox and p67phox translocation (397). Rac1 is the predominant protein expressed in monocytes, in contrast to Rac2 in neutrophils (137). Once activated appropriately, phagocytic cells produce large amounts of O2 over relatively short periods that are involved in host defense. In analogy to phagocytes, adventitial broblasts, vascular smooth muscle cells, and endothelial cells contain a membrane-associated NAD(P)H oxidase that utilizes NADH or NADPH as the electron donor to generate O2 via 1e-reduction of molecular oxygen (reaction 8) (for reviews, see Refs. 333, 766). NAD(P)H 2O2 3 NAD(P) H 2O2 (8)

There is evidence that NAD(P)H oxidase activity represents a major source of ROS in the vasculature (631, 692, 752), and there is some controversy regarding the orientation and cellular location of these enzymes. Whereas in phagocytes electrons are transferred across the membrane to extracellular oxygen, in vascular smooth muscle cells, O2 and H2O2 appear to be produced predominantly inside the cells, and addition of NAD(P)H to the cells augments O2 generation (333). For endothelial cells, there is evidence for extracellular release of O2 as indicated using cell-impermeable trapping agents (972). There are also differences in the protein components of the NAD(P)H oxidases in different vascular cells. Fibroblast and endothelial cells resemble phagocytes in that they contain mRNAs for gp91phox, p22phox, p47phox, and p67phox, whereas vascular smooth muscle cells appear to lack gp91phox and gp67phox (333, 766). Instead, these cells contain homologs of gp91phox, the expression of which increases cellular O2 production (918). A number of homologs including Nox1, -4, and -5, have been identied in vascular cells (147, 864), with endothelial cells expressing very low levels of Nox1, intermediate levels of Nox2, and abundant Nox4 mRNA (6, 864). In contrast, vascular smooth muscle cells express predominantly Nox4 and to a lesser extent Nox1 with negligible amounts of Nox2 (864). There also appear to be distinctions in Nox expression based on the particular type of blood vessel, as Nox2 is relatively more abundant in human aortic smooth muscle cells derived from resistance compared with conductance arteries (955). In addition, there is increasing evidence that Nox1 and Nox4 are located in different cellular compartments (398). In contrast to phagocytes, endothelial cells, vascular smooth muscle cells, and broblasts exhibit low basal activity for O2 generation (691), suggestive of a constitutively active oxidase. Consistent with this, Nox2 in endothelial cells appears to be present as a preassembled, intracellular complex including the p22phox, p47phox, and p67phox subunits (547). Similar to the situation in phagocytes, however, NAD(P)H oxidases in vascular cells can also be activated by stimuli such as angiotensin II, thrombin, platelet-derived growth factor, tumor necrosis factor- , interleukin-1, and for endothelial cells, mechanical forces (including shear stress) and vascular endothelial growth factor (972). Activation appears to involve the association of additional proteins with the oxidase components (972). In the case of angiotensin II-induced production of ROS by vascular smooth muscle cells, the early phase (30 s) is protein kinase C dependent, whereas the prolonged phase (30 min) is dependent on Rac, Src, and phosphatidylinositol 3-kinase (828). In endothelial cells, angiotensin II rapidly induces ROS production through serine phosphorylation of p47phox, and its enhanced bindwww.prv.org

Physiol Rev VOL

84 OCTOBER 2004



ing to p22phox (548). More recently, homologs of p47phox and p67phox have been identied and proposed to participate in the activation of the Nox family oxidases (929). However, even under stimulated conditions, the amounts of O2 produced by vascular cells are only a fraction of those generated by activated phagocytes and are commonly considered to represent second messengers for a number of key regulatory proteins and cellular responses, rather than toxic species that cause oxidative damage. For example, increased NAD(P)H oxidase activity and p47phox expression is involved in hypercholesterolemiainduced leukocyte-endothelial cell adhesion (902), and increased Nox4 expression during chronic hypertension has been associated with enhanced cerebral vasodilation in vivo (702). 2. Xanthine oxidase Xanthine oxidase is an iron sulfur molybdenum avoprotein with multiple functions and present in high concentrations in endothelial cells of capillaries and sinusoids (447). It exists in two forms, xanthine dehydrogenase and xanthine oxidase, of which the former is predominant. Upon oxidation of xanthine or hypoxanthine to uric acid, the dehydrogenase produces NADH, whereas the oxidase generates O2 . However, the dehydrogenase can be converted into the oxidase by nonreversible proteolytic attack or by reversible oxidation of thiol groups. Another signal identied within the endothelium for xanthine oxidase formation is oscillatory shear stress, a condition that is often found at sites prone to atherosclerotic lesion formation (612). The role of xanthine oxidase in the cellular production of O2 has been studied most intensively in the setting of ischemia reperfusion (609). 3. NOS NOS are a family of enzymes that catalyze the oxidation of L-arginine to L-citrulline and the potent vasodilator NO. In the context of the vasculature and atherosclerosis, eNOS and inducible NOS are most relevant. Active eNOS is a homodimer with each monomer consisting of a reductase (containing the binding sites for NADPH, FAD, and FMN) and an oxygenase domain (containing Zn, tetrahydrobiopterin, heme, and L-arginine) that are linked by a hinge region to which calmodulin binds. Reviewing the structure and functions of NOS is beyond the scope of the present work, and the interested reader is referred to several comprehensive and excellent recent reviews (11, 155, 248, 779, 836). In recent years, it has become apparent that under specic circumstances, eNOS may become uncoupled and thereby an important source of ROS. In the absence of sufcient cofactors such as tetrahydrobiopterin for enzyme catalysis, the enzyme may reduce molecular oxygen rather than transfer electrons to L-arginine, thereby
Physiol Rev VOL

generating O2 (987, 1071). The O2 is likely generated by the oxygenase domain of the enzyme through dissociation of a ferrous-dioxygen complex that is normally stabilized by tetrahydrobiopterin (42, 322, 987). NO may react with metal complexes, molecular oxygen (i.e., autoxidation) or O2 to form RNS, whereas direct reaction of NO with thiols is too slow to be of biological signicance (746, 1045). There are three major types of NO reactions with metals: the direct reaction of NO with the metal center, and NO redox reaction with dioxygen metal complexes and high valent oxocomplexes. For example, reaction of NO with iron sulfur (Fe4S4) clusters forms an iron nitrosyl complex. Different metal nitrosyl complexes vary in stability, and this dictates their biological relevance (1045). A facile reaction is that of NO with proteins containing heme. Biologicallly relevant reactions include those of NO with the heme proteins guanylyl cyclase, NOS, and hemoglobin. For example, binding of NO to heme of NOS results in reversible inhibition of the enzyme activity (335), whereas reaction of NO with the metallo-oxo complex of hemoglobin results in formation of methemoglobin and nitrate. NO is unstable in the presence of molecular oxygen. In aqueous solutions it gives rise to dinitrogen trioxide (N2O3) that undergoes hydrolysis to nitrite, whereas in hydrophobic environments, NO autoxidation forms NO2 and N2O3 (1045). Dinitrogen trioxide is a relatively mild 2e-oxidant, and its primary reaction is nitrosation such as nitrosation of thiols to S-nitrosothiols (RSNO). In addition to nitrosation caused by N2O3, nitrosothiols may be formed via intermediate 1e-oxidation of thiols, possibly mediated by NO2, and the subsequent reaction of thiyl radicals with NO (456). Thus nitrosothiol formation in vivo depends not only on the availability of NO and molecular oxygen but also on the degree of oxidative stress by affecting the steady-state concentration of thiyl radicals (456). As indicated in section IIB1, NO reacts rapidly with O2 to generate ONOO (reaction 1) (44). In fact, this reaction proceeds at near diffusion-controlled rates (k 1.9 1010 M 1 s 1) (488) and dictates that ONOO formation is kinetically favored over both NO autoxidation (k 2 106 M 1 s 1) and spontaneous O2 dismutation (k 5 105 M 1 s 1). Moreover, the reaction of NO with O2 is more rapid than either its reaction with enzyme-bound heme (k 102-106 M 1 s 1) or the reaction of O2 with superoxide dismutase (SOD) (k 2 109 M 1 s 1) (745). An emerging paradigm in vascular disease involves the balance between signals mediated by ROS and NO. In this context, LDL oxidation and lipid peroxidation is deemphasized in favor of the phenotypic implications of ROS-mediated signals (see sect. IIE).

84 OCTOBER 2004

1394 4. Myeloperoxidase


Myeloperoxidase is a heme-containing enzyme that catalyzes the conversion of Cl to the 2e-oxidant HOCl as the major reaction (reaction 9): H2O2 Cl H 3 HOCl H 2O (9)

Myeloperoxidase is the only human enzyme known to generate HOCl, and chlorinated biomolecules are therefore considered specic markers of oxidation reactions catalyzed by the enzyme (384). The myeloperoxidase/H2O2/Cl system can also give rise to 3-chlorotyrosine (377), chlorohydrins such as those of cholesterol and fatty acids (386, 1049), -chloro fatty acid aldehydes (950), and free amino acid or proteinbound tyrosyl radicals (385). Tyrosyl radicals themselves may participate in secondary oxidation reactions, including the oxidation of LDL (806). In addition, the myeloperoxidase/H2O2/Cl system or HOCl convert L-tyrosine into p-hydroxyphenylacetaldehyde (374) that itself can react with the amino head group of phospholipids (378, 391), and the -amino groups of protein lysine residues to generate hydroxy-amino acids (376). These hydroxy-amino acids themselves may then be converted by the myeloperoxidase/H2O2/Cl to highly reactive -hydroxy and , unsaturated aldehydes such as glyceraldehyde, 2-hydroxypropanal, and acrolein (17, 376). Furthermore, the myeloperoxidase/H2O2/Cl system and HOCl convert -amino acids to their corresponding aldehydes (379), and L-serine to the chemically well-characterized advanced glycation end product, N -(carboxymethyl)lysine (18). Thereby, and similar to the process of lipid peroxidation, the myeloperoxidase/H2O2/Cl system and HOCl can generate a series of secondary oxidation products that have the capacity to give rise to oxidized biomolecules including oxidized LDL capable of converting macrophages into foam cells (466). The myeloperoxidase/H2O2/Cl system and HOCl also oxidize nitrite to the nonradical oxidant nitryl chloride (NO2Cl) and the radical NO2, both of which promote nitration and can convert tyrosine into 3-nitrotyrosine (226, 227, 979). Recent studies provide evidence that myeloperoxidase, in fact, plays a major role in the generation of nitrating species in vivo and that formation of 3-nitrotyrosine is strictly dependent on the availability of NO2 (486). For example, in a mouse model of inammation, 3-nitrotyrosine levels increase in wild-type mice but not animals that lack functional myeloperoxidase (295), demonstrating that myeloperoxidase functions to generate RNS in vivo when nitrite/nitrate is available. 5. Lipoxygenases Lipoxygenases are iron-containing dioxygenases that catalyze the stereospecic insertion of molecular oxygen
Physiol Rev VOL

into polyunsaturated fatty acids to give rise to a complex family of biologically active lipids, including prostaglandins, thromboxanes, and leukotrienes (reviewed in Refs. 780, 811). Prostaglandins and thromboxanes (or prostanoids) comprise metabolites from arachidonate and similar fatty acids. Prostaglandins contain a cyclopentane ring and are derived from the action of cyclooxygenase I (also referred to as prostaglandin G/H synthase I) that is expressed constitutively in almost all tissues and that acts on arachidonate. The enzyme requires activation by a seeding peroxide to oxidize the heme-iron at the active site to an oxo-heme species and a protein-derived tyrosyl radical (compound I). The tyrosyl radical is thought to abstract a bisallylic hydrogen atom from arachidonate to initiate formation of prostaglandin G2 that is then reduced to prostaglandin H2 by the peroxidase activity of cyclooxygenase. Both prostaglandin G2 and H2 are rapidly transformed into other prostaglandins, such as thromboxane A2 and prostacyclin, several of which are involved in the regulation of vascular tone and homeostasis. For example, vascular endothelium produces prostacyclin that dilates blood vessels and is a powerful inhibitor of platelet aggregation, similar to NO. In contrast, thromboxane A2 exhibits opposing biologic activities of vasoconstriction and platelet aggregation. The non-heme iron-containing lipoxygenases oxidize certain fatty acids at specic positions of the carbon chain to their corresponding hydroperoxides that are the precursors of leukotrienes. Leukotrienes represent a family of chemicals that have potent biological activities and that differ from prostanoids in that they have a conjugated triene structure and no cyclopentane ring. These mediators may contribute to inammatory reactions and, in the case of slow-reacting substance A, to an increase in vascular permeability. Like cyclooxygenase, lipoxygenases require low levels of seeding peroxides to oxidize inactive Fe2 to active Fe3 enzyme and are likely affected by the peroxide tone of cells. In addition to the oxidation of fatty acids, 12- and 15-lipoxygenase have been reported to also oxygenate complex, esteried fatty acids, such as those in cholesterol esters and phospholipids (50, 87, 652). In vitro, 15lipoxygenase can oxidize LDL (51), and this is achieved by a combination of direct, enzymatic and indirect, nonenzymatic oxidation reactions (396, 965, 1076). Formation of nonenzymatic oxidation products has been linked to the ability of cyclooxygenase and lipoxygenases to generate oxidants in addition to the specically oxidized fatty acids. It is well known that cyclooxygenase also engages in the oxidation of other substrates (e.g., 13-cis-retinoic acid) via 1e-reactions (797), implying the generation of radicals as by-products during normal enzymatic reaction. Similarly, LOO are generated and released during the catalytic action of lipoxygenases (142) and may participate in subsequent nonenzymatic lipid peroxidation (665,

84 OCTOBER 2004



964, 965). In addition, thromboxane synthase cleaves prostaglandin H2 to 12-hydroxy-5,8,10-heptadecanoic acid and produces malonyldialdehyde. 6. Mitochondrial respiration As a by-product of electron ow through the mitochondrial electron transport chain, 12% of the molecular oxygen consumed may be converted to O2 (143), raising the possibility that this represents a major intracellular source of ROS. The steady-state levels of mitochondrial O2 depend on the activity of Mn-containing SOD (MnSOD), an enzyme located in the mitochondrial matrix that converts O2 to H2O2 and molecular oxygen. In addition to the electron transport chain reactions of the inner mitochondrial membrane, monoamine oxidase in the outer mitochondrial membrane may represent another source of H2O2. Within the mitochondria, O2 production occurs primarily at complex I (NADH dehydrogenase) and complex III (ubiquinone-cytochrome bc1). A number of cellular responses have been linked to mitochondrial O2 generation including growth arrest, apoptosis, and necrosis (551, 741). With respect to vascular disease, complications from diabetes have been linked to mitochondrial O2 generation. For example, overproduction of O2 has been associated with changes in glycosylation (212) and protein kinase C activation (671) in vascular cells. Overexpression of Mn-SOD appears to ameliorate many of these deleterious consequences of hyperglycemia (212, 671). These data are in keeping with known genetic alterations in mitochondrial energy metabolism that involve a predisposition to glucose intolerance and diabetes (597, 851). A recent study has also linked mitochondrial production of ROS to the early atherosclerotic lesion development (30), and emerging evidence indicates that many cardiovascular syndromes are associated with some evidence for mitochondrial dysfunction, although a causal role has yet to be established in vivo (for review, see Ref. 755). 7. Transition metals Free transition metals like iron and copper are strong catalysts for oxidation reactions in the presence of hydroperoxides, such as LOOH proposed to be seeded in LDL by 15-lipoxygenase (708); they catalyze homolytic cleavage of LOOH to lipid alkoxyl radicals that can initiate lipid peroxidation and other oxidation reactions. However, the concentration of free transition metals in vivo appears to be very low (e.g., see Ref. 749), and there is little convincing evidence that they are related to atherosclerosis. Indeed, an autopsy study on patients with hemochromatosis, a genetic disorder that results in elevated plasma and tissue levels of iron, showed that they have less coronary artery disease than age- and sexmatched controls (624).
Physiol Rev VOL

In addition to free iron, biological forms of iron such as heme, hemoglobin, and myoglobin all have the potential to catalyze oxidative reactions in the vessel wall. In vitro, these iron-containing molecules are able to oxidize isolated LDL (625). In contrast to free transition metals, heme also binds to and oxidizes LDL in diluted serum (119), raising the possibility of heme, e.g., derived from hemolysis, being an in vivo oxidant for LDL. In support of this notion, intravascular hemolysis increases atherogenicity of diet-induced hypercholesterolemia in the rabbit (246). 8. Other oxidants Lipid peroxyl radicals are regarded as the major chain carrier of nonenzymatic, free radical-mediated lipid peroxidation (112) and the ultimate precursor for LOOH. The presence of LOOH in human and animal atherosclerotic lesions (see sect. IIIB2) therefore implies the formation of LOO as intermediate species. Peroxyl radicalmediated peroxidation of linoleate, the major lipoprotein lipid that oxidizes readily, theoretically yields four different regioisomers of LOOH that do not accumulate with equal abundance (725) (Fig. 6). In pure lipids the thermodynamically favored 9- and 13-trans,trans-isomers predominate, whereas LDL and other lipoproteins that contain -TOH predominantly yield the 9-cis,trans- and

FIG. 6. Formation of specic regioisomers of lipid hydroperoxides during nonenzymatic lipoprotein oxidation in the presence and absence of -tocopherol ( -TOH). Lipids containing bisallylic hydrogen atoms such as cholesteryl linoleate are present in the cis,cis (Z,Z) conguration. Upon hydrogen abstraction, -fragmentation competes with oxygen addition. In the presence of suitable hydrogen donors such as -TOH, formation of the kinetically favored trans,cis (Z,E) regioismer predominates. In the absence of hydrogen donors ( -TOH), the thermodynamically favored trans,trans (E,E) regioisomer is formed in preference. [Adapted from Upston et al. (963).]

84 OCTOBER 2004




13-trans,cis-regioisomers of cholesteryl linoleate hydroperoxides (476, 964). This is explained by -TOH reacting with LOO before it acts as a chain carrier and oxidizes another lipid. In human atherosclerotic lesions, most LO(O)H are present as 9-cis,trans- and 13-trans,cis-regioisomers, particularly during the early developmental stages of the disease (967). This suggests that lipoprotein lipid peroxidation in the arterial wall most likely takes place in the presence of -TOH. As a consequence, -TO rather than LOO is likely the major radical oxidant that carries the chain reaction of lipid peroxidation (see sect. IIIC4). While different types of LOOH can be analyzed with high sensitivity and specicity by HPLC with postcolumn chemiluminescence detection (805, 846, 1075), they are metabolized readily in biological systems, complicating their use as markers of in vivo lipid peroxidation. LOOH are metabolized principally through peroxidase-mediated reduction to the corresponding alcohols. In the extracellular space, where lipoprotein lipid oxidation is believed to take place yet suitable peroxidases are not present, reduction of LOOH can be achieved by methionine residues of apolipoproteins (292, 293, 596). Therefore, the accumulation of LOOH plus corresponding lipid alcohol [i.e., LO(O)H] may represent a suitable index of the extent of LDL oxidation in the vessel wall (1055). Hydroxyl radicals may also be generated by reaction of metalloproteins with peroxides (13) and perhaps by the decomposition of ONOO (44, 868). Because of their extremely high reactivity, OH are commonly quantied indirectly with biomarkers such as o-tyrosine and m-tyrosine, and protein-bound 3,4-dihydroxyphenylalanine, which are produced from hydroxylation of phenylalanine and tyrosine, respectively (534). D. Antioxidant Defenses Oxidative modications within the arterial wall that may initiate and/or contribute to atherogenesis likely occur when the balance between oxidants and antioxidants shifts in favor of the former. Therefore, it is important to consider sources of oxidants in the context of available antioxidants. Many substances may prevent, or signicantly delay, the oxidation of other substrates. However, an antioxidant is dened as a substance being effective against oxidative damage when present in much smaller quantity than the substance that it protects (353). With regard to atherosclerosis, vascular antioxidants need to protect against 1e- (radical) and 2e-oxidants, both within and outside cells. In the context of the oxidative modication hypothesis, antioxidant protection of LDL in the extracellular space deserves focus, as oxidized LDL has many potential proatherogenic activities (57), and the cellular accumulation of oxidized LDL is considered a
Physiol Rev VOL

hallmark of atherosclerosis (882). In addition, cellular antioxidants are likely important in the context of the presence of heightened oxidative stress within the vessel wall and the known effect of oxidative events on key cellular activities such as NO-related bioactivities (see sect. IVC1). The following briey describes the antioxidant defenses in arterial wall cells and lipoproteins that counteract oxidative modications. The topic has been reviewed previously (895, 900), and for a more comprehensive, general review on antioxidant defenses, the reader is referred to an excellent monograph (353). 1. Enzymatic antioxidants The classic antioxidant enzymes are largely cell-associated proteins whose function is to maintain a reducing tone within cells (353) (Table 3); they may also be involved in the maintenance of extracellular antioxidants (420). Enzymatic antioxidants principally include SOD, catalase, glutathione peroxidases, glutathione reductase and transferases, thiol-dissulde oxidoreductases, and peroxiredoxins. Many of these enzymatic antioxidants are present in normal arteries, most likely within vascular wall cells as extracellular uid is largely devoid of enzymatic antioxidants (reviewed in Refs. 352, 897). A) SODS. SODs catalyze the univalent reduction and oxidation of O2 to H2O2 and molecular oxygen (reaction 10): O2 O2 2H 3 H2O2 O2 (10)

There are three forms of SOD in mammalian systems: the copper-zinc (Cu,Zn-SOD), Mn-SOD, and extracellular SOD (EC-SOD). The copper-zinc enzyme is present in virtually all cells, where most of it is located in the cytosol, with some activity in lysosomes, peroxisomes, nucleus, and the space between inner and outer mitochondrial membrane. The copper ion functions in the dismutation reaction by undergoing alternate oxidation and reduction, and this forms the basis for the ability of copper-chelating agents, such as diethyldithiocarbamate, to inhibit SOD (383). The rate of the dismutation reaction catalyzed by Cu,Zn-SOD is essentially independent of pH, in contrast to the noncatalyzed dismutation of O2 and that catalyzed by Mn-SOD (which decreases at alkaline pH). Manganese-containing SOD is largely located in the mitochondria, is cyanide insensitive, and contributes 10% of total cellular activity. As indicated by its name, EC-SOD (587, 588) is an extracellular form of the enzyme. It also contains copperzinc and is a notable exception in that signicant amounts of this antioxidant enzyme are present in the normal arterial wall outside cells (907). The enzyme is bound to heparan sulfate proteoglycans in the glycocalyx of various cells, including endothelial cells, and in the connecwww.prv.org

84 OCTOBER 2004





Cellular antioxidants
Antioxidant Mode of Action Location

Cu,Zn-SOD Mn-SOD Catalase Classic glutathione peroxidase (cGPx) Phospholipid hydroperoxide glutathione peroxidase (PHGPX) Glutathione reductase Glutathione S-transferase

Enzymes Catalyzes dismutation of O2 into H2O2 and O2. Catalyzes dismutation of O2 into H2O2 and O2. Converts H2O2 into H2O and O2. Reduces H2O2 and fatty acid hydroperoxides to H2O and fatty acid alcohol, respectively, by coupling with oxidation of GSH to GSSG. Reduces hydroperoxides of esteried fatty acids and cholesterol.

Cytosol, lysosomes, and nucleus Mitochondria Restricted largely to peroxisomes Found predominantly in the cytosol but also present in mitochondria and nucleus Membrane bound

Protein-disulde isomerase (PDI) Thioredoxin Thioredoxin reductase Glutaredoxin (or thioltransferase) Peroxiredoxins (or thiolspecic antioxidants)

Methionine sulfoxide reductases Heme oxygenase

Reduces GSSG to GSH and thereby cooperates with peroxidases. Metabolizes xenobiotics by conjugation with GSH; some transferases show glutathione-peroxidase-like activity with organic hydroperoxides. Catalyzes formation of new disulde bonds and the rearrangement of existing ones by means of exchange with dithiol/disulde groups at the enzymes active site. Reduces protein disuldes to corresponding thiols, also metabolizes H2O2 and lipid hydroperoxides. Reduces oxidized thioredoxin and PDI with the aid of NADPH. Catalyzes thiol-disulde interchange with proteins, also has dehydroascorbate-reducing activity. React with H2O2 or peroxides and may remove thiyl radicals, causing SH group oxidation that is repaired by the thioredoxin system: the specic function of this thioredoxindependent peroxide reductase system remains to be established (140): several peroxiredoxins exist in mammalian cells (280, 465). Reduce protein methionine sulfoxides back to methionines at the expense of reduced thioredoxin. Removes pro-oxidant heme and converts it to the potential antioxidants biliverdin and bilirubin. Also produces the potential pro-oxidant iron. However, this is linked to synthesis of ferritin (992) so that overall heme oxygenase appears to provide antioxidant activity. Sequestration of metal ions Principal store of intracellular iron. Each protein binds 57 ions of metals such as Zn2 , Cu , Cd2 , and Hg2 via thiolate bonds. Signicant proportion of total cell protein thiol. Low-molecular-mass agents Major nonproteinaceous thiol, involved as cofactor for glutathione peroxidases, also involved in protein folding and ascorbate metabolism and generally preventing protein SH groups from oxidation and cross-linkage; scavenger of reactive species. Cofactor for several enzymes, cooperates with GSH and has the potential to directly scavenge ROS. Scavenger of LOO protecting membranes from radical-induced oxidative damage. Plays essential role in electron-transport chains of mitochondria and other cellular membranes, also scavenges LOO and synergizes with vitamin E in the protection of cell membranes from radical-induced oxidative damage

Colocalizes with peroxidases Cytosol and membrane bound

Primarily in the lumen of the endoplasmic reticulum, but also associated with other membranes Primarily in endoplasmatic reticulum, but also found on cell surface Similar to thioredoxin Predominantly in cytosol Located at different sites, depending on type of protein

Cytosol Cytosol

Ferritin Metallothioneins

Cytosol Cytosol and nucleus


Throughout the cell

Ascorbic acid (vitamin C) -Tocopherol (vitamin E) Ubiquinol-10 (CoQ10H2)

Throughout the cell All membranes All membranes

[Adapted from information provided in Halliwell and Gutteridge (353).]

tive tissue matrix. In human aorta, the enzyme is localized to the connective tissue matrix and is produced by smooth muscle cells (686). Recent evidence suggests that the enzyme exists in two forms, each with a unique disulde pattern, and with only one of the two forms being active (718). The synthesis of EC-SOD by smooth muscle
Physiol Rev VOL

cells is modulated by cytokines, growth factors, vasoactive factors, and oxidants (906, 908), suggesting that changes in enzyme activity may occur in vascular diseases. Consistent with this, SOD activity is decreased by homocysteine (675) and increased by angiotensin II and hypertension (281). Indeed, a key function of Cu,Zn-SOD

84 OCTOBER 2004



is thought to be protection against O2 -induced inactivation of endothelial cell-derived NO (3). In direct support of this contention, overexpression of EC-SOD improves endothelial function in a rat model of hypertension (245). In the presence of bicarbonate, Cu,Zn-SOD also has peroxidase activity towards H2O2 (399, 798) that results in the oxidation of cosubstrates and may inactivate the enzyme distinct from that seen with H2O2 at high pH (402). Reducing substances like urate can prevent inactivation of the enzyme (399). An additional feature of EC-SOD is its ability to bind to and protect type I collagen from oxidative fragmentation (717). B) CATALASE AND PEROXIDASES. Two types of enzyme usually metabolize the H2O2 resulting from the dismutation of O2 or generated by oxidase enzymes including xanthine oxidase. Catalase directly decomposes H2O2 to water and molecular oxygen (reaction 11), whereas peroxidases eliminate H2O2 by using it to oxidize another substrate (reaction 12): 2H2O2 3 2H2O Substrate-H2 O2 2H2O (11) (12)

H2O2 3 substrate

C) GLUTATHIONE-DEPENDENT ANTIOXIDANT DEFENSES. Glutathione peroxidases cooperate with catalase in the removal of H2O2 in vivo by using reduced glutathione (GSH) to reduce H2O2 to H2O and oxidized glutathione (GSSG) (reaction 13):

sociated with endothelial dysfunction and an increase in circulating and aortic concentrations of F2-isoprostanes (252), i.e., secondary oxidation products formed during the nonenzymatic oxidation of arachidonic acid (640, 1084) that are also used as a marker of oxidative stress (526, 642, 712, 772). Phospholipid hydroperoxide glutathione peroxidase (PHGPx) is the only enzyme known to reduce complex lipid hydroperoxides in lipoproteins (576, 804). In addition to GSH, PHGPx can utilize a number of different low-molecular-weight thiols as reducing agents. This isoform is membrane bound (944) and, like the classic glutathione peroxidase, not found in extracellular uids. The tetrameric gastrointestinal glutathione peroxidase found in the cells lining the gastrointestinal tract is most likely involved in the detoxication of dietary peroxides (1043). Human plasma contains low concentrations of a glycosylated peroxidase, now called extracellular peroxidase, that acts on H2O2 and phospholipid hydroperoxides (928). It is less clear whether, and if so to what extent, this isoform acts as a glutathione peroxidase, as plasma levels of GSH are low compared with the Michaelis constant (Km) of the enzyme. In addition to extracellular peroxidase, human and rat plasma contain selenoprotein P (108) that reduces phospholipid hydroperoxides (but not H2O2) (791) similar to PHGPx. Glutathione peroxidases operate in concert with glutathione reductase that catalyzes the reduction of GSSG at the expense of NADPH (reaction 15): GSSG NADPH H 3 2GSH NADP (15)


2GSH 3 2H2O



Glutathione peroxidases are widely distributed in animal tissues and can act on peroxides other than H2O2. Most importantly with regard to oxidative modication in the artery wall, they can catalyze GSH-dependent reduction of LOOH to the corresponding alcohol (LOH) (reaction 14): LOOH 2GSH 3 LOH H 2O GSSG (14)

This conversion represents an antioxidant defense as the potential to form pro-oxidants from the degradation of hydroperoxides is negated. Glutathione peroxidases are tetrameric enzymes that contain and require selenium for activity. Selenium actively participates in the catalytic reaction (249), and this is often the basis for antioxidant protection offered by supplemental selenium. Selenium-containing peroxidases comprise a family of enzymes of at least four types. The classic glutathione peroxidase (cGPx) acts on H2O2 and hydroperoxides of fatty acids and cholesterol, but not esteried lipids such as those present in lipoproteins. In the mouse, heterozygous deciency of the enzyme is asPhysiol Rev VOL

NADPH is provided primarily by the oxidative pentose phosphate pathway (143) that is initiated by glucose6-phosphate dehydrogenase and that maintains the cellular redox couple NADPH/NADP in balance. In this context, glucose-6-phosphate dehydrogenase can be considered an antioxidant. For example, overexpression of glucose-6-phosphate dehydrogenase in endothelial cells decreases oxidative stress and increases the bioavailability of NO (540). In addition to its central role in glutathione peroxidase activity, GSH is involved in several other antioxidant pathways, including direct scavenging of oxidants, ascorbate metabolism, the maintenance of protein sulfhydryl groups, and the detoxication of xenobiotics via the action of glutathione S-transferases (reviewed in Refs. 367, 910). Some glutathione transferases show peroxidase-like activity, including against phospholipid hydroperoxides (421), suggesting that these enzymes may contribute to the cellular antioxidant defense. D) THIOL-DISULFIDE OXIDOREDUCTASES. The ratio of GSH to GSSG regulates the activity of protein disulde isomerases, enzymes important in the correct folding of proteins during their synthesis. Protein disulde isomerases are

84 OCTOBER 2004



also found on the surface of cells where they have been proposed to be involved in the control of the redox state of existing exofacial protein thiols or reactive disulde bonds (450), and transnitrosation reactions (i.e., the movement of the nitrogen monoxide group -NO from one molecule to another), and the ordered movement of NO across the plasma membrane (756, 1098). Protein disulde isomerases belong to a group of enzymes called thioldisulde oxidoreductases that also includes thioredoxin and glutaredoxin. While thioredoxin acts in conjunction with thioredoxin reductase and NADPH, glutaredoxin can be reduced directly by GSH (408). As well as acting as thioltransferases on proteins such as ribonucleotide reductase and methionine sulfoxide reductase (408), these oxidoreductases participate in the antioxidant defense in many different ways and may play a major role in cellular redox signaling (409). For example, protein disulde isomerases also have dehydroascorbate reductase activity (1026) and therefore are involved in the maintenance of cellular ascorbate, as shown for glutaredoxin (703) and thioredoxin reductase (604, 605). In addition, protein disulde isomerases, thioredoxin, and glutaredoxin all reduce lipid hydroperoxides (65), mitochondrial glutaredoxin is involved in dethiolation reactions (451), and thioredoxin can reactivate oxidized glyceraldehyde-3phosphate dehydrogenase. Interestingly, the proteins are produced and at least some of them may be secreted by various cells (655, 786), raising the possibility that they also contribute to the antioxidant defense in extracellular uid, although it is unknown whether they can mediate the reduction of lipoprotein lipid hydroperoxides. E) PEROXIREDOXINS. Peroxiredoxins are a family of antioxidant enzymes (482) that comprises several members located in the cytosol, mitochondria, peroxisomes, and plasma membrane of cells, as well as in plasma (reviewed in Ref. 280). The enzymes commonly exhibit peroxidase activity that is dependent on reduced thioredoxin and/or GSH. Peroxiredoxins exist as homodimers and all contain an amino-terminal, reactive cysteine residue that is converted to sulfenic acid via reaction with H2O2 (140). The sulfenic acid is a reaction intermediate and either reacts with an accessible thiol such as that of the other subunit to form an intermolecular disulde that can then become reduced by thioredoxin to reestablish active peroxiredoxin. Alternatively, the sulfenic acid may become oxidized further to sulnic acid so that it is no longer reduced by thioredoxin (1082), but instead by a recently discovered, sestrin-dependent reduction pathway (103, 1062). There is increasing evidence that peroxiredoxins play an important role as antioxidants in vivo. For example, mice with a targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress (1013). In addition to their role as a peroxidase, individual members of the peroxiredoxin family appear to serve a viariety of functions associated with different biological processes
Physiol Rev VOL

such as cell proliferation, differentiation and gene expression (280). F) NONENZYMATIC REDUCTION OF LIPID HYDROPEROXIDES. Despite the overall lack of the major antioxidant enzymes in extracellular uid, hydroperoxides of lipoprotein phospholipids and cholesterylesters may be reduced to the corresponding alcohols. This reduction appears to be mediated via a nonenzymatic reaction (803) that nonetheless requires apolipoproteins. Recent evidence suggests that methionine residues in apolipoproteins A-I, A-II (292, 595) and, to a lesser extent, apolipoprotein B-100 (generically referred to as MetApo) (596), reduce lipoprotein lipid hydroperoxides. In exchange for hydroperoxide reduction, the methionine residues are oxidized to methionine sulfoxide (MetO) (292) (reaction 16): LOOH MetApo 3 LOH MetOApo (16)

The physiological relevance of this lipid hydroperoxide reduction has not been demonstrated. In vitro, the above reaction is slow, although it is accelerated by unknown factor(s) in liver (154), and a slow reduction could still be important under circumstances such as in an atherosclerotic vessel where the average residence time of lipoproteins is long. Peptide methionine sulfoxide reductase acts on methionine sulfoxides in lipid-free and lipid-associated apolipoprotein A-I, suggestive of enzymatic repair of the oxidized protein (850), although it remains unclear whether the cellular sulfoxide reductase can act on extracellular apolipoprotein(s). 2. Metal sequestration Transition metals, specically iron and copper, are essential for the synthesis of a very large range of proteins, including enzymes, like eNOS, that play a central role in the normal function of blood vessels. However, these metals can undergo 1e-transfer reactions that result in autoxidation reactions or the decomposition of peroxides to peroxyl, alkoxyl, and hydroxyl radicals. For example, transition metals can induce oxidative damage to lipoproteins, and copper is commonly used as the in vitro oxidant for LDL (234). Thus binding of adventitious transition metals to inactive chelates in the vascular wall may represent an antioxidant defense. Several proteins, such as ferritin, transferrin, haptoglobin, hemopexin, and ceruloplasmin, specically bind biological iron and copper complexes and are considered to be part of the bodys antioxidant defense system (352). A) BINDING PROTEINS FOR BIOLOGICAL IRON AND COPPER. Ferritin, the principal cellular iron-binding protein, comprises 24 subunits of two types (H- and L-chains). The H-chains contain the metal-binding site and can oxidize Fe2 to Fe3 , a process required for the intact protein to take up iron. The synthesis of ferritin is regulated tightly and in

84 OCTOBER 2004



concert with that of transferrin receptors, via binding of iron-regulatory proteins to iron-responsive elements (481). When iron is low, binding of the regulatory proteins increases translation of transferrin receptor mRNA, while it inhibits that of ferritin mRNA. Conversely, when cellular iron is high, transferrin receptor mRNA is degraded rapidly. Synthesis of ferritin H-chains is also upregulated following activation of cellular heme oxygenase-1 (993) that produces Fe2 , carbon monoxide, and biliverdin from the oxidative degradation of heme. In the extracellular space, iron is bound to transferrin that transports the metal to the various tissues. Importantly, under normal conditions, transferrin is loaded to only 20 30% so that there is substantial iron binding capacity remaining and free iron is essentially nondetectable. In addition, human plasma contains haptoglobin and hemopexin that can prevent the prooxidant activity of hemoglobin (344) and heme (36), respectively. For example, hemopexin can inhibit in vitro LDL oxidation induced by heme (29) and hemoglobin (626). Albumin transports dietary copper to the liver where it is incorporated into ceruloplasmin for release into circulation and transport to various tissues. Ceruloplasmin has ferroxidase activity that is required for iron incorporation into ferritin (see above). The protein can also catalyze oxidation of a wide range of phenols and, surprisingly, was reported to induce in vitro (223) and to faciliate cell-mediated, metal-dependent LDL oxidation (648). As a result of this, it has been speculated (648) that ceruloplasmin may participate in LDL oxidation in the arterial wall. It should be noted, however, that many more proteins bind metals nonspecically. For example, albumin has several metal binding sites and at a concentration similar to that in the vascular wall (860), is able to inhibit in vitro lipoprotein oxidation induced by transition metals (982) and ceruloplasmin (223). Similarly, effective antioxidation of lipoproteins in the presence of Cu2 is mediated by the high-molecular-weight fraction of human suction blister uid (178). B) HEME OXYGENASES. Heme oxygenases catalyze the breakdown of heme to carbon monoxide, iron, and biliverdin, the latter of which is then used to synthesize bilirubin via the action of NADPH-dependent biliverdin reductase (575). Of the three isoforms, heme oxygenases-2 and -3 are expressed constitutively, whereas heme oxygenase-1 is induced in response to various stimuli, including heme, angiotensin II, NO, inammatory cytokines, ultraviolet irradiation, and heat shock. Iron release from the active enzyme results in increased synthesis of ferritin, and this has been proposed to restrict the participation of cellular iron in oxidation reactions (993). The overall effect of heme oxygenase may be seen as that of removing the potential prooxidants heme and iron, while at the same time proPhysiol Rev VOL

ducing the antioxidants biliverdin and bilirubin (see below). Induction of heme oxygenase (previously known as heat shock protein 32) represents a general response of cells to oxidative stress (20) and has been proposed to represent an antioxidant defense (891). Indeed, cells decient in heme oxygenase-1 are hypersensitive to oxidants like H2O2 (726), and experiments modulating cellular enzyme activity demonstrate that heme oxygenase-1 can mediate protection against oxygen toxicity, although protection is seen only over a narrow range of enzyme expression (197). Multiple mechanisms appear to be involved in this protection, including the formation of bilirubin and possible upregulation of catalase and glutathione content (411). Deciency in heme oxygenase-2 results in increased sensitivity to hyperoxia and increased markers of oxidative injury (196). Recently, biliverdin reductase has been proposed as a cellular protective agent via regeneration of bilirubin (32). By comparison to radical oxidants, relatively little is known about antioxidants effective against 2e-oxidants such as HOCl, against which protein thiols provide the primary defense (414) so that albumin in the vascular wall may be protective. However, in the early stages of atherosclerosis, when the albumin concentration is low (860) yet HOCl is likely to be produced (369), other protein thiols may be targets for HOCl. Thus this type of antioxidation could become limited or negated by loss of function to essential proteins such as those found in extracellular space (Table 4) and cell plasma membranes. 3. Nonproteinaceous antioxidants As well as protein antioxidants, there are several low-molecular-weight compounds in addition to GSH that are thought to contribute to the antioxidant defense systems. For example, there is a large body of literature on the role of dietary antioxidants in diseases including atherosclerosis (266). In addition, there are several compounds synthesized in our body that can act as antioxidants. In the following, important low-molecular-weight antioxidants will be divided into water- and lipid-soluble compounds. A) WATER-SOLUBLE ANTIOXIDANTS. Biological systems contain a large number of different redox-active compounds. These include the endogenous compounds uric acid and bilirubin, as well as diet-derived compounds like vitamin C and a variety of avanoids and polyphenols. The latter include compounds for which benecial effects, such as improvement of vascular function (see, e.g., Ref. 214), have been reported. However, avonoids and polyphenols are poorly absorbed, extensively metabolized, and possess only modest antioxidant activity in vitro so that they are not likely to make a signicant contribution to the

84 OCTOBER 2004





Extracellular antioxidants

Antioxidant Defense

Erythrocytes EC-SOD Extracellular peroxidase

May take up O2 and H2O2 for metabolism by intracellular antioxidant defenses. Enzymes Exists in relative abundance, particularly within the artery wall. Present at comparatively (to cellular peroxidases) low concentration. Source of reducing equivalents not clear, particularly in light of low concentrations of GSH in extracellular space. Proteins Bind iron to prevent it from pro-oxidant activity. Acute-phase protein that can inhibit iron- and copper-induced lipid peroxidation. Binds copper tightly and iron weakly, although albumin-bound copper remains redox active. Major source of extracellular thiols. Binds free hemoglobin, thereby preventing it from participating in unwanted redox reactions. Binds heme and prevents it from participating in unwanted redox reactions. Methionine residues have the potential to chemically reduce phospholipid and cholesterylester hydroperoxides to the corresponding alcohols. Nonproteinaceous compounds Present at high concentrations. Has the potential to scavenge H2O2 (678). Scavenges ROS and RNS and can also bind iron and copper ions. Efcient scavenger of different oxidants, particularly 1e-oxidants. Provides the rst line of antioxidant defense for human plasma lipids against various oxidants (135). Scavenges ROS and RNS and protects albumin-bound fatty acids from oxidation. Like ascorbate, albuminbound bilirubin reduces lipoprotein-associated -TO . Efcient scavenger of LOO , although there is evidence that it does not act as a chain-breaking antioxidant for lipoprotein lipids. Not effective against 2e-oxidants. Present in very low concentrations only. However, it appears to represent the rst line of lipid-soluble antioxidant defense in human lipoproteins (666).

Transferrin and lactoferrin Ceruloplasmin Albumin Haptoglobin Hemopexin Apolipoproteins

Glucose Uric acid Ascorbic acid (vitamin C) Bilirubin -Tocopherol (vitamin E) Ubiquinol-10 (CoQ10H2)

[Adapted and modied from Halliwell and Gutteridge (353) and Stocker and Frei (897).]

overall antioxidant defenses in humans. The following discussion is therefore limited to vitamin C, uric acid, and bilirubin. I) Ascorbate (vitamin C). Most animals can synthesize ascorbate from glucose, but humans and other primates lost gulonolactone oxidase required for the terminal biosynthetic step, and so depend on dietary intake of the vitamin. Vitamin C is ubiquitous in biological uids and, at physiological pH, present as the mono-hydro conjugate base ascorbate. Ascorbate is labile due largely to its redox potential of E1/2 of approximately 282 mV at pH 7.0 (104) and generally considered to function as a reducing agent capable of enhancing enzymatic activity through maintenance of the iron center in the active, ferrous state. Ascorbate is a cofactor for several enzymes engaged in hydroxylation reactions. Relevant to the vascular wall, ascorbate is required for the biosynthesis of collagen via proline and lysine hydroxylases. Collagen formed in the absence of ascorbate is insufciently hydroxylated and does not form proper bers, resulting in fragile blood vessels. This inherent metal-reducing activity is also the basis for the pro-oxidant activity of ascorbate in vitro, attributed to the effective redox cycling of iron and the production of hydroxyl radicals through Fenton chemistry (351). There is compelling evidence, however, that this pro-oxidant activity is not observed in vivo where ascorbate generally protects biological molecules from oxidaPhysiol Rev VOL

tion (129) and even after iron supplementation (55). Indeed, ascorbate is a quantitatively important antioxidant (1023); qualitatively, it also provides the rst line of defense against oxidative damage in human plasma (267, 269, 835), where it is considered the most effective watersoluble antioxidant (265, 270) (Table 4). The potential protective activities of vitamin C related to atherosclerosis have been reviewed previously (135). Ascorbate is generally regarded as a primary, rst line protective agent that repairs or nullies free radicals by donating a single electron followed by a proton to yield a chemically reduced, nonradical product and ascorbyl radical that readily dismutates to ascorbate and dehydroascorbic acid. Both ascorbyl radical (9, 104) and dehydroascorbic acid (604, 620, 657, 703) can be reduced by glutathione-dependent enzymatic systems, effectively recycling the pool of bioavailable vitamin C. Ascorbate at physiological concentrations inhibits LDL lipid peroxidation initiated by vascular cells (591), activated neutrophils (896), and cell-free systems (802). This is achieved by ascorbate scavenging aqueous oxidants and acting as a coantioxidant for LDLs -TOH (270, 1058) (see sect. IIIE). For example, ascorbate efciently scavenges aqueous peroxyl (33, 34) and protein radicals (202, 1052, 1060) that can initiate LDL lipid peroxidation. Ascorbate also stongly attenuates, though does not completey prevent, LDL and plasma protein oxidation induced by the 2e-oxidant HOCl (134, 365, 373), indicating that the

84 OCTOBER 2004



vitamin could contribute to the antioxidant defense against HOCl. However, the antioxidant protection offered by ascorbate against ONOO is limited. Thus a recent study calculated that under conditions relevant for the extracellular space (i.e., pH 7.3, 100 M ascorbate, 1 mM carbon dioxide), the vitamin would be expected to scavenge only 3.5% of the ONOO (10 M); at 10 mM (i.e., reecting intracellular concentrations), ascorbate would scavenge 67% of ONOO (512). Together, these studies show that ascorbate is highly effective in preventing oxidation reactions induced by most 1e-oxidants and that it also strongly protects, but does not completely prevent, oxidative damage induced by 2e-oxidants, particularly ONOO . The ability of ascorbate to reduce -TO to -TOH, recognized rst by Packer et al. (688), is now well established as a mechanism that spares vitamin E from oxidation in micelles (62, 1059) and isolated biological membranes (462, 606). Ascorbate completely inhibits LDL lipid oxidation initiated by aqueous and lipophilic peroxyl radicals (78, 79, 802), horseradish peroxidase (1058), and lipoxygenase (965) in vitro. At least in the case of horseradish peroxidase, addition of ascorbate results in immediate disappearance of -TO and cessation of lipid peroxidation, with concomitant formation of ascorbyl radical (1058). Despite these data, however, the importance of this interaction for in vivo maintenance of vitamin E and inhibition of lipid oxidation remains to be established (113, 416). Another example of synergistic activity of ascorbate is the maintenance of cellular glutathione via reduction of glutathione thiyl radical (228). Reduction of glutathione thiyl radical by ascorbate is thermodynamically favored and kinetically fast ( G 60 kJ/mol, k 6 108 M 1 s 1) (930, 1014) so that ascorbate is a preferred radical sink in cells (914) maintaining GSH in the antioxidant active, reduced form. In addition to oxidant scavenging, ascorbate has a number of potentially protective activities related to atherosclerosis and cardiovascular disease. Patients with unstable coronary syndromes (1001) or hypertension have low plasma concentrations of ascorbate, and vitamin C supplements have the potential to attenuate defective endothelium-dependent vasodilation (see sect. IVC1). Multiple mechanisms may operate (603), including the maintenance of eNOS activity, attenuation of cellular oxidative stress, inhibition of LDL oxidation, and preservation of compounds that exhibit bioactivity similar to authentic NO, such as S-nitrosothiols. Ascorbate can also compete with O2 for reaction with NO, although effective competition is observed only at supraphysiological concentrations of vitamin C ( 10 mM) (444). Ascorbate may also maintain NO synthesis by eNOS that requires cofactors such as NADPH, avin adenine dinucleotide, avin mononucleotide, and tetrahydrobiopPhysiol Rev VOL

terin. A deciency in some of these cofactors can change the enzyme into an oxidase that produces O2 in addition to, or in place of, NO (987). Addition of ascorbate to aortic endothelial cells in vitro enhances eNOS activity, and this is due to an increase in cellular tetrahydrobiopterin (415). Ascorbate chemically stabilizes tetrahydrobiopterin, likely due to reduction of the 1e-oxidation product trihydrobiopterin radical (711) rather than dihydrobiopterin (989). Therefore, ascorbate effectively increases the half-life and concentration of tetrahydrobiopterin in cells (392) and decreases O2 production by NOS (986). In contrast to ascorbate, GSH does not appear to be important in the preservation of cellular tetrahydrobiopterin (415). Chemical stabilization also attenuates autoxidation of tetrahydrobiopterin, a process that itself can cause inactivation of NO (607). Furthermore, ascorbate may preserve NO bioavailability indirectly by sparing cellular thiols, such as GSH, that have the potential to stabilize NO via formation of S-nitrosothiols (431). The preservation of NO formation and bioavailability has potential downstream effects on vascular homeostasis independent of vessel relaxation. These include inhibition of leukocyte adhesion to endothelial cell, smooth muscle cell proliferation, and platelet aggregation (135, 504). Supplemental vitamin C protects leukocytes from smoke-induced adhesion to micro- and macrovascular endothelium in hamsters (536) and humans (1065). The underlying mechanism for the inhibitory effect remains unclear, although the activation of important monocyte adhesion proteins, such as CD11b, is under redox regulation and hence a potential site of action of ascorbate (67). Other factors that may be involved in the regulation of leukocyte adhesion are platelet activating factor-like lipids formed during nonenzymatic phospholipid oxidation (382, 538) and F2-isoprostanes (629), raising the possibility of ascorbate modulating cell adhesion via regulation of lipid oxidation. II) Uric acid. Uric acid is produced by the oxidation of hypoxanthine and xanthine catalyzed by xanthine oxidase and dehydrogenase (see sect. IIC2). At physiological pH almost all uric acid is present as urate monoanion. While in most species urate is effectively metabolized by urate oxidase, humans and other primates lack this enzyme so that urate accumulates to high concentrations in the blood (200 400 M). Inside cells urate is present at much lower concentration. Urate can directly scavenge singlet oxygen, OH and peroxyl radicals (16), certain oxidants produced by enzymes (1058) and CO3 and NO2 derived from ONOO (867). These ndings led Ames et al. (16) to propose that the biological function of urate may be that of an antioxidant. Indeed, scavenging of ONOO by urate may protect proteins against nitration. Urate also binds transition metals (185) that may be relevant for LDL lipid peroxidation in the vascular wall (see, e.g., Ref. 527). Reaction of urate with 1e-oxidants leads to the formation

84 OCTOBER 2004



of urate radical that can be reduced by ascorbate. However, unlike ascorbate, urate is not able to reduce -TO (see above). III) Bilirubin. Bilirubin is the end product of heme degradation in humans, with 275 mg or 500 mmol being produced each day. Bilirubin is a strong reducing agent and a potential physiological antioxidant (901). In extracellular uids, the pigment is present at 15 M and predominantly bound to albumin, rendering the otherwise highly lipophilic pigment water soluble. Free and albumin-bound bilirubin is able to reduce -TO and to inhibit plasma and LDL lipid peroxidation (663), although likely as a secondary line of antioxidant defense behind ascorbate (269). Bilirubin can also protect proteins against oxidation in vitro (662), and when bound to albumin the pigment can protect cells against oxidative damage (1067, 1068). Within cells, bilirubin appears to be present primarily within membranes and at submicromolar concentrations; higher concentrations are cytotoxic. To date, few studies have attempted to provide direct evidence for bilirubin acting as an important antioxidant in vivo, although in rats hyperbilirubinemia attenuates oxidative injury in response to hyperoxia (195). B) LIPID-SOLUBLE ANTIOXIDANTS. In addition to aqueous antioxidants, lipid-soluble antioxidants also play an important role in preventing oxidative damage in biological tissues. Tocopherols, that make up vitamin E, and ubiquinols are the major lipid-soluble antioxidants in lipoproteins and cells (93, 233). Indeed, lipoproteins are the primary vehicles for the transfer of vitamin E from the liver to peripheral tissues (467, 957). Lipoproteins also carry carotenoids that have received attention as antioxidants in the context of cardiovascular disease. However, compared with vitamin E and ubiquinols, carotenoids are generally poor antioxidants (111), except for singlet oxygen, an oxidant of presently unknown relevance to atherosclerosis. Also, the nature of the relationship between cardiovascular disease and all, or specic, carotenoids remains controversial (494, 829) so that the following section will be limited to vitamin E and ubiquinol. I) Vitamin E. Vitamin E is a nutritional term that refers to a fat-soluble, dietary factor essential to permit normal reproduction of rats. Eight different, naturally occurring substances have vitamin E activity in animals: d- -, d- -, d- -, and d- -tocopherols and d- -, d- -, d- -, and d- -tocotrienols. The tocopherols have three asymmetric carbon atoms, giving rise to eight optical isomers, of which RRR- -tocopherol (formally called d- -tocopherol) is the most active form of vitamin E. The terms -TOH and vitamin E are commonly, though incorrectly, used interchangeably. Synthetic vitamin E, also called all-rac- -tocopherol, contains 12.5% RRR- -tocopherol together with the seven other -isomers that are biologically less active.
Physiol Rev VOL

Being a fat-soluble molecule, -TOH tends to localize in membranes and lipoproteins. Indeed, -TOH is quantitatively and qualitatively the major antioxidant in extracts prepared from LDL (234) and central to the control of radical-induced lipid peroxidation (see sect. IIIC4). As indicated in section IIB1, tocopherols and tocotrienols are excellent scavengers of LOO , and this is generally thought to be the major antioxidant action of the vitamin (reviewed in Ref. 112). In the case of -TOH, the rate constant for the reaction with LOO (reaction 5) is about four orders of magnitude faster than that for the reaction of LOO with LH (reaction 4) (110). The resulting -TO is relatively nonreactive and, at least in some systems such as micelles, has a long half-life (t1/2 5 min, Ref. 62). However, -TO can react further with LOO or another radical species (R ) to yield nonradical products (NRP in reaction 17): -TO -TO LOO 3 NRP R 3 NRP (17a) (17b)

In the case of LOO (reaction 17a), 8a-hydroperoxy tocopherones are formed that hydrolyze to tocopheryl quinone epoxides, whereas in the case of R (reaction 17b), 8a-substituted tocopherone adducts are formed that hydrolyze to tocopheryl quinone (560) (Fig. 7). In addition to scavenging peroxyl radicals, -TOH can also react with singlet oxygen and the 2e-oxidants HOCl and ONOO . In the latter case, -tocopheryl quinone is formed via tocopheroxylium cation (Fig. 7). It follows from the above that one molecule of -TOH can, in principle, scavenge two molecules of radicals such as LOO . The extent to which this takes place in vivo is largely unknown. Alternatively, -TO produced as a result of initial radical scavenging (reaction 5) may be reduced. As mentioned earlier, ascorbate rapidly (k18 1.5 106 M 1 s 1) reduces -TO back to -TOH. Several other biological reducing agents, such as ubiquinols (647), bilirubin (663), -tocopherylhydroquinone (666), caffeic acid, 2-hydroxyestradiol, and epinephrine also reduce -TO to -TOH (1059). Like ascorbate, -TOH can reduce transition metals including iron and copper, and this may result in prooxidant effects of the vitamin (497). Perhaps more importantly, -TO has a nite reactivity with lipids and can abstract hydrogen from LH (reaction 18): -TO LH 3 -TOH L (18)

While the rate constant for reaction 18 is very low (k19 5 10 2 M 1 s 1) (81), we will see in section IIIC4 that this reaction can become relevant for in vitro LDL oxidation.

84 OCTOBER 2004



FIG. 7. Scheme of major pathways of -TOH oxidation. Two-electron oxidants such as HOCl and ONOO oxidize -TOH to the intermediate tocopheroxylium cation ( -TO ), which hydrolyzes to -tocopherylquinone ( -TQ). Radical oxidants (R ) generate the -TO that can further scavenge radicals, to produce 8asubstituted tocopherone adducts, or scavenge LOO , to produce 8a-hydroperoxy-epoxytocopherones. These hydrolyze to -TQ and -tocopheryl quinone epoxides (TQEs), respectively. [Adapted from Terentis et al. (939).]

In addition to -TOH, -tocopherol is present in lipoproteins but is less antioxidant active than -TOH and, hence, less able to control radical-induced LDL lipid peroxidation (1051). However, -tocopherol may be important in the detoxication of NO2 (153, 166), although the physiological signicance of this remains unknown. Interestingly, -tocopherol, but not -TOH, has recently been reported to inhibit both carrageenan-induced inammation in rats and the associated increase in lipid peroxidation and proinammatory eicosanoids (449). This could be relevant given the importance of inammation in atherogenesis (see sect. VC). II) Coenzyme Q10. Coenzyme Q10 belongs to a family of compounds known as ubiquinones that are fat-soluble molecules synthesized by all animals including humans and that contain a benzoquinone structure with anywhere from 1 to 12 isoprene units. Ubidecaquinone or coenzyme Q10 has 10 isoprene units and is the predominant form of ubiquinone in humans. Coenzyme Q10 is found in virtually all cell membranes, as well as lipoproteins (233). Its ability to accept and donate electrons is critical to its physiological functions, and coenzyme Q10 can exist in three oxidation states: the fully reduced ubiquinol-10 form (CoQ10H2), the ubisemiquinone radical intermediate (CoQ10H ), and the fully oxidized ubiquinone-10 form (CoQ10). Coenzyme Q plays an important part as an electron and proton transfer agent in mitochondrial ATP production and in the maintenance of optimal pH of lysosomes (168). In its reduced form, ubiquinol is an effective fatsoluble antioxidant (268, 461). The presence of a signicant amount of ubiquinol in cell membranes, along with
Physiol Rev VOL

enzymes that are capable of reducing ubiquinone back to ubiquinol, supports the idea that the latter is an important cellular antioxidant (233). Indeed, CoQ10H2 can inhibit protein and lipid oxidation in cell membranes (254). It also provides the rst line of lipid-soluble antioxidant defense against human LDL lipid peroxidation (896), although it is present in smaller quantity than -TOH. Ubiquinol-10 reduces -TO (reaction 19) (646) and its ability to interact with -TOH (433) probably accounts for its strong inhibition of lipid peroxidation. -TO CoQ10H CoQ10H CoQ10H2 3 -TOH O2 3 CoQ10 H CoQ10H O2 -TOH (19) (20) (21)

-TO 3 CoQ10

CoQ10H can react with O2 to produce CoQ10, H and O2 (reaction 20) (674). This reaction increases the formation of O2 and hence the possibility for oxidative stress in the aqueous phase (433), although it provides overall antioxidant protection to lipids as O2 is inefcient in initiating lipid peroxidation. In addition, CoQ10H may also reduce -TO back to -TOH (905) (reaction 21), resulting in the formation of CoQ10 that does not react with O2. In addition to its interaction with vitamin E, there is some evidence that coenzyme Q-dependent electron transport across the cell membrane can be used to regenerate ascorbate from the ascorbyl radical (22).

84 OCTOBER 2004



E. Redox Reactions in Cell Signaling There is now a wide appreciation that the concept of oxidative stress in the vasculature has become more complex in recent years. Although the above discussion on ROS focused principally on their capacity to affect oxidative damage, we now know these species have specic roles in the modulation of cellular events. Importantly, in the case of redox signaling this is achieved by discrete, localized redox circuitry rather than generalized oxidative stress (309). This realization represents a signicant departure from traditional views that ROS are simply a by-product of normal oxidative metabolism or a tool through which phagocytes accomplish antimicrobial action. With this paradigm shift comes the challenge of understanding how ROS production is regulated and localized within cells in both normal and pathological circumstances. Current evidence would support a role for ROS as a generalized injury response in tissues. This contention is supported by observations that ROS may underlie growth promotion and the response to many repair stimuli such as platelet-derived and epidermal growth factors. Moreover, this role for ROS in the injury response is in keeping with their role in antimicrobial

action and cell killing, two functions that often precede tissue repair. Only further investigation will determine if this paradigm for ROS in the vasculature proves true and to what extent these species mediate vascular pathology (see sect. V). 1. Targets of ROS in signal transduction Intracellular production of ROS is elicited in response to a host of stimuli (Table 5). To differentiate a nonspecic response from signal transduction, several groups overexpressed antioxidant enzymes to scavenge stimulus-induced ROS. Addition of catalase to rat vascular smooth muscle cells scavenges ROS and limits protein tyrosine phosphorylation and cell growth in response to platelet-derived growth factor (923). In addition, tyrosine phosphorylation due to epidermal growth factor or angiotensin II is inhibited by intracellular catalase overexpression (26, 971). These approaches support a role in cell signaling; however, little insight is provided concerning the specic targets of ROS. For ROS to mediate signaling, one would assume that some specic protein modication would be involved. Available evidence supports a role for protein thiol groups in this process as they represent a well-known target for



Generation of reactive oxygen species in vascular cells induced by different stimuli

Species Source Cell Type Effect(s) Reference Nos.




H2O2 H2O2 O2 H2O2 H2O2 H2O2 O2 , H2O2 O2 , H2O2 H2O2 O2 O2 , H2O2 O2 , H2O2 O2 , H2O2

Unknown Nox isoform Nox isoform Nox isoform Unknown Nox isoform

Receptor tyrosine kinases Fibroblasts Smooth muscle Smooth muscle Fibroblasts Receptor serine/threonine kinase Endothelial Fibroblasts G protein-coupled receptors Endothelial Smooth muscle Smooth muscle Smooth muscle Endothelial Endothelial Smooth muscle Cytokines

Growth Growth Induction of MCP-1 Unknown Growth inhibition Unknown Production of NO, hypertension Cell hypertrophy, p38 activation Proliferation, hypertrophy Proliferation Unknown Unknown Cell growth, p38 activation, HIF-1 activation Unknown Unknown Unknown Unknown Unknown JNK activation Unknown

841 970 593 923 183, 943 941, 942 519 973, 956 530, 407, 406 321,

Angiotensin II

Serotonin Bradykinin Thrombin

Nox isoform Nox isoform PLD-dependent oxidase Nox isoform Cyclooxygenase Nox isoform Nox isoform

1097 531 924 713, 760

TNFIL-1 IFNShear stress Shear stress

O2 O2 , H2O2 O2 O2 , H2O2 O2 OONO O2

Unknown Nox isoform Unknown Nox isoform Unknown eNOS unknown Unknown

Endothelial Fibroblasts Endothelial Fibroblasts Endothelial Other Endothelial Endothelial

650 617 599 616 599 310 523

EGF, epidermal growth factor; HIF-1, hypoxia-inducible factor-1; IFN- , interferon- ; IL-1, interleukin-1; JNK, c-Jun amino-terminal kinase; MCP-1, monocyte chemotactic protein-1; PDGF, platelet-derived growth factor; PLD, phospholipase D; TGF- 1, transforming growth factor- 1; TNF- , tumor necrosis factor- . [Adapted from Chen et al. (145).] Physiol Rev VOL
84 OCTOBER 2004




reactive species (Table 6). Certain cysteine residues, particularly those surrounded by basic amino acids, exhibit pKa values in the range of 5.0 such that they are not protonated at physiological pH (564, 1105), making them particularly attractive for redox reaction signaling. This situation is illustrated by the bacterial transcription factor OxyR. OxyR positively regulates several target genes involved in the response to ROS, and this activity depends on a critical cysteine residue (Cys-199) (509). This residue is subject to distinct redox modications (S-OH, S-S, and S-NO), each of which produces specic functional responses (483), lending credence to the notion that redoxmediated thiol modication is one mechanism for signal transduction. Recently, a number of proteins have been identied as targets for ROS-mediated signal transduction. A) THIOREDOXIN. Thioredoxin is ubiquitously expressed in endothelial cells and medial smooth muscle cells. It is a major cytosolic protein thiol reductant and appears to be a target for ROS with implications for cell signaling. In its reduced state, thioredoxin forms a complex with apoptosis signal-related kinase-1 in a manner that inhibits kinase activity (792). This interaction between the two proteins is regulated by the redox status of thioredoxin. Oxidation of the sulfhydryl groups of Cys-32 and Cys-35 of thioredoxin by reagent H2O2 or cytokine-stimulated ROS production releases the protein from the kinase leading to kinase activation and the stimulation of downstream targets such as c-Jun amino-terminal kinase and p38 kinase (324, 792). In addition, Cys-62 and Cys-69 represent a second dithiol/disulde motif implicated in the transient redox regulation of thioredoxin activity (1021), and Snitrosation of Cys-69 has also been linked to the antiapoptotic activity of thioredoxin (1077). B) ACONITASE. Aconitase is present in both a mitochondrial and cytosolic form and is involved in the citric acid cycle that catalyzes the conversion of citrate to isocitrate. The enzyme contains a cubane moiety [Fe4S4]2 consisting of three cysteine-ligated iron residues and the fourth available for interaction with substrate during the catalytic cycle (49). This iron residue is also available for reaction with ROS and RNS, and its loss has been linked to formation of a Fe3S4 cluster and enzyme inactivation (288, 477). Aconitase is inactivated rapidly by O2 , and this has led to the suggestion that inactivation of aconi6. Selected reactive oxygen species and their known biologic targets
Species Biologic Target/Reactant


O2 H2O2

Metals, NO, iron sulfur clusters Metals, thiols, methionine residues

[Adapted from information provided in Halliwell and Gutteridge (353).] Physiol Rev VOL

tase may be useful as a sensitive measure for intracellular O2 (287), although H2O2, NO, and ONOO also inactivate the enzyme. In intact cells, reactivation of the enzyme is achieved rapidly by iron sulfur cluster reduction and Fe2 insertion, suggesting that iron sulfur center recycling could serve adapative functions related to cellular redox signaling (286). Cytosolic aconitase is identical to the iron-regulatory protein 1 that regulates intracellular iron by controlling biosynthesis of the transferin receptor and ferritin via binding to the iron-response element in the 3 -untranslated region of the mRNA for these proteins (224). Loss of iron from the Fe4S4 cluster (and loss of aconitase activity) induces binding of iron-regulatory protein to the iron response element that represses ferritin translation and stabilizes transferrin receptor message. This pathway is subject to redox regulation as cells or intact organs exposed to H2O2 exhibit reduced ferritin synthesis and upregulation of transferrin receptor mRNA (644, 701). The mechanism for this effect is complex, as H2O2 releases Fe from iron-regulatory protein, but such H2O2-treated protein is not able to bind to iron-response elements (700), suggesting some other signaling mechanism for changes in iron status mediated by iron-regulatory protein. This contention is supported by observations that H2O2 treatment of cell lysates does not stimulate binding of ironregulatory protein to response elements (75). Thus the specic role of ROS in regulating aconitase and, as a consequence, iron-regulatory protein activity remains to be determined. C) SOLUBLE GUANYLYL CYCLASE. Guanylyl cyclases are enzymes responsible for the synthesis of the second messenger cGMP that mediates many physiological functions including vasorelaxation and inhibition of platelet aggregation and smooth muscle cell proliferation (427). Soluble guanylyl cyclase is a heterodimeric enzyme consisting of an - and -subunit and containing heme as the single prosthetic group that is crucial for binding of and activation by NO. In addition to this activation pathway, there is evidence for modulation of the activity of soluble guanylyl cyclase by translocation, cations, adenine nucleotides, allosteric changes, and oxidative modication (272, 705, 789, 1096). With regard to regulation by oxidative processes, early studies showed that the redox state of heme and protein thiols is important (339). The enzyme is reversibly inactivated by the quinoxalin derivative 1H[1,2,4]oxadiazole[4,3-a]-quinoxalin-1-one (ODQ) via oxidation of heme iron (1106). Guanylyl cyclase has also been reported to undergo reversible inactivation via formation of mixed disulde bonds (84), while other reports provide evidence for peroxides activating the isolated enzyme (reviewed in Ref. 1009), and fatty acid hydroperoxides the enzyme in intact platelets (102). To reconcile these ndings, it has been proposed that reversible oxidation of a single cysteine residue, possibly via glutathiowww.prv.org

84 OCTOBER 2004



lation, activates whereas oxidation of additional, essential thiol groups inactivates the enzyme (1069). The in vivo relevance of modulation of soluble guanylyl cyclase activity via redox processes other than NO binding remains to be established. However, blood vessels exposed to H2O2 exhibit relaxation that is blocked by methylene blue, an inhibitor of soluble guanylyl cyclase (109). The activity of H2O2 to increase smooth muscle cell cGMP is dependent on catalase and is temporally related to the formation of compound I. The specic mechanism whereby compound I may activate guanylyl cyclase is not yet clear but may involve some change in the oxidation state of heme iron (148). Emerging evidence that H2O2 also acts as an endothelium-derived hyperpolarizing factor suggests that the mechanism outlined above is relevant for the control of vascular tone (598). D) RAS. Ras GTPases are a family of 21-kDa proteins that serve as molecular switches that control many aspects of cellular function including proliferation, motility, differentiation, and death. There is a reversible interaction between RNS and Ras that results in its nitrosylation at Cys-118 and activation via GDP/GTP exchange (517). Among the known Ras effectors, phosphatidylinositol 3 kinase appears particularly important for propagating the RNS signal (200), and this RNS response is dependent on Ras-mediated Raf-1 activation (199). The modication of Ras at Cys-118 has also been implicated in ROS-mediated Ras activation, particularly in cells exposed to either advanced glycation end products (518) or angiotensin II (4a). Thus Ras appears to be a target of ROS/RNS, and further study will be required to identify the exact role of posttranslational oxidative Ras modication in cell signaling pathways. E) TYROSINE KINASES. Nonreceptor tyrosine kinases, particularly the Src-family kinases, are frequently implicated as targets of ROS. Treatment of T cells with either H2O2 or thiol-modulating agents such as diamide results in the tyrosine phosphorylation of multiple proteins (656), including Src, Lck, and Fyn. It is now widely recognized that Src-family tyrosine kinases are activated by oxidative events (1, 203, 656, 971), and this process is involved in the activation of many downstream kinases such as the mitogen-activated protein kinase (MAPK) family, Akt, protein kinase C, and the epidermal growth factor receptor kinase (for review, see Ref. 332). In addition, ROS also activate other tyrosine kinases, such as c-Abl, pyk2, Jak2, and others (510, 853, 927). This activation is likely indirect, perhaps through inhibition of tyrosine phosphatases (see below). A comprehensive review of all tyrosine kinase pathways sensitive to ROS-mediated activation is beyond the scope of this review; however, the interested reader is directed to recent excellent reviews on the subject (332, 767). F) PROTEIN TYROSINE PHOSPHATASES. Protein tyrosine phosphatases are important for the signaling mediated by celPhysiol Rev VOL

lular tyrosine kinases, because these kinases are under a tonic inhibition by the phosphatases. Protein tyrosine phosphatases share an active site motif consisting of an invariant cysteine and an arginine separated by ve residues (I/V-C-X-X-G-X-X-R-S/T, where X is any amino acid) (35). This sequence motif confers a low pKa environment that facilitates the cysteine residue to function as a nucleophile but also renders it susceptible to oxidation. Consistent with this fact, treatment with H2O2 leads to inactivation of many phosphatases via cysteine oxidation to a sulfenic acid, both with the isolated protein (136, 198, 532) and in cells in response to epidermal growth factor (532). Recent data suggest the sulfenic acid moiety in protein tyrosine phosphatase 1B is converted readily into a sulfenyl-amide species, in which the sulfur atom of the catalytic cysteine is covalently linked to the main chain nitrogen of an adjacent residue (793). This is accompanied by large conformational changes in the catalytic site that inhibit substrate binding and that protect the activesite cysteine residue from irreversible oxidation to sulfonic acid and permit redox regulation of the enzyme by promoting its reversible reduction by thiols. These studies suggest that at least part of H2O2 signaling is mediated through the inactivation of protein tyrosine phosphatases. Indeed, in cultured cells, stimulation with platelet-derived growth factor leads to reversible inactivation of the SH2 domain-containing protein tyrosine phosphatase (SHP-2) that requires its association with the platelet-derived growth factor receptor (621). Moreover, Rac-dependent Rho GTPase inactivation now appears to be due to NADPH oxidase-mediated inactivation of a low-molecular-weight protein tyrosine phosphatase (669). In addition to inactivation, H2O2 may also alter the cellular content of protein tyrosine phosphatases. In particular, treatment of HeLa cells with H2O2 is characterized by rapid degradation of the Cdc25C (807), a phosphatase involved in the cell cycle progression and checkpoint control. This effect of H2O2 is due to cysteine disulde formation in Cdc25C, as it can be recapitulated by mutation of either cysteine residues at positions 377 and 330 in the protein. Thus H2O2 may impair protein tyrosine phosphatase activity through either enzymatic inactivation or protein degradation. Although cysteine oxidation plausibly explains protein modication by H2O2, one must also consider potential cellular means by which this protein modication is controlled. Oxidation of cysteine beyond sulfenic acid is generally considered to be irreversible (156), a situation poorly suited for temporal control of any signaling event. However, cells appear to have access to several options to deal with this situation. As indicated above, one solution to this problem is formation of an intramolecular sulfenylamide bond (793). In addition, a recent study showed that at least in the case of peroxiredoxin, oxidation of cysteine to its sulnic acid is a reversible process via a sestrinwww.prv.org

84 OCTOBER 2004



dependent pathway (103, 1062). Furthermore, glutathiolation via a redox-sensitive mechanism offers an alternative solution (39). Indeed, the process of glutathiolation is now well recognized and has been implicated in the posttranslational modication of many proteins in response to ROS/RNS (for review, see Ref. 490). Reversibility of the oxidation-mediated protein modication can be achieved via the action of glutaredoxin (39). It remains to be seen if the regeneration of reduced protein cysteines is also a regulated process. In contrast to sulfenyl-amide bonds and glutathiolation, formation of intra- and intermolecular sulnamide bonds, as can be observed upon exposure of proteins to HOCl, does not appear to be a reversible modication (750). Although inactivation of protein tyrosine phosphatases by H2O2 may, in part, explain redox-sensitive signaling, many questions remain. For example, little is known about the specic mechanisms involved in H2O2-mediated protein tyrosine phosphatase inactivation. Although reagent H2O2 inactivates multiple forms of protein tyrosine phosphatases, engagement of platelet-derived growth factor with its receptor specically inactivates SHP-2 (621), and the basis for this selectivity is not clear. As is the case for other signaling microdomains, the source(s) of ROS stimulated by ligand engagement might be expected to bear some spatial or vectorial arrangement to their intended targets. Although many features of H2O2 as a signaling molecule parallel that of NO, we have little knowledge at present of how H2O2 may function as a paracrine mediator. G) KELCH DOMAIN-CONTAINING PARTNER (KEAP1). Phase 2 genes encode for proteins including glutathione reductase and heme oxygenase-1 that protect against the damage of electrophiles and ROS, and many of these genes are regulated by upstream antioxidant response elements that are targets of the leucine zipper transcription factor Nrf2. Under basal conditions, a homodimer of Keap1, a recently identied, cysteine-rich protein associated with the actin cytoskeleton, binds very tightly to Nrf2 so that the transcription factor is anchored in the cytoplasm, thereby repressing the activity of Nrf2 by targeting it for ubiquitination and proteasome degradation (442, 888). Inducers of phase 2 enzymes disrupt the Keap1-Nrf2 complex. This allows Nrf2 to translocate to the nucleus, where it binds (in heterodimeric combinations with other basic leucine zipper proteins) to antioxidant response elements of phase 2 genes and accelerates their transcription. Inducers of phase 2 genes belong to nine structurally highly diverse classes of chemicals that share only a few common properties (206), including the capacity to modify cysteine residues. The mechanism underlying this induction has been claried recently (1007). Inducers of the phase 2 response interact with specic thiol groups of Keap1 eventually causing the formation of an intermolecular disulde bond,
Physiol Rev VOL

most likely involving Cys-273 from one and Cys-288 from the other Keap1 molecule. This results in conformational change that renders Keap1 unable to bind to Nrf2 so that it can translocate into the nucleus to enhance phase 2 gene transcription. The Keap1-Nrf2 system may be unique in that it depends initially on different types of chemical modication of cysteine thiols and that the modifying agents then appear to be displaced by intermolecular sulfhydryl disulde interchange to lead to a covalent disulde dimer of Keap1 (1007). H) TRANSCRIPTION FACTORS. I) Nuclear factor B. Within the vessel wall, the transcription factor nuclear factor B (NF- B) plays a critical role in the regulation of inammatory and immune response genes relevant to atherosclerosis. Normally, NF- B is restricted to the cytoplasm through an interaction with its inhibitor, I- B. Activation of NF- B is accomplished through phosphorylation and ubiquitination of I- B (52), leading to translocation of NF- B to the nucleus and permissive phosphorylation of Ser-276 on the p65 subunit (302). DNA binding of NF- B appears to require a reducing environment in the nucleus (600), possibly provided by nuclear translocation of thioredoxin (401) and redox factor-1 (1070). An oxidizing stimulus in the cytoplasm appears to be associated with I- B degradation (549), and it has been proposed that H2O2 activates NF- B in certain cell lines via this mechanism (816). However, the contribution of redox regulation in NF- B activation is still subject to intense debate. Troubling aspects include many conicting reports, reliance on indirect support such as the use of nonspecic agents like the copper chelator pyrrolidine dithiocarbamate as antioxidants, and the lack of specic targets for redox-mediated posttranslational modication (reviewed in Ref. 549). Also, modulation of intracellular production of O2 via Rac/NADPH oxidase does not mediate NF- B signaling, but rather lowers the magnitude of its activation (366). However, I- B contains redox-sensitive methione residues such as Met-45, the oxidation of which can be achieved by 2e-oxidants such as taurine chloramines, and this leads to inhibition of NF- B activation (464). Also, H2O2 promotes phosphorylation of human ribonuclear protein-U (903) that regulates specic SCF (Skp-1/Cul/F box) family ubiquitin ligase involved in I- B degradation (189). These observations lend plausibility to the notion that ubiquitination of I- B may be a redoxsensitive step for NF- B activation (549). The notion that NF- B plays a role in atherosclerosis has received much attention, as activation of this transcription factor in vascular cells such as endothelial cells, smooth muscle cells, and macrophages leads to or enhances the expression of several genes, including those encoding for certain cytokines, leukocyte adhesion molecules, matrix metalloproteinases, cyclooxygenase-2, and inducible NOS (163, 975). Thus activation of NF- B can promote the recruitment and activation of inammatory

84 OCTOBER 2004



cells in the vessel wall. Indeed, activated NF- B has been identied in endothelial cells, smooth muscle cells, and macrophages in human atherosclerotic lesions (74, 83), where it may contribute to the dysregulation of vascular smooth muscle cell function (74, 654). Also, NF- B activation is seen in atherosclerosis-prone mice in response to a high-fat, high-cholesterol diet (552). What is less clear is how precisely NF- B is activated during atherogenesis, although induction of inammatory genes and activation of NF- B-like transcription factors cosegregate with aortic atherosclerotic lesion formation in mice (553). In vitro several pathological stimuli, including oxidized LDL (552) and microorganism components such as Chlamydia pneumonia (495), are able to activate the transcription factor. II) AP-1. Another transcription factor thought to be redox-sensitive is AP-1, a member of the basic leucine zipper family of proteins that plays an important role in the regulation of growth, differentiation, and stress adaptation of cells. AP-1 is a heterodimer consisting of c-Fos and Jun, typically c-Jun. The activation of AP-1 occurs at multiple levels, including changes in Fos and Jun mRNA, effects on Fos and Jun protein turnover, posttranslational modication of Fos and Jun, and interaction with other transcription factors (reviewed in Ref. 837). With respect to redox regulation of AP-1 activity, the rst and third of these mechanisms appear most relevant and involve activation of the MAPK cascade (144). Whereas growth factor-induced AP-1 activation typically involves the extracellular signal-regulated kinase subgroup of MAPK, oxidative stress and cytotoxic stress principally mediate AP-1 activation through the c-Jun amino-terminal and p38 kinase pathways (144). In particular, c-Jun amino-terminal kinase is activated by H2O2 leading to both c-Jun phosphorylation with concomitant increased AP-1 transactivation (146) and activation of ATF2, which enhances transcription of c-Jun (342). The two major pathways of H2O2-induced AP-1 activation involve MAPK stimulation through either apoptosis signal-regulating kinase 1 (ASK1) (952) or inhibition of MAPK phosphatases (139) (see above). Thus, in some cases, transcription factor activation is a downstream target of redox-sensitive signal transduction. A number of other transcription factors are redox sensitive and all contain critical cysteine residues that dictate, in large part, their DNA binding (reviewed in Ref. 145). Thus far, a comprehensive mechanism that explains the redox sensitivity of these transcription factors is not available. Although in many cases a chemically reduced state of the respective cysteine residue facilitates DNA binding by these transcription factors, the specic nature of their contribution to redox-sensitive signaling is not yet clear. Moreover, we are only beginning to develop paradigms on how specic redox-related signals in the cytosol may translate into DNA binding of transcription factors.
Physiol Rev VOL

Thus considerable work is needed to link specic redoxrelated events into a coordinated genetic program. 2. Targets for RNS in cellular signaling It is now known that a number of RNS participate in cell signaling within the vasculature (Table 7) as well as many other tissues (for review, see Ref. 432). The prototypical RNS involved in cell signaling is NO produced by NOS. Once synthesized, NO may interact with a variety of species yielding its oxidation or reduction, and resulting in the production of a spectrum of RNS (Tables 1, 2, and 7). Let us now turn our attention to the targets of these RNS that are relevant to the vasculature. To consider targets of RNS, let us focus initially on NO reactions with proteins. Initially, it was thought that all the biologic activity of NO was readily attributable to its diffusion and reaction with a single target, the soluble isoform of guanylyl cyclase (638). Contemporary understanding of NO biology lies in stark contrast to this concept. We now know that NO has a number of relevant biologic targets that are dictated, in part, by both its site of synthesis, its relative concentration, and the availability of coreactants. At physiologically relevant low nanomolar concentrations, the predominant reactions of NO are with heme and heme-copper centers. The reaction with O2 will not be considered here, despite the fact that kinetic considerations alone indicate it to be a favored reaction, and its product, ONOO , has properties distinct from those of NO (see sect. IIC3). Perhaps the best-characterized heme target for NO is the soluble isoform of guanylyl cyclase. This heme protein binds NO with a bimolecular rate constant of 108 M 1 s 1 (31) permitting its effective competition with other NO targets and facilitating the well-characterized increase in cGMP in response to NO (428). Binding of NO to the heme results in an initial six-coordinated NO-Fe2 histidine complex. Subsequent breakage of the histidineto-iron bond leads to formation of a ve-coordinated nitrosyl-heme complex that initiates a conformational change resulting in activation of the enzyme (reviewed in


7. Selected reactive nitrogen species implicated in cell signaling

Species Biologic Target/Reactant


Thiols*, metals, O2 , O2 Thiols, metals, O2 Thiols, metals, O2 Metals Thiols, metals, tyrosine, methionine Thiols, O2 Thiols, iron sulfur clusters

* Thiol nitrosation requires the presence of an electron acceptor. [Adapted from information provided in Halliwell and Gutteridge (353).] www.prv.org

84 OCTOBER 2004



Ref. 272). The resulting increase in cGMP is largely responsible for vasodilation and the inhibition of platelet aggregation and proliferation of smooth muscle cells (561, 638). Another important target for NO at physiological concentrations is the heme-copper protein cytochrome oxidase (158). Binding of NO inhibits the oxidase, and this is associated with an improvement in the efciency of energy metabolism in the mitochondria. As a consequence, endogenously produced NO from the endothelium has considerable inuence over tissue oxygen consumption (839). Compared with NO, ONOO is a poor agonist for soluble guanylyl cyclase (936), and it irreversibly inhibits mitochondrial respiration through the release of iron from iron sulfur centers (747). When considering the role of NO in signal transduction, it is important to recognize that multiple isoforms and splice variants of NOS exist in discrete cellular compartments permitting the enzymes to fulll distinct functions. For example, both skeletal and cardiac muscle cells express all three different isoforms of NOS in several different cellular compartments. Localization of eNOS to the plasmalemma facilitates regulation of -adrenergicmediated force production (37), whereas NOS-derived NO controls respiration at the level of cytochrome c oxidase (see above). The presence of NOS in the sarcoplasmic reticulum affords control of calcium homeostasis that, paradoxically, enhances cardiac contractility (37). Finally, the specic functions of constitutive and inducible isoforms of NOS that exist in the cytosol remain unknown. Thus emerging data indicate the site of NO generation has important implications for NO-mediated signal transduction, consistent with the growing appreciation that signaling takes place within the connes of subcellular compartments that are integral to both the specicity and phenotypic response of such signals. The concentration of NO produced within a cell also has signicant implications for the ultimate signals produced. For example, under certain pathological conditions such as inammation, upregulation of inducible NOS affords production of NO at low micromolar concentrations. In this concentration range, NO competes effectively with SOD for O2 , facilitating formation of ONOO and other RNS. This increase in tissue RNS, a condition termed nitrosative stress (364), leads to the modication of cellular targets such as thiols, proteins, and lipids, many of which have implications for cellular signaling. A) LOW-MOLECULAR-WEIGHT THIOLS. The production of RNS within cells has important implications for cellular thiol status. Within cells, the most abundant low-molecularweight thiol is GSH with concentrations in the range of 15 mM (89). This abundance of GSH facilitates the formation of its nitrated (GSNO2) and nitrosated (GSNO) forms that may serve, in part, as tissue buffers of NO (1045). The formation of nitrosated glutathione has been
Physiol Rev VOL

observed in vivo (294), although the exact concentrations that occur within cells remain a matter of question. Recent data suggest that S-nitroso species are present in tissues at concentrations of 40 nM (774) comparable to that of NO itself (578). These GSH adducts possess biologic activity that is comparable to NO, including vasodilation and inhibition of platelet aggregation (430, 431, 618). The reaction of NO with GSH is by no means exclusive. Indeed, low-molecular-weight thiol adducts of NO have been demonstrated with a variety of species such as cysteine, homocysteine, and synthetic species including N-acetyl cysteine and penicillamine (for review, see Ref. 405). The abundance of GSH over other lowmolecular-weight thiols suggests its role in NO biology is likely more profound than for the other species. Despite this, however, important questions remain. For example, we know precious little about the relative contribution of NO adducts of GSH with regard to the biologic activity of NO, and to what extent they contribute to posttranslational protein modication (see below). B) PROTEIN THIOLS. Given that thiols represent a prominent biologic target for RNS (Table 7), it is perhaps not surprising that protein cysteine residues are also subject to modication mediated by RNS. This concept was initially brought to light through the demonstration that albumin and tissue-type plasminogen activator may form S-nitrosated species (871, 874, 875) with biologic activity reminiscent of authentic NO (472). Evidence that S-nitrosation of protein cysteine residues is a motif for NOrelated signaling is now pervasive in nature. For example, the function of L-type calcium channels in the heart is subject to modulation through S-nitrosation (122), and the function of the ryanodine receptor is readily modied by receptor S-nitrosation at Cys-3639 (922). S-Nitrosation of thioredoxin is thought to activate apoptosis signal-regulating kinase 1 (920). Indeed, NO synthesis by many cells results in S-nitrosation of numerous proteins (328), although the particular functional consequences of these phenomena remain to be determined. This widespread utilization of S-nitrosation throughout nature has prompted considerable speculation that it represents a conserved method of signaling throughout biologic systems (217). Initially it was thought that any protein thiol species would be subject to modication by RNS; however, just as some cysteine residues have a predilection for oxidative modication (see above), it appears the same holds true for modication via RNS (872). Such implied selectivity supports the notion that this phenomenon may represent another means for allosteric control of protein function (634). The specic mechanism(s) that control protein nitrosation are not yet clear, but using the paradigm of protein phosphorylation, some investigators have proposed consensus motif(s), such as adjacent aspartate or glutamate residues, for this process (872, 873). Conceptuwww.prv.org

84 OCTOBER 2004



ally, this proposal is attractive as protein phosphorylation is controlled, in part, by consensus motifs that dictate targets for kinases and phosphatases. With regard to the latter, one might expect enzymatic mechanism(s) for the regeneration of cysteine residues from their S-nitrosated forms. C) GLUTATHIOLATION. The chemical modication of protein thiols in the setting of ROS and RNS does not occur in isolation. Considering its relative abundance, it is not surprising that GSH functions as a prominent coreactant for protein thiol modication in the face of ROS and RNS. Considerable evidence, dating back some 20 years, indicates that GSH is involved in the dynamic regulation of protein function through the reversible formation of mixed disuldes involving protein cysteinyl residues (303). Early data demonstrating protein S-glutathiolation were largely derived from the exposure of cells to toxic levels of oxidants or activation of an inammatory response from neutrophils (141), macrophages (961), and monocytes (764). Such studies readily demonstrated a number of S-glutathiolated proteins that spanned a broad range of cellular functions including metabolism (glyceraldehyde-3-phosphate dehydrogenase and creatine kinase) (164, 764), the cytoskeleton (actin) (141), and antioxidant protection (SOD and glutathione transferase) (180, 812) to name a few. For a more complete list of S-glutathiolated proteins, readers are directed to an excellent review (490). With regard to cell signaling in the context of ROS and RNS, the potential formation of S-glutathiolated protein adducts has several attractive features. First, S-glutathiolation of protein cysteine residues protects against higher oxidation states of the protein thiol, thereby preserving the reversibility of this type of modication (39). Second, reduced protein thiols can be regenerated from their S-glutathiolated forms enzymatically through the action of protein disulde isomerase, mitochondrial glutaredoxin, or thioredoxin (451, 458). For example, the production of ROS in response to epidermal growth factor is temporally related to glutathiolation of protein tyrosine phosphatase 1B that is reversed by glutaredoxin (38, 39). The speculation that S-glutathiolation protects proteins from irreversible oxidation and loss of function is supported by data in yeast (331) and cardiac tissue (219) where glutathiolation of glyceraldehyde-3-phosphate dehydrogenase preserves its function under conditions of high oxidative stress. Protein S-glutathiolation has also been implicated in the control of ubiquitination (445), the binding of transcription factor c-Jun to DNA (491), and sarcoplasmic Ca2 -ATPase activity (994). 3. Summary From the preceding paragraphs, it should be clear that ROS and RNS are routine products found in biologiPhysiol Rev VOL

cal tissues. Although once thought to exist principally in the setting of inammation, it is now clear that they may also mediate a number of physiological responses that are pervasive in nature. Within the vasculature specically, NO is a major mediator of normal vascular homeostasis manifest as the maintenance of vascular tone, blood uidity, and leukocyte entry into tissues. Roles for ROS are best established for H2O2 that has been implicated in the vascular injury response and, perhaps, various forms of hypertrophy for both smooth muscle cells and cardiac myocytes. In later sections we will touch on the notion that production of ROS and RNS is often increased in the setting of vascular pathology and that increases in both oxidative and nitrative stress may lead to signicant phenotypic changes of vascular and inammatory cells that contribute importantly to human disease. F. ROS and Cell Proliferation The accumulation and hypertrophy of smooth muscle cells are characteristic of atherosclerotic, restenotic, and hypertensive vascular diseases. Many pathological vascular conditions also involve to some degree the proliferation of endothelial cells and broblasts. Overall, the net balance between proliferation and apoptosis/necrosis determines the extent of cell growth. A role of ROS in the control of growth of vascular cells is supported best for H2O2 mediating a proliferative phenotype in vascular smooth muscle cells (24, 758, 761, 1097). In fact, H2O2 may be required for smooth muscle cell survival, as overexpression of catalase inhibits proliferation and can induce apopotosis (100). Low concentrations (i.e., 10 M) of added H2O2, but not O2 , are also mitogenic to or enhance the survival of other cells (107) including endothelial cells (904). ROS derived initially from mitochondria and then NAD(P)H oxidase have also been suggested to be responsible in the autonomous proliferative response of endothelial cells to hypoxia (810). In contrast to these low concentrations, H2O2 at 50 M, corresponding to intracellular concentrations of 1 M (76), can cause cultured cells to undergo growth arrest, apoptosis, or necrosis (550). The molecular mechanism(s) by which low concentrations of H2O2 stimulate growth of vascular cells remains poorly understood. Unlike the situation in bacteria with the transcription factor OxyR (1107) a similarly acting sensor for H2O2 has not been identied in mammalian cells. In fact, human cells respond to H2O2 in a complex manner, with a multitude of genes affected. For example, cells with 10-fold increase in cellular H2O2 concentration due to overexpression of Nox1 show increased expression of some 200 genes, whereas overexwww.prv.org

84 OCTOBER 2004



pression of Nox1 plus catalase reverts 70% of the altered genes to normal (21). Many of the genetic changes seen are in proteins related to cell cycle, signal transduction, and transcription rather than antioxidant defense, indicating that the response triggered by H2O2 is specic and different from the stress response seen in bacteria. For example, in vascular smooth muscle cells in vitro, cell growth-enhancing, low concentrations of H2O2 activate multiple intracellular proteins and enzymes, including the epidermal growth factor receptor, c-Src, p38 MAPK, Ras, and Akt/protein kinase B (332). In contrast, intermediate concentrations of added H2O2 (100 M) inhibit seruminduced progression through the cell cycle via a decrease in cyclin A expression and cyclin-dependent kinase 2 activity, as well as upregulation of p21 and p53, whereas higher concentrations of H2O2 ( 500 M) cause apoptosis of vascular smooth muscle cells (201). It is known, however, that in addition to the potential targets described above, many growth factor-mediated responses also involve the generation of ROS as a component of their signaling, although at present little detail is known of the molecular mechanism(s) underlying these responses. For example, growth factors including platelet-derived growth factor (923) and epidermal growth factor (26) trigger H2O2 production. Similarly, vascular endothelial growth factor-mediated proliferation and migration of endothelial cells appear to depend on ROS production (2, 160, 972). Growth factor receptors may be activated through both ligand-dependent and -independent means, although these two processes are distinct (146, 765). This distinction has functional implications, since ligand-induced epidermal growth factor receptor activation is regulated, in part, through receptor internalization and degradation, whereas H2O2-mediated receptor transactivation is not (765). The latter fact has been cited as one potential mechanism for the relation between ROS and unregulated cell growth (765). The specic extent to which ROS contribute to vascular cell growth remains to be determined. Teleologically, one could envision cell growth mediated by ROS as part of a spectrum that encompasses the tissue injury response. Indeed, the response to cellular injury is characterized by the recruitment of inammatory cells such as neutrophils and macrophages. These cells are needed to clean the injured area of necrotic debris through phagocytosis, a process associated with the production of ROS. This burst of ROS also appears critical for the clearance of neutrophils and macrophages from damaged tissue (1101), a prelude to the resolution of inammation and formation of scar tissue. Thus it is not surprising that ROS, an important component of inammation, would be involved in the regrowth of tissue after damage.
Physiol Rev VOL

G. Redox Reactions in Cell Death There is now a growing body of evidence that ROS play a role in both cellular necrosis and apoptosis. It has long been known that ROS in sufcient high doses will lead to cell killing, as would be expected with any compound. More recently, however, it has become clear that ROS generated within cells play an important role in cellular fate. In particular, the role of ROS in apoptosis, or programmed cell death, has been examined in great detail. Early hints that ROS may be involved in apoptosis were derived from apoptosis induced by the cytokine tumor necrosis factor- . In cytokine-exposed cells, mitochondria undergo prominent morphological changes that coincide with cell death (601), and reducing ambient oxygen levels affords some protection (660). The involvement of mitochondrial ROS in the response to this cytokine is supported by observations that inhibition of mitochondrial respiration at complex I limits apoptosis induced by tumor necrosis factor- (318). Apoptosis from tumor necrosis factor- may also be inhibited by Mn-SOD, further implicating the involvement of ROS in this process (247). The role of mitochondrial ROS extends to a form of programmed cell death known as anoikis that results from the loss of cell attachment to extracellular matrix (273). This process is associated with a signicant increase in intracellular ROS that appears derived from mitochondria (544). Mitochondrial production of ROS results in the activation of components of the apoptotic pathways, such as caspases and c-Jun amino-terminal kinase (JNK), and inhibition of mitochondrial ROS generation ameliorates anoikis (544). Although the data outlined above point to mitochondrial ROS as critical for apoptosis, other means of programmed cell death require ROS from sources outside the mitochondrion. Neutrophils are recruited to sites of inammation, and their clearance from these sites requires apoptosis. Neutrophil apoptosis triggered by phagocytosis of complement- or immunoglobulin-opsonized particles is dependent on ROS generation, as cells decient in active NADPH oxidase do not undergo apoptosis in response to phagocytosis (167). It appears that ROS produced during phagocytosis cause activation of caspase-8 and subsequent induction of the extrinsic apoptotic pathway (1101) via a mechanism that remains to be determined. Damage to DNA has long been known to be important for carcinogenesis, and recent data implicate DNA damage in the process of atherosclerosis (30). Cellular ROS are now implicated in the apoptotic response to DNA damage. For example, DNA damage is associated with rapid activation of p53 that subsequently promotes cellular apoptosis, in part, via ROS (724). Consistent with this

84 OCTOBER 2004



observation, p53 overexpression results in increased cellular ROS generation and apoptosis (453). In this regard, a transcription factor known as REDD1 has been identied as one important downstream target of p53 (230). The upregulation of REDD1 in response to DNA damage is associated with increased production of and an increased sensitivity to ROS, by presently unknown mechanism(s). H. Redox Reactions in Platelet Function 1. Platelets and cardiovascular disease The critical role for platelets in the acute manifestations of atherosclerosis is supported by data that platelet inhibition yields a reduction in myocardial infarction and stroke (161). To prevent inappropriate thrombus formation and vascular events, platelet function is strictly regulated in the vasculature. In particular, a number of autocrine and paracrine factors are secreted by platelets and the adjacent endothelium to prevent platelet adhesion and aggregation. Many of these control mechanisms are under redox regulation and, in many cases, involve ROS and RNS. 2. ROS and platelet aggregation Platelet aggregation is associated with considerable oxidative stress manifest as a burst of oxygen consumption (92) and an increase in GSSG (106). This increase in GSSG arises, in part, from ROS such as O2 (260, 585) and H2O2 (912) that are produced during the aggregation. Implicated sources for these ROS produced during aggregation include cyclooxygenase, lipoxygenase (856), and even NADPH oxidase (503, 825). Platelets may also be exposed to ROS that arise from the vascular wall, particularly in the setting of atherosclerosis or its established risk factors such as hypercholesterolemia (473, 680) and diabetes (940). This association between platelet activation and ROS production has driven considerable investigation into the potential role(s) of these species in regulating platelet function. Early investigation of ROS and platelet aggregation focused on O2 . Platelets exposed to ROS from xanthine/ xanthine oxidase undergo aggregation and serotonin release (356). Chronic exposure of platelets to low uxes of O2 also appears to sensitize the platelet response to thrombin (356), suggesting there is a synergy between receptor-mediated aggregation and ambient O2 . Consistent with these observations, SOD inhibits thrombin-stimulated platelet adhesion and aggregation (796). The mechanisms underlying these observations are not entirely clear but may reect a stimulatory effect of O2 on platelet thromboxane production that, in turn, enhances aggregation (636). The effect of H2O2 on platelet aggregation has been mixed. The presence of H2O2 at low micromolar concenPhysiol Rev VOL

trations inhibits the aggregation (912), in part, by raising intracellular cGMP (15). Although not studied in detail in platelets, this effect of H2O2 on intracellular cGMP may relate to ndings in vascular smooth muscle in which H2O2-mediated formation of catalase compound I activates guanylyl cyclase (109). Higher concentrations of H2O2, in the millimolar range, appear to stimulate platelet aggregation (776). This observation may be physiologically relevant to certain platelet agonists. For example, collagen appears to stimulate considerable platelet H2O2 production that may be involved in platelet arachidonic acid mobilization and thromboxane production (719). In fact, H2O2 has also been implicated in platelet priming that facilitates tyrosine phosphorylation of the brinogen receptor that is ultimately required for aggregation (436). This latter contention is supported by data that ultraviolet irradiation enhances platelet aggregation through the upregulation of brinogen binding sites as a direct result of activation of protein kinase C mediated by ROS (983). Thus the role of ROS in modulating platelet function is dependent on the particular type and concentration of ROS involved. Part of this ambiguity concerning ROS and platelet function may result from an incomplete understanding of platelet aggregation and the factors that inuence this process. It may turn out that investigation into the autocrine aspects of platelet aggregation has been misplaced. Most early reports focused on the products of platelet aggregation, such as O2 , and how these products may alter the aggregation response. However, in vitro, platelet aggregation is an all-or-none type of response in which all the platelets are activated simultaneously. In the setting of an all-or-none event, it is unlikely that factors released from aggregating platelets will have material impact on the same population of platelets that have been committed to aggregation. Rather, it is much more likely that autocrine factors elaborated from activated platelets will have a more profound impact on subsequent populations of platelets that approach a site of arterial injury. This latter process is known as platelet recruitment, and its recognition has shed important light onto the autocrine behavior of platelet aggregation. If one studies both platelet aggregation and the formation of ROS in real time, the release of ROS and RNS occurs near the end of the aggregation process (260). This observation reinforces the notion that reactive species from platelets may have a more profound impact on platelet recruitment rather than aggregation. The relation between ROS and platelet recruitment has recently been examined. In washed platelets, the release of O2 in response to collagen appears to be due to NAD(P)H oxidase, and inhibition of this signal is associated with a marked reduction in platelet recruitment to a growing thrombus (503). Other agonists are also associated with platelet O2 production. For example, ADP-stimulated

84 OCTOBER 2004



platelets exhibit O2 production that may, in part, be due to eNOS, as a large part of this signal is lost in platelets from mice lacking the NOS-3 gene (261). In the context of atherosclerosis and its associated increase in ambient O2 , one would expect platelet recruitment to also be enhanced by the vascular ux of O2 . 3. RNS and platelet aggregation With regard to a role of RNS, the effect of NO on platelet aggregation is the best characterized. This information is derived from long-standing knowledge that an endothelium-derived product inhibits the adhesion and aggregation of platelets to the endothelial surface (23). Once the identity of endothelium-derived relaxing factor was established as NO, it was rather straightforward to demonstrate that endothelial-derived NO limits the adhesion and aggregation of platelets (748). These observations were completely consistent with previous data indicating that NO donors inhibited platelet aggregation in a cGMP-dependent manner (618). A large body of work has demonstrated that authentic NO activates the plateletsoluble isoform of guanylyl cyclase, increasing cGMP and resulting in reduced intracellular calcium (619) and inactivation of the thromboxane receptor (1011). Both of these effects act to inhibit the aggregation and adhesion of platelets. In addition to NO, ONOO has been investigated with regard to its effects on platelets. In fact, the action of ONOO is complex. In washed platelets, ONOO induces aggregation and even reverses any inhibitory effects of NO donors (637). In contrast, the presence of plasma transforms ONOO into an inhibitor of platelet aggregation (637). These divergent results are likely due to ONOO reaction with plasma constituents. In the presence of proteins and low-molecular-weight thiols, ONOO is a potent nitrosating agent that can form S-nitrosothiols (45) that, as discussed above, possess biologic activity similar to authentic NO (430). Up to this point, we have restricted our discussion to RNS that are external to the platelet. However, platelets themselves are capable of producing RNS as they contain isoforms of NOS (615, 801). During the aggregation response, platelets produce NO (579) that has modest autocrine implications, as inhibition of platelet NO synthesis by treatment with NG-nitroarginine methyl ester enhances aggregation only by 10 15% (262). In contrast, the recruitment of subsequent platelets is markedly enhanced if aggregation-induced NO production by platelets is inhibited (262). These observations may be clinically relevant as the bioactivity of platelet-derived NO is also altered in the setting of atherosclerosis and its risk factors. For example, patients with acute coronary syndromes have impaired platelet NO production compared with individuals without active atherosclerosis (264). In
Physiol Rev VOL

terms of atherosclerosis risk factors, impaired platelet NO bioactivity has been described in association with essential hypertension (116) and smoking (425). Thus considerable data indicate that platelet NO production is involved in the regulation of platelet aggregation and, more importantly, platelet recruitment to a growing thrombus. One implication of the data demonstrating plateletderived NO production involves its reaction with O2 . In particular, data demonstrating that O2 enhances platelet aggregation and recruitment must be interpreted with some caution. Because platelets produce NO during aggregation, and platelet-derived NO inhibits platelet recruitment (262), it is possible that the major effects of O2 on platelets is related to its ability to quench the bioactivity of NO (44). Indeed, treatment of aggregating platelets with SOD enhances platelet-derived NO, and inhibition of NO production boosts aggregation-induced O2 production (259, 260). These observations underscore the notion that NO bioactivity is tightly linked to ambient levels of O2 . III. OXIDATIVE MODIFICATION HYPOTHESIS OF ATHEROSCLEROSIS A. Original Hypothesis In 1989, Steinberg et al. (882) proposed the original oxidative modication hypothesis of atherosclerosis, based on the hypothesis that oxidation represents a biologic modication analogous to the chemical modications discovered by Brown and Goldstein that give rise to a foam cell (see sect. IIIB1). Accordingly, oxidized LDL contributes to atherogenesis by 1) aiding the recruitment of circulating monocytes into the intimal space, 2) inhibiting the ability of resident macrophages to leave the intima, 3) enhancing the rate of uptake of the lipoprotein leading to foam cell formation, and 4) being cytotoxic, leading to loss of endothelial integrity (743). The latter property was proposed to provide the link between fatty streak formation due to lipid inltration and the progression of the fatty streak to more advanced lesions according to the response-to-injury hypothesis of atherogenesis (882). As such, a key feature of the oxidative modication hypothesis is that it no longer presupposed the loss of endothelial cells as an initiating event in atherogenesis. B. Evidence in Support of the LDL Oxidation Hypothesis 1. LDL does not support foam cell formation Although macrophages were identied as the predominant cell type that gives rise to foam cells, early

84 OCTOBER 2004



atherosclerosis research was hampered by observations that LDL particles did not appear to be atherogenic in vitro as macrophages incubated with LDL failed to internalize excess lipoprotein-cholesterol due to downregulation of the LDL receptor (316). Thus foam cell formation did not appear to be mediated by the LDL receptor, a fact consistent with the occurrence of atherosclerosis in patients with familial hypercholesterolemia, who lack functional LDL receptors. In a search for alternative receptors, Goldstein et al. (317) observed that acetylation of LDL leads to extensive macrophage cholesterol uptake and foam cell formation. This phenomenon is mediated by a saturable, specic receptor later termed the acetyl-LDL receptor (317). It is now known that this receptor is one of many so-called scavenger receptors present on macrophages and other cell types (501). The original description of the acetyl-LDL receptor did acknowledge that there was no known means of LDL acetylation in vivo (317). However, Brown and Goldstein did speculate that other, as yet unknown, modications of LDL could facilitate its recognition by this acetyl-LDL receptor. Approximately two years later, Henriksen et al. (395) found that LDL incubated with endothelial cells did serve as a ligand for macrophage foam cell formation. Considerable work has since established that several receptors on macrophages and other cells function as scavenger receptors (500). The original acetyl-LDL receptor has been identied and exists in two forms known as scavenger receptors A1 and A2 (493). Other receptors such as CD68, CD36, SR-B1, and LOX-1 are also known to possess properties similar to the classic scavenger receptors (500). 2. Oxidative modications in atherosclerotic lesions In studies dating back half a century, it was recognized that oxidation represented a chemical modication occurring in atherosclerosis. However, this recognition of oxidative modications was limited originally to that of lipids, and it was not linked to the formation of foam cells until 1984, when it was realized that conversion of LDL into a high-uptake form via incubation with endothelial cells was associated with oxidation of the lipoprotein (886). A) LIPID OXIDATION. Using direct chemical tools for analysis, early studies clearly established the presence of oxidized lipids in human atherosclerotic lesions (95, 128, 304, 307, 361). Approximately half a century ago, Glavind et al. (307) reported that the content of peroxides in a chloroform extract prepared from human diseased aorta strongly correlated with the degree of atherosclerosis, whereas normal arteries did not contain lipid peroxides. As a result, these authors suggested lipid peroxidation was either secondary to the deposition of lipids or played an active role in the pathogenesis of atherosclerosis.
Physiol Rev VOL

I) Fatty acid oxidation products. Several different types of fatty acid oxidation products have been reported to be present in human atherosclerotic lesions. Of these, hydroxy products of linoleic acid or hydroxyoctadecaenoic acids (HODEs) were the rst to be detected (94, 360, 938). These, together with hydroxyeicosatetraenoic acids (HETEs or hydroxy fatty acid oxidation products of arachidonic acid), are the most abundant type of oxidized lipid in atherosclerotic lesions (128, 915, 1006). Most of these products are present as cholesterol esters (507, 915). This is not surprising given that cholesteryllinoleate and cholesterylarachidonate are the major, readily oxidizable lipid in LDL (234), and LDL is the major source of lipids that accumulate during atherosclerosis. As judged by stereospecic analysis, most esteried and nonesteried HODEs are derived from nonenzymatic oxidation reactions (251, 966, 1006). This is consistent with the observation that during lipoxygenase-mediated LDL oxidation, enzymatic oxidation reactions are quickly superceded and dominated by nonenzymatic oxidation reactions (396). In addition, most of the esteried HODEs in human atherosclerotic lesions are generated in the presence of -TOH, as judged by their regioisomeric distribution (966) (Fig. 6). Human atherosclerotic lesions also contain oxo-octadecaenoic acids (507, 916, 1006) and F2-isoprostanes (308, 731), the latter representing secondary radical oxidation products of arachidonic acid (642). However, these lipid oxidation products generally occur at concentrations 20- to 40-fold lower than those of HODEs and HETEs (580, 1006). II) Oxysterol. Like fatty acids, cholesterol can undergo enzymatic and nonenzymatic oxidation to a range of oxysterols, and a number of studies reported the presence of oxysterols in organic extracts of human aortas (reviewed in Ref. 97). The product of mitochondrial 27hydroxylase, i.e., 27-hydroxycholesterol (previously also referred to as 26-hydroxycholesterol), is the most abundant oxysterol in atherosclerotic lesions (861) and human macrophage foam cells (602). Its concentration increases in parallel with that of cholesterol and increasing severity of atherosclerosis (127, 861, 966), suggesting that 27-hydroxycholesterol may be produced by cells in atherosclerotic lesions in response to cholesterol accumulation (97). After 27-hydroxycholesterol, 7-ketocholesterol is the next most abundant oxysterol in advanced human atherosclerotic lesions, followed by 7 - and 7 -hydroxycholesterol. The latter three oxysterols are generally considered to be nonenzymatic oxidation products derived from dietary sources or generated in vivo. Other oxysterols present in human lesions include 7 -hydroperoxycholesterol that may represent a major cytotoxin (151). Oxysterols appear to concentrate in foam cells (602), although with the exception of 27-hydroxycholesterol, their tissue concentrations do not generally parallel disease severity (127).

84 OCTOBER 2004



Oxysterols are predominantly present in esteried form (98), as mono- and diesters, for presently largely unknown reasons. However, despite their presence, there is no direct evidence in humans that oxysterols contribute to atherosclerosis (97). B) PROTEIN OXIDATION. In addition to lipid oxidation, there is also good evidence for protein oxidation in human atherosclerotic lesions (for reviews, see Refs. 276, 384). Such evidence comes principally from studies employing either immunohistochemical methods based on antibodies that recognize protein-bound oxidation products, or analytical methods such as high-performance liquid chromatography or gas chromatography/mass spectrometry. The initial documentation for the presence of oxidized proteins including LDLs apolipoprotein B-100 in human lesions comes from immunohistochemical studies (see sect. IIIB3). While this approach provides important information on the location of oxidized proteins, its disadvantages include the potential interference from structurally related molecules and its semi-quantitative nature. On the other hand, the analytical methods used offer quantitative information and high specicity, although they generally do not provide information on the location of the oxidized proteins. In general, the types of protein oxidation observed in atherosclerotic lesions are similar to those observed during in vitro oxidation of LDL. As mentioned earlier, oxidative damage to proteins may result from electrophilic (2e-) and radical (1e-) reactions, e.g., initiated by electron leakage, metal-ion-dependent reactions, autoxidation of lipids and sugars, and breakdown products of lipid oxidation. The products include several reactive species such as hydroperoxides and protein-bound reductants (notably dopa), as well as compounds that retain the initial oxidant as a covalent adduct (190). The latter are commonly formed as a result of proteins undergoing electrophilic addition and substitution reactions, or radicalradical recombination reactions that give rise to specic markers of oxidative damage, indicative of the oxidant(s) involved (see sect. IIB). Compared with normal arteries, human carotid endarterectomy samples contain higher concentrations of several amino acid oxidation products (i.e., dopa, o-tyrosine, m-tyrosine, hydroxyleucine, and hydroxyvaline) indicative of OH-mediated protein oxidation (276). In addition, such lesions contain elevated levels of o,o -dityrosine suggestive of the involvement of HOCl-mediated reactions (276). The latter notion supports an earlier nding that atherosclerotic lesions contain increased concentrations of chlorotyrosine, thought to represent a characteristic marker for myeloperoxidase-mediated oxidation reactions (377). However, limited information is available regarding the relationship between the accumulation of markers of oxidized proteins and severity of atherosclerosis. Upston et al. (966) reported the absence of a clear
Physiol Rev VOL

disease stage-dependent accumulation of several amino acid oxidation products, except dityrosine, although the study did not exclude the possibility that specic tyrosine modications may be early disease events (966). 3. Oxidized LDL is present in atherosclerotic lesions If oxidized LDL is a required feature of atherosclerosis, it stands to reason that one should be able to detect this form of LDL in atherosclerotic lesions. The rst approach to this issue utilized antibodies that recognize epitopes on oxidized LDL that are not present in its native, nonoxidized form. The oxidation of polyunsaturated fatty acids can lead to the formation of aldehydes that modify lysine residues in apolipoprotein B-100 (see Ref. 234 and sect. IIID). Adducts of lysine residues with malondialdehyde and 4-hydroxynonenal have been characterized extensively and antibodies raised against them. These antibodies avidly stain atherosclerotic lesions in LDL receptor-decient rabbits (82, 348), apolipoprotein E-decient mice (694), and humans (695, 1089) with no demonstrable staining in normal arteries. As the oxidative modication hypothesis would predict, these epitopes largely colocalize with macrophages (348), although one might also argue they are not specic for LDL and could represent modication of other proteins in the atherosclerotic lesion. Inconsistent with this possibility, however, is a study showing that LDL isolated from atherosclerotic lesions possesses properties that resemble those of oxidized LDL formed in vitro (1089). Furthermore, LDL isolated from human atherosclerotic lesions contains elevated levels of chlorotyrosine (534) and o,o -dityrosine (377), as assessed by gas chromatrography-mass spectrometry. These ndings demonstrate that lesion LDL is oxidatively modied, and they suggest that HOCl is a likely oxidant participating in these modication reactions. Indeed, there is antibody-based evidence that apolipoprotein B-100-containing lipoproteins of human atherosclerotic lesions are modied by HOCl (368), and lesion lipoproteins contain high ratios of 3,5-dichlorotyrosine to 3-chlorotyrosine (966), indicative of local HOCl production, as would be expected if active myeloperoxidase binds to LDL (133). 4. Circulating oxidized LDL LDL circulates in plasma, and a portion traverses the subendothelial space to arrive back in the circulation (820, 821). The plasma content of antioxidants provides potent protection against oxidation (269) and, as a consequence, the putative site of LDL oxidation is the subendothelial space. One might expect the transit of LDL across this space to yield small amounts of circulating LDL that is oxidized. Indeed, chemical analysis of circulating LDL has been reported to yield a minor fraction, termed LDL that exhibits an enhanced content of oxiwww.prv.org

84 OCTOBER 2004



dized lipid (830). Consistent with these ndings, human plasma contains immunoreactivity towards epitopes generated from oxidized LDL (409b, 693). However, the existence of oxidized LDL in the circulation remains controversial on the basis of potential artifacts that may occur during the ex vivo handling of plasma and isolation of LDL. Although the aforementioned data do not address a causal relation between oxidized LDL and atherosclerosis, several studies have shown that circulating levels of oxidized LDL epitopes can be used to distinguish between patients with and without clinically evident atherosclerosis (409a 409d). Using immunologic methods that detect oxidized phosphatidylcholine [including 1-palmitoyl-2-(9oxononanoyl)phosphatidylcholine] and their protein adducts (441), but not native, acetylated, or malondialdehdye-treated LDL, Ehara and co-workers (221, 222) also reported that acute coronary syndromes are characterized by increased circulating levels of oxidized LDL. Together, these data indicate that relatively small amounts of LDL containing different types of oxidation-specic epitopes can be detected in the blood and may reect atherosclerosis and its different manifestations. What is less clear at present is where these epitopes originate from and which, if any, of the different oxidation-specic epitopes directly relate to and/or are important for disease burden (959). 5. Autoantibodies to oxidized LDL If oxidative modications of apolipoprotein B-100 resulted in the formation of neoepitopes, one might expect them to be immunogenic, and this expectation has proven true (697). Oxidized LDL is immunogenic. A large number of epitopes within the apolipoprotein B-100 component of oxidized LDL have been identied that provoke an immune response (257), and autoantibodies against malondialdehyde-modied lysine residues have been demonstrated in the serum of both rabbits and humans (695). Some studies have reported that the titer of these autoantibodies is associated with the burden of and may predict progression of atherosclerosis (574, 795) and myocardial infarction (232, 1066). Higher titers of autoantibodies have also been associated with coronary artery disease (105), peripheral atherosclerosis (56), and higher risk for restenosis following balloon angioplasty (299). In addition, there is support for a role for antioxidized autoantibodies in animal atherosclerosis. For example, circulating titers of autoantibodies to oxidized cardiolipin correlate with the extent of atherosclerosis in apolipoprotein E-decient mice (732). In LDL receptor-decient mice fed an atherogenic diet, serum titers of autoantibodies increase over time and correlate with both the extent of blood cholesterol and lesion size (696) and the aortic content of oxidized LDL. Autoantibodies against oxidized
Physiol Rev VOL

phospholipid epitopes, present either as lipids or as lipidprotein adducts, may directly affect atherosclerosis by inhibiting macrophage uptake of oxidized LDL (412). In support of this contention, immunization with apolipoprotein B-100 peptides against which high levels of antibodies are present in healthy humans, reduces atherosclerosis in apolipoprotein E-decient mice (258). It is worth noting here, however, that the above-mentioned correlations between atherosclerosis and cardiovascular disease burden on the one hand and circulating levels of oxidized LDL epitopes and autoantibodies to oxidized LDL on the other hand are not observed consistently (see sect. IIIF1C) and also not immediately consistent with biochemically assessed oxidant markers and the extent of atherosclerosis (see sect. IIIC). 6. Potential proatherogenic activities of oxidized LDL In addition to its activity to support foam cell formation, oxidized LDL also has a number of other potential proatherogenic properties (Table 8). Endothelial cell activation is among the early events of atherosclerosis, and products of oxidized LDL facilitate this process (480, 511). Once oxidized, LDL increases its substrate suitability for sphingomyelinase, an enzyme that promotes LDL aggregation thereby enhancing its macrophage uptake (813). The initial oxidation of LDL and formation of what is often referred to as minimally modied LDL stimulates adjacent endothelial cells and smooth muscle cells to synthesize and secrete monocyte chemotactic protein-1 (754) that is thought to facilitate the recruitment of monocytes into the arterial wall (659, 1087). This activity of minimally modied LDL is contained in its lipid fraction

8. Potential proatherogenic activities of oxidized LDL

Oxidized LDL supports macrophage foam cell formation. Oxidized LDL-derived products are chemotactic for monocytes and T cells and chemostatic for tissue macrophages. Oxidized LDL-derived products are cytotoxic and can induce apoptosis. Oxidized LDL is mitogenic for smooth muscle cells and macrophages. Oxidized LDL alters inammatory gene expression in vascular cells. Oxidized LDL can increase expression of macrophage scavenger receptors. Oxidized LDL is immunogenic and elicits autoantibody formation and activated T cells. Oxidized LDL may undergo aggregation, which independently leads to enhanced uptake. Oxidized LDL is a substrate for sphingomyelinase, which aggregates LDL. Oxidized LDL induces tissue factor expression and platelet aggregation. Products of oxidized LDL impair NO bioactivity. Oxidized LDL binds C-reactive protein activating the complement pathway. [Adapted from information provided in Tsimikas and Witztum (960).] www.prv.org

84 OCTOBER 2004



(1018). The importance of monocyte chemotactic protein-1 for atherosclerosis is highlighted by the observation that mice decient for the protein (323) or its receptor (72) show attenuated disease development. The formation of oxidized LDL in the subendothelial space can also facilitate atherogenic progression. There are dual activities of oxidized LDL that could enhance the arterial content of inammatory cells. For example, and as pointed out earlier, oxidized LDL is chemotactic for monocytes (742) and T lymphocytes (611) by virtue of its content of lysophosphatidylcholine, formed during oxidation (886). In addition, oxidized LDL is chemostatic for macrophages (742). Thus the enhanced entry and impaired egress of inammatory cells would be expected to stimulate arterial inammation, a process strongly implicated in atherosclerosis (556). Finally, oxidized LDL limits the biologic activity of endothelium-derived NO (505), and the loss of NO bioactivity is associated with increased inammatory cell entry into the arterial wall (504). The gene expression pattern in the arterial wall is also subject to inuence by modied forms of LDL. For example, minimally modied LDL as well as oxidized LDL can induce macrophages to express scavenger receptor, thereby enhancing foam cell formation and lipoprotein uptake (622). A number of genes associated with inammation are also upregulated by oxidized LDL such as monocyte chemotactic protein-1, serum amyloid A, ceruloplasmin, and heme oxygenase-1 (552). In addition, a recent discovery is the stimulating effect of oxidized LDL on macrophage expression of peroxisome proliferator activated receptor- . This has been shown to alter scavenger receptor (CD36) expression and the expression of proinammatory genes (244). Thus oxidized LDL has a number of biologic activities that could, in theory, contribute to the process of atherosclerotic lesion formation. 7. Scavenger receptors and atherosclerosis The oxidative modication hypothesis holds that LDL recognition by the scavenger receptor is a prerequisite for foam cell formation. This notion is supported by considerable experimental evidence. Mice lacking the scavenger receptor-A gene demonstrate a defect in the binding and degradation of modied LDL (500). In mice lacking the apolipoprotein E gene, deletion of the scavenger receptor A confers resistance to atherosclerosis (925). Similarly, macrophages derived from mice lacking the CD36 scavenger receptor demonstrate reduced uptake of modied LDL (676) and reduced atherosclerosis when crossed with the apolipoprotein E-decient mouse (243). These data are consistent with a critical role of scavenger receptors in early atherosclerosis.
Physiol Rev VOL

8. Antioxidant studies If one accepts the notion that LDL oxidation is an essential feature of atherosclerosis, then inhibiting LDL oxidation should limit atherosclerosis. This concept has been tested primarily in animals with a number of structurally distinct antioxidant compounds that can inhibit LDL oxidation in in vitro assays. In the following paragraphs, we will briey touch upon this body of evidence with particular attention to the specic antioxidant compounds that have been tested. Arguably the strongest evidence in support of antioxidant compounds providing protection against atherosclerosis comes from studies with probucol (594). Probucol is a synthetic cholesterol-lowering drug that also possesses antioxidant activity (590, 709). The lipophilic drug associates with and effectively protects LDL against in vitro oxidation induced by copper ions (489, 709), although it is a sterically hindered phenol, and its peroxyl radical scavenging activity is only 16% of that of -TOH (737). Early studies with probucol demonstrated inhibition of atherosclerosis in rabbits (502, 937) and monkeys (1050). Kita et al. (489) treated Watanabe heritable hyperlipidemic (WHHL) rabbits with probucol and observed an 87% reduction in lesion area and LDL resistance to oxidation compared with those animals not treated with probucol. These ndings prompted the authors to conclude the reduction of atherosclerosis was due to the antioxidant effect of probucol; however, probucol also produced a 17% reduction in serum cholesterol. Carew et al. (125) controlled for the cholesterol-lowering effect of probucol with lovastatin, an inhibitor of 3-hydroxy-3methylglutaryl coenzyme A reductase. Similar reductions in total cholesterol were observed with lovastatin and probucol; however, the latter provided an additional 48% reduction in atherosclerosis (125), suggesting that probucol inhibited atherosclerosis due to its antioxidant activity. This contention was supported in a study with modied WHHL rabbits treated with a structural analog of probucol devoid of cholesterol-lowering properties (583). Both probucol and the analog inhibited LDL oxidation and reduced atherosclerosis, suggesting an antioxidantmediated mechanism for reduced lesion formation. Subsequent studies in primates (800), cholesterol-fed rabbits (834), and hamsters (704) have also demonstrated a reduction in atherosclerosis with probucol. The situation appears more complex in murine models of atherosclerosis, where probucol promotes atherosclerosis in the aortic root (61, 630, 1104) but inhibits disease formation at more distal sites (1054). There have been two studies testing the antiatherosclerotic activity of probucol in humans. The Probucol Quantitative Regression Study (PQRST) reported probucol to be ineffective in attenuating lumen loss in the

84 OCTOBER 2004



femoral arteries in hypercholesterolemic subjects over 3 years, as assessed by quantitative angiography (1010). Importantly however, this method does not directly assess disease burden (see sect. IVA). In contrast, the Fukoaka Atherosclerosis Trial (FAST) observed probucol to signicantly decrease atherosclerosis progression in the carotid artery of hypercholesterolemic patients, as assessed by the intima-to-media thickness determined by B-mode ultrasound (808). In humans, probucol (934, 935) and a probucol analog with one of its two phenol moieties present as succinate ester (935), also protect against restenosis after percutaneous coronary intervention. A number of other antioxidants have also been tested for their ability to inhibit atherosclerosis in animal models of the disease. N,N -diphenyl-phenylenediamine (DPPD) is an aniline compound that attenuates atherosclerosis in the aorta of cholesterol-fed rabbits (865), and similar ndings have been reported in a murine model of atherosclerosis (932). In addition, 2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran (BO-653), a synthetic antioxidant with structural components of vitamin E (673), inhibits atherosclerosis in both rabbit and murine models (174). Similarly, 3,3 ,5,5 -tetrabutyl-1,1 -biphenyl4,4 -diol, a lipophilic bisphenol, inhibits atherosclerosis in mice decient in apolipoprotein E and the LDL receptor (1056). Furthermore, supplementation of the diet with butylated hydroxytoluene reduces atherosclerotic lesions in cholesterol-fed rabbits (64, 271). A common feature of all of these compounds is that they can inhibit LDL oxidation in vitro. Thus a number of lipid-soluble, synthetic antioxidants have been used to demonstrate an association between a reduction in atherosclerosis and ex vivo inhibition of LDL oxidation. The effect of vitamin E on atherosclerosis in animals and cardiovascular disease in humans is discussed in section IIIF. C. LDL Oxidation As we have learned, there is now convincing evidence that oxidatively modied LDL exists in atherosclerotic lesions, yet it remains largely unknown where precisely within the vessel wall, how, and to what extent, LDL becomes oxidized during atherogenesis. In addition to intrinsic properties of the lipoprotein, factors that prolong the life/residence time of LDL may also be conducive to oxidation. For example, proteoglycans not only trap LDL in the extracellular matrix of the intimal space, but also change the conformation of apolipoprotein B-100 (120), and such proteoglycan-exposed LDL shows greater sensitivity than native LDL to subsequent in vitro oxidative modication by Cu2 (121, 422) but not other oxidants (967). It is generally upheld (882) that LDL oxidation must occur in the arterial wall rather than the circulation, as
Physiol Rev VOL

lipoprotein lipids in plasma are well protected from oxidation due to the robust antioxidant defenses (897). It is noteworthy that LDL itself contains and in fact is the major transport vehicle for most of the plasma -TOH. Furthermore, oxidized lipoproteins that may exist or form in plasma are diluted rapidly by either hepatic clearance (976) or accumulation and subsequent degradation in the arterial wall (460). Consistent with this, the plasma concentrations of oxidized LDL, as assessed by immunologic techniques, and oxidized lipids, determined by analytical techniques, in healthy humans are extremely low (895). For example, LOOH are present in the low nanomolar range, and there is no evidence that they are specically associated with LDL (80). The situation is similar in patients with severe cardiovascular disease. Plasma of these subjects shows signs of mild oxidative stress, not damage, as indicated by a slightly elevated proportion of ubiquinone-10 to total coenzyme Q (157, 514), and the decreased concentrations of ascorbate (1001). Apart from these minor differences, concentrations of antioxidants and oxidant markers do not correlate with the extent of atherosclerosis (1001). In sharp contrast to the plasma situation, and as we have seen, atherosclerotic lesions contain substantial amounts of oxidized lipid. Despite this however, homogenates of advanced human plaque also contain ascorbate, uric acid, and -TOH in quantities comparable to human plasma (see sect. IIIF), sufcient to efciently block LDL oxidation in vitro (269). 1. Putative oxidants involved Much research has concentrated on modeling LDL oxidation mediated by putative physiological oxidizing species, including cells, in the presence of various antioxidants. In vitro, LDL oxidation is initiated by a variety of oxidants including 1e-oxidants (i.e., radical) and 2e-oxidants (i.e., nonradical). Many studies have attempted to determine the oxidants contributing to oxidative processes in atherosclerotic lesions. In most cases, the approach chosen has been indirect. This is not surprising, given the labile nature of most of the biologic oxidants potentially involved. In the case of human atherosclerotic lesions, a common biochemical approach has been to rst chemically dene the footprint of products of a particular oxidant with target molecules (see sect. IIB) and to then analyze vessels and materials derived from them for the presence of these footprints. With the advent of murine models of atherosclerosis, molecular approaches such as the use of animals decient in a specic oxidantforming enzyme have been utilized increasingly. Together, these studies have provided useful insight into the origin and nature of the oxidative modications taking place during atherogenesis. For example, there is now convincing evidence for the participation of myelowww.prv.org

84 OCTOBER 2004



peroxidase and oxidants derived from this enzyme. Other oxidants, both enzymatic and nonenzymatic, have also been suggested to be involved. However, the approaches taken all have their limitations. For example, not in all cases has it been possible to localize the oxidative modication to LDL or even lipoproteins. Also, while the analysis of human atherosclerotic material provides direct information on the human disease, in most cases such information represents a snapshot of a single or few time points of what represents a disease developing over decades. In contrast, animal studies provide the possibility to follow changes over disease progression, or regression, yet suffer from the limitation that there is no single animal model in which atherosclerosis truly reects the human pathogenesis. This may be reected, for example, in differences in the activity of a particular oxidant-producing enzyme (e.g., myeloperoxidase) in human versus animal atherosclerotic lesions so that manipulation of such enzyme in the animal model does not necessarily provide useful information about human atherosclerosis. A further limitation of animal models is that interventions are commonly carried out before substantial disease has developed, whereas in humans, interventions mostly engage subjects with established atherosclerosis. Keeping these limitations in mind, let us now review the evidence for and against the involvment of different ROS and RNS in oxidative modications in atherosclerosis. A) SUPEROXIDE ANION RADICAL. Since the early discovery by Henriksen et al. (395), vascular cells including endothelial and smooth muscle cells and macrophages have attracted much attention as sources of oxidants, as they all can oxidize LDL to a form recognized by the acetyl LDL receptor. As described in section IIC, vascular cells contain NAD(P)H oxidases capable of generating O2 , and recent data suggest that Nox isoforms may have a role in atherosclerosis. For example, early atherosclerosis in Watanabe hyperlipidemic rabbits (that lack an LDL receptor) is associated with excess vascular production of O2 due to NAD(P)H oxidase activity (1015). Consistent with this observation, diet-induced atherosclerosis in primates is associated with excess vascular O2 and upregulation of p22phox (cytochrome b-245 alpha polypeptide, CYBA) and p47phox (neutrophil cytosolic factor 1, NCF1), two features that abate with regression of atherosclerosis through dietary cholesterol lowering (363). However, a causal role for NAD(P)H oxidase in atherosclerosis is controversial. Mice lacking gp91phox (Nox2) have no demonstrable difference in either the apolipoprotein E / or diet-induced models of atherosclerosis (484). Two studies have examined the effect of p47phox on atherosclerosis in the apolipoprotein E / model (41, 413). Both observed no difference in atherosclerosis at the level of the aortic sinus as a function of p47phox status; however, one study examined atherosclerosis in the descending aorta and found that p47phox / animals had considPhysiol Rev VOL

erably less atherosclerosis than their p47phox / counterparts (41). Recent studies in human tissue suggest that Nox isoforms are involved in atherosclerosis. Vascular production of O2 increases as a function of risk factors for disease (346), suggestive of NAD(P)H oxidase playing a role in the disease. Atherosclerotic lesions contain abundant p22phox and gp91phox in the vicinity of macrophages that correlated with the severity of atherosclerosis (463, 864). In contrast, Nox4 was found exclusively in nonphagocytic cells, and it did not vary with atherosclerotic lesions. Analysis of tissue in patients undergoing bypass surgery revealed that diabetes is characterized by increased expression of p22phox, p47phox, and p67phox (neutrophil cytosolic factor 2, NCF2), compared with nondiabetics (345). Given that diabetics have disproportionably more cardiovascular events than nondiabetics, these data suggest that NADPH oxidase activity has a role in the clinical expression of atherosclerosis. However, the specic contribution of each Nox isoform to atherosclerosis and the clinical expression of cardiovascular events remain to be determined. In addition to NAD(P)H oxidases, xanthine oxidase has been implicated in endothelial cell O2 production in experimental models of hypercholesterolemia. Cholesterol-fed rabbits exhibit an increase in endothelial O2 production that is inhibited by oxypurinol (680), a xanthine oxidase inhibitor. This increased O2 ux from xanthine oxidase contributes to impaired endothelial NO bioactivity in the setting of hypercholesterolemia (123, 680), heavy smoking (343), and coronary artery disease (866), although the regulation of endothelial xanthine oxidase is not entirely clear. Some evidence suggests that endothelial xanthine oxidase activity is increased in response to interferon- (216) or the binding of neutrophils to the endothelial surface (1008). Other data suggest that endothelial xanthine oxidase is actually located extracellularly and derived from a circulating pool of enzyme that is increased in the setting of hypercholesterolemia (1031). More recently, evidence has been presented suggesting that NAD(P)H oxidase maintains endothelial cell xanthine oxidase and that xanthine oxidase is responsible for increased ROS production in response to oscillatory shear stress (612). Oscillatory shear stress occurs at sites of the circulation that are vulnerable to atherosclerosis, although a direct role for xanthine oxidase in atherosclerosis has not been investigated to date. It is also possible that eNOS contributes to cellular O2 in the setting of vascular disease, because hypercholesterolemia (735), atherosclerosis (524), diabetes (400), and hypertension (520) have all been associated with eNOS uncoupling. Moreover, animals that serve as models of atherosclerosis and that have been treated with tetrahydrobiopterin or its precursor exhibit a decrease in vascular O2 and enhancement of NO bioactivity (346,

84 OCTOBER 2004



524). Tetrahydrobiopterin also improves endothelium-dependent vasodilation in chronic smokers (387). Thus considerable evidence exists for eNOS-derived O2 production, although the precise mechanism(s) responsible for this phenomenon and how it relates to atherosclerosis remains unknown. As indicated above, the specic role of O2 in oxidative modication during atherosclerosis, particularly that related to LDL oxidation, remains unclear. Consistent with its relative chemical reactivity, O2 is not able to oxidize LDL, in contrast to its protonated form, the hydroperoxyl radical (HO2 ) (48). However, at physiological pH only a fraction of O2 produced is present as HO2 . This suggests that O2 -generating systems, including NAD(P)H oxidases, are by themselves not efcient in oxidizing LDL (48), a notion conrmed experimentally for macrophages (289, 448), although superoxide has been proposed as a mediator of LDL oxidation by endothelial cells (883). However, O2 may act as the precursor for chemically more reactive oxidants, such as ONOO and H2O2 and oxidants derived from them, and these may participate in LDL oxidation in the vessel wall. B) RNS. Using a sensitive and specic method involving gas chromatography and mass spectrometry, Leeuwenburgh et al. (533) reported LDL from aortic atherosclerotic intima to contain 90-fold higher levels of proteinstandardized 3-nitrotyrosine than plasma LDL. This is consistent with an earlier study reporting increased tyrosine nitration in atherosclerotic lesions based on an immunological approach (47) and implicates RNS in the oxidation of LDL and other targets in the vessel wall. In addition to eNOS, inducible NOS is expressed in atherosclerotic lesions of humans (114) and rabbits (567), providing potential sources for RNS. Although commonly assumed, the presence of 3-nitrotyrosine in human lesions does however not prove the involvement of ONOO . The reason for this is that 3-nitrotyrosine is also formed from the reaction of NO with HOCl (1048) or tyrosine phenoxyl radicals (341). In biological samples, ONOO and myeloperoxidase leave similar footprints with regard to protein nitration (479). Indeed, the myeloperoxidase/H2O2/nitrite system modies LDLs apolipoprotein B-100 and lipids, probably via formation of NO2 (115, 723), and such modied LDL can convert macrophages into foam cells (723). In addition, in vitro reaction of nitrite with HOCl gives rise to nitryl chloride (NO2Cl) that can chlorinate and nitrate protein tyrosine residues (226), as well as oxidize LDL lipids (699), although the biological signicance of this is not clear. C) MYELOPEROXIDASE. The role of myeloperoxidase and myeloperoxidase-derived oxidants in atherosclerosis has been reviewed recently (384, 720). Heinecke and co-workers (184) were the rst to report the presence of active myeloperoxidase in human atherosclerotic lesions. The
Physiol Rev VOL

involvement of myeloperoxidase activity in oxidation reactions taking place during atherogenesis in humans is also supported by the detection of footprints of myeloperoxidase/HOCl, including HOCl-modied proteins (368), 3-chlorotyrosine (377), p-hydroxyphenylacetaldehyde (375), and p-hydroxyphenylacetaldehyde-ethanolamine (391). The potentially important nding of myeloperoxidase activity has been conrmed for lesions in humans (368, 581, 917), Watanabe heritable hyperlipidemic rabbits (85), and rabbits fed a high-cholesterol diet (582). In contrast, active myeloperoxidase appears to be absent in atherosclerotic lesions in LDL receptor / and in apolipoprotein E / mice (90), and therefore is not likely to contribute to atherogenesis in these animal models. This highlights one of the limitations of using animal models to study the pathogenesis of the human disease. It suggests that myeloperoxidase-decient mice are not suitable to evaluate the potential role of this protein in human atherogenesis. Mice overexpressing myeloperoxidase may be a more useful tool for this purpose. Hypochlorite-modied LDL is potentially proatherogenic (132). In vitro studies have shown that HOCl-modied LDL can stimulate macrophage foam cell formation (371) via binding to class B scavenger receptors (589), increases leukocyte adherence and migration into blood vessels (555), increases ROS production by leukocytes (499), and has chemotactic activity for neutrophils (but not monocytes) (1061). Myeloperoxidase may oxidize LDL via reactive amino acid intermediates, such as the tyrosyl radical (806), p-hydroxyphenylacetaldehyde (391), or -hydroxy aldehydes (466). In addition, myeloperoxidase-derived HOCl may convert LDL into a high-uptake form of the lipoprotein via reaction with apolipoprotein B-100, with little oxidation of the lipids (371, 373). HOCl reacts readily with the N -amino groups of lysine residues, resulting in the formation of N-chloramines and increased negative charge of the lipoprotein particle (373). A small proportion of these chloramines break down to aldehydes (373, 1078), which may contribute to the cross-linking and aggregation of HOCl-exposed LDL. Other amino acid residues, such as cysteine and methionine, are also modied (373, 1081). Chloramines can break down to generate alkoxyl radicals that induce lipid peroxidation (370), although the overall extent of lipid oxidation, relative to protein oxidation, is small. D) LIPOXYGENASES. Several lines of evidence support a role for lipoxygenase in atherosclerosis. 15-Lipoxygenase and 5-lipoxygenase are expressed in atherosclerotic lesions of humans (1090) and apolipoprotein E / mice, respectively (613). Also, disruption of the 12/15-lipoxygenase gene or decreased expression of 5-lipoxygenase diminishes disease in apolipoprotein E / and in LDL receptor / mice (176, 298, 613). Furthermore, inhibiting 15-lipoxygenase lowers lesion formation in rabbits fed a high-fat and high-cholesterol diet (824).

84 OCTOBER 2004



There is indirect evidence in support of oxidative events in general and LDL oxidation in particular contributing to the observed link between lipoxygenase and atherosclerosis. Thus 15-lipoxygenase and epitopes of oxidized LDL colocalize in human lesions (1090), and the expression of 15-lipoxygenase in rabbit arteries results in the appearance of oxidized lipid-protein adducts (1088). Also, the plasma and urinary concentrations of isoprostanes correlate positively with 12/15-lipoxygenase activity and disease extent in apolipoprotein E / mice (175). In addition, oxidation products specic for 15-lipoxygenase have been reported to be present in lesions (251, 508), and the isolated enzyme (51), cells containing 12/15-lipoxygenase (1108), or overexpressing 15-lipoxygenase can oxidize LDL in vitro (54, 237), although the underlying mechanism for this remains unclear. Emerging evidence has heightened the interest in the contribution of lipoxygenase to atherosclerosis. Analysis of atherosclerosis-prone and atherosclerosis-resistant mice identied a region on chormosome 6 that conferred resistance to atherosclerosis despite elevated levels of lipids (614). Further analysis of this locus determined that 5-lipoxygenase was one putative gene on chromasome 6 that conferred susceptibility to atherosclerosis (613). This suspicion was conrmed through the use of mice lacking one copy of the 5-lipoxygenase gene that, when bred with LDL receptor / mice, demonstrated a dramatic decrease in atherosclerosis (613). This observation has now been extended to humans as variant 5-lipoxygenase alleles segregate with evidence of atherosclerosis by carotid imtimal-to-medial thickness measurements on ultrasound (218). Thus 5-lipoxygenase appears to be one lipoxygenase isoform that is particularly germane to the development of atherosclerosis in both experimental animals and humans. E) TRANSITION METALS. It has been known for a long time that the oxidative modication of LDL by vascular cells is absolutely dependent on the presence of low concentrations of transition metals, such as copper and iron, in the medium (reviewed in Ref. 290). For example, it can be completely prevented by the inclusion of metal chelators such as ethylenediamine tetraacetic acid or relatively small amounts of serum (that contains metal-binding proteins). This is also true for LDL oxidation induced by monocytes in which NADPH oxidase activity is stimulated by opsonized zymosan (138). In this case, iron contaminating the commercial preparations of zymosan has been shown to be required for LDL oxidation (1072). However, both monocytes (150) and neutrophils (130, 896) can oxidize LDL in metal-independent ways. Where transition metals are involved, the role of the cells appears to be to maintain the metal in the reduced form, thereby allowing it to redox cycle and to react with traces of LOOH (290, 291) (reaction 22)
Physiol Rev VOL

Mn LOOH 3 Mn




In fact, incubating LDL in serum-free medium in the presence of copper or iron ions mimics the process of cell-mediated oxidation of the lipoprotein (see sect. IIIC2). This has raised interest in the possibility that transition metals may participate in oxidative modication reactions in atherosclerotic lesions. Indeed, iron deposits are present in human lesions (1092). As pointed out earlier however, in vivo, transition metals are usually present as complexes to carrier proteins that prevent participation in inadvertent redox reactions, although it is possible that hemin (29) or hemoglobin derived from ruptured erythrocytes (690) may contribute to oxidation reactions. Macrophages that have previously phagocytosed iron-rich materials such as erythrocytes can exocytose redox-active iron that is capable of oxidizing LDL (1093). The possible contribution of transition metals to LDL oxidation during atherogenesis is supported by the presence of free transition metals in advanced human lesions (515, 859, 870). However, increasing or decreasing plasma and tissue stores of iron does not affect the formation of atherosclerotic lesions in cholesterol-fed rabbits (179). Also, in apolipoprotein E / mice, iron overload decreases lesion size despite detectable increases in hepatic concentrations of markers of oxidative events in the liver (485). Similarly, dietary supplementation with copper decreases atherosclerosis in cholesterol-fed rabbits (516), while copper deciency increases atherosclerosis in C57B mice (354). Together, these results indicate that iron and copper are not likely important catalysts for oxidation events leading to atherosclerosis and that studies using free transition metals such as Cu(II) to oxidize LDL in vitro may not be meaningful biologically. F) OTHER OXIDANTS. As indicated in section IIIB2B, there is some evidence for OH contributing to oxidative reactions in atherosclerosis based on the nding that certain hydroxylated amino acids are increased in human endarterectomy specimens (276) and in the artery wall of monkeys in early diabetic vascular disease (716). There is also a recent suggestion for a role of ozone in atherosclerosis based on the presence of cholesterol ozonolysis products in human carotid endarterectomy specimens (1028). Activation of leukocytes in arteries showing advanced atherosclerotic disease has been proposed to result in the generation of ozone, as assessed by the conversion of indigo carmine to isatin sulfonic acid, and that of cholesterol to specic cholesterol oxidation products that cause cytotoxicity and conversion of LDL into a high-uptake lipoprotein (1028). However, it remains controversial whether activated leukocytes produce ozone, and a recent study has shown that conversion of indigo carmine to isatin sulfonic acid can be mediated by ROS other than ozone (478). It will be important therefore to verify the

84 OCTOBER 2004



specicity of the cholesterol oxidation products detected (1028) to substantiate a participitation of ozone in oxidative events in atherosclerosis. What is clear is that human atherosclerotic lesions contain relatively large amounts of hydroxylated fatty acids associated with lipoprotein cholesterylesters and derived via nonenzymatic reactions. As mentioned in section IIIC2A, hydroxylated cholesterylesters are the major class of oxidized lipid present in advanced atherosclerotic plaque (672, 915, 966) and more abundant than isoprostanes and hydroxides of nonesteried fatty acids (1006). This implies that their precursors, i.e., lipoprotein-associated, esteried LOOH, LO , and LOO are generated as lesions develop. As both LO and LOO are scavenged rapidly by -TOH, it follows further that -TO must also be formed in human lesions. 2. High-uptake or oxidized LDL It is important to emphasize that although commonly used (as in sect. IIIC6), the term oxidized LDL does not dene a characterized molecular species. In fact, oxidized LDL represents a heterogeneous population of modied forms of LDL that differ greatly in their chemical composition and functional properties (881). The differences in the chemical composition are due to individual differences in the lipid and antioxidant content of LDL, as well as the choice of the oxidant and the incubation conditions used to prepare oxidized LDL. Copper ions are commonly used as the oxidant and incubations carried out for prolonged periods of time. This causes drastic alterations to the lipoprotein particle that, as a result, gains alternative functions (Table 8). For example, as pointed out earlier, oxidized LDL is no longer able to effectively interact with the receptor for native LDL and instead is recognized by scavenger receptors, and upon exposure to macrophages induces cellular cholesterol accumulation. In fact, gain of this alternative function, also referred to as formation of high-uptake LDL, was used as the earliest denition of oxidized LDL (395, 885, 886). It is worth noting, however, that even such a functional denition does not characterize oxidized LDL unambiguously, as its relation with the various chemical modications remains largely unknown. Much of our knowledge on how native LDL is converted to oxidized LDL originates from in vitro studies exposing LDL to copper ions or to cells cultured in transition metal-containing medium (349, 707, 882, 885, 886). Under these experimental conditions, formation of oxidized LDL is generally a fast process, characterized by a sequence of events starting with the complete loss of LDLs endogenous antioxidants including CoQ10H2 and -TOH, followed by the conversion of a majority of the polyunsaturated fatty acids to their corresponding hydroperoxides. These primary lipid oxidation products then fragment to secondary lipid oxidation products such
Physiol Rev VOL

as malonyldialdehyde or 4-hydroxynonenal that then react with the N -amino group of lysine residues of apolipoprotein B-100 such that the particles electrophoretic mobility increases and the lipopoprotein becomes high uptake (reviewed in Ref. 234). When LDL is oxidized rapidly by transition metals, no measurable modication into high uptake forms occurs during the period when LDL still contains -TOH (234, 235). -Tocopherol strongly inhibits the degradation of LOOH to secondary lipid oxidation products such as 4-hydroxynonenal (see, e.g., Ref. 815). It follows from the above discussion that any condition that gives rise to LOOH has the potential to generate high-uptake LDL if transition metals are available. In general, substantial LDL lipid peroxidation can be achieved by sufciently reactive 1e-oxidants, although it is less clear whether transition metals are available in biological tissue like arteries. However, in vitro high-uptake LDL can also be generated in the absence of transition metals, as suggested by experiments carried out in the presence of the metal chelator diethylenetriamine pentaacetic acid. For example, Graham et al. (330) observed that reagent ONOO converts LDL to a form recognized by the macrophage scavenger receptor. Similar to the situation with copper ions, the modications reported for ONOO involve radical reactions, as shown directly by the formation of -TO and lipid peroxidation. In addition, ONOO also induces the loss of N -amino groups of lysine residues, and this process is associated with an increase in the relative electrophoretic mobility of the lipoprotein particle (330). Interestingly, -TOH is not able to prevent ONOO -induced loss of N -amino groups of lysine residues (947), suggesting that this modication occurs via pathway(s) separate from lipid peroxidation. In addition to ONOO , the myeloperoxidase/H2O2/ nitrite system causes nitration of LDL protein tyrosine residues, lipid peroxidation and binding of the lipoprotein to macrophages that results in foam cell formation (723). This provides a possible metal-independent pathway by which mononuclear phagocytes generate oxidized LDL in the vessel wall, although the particular nature of the alterations induced by the oxidizing conditions and responsible for the altered function remains unclear. What is known is that increased binding and degradation of LDL oxidized by the myeloperoxidase/H2O2/nitrite system is observed before measurable modication of N -amino groups of lysine residues takes place, and it is independent of lipoprotein aggregation and the scavenger receptor class A type I (723). It is not known at present how formation of high uptake LDL by this oxidative path relates to the consumption of LDLs -TOH. A common feature of the above-described pathways that lead to oxidized LDL is the occurrence of substantial lipid peroxidation, characteristic of the participation of 1e-oxidation reactions. This contrasts with the situation

84 OCTOBER 2004



observed with the 2e-oxidant HOCl that also converts LDL into a high uptake form for macrophages (371). As mentioned earlier, oxidation of LDL by HOCl is characterized by the immediate and preferential oxidation of amino acid residues of apolipoprotein B-100 (with lysine residues representing the single major target) in the absence of substantial consumption of -TOH and occurrence of lipid peroxidation. Similar to the situation with ONOO , -TOH does not inhibit HOCl-induced oxidation of LDLs lysine residues (372). In summary, formation of high-uptake LDL via oxidative processes can occur in two ways, one mediated by radical oxidants and the other mediated largely by 2eoxidation reactions (Fig. 8). The two pathways differ from each other in several ways. For example, only the pathway mediated by radicals shows a requirement for extensive lipid peroxidation, and the 2e-oxidant pathway is not impacted on by lipid-soluble antioxidants such as -TOH. 3. Minimally modied LDL Minimally modied LDL is a term introduced to describe LDL less drastically oxidized than LDL after its prolonged exposure to high concentrations of copper ions. Minimally modied LDL is a functional term referring to LDL that is 1) still recognized by the receptor for native LDL, 2) not recognized by macrophage scavenger receptors, and 3) capable of stimulating the release from cultured endothelial cells of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor (58, 754). These biological activities of minimally modied LDL are distinct from those of native LDL and oxidized LDL (58, 171, 659, 754). Information on the chemical

moieties responsible is available from studies showing that the induction of monocyte adhesion to endothelial cells seen with minimally modied LDL can be mimicked by oxidized phospholipids isolated from 1-palmitoyl-2arachidonoyl-sn-glycero-3-phosphocholine that has undergone autoxidation (1020). Three biologically active oxidized arachidonic acid-containing phospholipids have been identied, namely, 1-palmitoyl-2-(5-oxovaleryl)-snglycero-3-phosphocholine, 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine (1018), and 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-glycero-3-phosphocholine (1020). 4. Role of vitamin E in LDL oxidation As we have seen, there is good evidence for implicating oxidized LDL in atherosclerosis, although the identities of the oxidants that modify LDL in blood vessels remain speculative. Consequently, research on LDL oxidation has been disparate, employing a myriad of largely nonphysiological conditions in vitro. A number of early and inuential studies focused on LDL oxidized by a large molar excess of cupric (Cu2 ) ions over several hours (234, 236). As mentioned, such conditions are strongly oxidizing and result in a drastically oxidized lipoprotein capable of generating foam cells in vitro (566). During formation of such oxidized LDL, all -TOH in the lipoprotein is depleted (236). This is in stark contrast to LDL retrieved from atherosclerotic tissue that contains relatively normal levels of -TOH (672, 939, 967) but can also generate foam cells (884). A) TOCOPHEROL-MEDIATED PEROXIDATION. LDL contains 6 12 molecules of -TOH per particle (234, 896) as its major redox-active constituent (Table 9), so it is important to

FIG. 8. Conversion of native LDL into high uptake LDL via oxidative processes mediated by 1e-oxidants or radicals (left) and by 2e-oxidants (right). Radical-induced oxidative modication of LDL proceeds largely via distinct phases. Primary lipid peroxidation (a) refers to the period during which endogenous antioxidants such as -TOH are being consumed and LOOH accumulate. Following depletion of endogenous antioxidants, secondary lipid oxidation proceeds (b), characterized by the breakdown of LOOH to reactive aldehydes and other products, and the general loss of polyunsaturated fatty acids (PUFA). As a result, minimally modied LDL (mmLDL) may be formed. ApoB-100, apolipoprotein B-100.

Physiol Rev VOL

84 OCTOBER 2004




discern the role of -TOH in the process of LDL oxidation, particularly that mediated by radical oxidants. If LDL particles are exposed to a strong oxidant or encounter radicals with high frequency, -TOH is consumed rapidly and there is little concomitant formation of LOOH (78, 81, 234, 236, 433). Under these conditions, -TOH ostensibly performs an antioxidant role. In sharp contrast, if LDL particles encounter mild oxidants or radicals with low frequency, consumption of -TOH is much slower and associated with a comparatively large accumulation of LOOH (78, 81, 433, 802, 896). It is important to consider that depletion of LDLs -TOH is required for accumulation of secondary lipid oxidation products such as aldehydes (235) and F2-isoprostanes (570), although some transformation of LOOH into hydroxyalkenals takes place in the presence of the vitamin (815). It is these secondary lipid oxidation products that are largely responsible for the atherogenic properties of in vitro oxidized LDL (412, 721, 722, 885). Thus under strongly oxidizing conditions, the antioxidant function of -TOH is in inhibiting an initial step in the overall conversion of native to high uptake LDL. However, there is little evidence that strongly oxidizing conditions persist in vivo in atherosclerotic vessels. It is also important to recognize that in vivo LDL is surrounded by a myriad of other molecules, some of which will also react with the oxidants present, thereby essentially decreasing the frequency with which the lipoprotein particles themselves encounter radicals. Therefore, conditions of mild oxidants and low uxes of radical oxidants appear more likely relevant in vivo. Under such conditions, the extent and ability of LDL lipid to oxidize is controlled primarily by -TOH, as shown unambiguously by in vitro experiments. Thus so long as -TOH remains in the particle, the process of LDL lipid peroxidation under mild oxidative conditions follows a model of tocopherolmediated peroxidation (77, 81, 169, 433, 443, 496, 893, 968, 1057, 1058). In tocopherol-mediated peroxidation, -TOH

FIG. 9. Tocopherol-mediated peroxidation of LDL. According to the model, -TOH acts as a phase-transfer agent reacting with aqueous radical oxidants (R ) that results in formation of -TO and hence import of radicals from the aqueous into the lipid phase. The model predicts that there is only one radical (mostly -TO ) contained in an oxidizing LDL particle. Suitable reductants or coantioxidants (XH) react with this -TO thereby regenerating -TOH at the expense of formation of a coantioxidant-derived radical (X ) that exports the radical back into the aqueous phase ( Xaq) where it eventually gives rise to nonradical products (NRP). In the absence of coantioxidants, -TO is forced to react with a lipid molecule containing bisallylic hydrogen atoms (LH), thereby initiating a chain reaction, in which -TO is the chain-carrying radical (chain transfer activity of vitamin E). In this chain reaction many molecules of LOOH can be formed without consumption of -TOH. Tocopherol-mediated peroxidation is also inhibited under conditions of high radical ux, i.e., when LDL particles encounter radical oxidants at high frequency. Under this condition (not shown), a second radical oxidant reacts with an oxidizing LDL particle before its -TO initiates lipid peroxidation via reaction with LH.


Chemical composition of LDL

Weight, % Mol/LDL LH/LDL*


Protein Apolipoprotein B-100 Cholesterol esters Phospholipids Cholesterol Triacylglycerols -TOH CoQ10H2 22.0 42.3 22.3 9.6 5.9 1.9 3.8 3.9 0.7 2.7 1 1,600 700 600 180 612 0.51.0 1,165 375 0 50 Lipids


Major lipid and antioxidant components are shown only. For more detailed information, see Ref. 234. * LH refers to lipids containing bisallylic hydrogen atoms. Physiol Rev VOL

does not act as a classic chain-breaking antioxidant and the fate of -TO determines whether vitamin E in LDL exhibits pro- or antioxidant activity. Tocopherol-mediated peroxidation of LDL and the central role exerted by -TOH in this model is described in Figure 9 (77, 78, 81, 433, 893, 968). Essentially, -TO replaces LOO as the peroxidation chain-carrying species and unless the former radical is eliminated, a large proportion of lipid in LDL can oxidize without signicant loss of vitamin E. The -TO is less reactive than the LOO and as such tocopherol-mediated peroxidation represents a model of retarded lipid peroxidation relative to that caused by LOO in the absence of vitamin E. However, as -TOH is highly reactive towards various oxidants, the mere presence of vitamin E in LDL renders the lipoprotein susceptible to oxidation (78, 81, 497, 1051). This property is referred to as the phase-transfer activity of -TOH. Thus, in tocopherol-mediated peroxidation, the greater the content of vitamin E in LDL, the more susceptible the lipoprotein will be to oxidation. As mentioned above, the strength of the oxidizing conditions largely determines whether -TOH exerts a pro- or antioxidant function in LDL. Thus, under mild oxidant ux, -TOH may exert pro-oxidant activity (81,

84 OCTOBER 2004




664). In addition, the type of oxidant involved impacts the function of vitamin E. Whereas -TOH may be an effective antioxidant for 1e-oxidants in lipid environments (112), it does not protect LDL against oxidative modication by 2e-oxidants such as HOCl (372) and ONOO (947). As both 1e- and 2e-oxidants are implicated in oxidative processes in atherosclerosis, it is difcult to predict the overall contribution of -TOH to LDL oxidation in atherosclerosis. D. Antioxidant Status in Atherosclerotic Lesions Compared with our knowledge of lipid changes in atherosclerosis, little is known of the accompanying changes to vascular wall antioxidants. This is true even in studies of animal models of atherosclerosis. The data currently available are primarily restricted to studies of advanced vascular disease and components released from homogenates of large pieces of aortic tissue. Thus systematic studies on antioxidant changes at various disease stages and, in focal areas of the intima, are not readily available. In addition, the currently available information is not entirely consistent, for example, when data from human lesions are compared with those of lesioned material isolated from animals used as models of the human disease. Furthermore, it is worth noting that the interpretation of changes to antioxidant defenses is complicated because the same material is not also analyzed for the extent of presence of oxidized biomolecules. For example, an increase in an antioxidant defense is commonly interpreted as a biological response to increased oxidative stress without knowledge of whether this is associated with an overall decrease or increase in oxidative tissue damage, and despite the fact that oxidants do not necessarily affect the expression of antioxidant enzymes (909). With these limitations in mind, the following discussion serves as an indication of the gross changes in vascular wall antioxidants that may occur during disease progression. Recent studies addressing the stage-dependent changes in antioxidant content and quality in diseased vessels are also highlighted. 1. Proteinaceous antioxidants There is evidence that the levels of some important proteinaceous antioxidants are altered in the diseased vascular wall (Table 10), although information on antioxidant enzyme expression in human atherosclerosis is limited (reviewed in Ref. 892). A) SOD AND CATALASE. The activity of EC-SOD, the major SOD isoenzyme in the arterial wall, was reported to be increased in highly cellular rabbit lesions, but decreased in advanced, connective tissue-rich human lesions (567). Overall, however, the activity of the different SOD isoenzymes does not appear to be altered drastically compared
Physiol Rev VOL

10. Contents of antioxidants in human plasma and homogenates of normal human arteries and advanced atherosclerotic lesions
Antioxidant Plasma Normal Artery Plaque

Enzymes GSH-peroxidase, mU/mg protein GSH reductase, mU/mg protein GST-peroxidase, mU/mg protein Total GST, mU/mg protein EC-SOD, U/mg protein Cu,Zn-SOD, U/mg protein Mn-SOD, U/mg protein Ascorbic acid, nmol/mg protein Uric acid, nmol/mg protein -Tocopherol, mmol/mol cholesterol -Tocopherol, mmol/mol C18:2 -Tocopherol, mmol/mol cholesterol Coenzyme Q10, mmol/mol cholesterol 5 0.4 0 0.1 0.060.25 ND ND 0.111.88 2.05.6 8.923.7 8.916.3 0.51.1 0.30.8 11.9 3.8 3.6 1.1 1.4 20.9 77 90 3.6 1.3 3.3 6.3 28.6 0.24 1.5 2.1 0.4 0.4 5.3 55 42 1.9 0.9 2.3 4.8 21.8 0.18 0.15

3.2 1.2 ND 22.5 104 100 2.5 0.12 0.11 4.2 6.0 49 50 1.4 0.07 0.09 1.7

Nonproteinaceous antioxidants

ND 1.5 1.5

C18:2, cholesteryllinoleate; GST, glutathione transferase; ND, not detected. [Adapted from information provided in Stocker (895).]

with normal arteries (Table 10) (reviewed in Ref. 892). In a recent study, t Hoen et al. (943b) reported mRNA levels of antioxidant enzymes in the aortic arch of wild-type and apolipoprotein E / mice of different age fed a regular chow. The mRNA levels of Cu,Zn-SOD (SOD1), Mn-SOD (SOD2), and catalase were increased in apolipoprotein E / mice in the period preceding lesion formation in the aortic root (weeks 6 12), but were decreased at 34 wk, when lesions had developed (943b). As we have seen, a decrease in the activity of Cu,Zn-SOD (205) or EC-SOD (459) may lead to decreased bioavailability of NO and hence dysfunctional endothelium-dependent vasodilation and increased production of ONOO . Chronic inhibition of Cu,Zn-SOD in rats has also been reported to result in increased nonenzymatic lipid peroxidation (569), indicating the potential for a protective role of SODs in atherosclerosis. In apparent contradiction to this notion however, overexpression of Cu,Zn-SOD in fat-fed C57BL/6 mice increases rather than decreases lesion formation (958). Also, after 1-mo atherogenic diet, aortic lesions in apolipoprotein E / mice are larger in wild-type than in EC-SOD-decient mice, and there is no differences between the EC-SOD genotypes in the larger lesions seen after 3 mo on the diet or after 8 mo on normal chow (826). In addition, on a wild-type background, there are no effects produced by the absence or presence of EC-SOD on atherogenic diet-induced aortic root lesions (826). In these studies, the urinary excretion of F2-isoprostanes was related to the rates of atherogenesis but was not

84 OCTOBER 2004



inuenced by the EC-SOD genotype. Likewise, the ECSOD status has no effect on the staining for oxidized LDL epitopes in aortic root sections (826). Together, these ndings indicate that EC-SOD appears to have surprisingly little inuence on atherogenesis in mice and that the role of SOD in intimal LDL oxidation and atherogenesis remains unknown. B) GLUTATHIONE-RELATED ANTIOXIDANTS. Compared with normal internal mammary arteries, selenium-dependent glutathione peroxidase and glutathione reductase activities are decreased in human carotid atherosclerotic plaques, with no measurable changes to glutathione transferase activity (521). In contrast, selenium-independent glutathione peroxidase activity is increased in plaque (Table 10). In lesions of rabbits fed a hyperlipidemic diet, total thiol compounds and selenium-dependent glutathione peroxidase activity has been reported to progressively rise from 10 to 60 days, whereas the activities of catalase, glutathione reductase, and glutathione transferase significantly decrease, and selenium-independent glutathione peroxidase activity is not detectable (194). At 80 days, there is a signicant decrease in the vascular content of GSH that is associated with reduced activity of -glutamyl transpeptidase but not -glutamylcysteine synthase (522), both enzymes involved in the de novo synthesis of GSH. In parallel, thiobarbituric acid-reactive substances in the vessel wall increase about three times when expressed per gram tissue (194, 522). In apolipoprotein E / mice, mRNA levels of glutathione peroxidases in the aortic arch increase in the period preceding lesion formation in the aortic root, but they decrease at 34 wk, when lesions have developed, similar to the changes seen for SOD and catalase (943b). When Japanese quails are fed a cholesterolenriched diet, comparable levels of glutathione-related enzymes are found between control and atherosclerotic arteries and between arteries derived from cholesterolfed animals whether or not they develop macroscopic lesions (312). Thus the changes in glutathione-related antioxidant enzymes during atherosclerosis are inconsistent between species and between animal models of atherosclerosis. The latter study suggests that atherogenesis proceeds in the absence of gross changes to glutathionedependent enzymatic antioxidants; however, the relevance to human atherosclerosis remains unknown. C) HEME OXYGENASE. Heme oxygenase-1 is induced by oxidative stress (992) and is expressed in cells of human atherosclerotic lesions (1012). Thus increased heme oxygenase-1 activity could represent a local antioxidant response (891), particularly if biliverdin reductase activity was present together with ferritin synthesis (28, 992). This scenario would result in removal of heme and, hence, the removal of a potential pro-oxidant, the generation of bilirubin, a coantioxidant for -TOH (663), and the sequestration of iron (28).
Physiol Rev VOL

There is increasing evidence that induction of heme oxygenase provides protection against atherosclerosis and related diseases. Indeed, upregulation of heme oxygenase-1 activity by heme, transfection, or gene transfer reduces atherosclerosis in mice decient in LDL receptor or apolipoprotein E / mice and in porcine coronary arteries (213, 439, 457), whereas pharmacological inhibition of heme oxygenase enhances atherosclerosis in LDL receptor / rabbits (438). Induction of heme oxygenase-1 also protects against intimal hyperplasia in rat aorta following balloon injury (953), and expression of the enzyme can determine cardiac xenograft survival (862). In contrast to SOD, catalase, and glutathione peroxidases, the expression of heme oxygenase-1 remains increased over the course of disease development in apolipoprotein E / mice (943a). Whether this apparent protective effect of heme oxygenase depends on an antioxidant activity remains unclear. What is clear is that increased heme oxygenase-1 protects against vascular constriction and inhibits the proliferation of vascular smooth muscle cells (213) via induction of apoptosis (563). Heme oxygenase-derived carbon monoxide has been implicated in this process (685), as well as other potentially protective activities such as endothelium-dependent relaxation (1099) and inhibition of apoptosis of endothelial cells (96, 863). D) OTHER PROTEINS. Developing lesions have decreased ratios of albumin and apolipoprotein A-1 to LDL (860, 1085). Relative decreases in albumin may promote the availability of transition metal ions via decreased metal binding, or lower the concentration of sacricial thiols to scavenge 2e-oxidants. Decreased apoplipoprotein A-1 infers a relative decrease in the content of HDL in the vascular wall. This could also favor oxidative events as a number of antioxidant activities have been assigned to HDL (571). The molecular basis for an antioxidant action of paraoxonase (an aryl esterase) is obscure, yet in HDL it has been reported to exert antioxidant activity including inhibition of lipid peroxidation (571, 1017). Paraoxonase is present in interstitial uid associated with HDL (572), and gene knockout studies demonstrate increased (although small) lesion formation with decreased paraoxonase (842). Nonetheless, direct interaction of HDL paraoxonase with LDL lipid oxidative events in developing lesions remains to be shown. A decrease in the relative concentration of intimal HDL would also decrease methionine residue availability for LOOH reduction and removal of potential pro-oxidants. 2. Nonproteinaceous antioxidants Most of the atherosclerosis-associated changes to enzymatic antioxidants described above are likely to take place within vascular wall cells. While an altered intracellular redox environment may be atherogenic (679), eviwww.prv.org

84 OCTOBER 2004



dence also suggests that changes in extracellular and nonenzymatic antioxidants play a role in disease initiation and/or progression (882). In particular, antioxidants that are associated with LDL and required to inhibit lipoprotein lipid peroxidation are thought to be decient and/or ineffective. As plasma constituents enter normal and atherosclerotic vessels (860), all of the low-molecularweight, nonproteinaceous antioxidants described in section IID3 may be present in arterial walls. However, as this material is difcult to obtain, nonproteinaceous antioxidants have not been characterized systematically, and to date, their content has only been studied in tissue homogenates prepared from normal or diseased tissue (Table 10). A) AQUEOUS ANTIOXIDANTS. The transfer of aqueous nonproteinaceous antioxidants, such as ascorbate and urate, to the intima likely occurs via simple diffusion. Thus the concentration of these antioxidants in the extracellular space of the vascular wall may approximate that of the lumen. Indeed, the concentration of ascorbate in interstitial uid (178) and lymph (633) is similar to that in plasma. I) Vitamin C. Normal arteries contain approximately one-third the concentration of ascorbate than normal human plasma (915) (Table 10). Although it is not clear whether ascorbate originates from extra- or intracellular compartments, it is reasonable to expect a portion of the ascorbate detected to be extracellular. An early study found the concentration of ascorbate in diseased human aorta to be comparable to that found in plasma (1038). This nding was validated recently by a study that showed elevated levels of ascorbate in advanced human atherosclerotic plaque compared with normal arteries (915). Furthermore, only small amounts of vitamin C were present as dehydroascorbic acid (the 2-electron oxidation product of vitamin C) in atherosclerotic plaque. Together, the limited information available to date suggests that there is no gross alteration or deciency in the arterial vessel wall content in ascorbate with atherosclerosis. As indicated, these studies do not however rule out the possibility of temporal or local (e.g., intra- versus extracellular) alterations in ascorbate concentrations during atherosclerosis. II) Urate. Compared with human plasma, healthy arteries contain signicantly less urate. In contrast, the concentrations of urate in advanced human lesions are comparable to those in plasma (Table 10) and in some lesions approach if not exceed the limit of its solubility in aqueous solution (915). Thus, like with ascorbate, currently available evidence suggests that urate levels in the vessel wall do not become decreased during atherosclerosis. It remains to be established whether uric acid provides antioxidant protection in vivo, and the role of uric acid in cardiovascular disease is still unclear, despite a long-standing association between hyperuricemia and atherosclerosis. Some studies have suggested a protective
Physiol Rev VOL

role of uric acid (43, 858). For example, reaction of urate with ONOO results in formation of a compound that can relax blood vessels, apparently via release of NO (858). However, some (241, 738, 759) but not all studies (170) have reported a direct association between uric acid concentrations and atherosclerosis, hypertension, and cardiovascular mortality. Of potential relevance, urate has been shown to stimulate the proliferation of vascular smooth muscle cells in vitro, and this has been proposed to be important in the setting of ischemia reperfusion where substantial increases in the vessel concentration of uric acid may occur (759). Also, and potentially interesting in the context of the suprasaturable concentrations of uric acid present in some human plaque samples (915), urate crystals derived from injured cells have been shown to act as a danger signal in inammation (840) that may contribute to leukocyte recruitment to atherosclerotic lesions. III) Bilirubin. There is increasing evidence supporting an inverse association between cardiovascular disease and plasma levels of bilirubin (207, 410, 543, 822, 823, 1002). Whether this reects a direct protection by the bile pigments, or simply a surrogate measure for increased heme oxygenase activity, remains to be established. As indicated earlier, a protective role has been attributed to the heme oxygenase product carbon monoxide (684). However, recent studies indicate that bilirubin may be protective by inhibiting the proliferation of vascular smooth muscle cells (563), by mechanism(s) yet to be established. Unfortunately, there is no direct information available at present on the concentration of bilirubin in diseased or healthy arteries. B) LIPID-SOLUBLE ANTIOXIDANTS. In the healthy vessel the concentrations of lipophilic nonproteinaceous antioxidants resemble the concentration of lipoprotein lipid present in interstitial uid (178). They are considerably lower than their respective plasma levels or the vessel concentration of albumin (860). This is not surprising, given that lipophilic antioxidants are associated with lipoproteins, the concentration of which is low in healthy vessels. By implication, lipid-soluble antioxidants detected in healthy arteries are probably located within cells (860). However, as atherosclerotic lesions develop, lipoproteins including LDL, with their full complement of antioxidants, transfer to the vessel wall from plasma. Thus it is reasonable to assume that, as lesions develop, an increasing proportion of the lipid-soluble antioxidants detected is localized extracellularly within lipoproteins and lipid depositions derived from them. I) Vitamin E. Concordant with the above data for ascorbate and urate, the levels of -TOH in homogenates of early, intermediate, and advanced human atherosclerotic lesions are comparable to plasma levels of the vitamin (915, 939, 967) (Table 10). Similar results have been reported for lipoproteins isolated from human lesions

84 OCTOBER 2004



representing different developmental stages (672, 939), and this is true whether -TOH is expressed per free cholesterol molecule or per cholesteryllinoleate, the major readily oxidizable lipid in lesions. In apparent contrast, Carpenter et al. (126) suggested that -TOH is depleted in macrophage-rich lesions, based on both comparatively low ratios of -TOH to cholesterol and the presence of hydroxycholesterol (126). It is worth noting that the biological relevance of expressing -TOH relative to cholesterol is not known, as the vitamin is generally considered to affect lipid peroxidation rather than oxysterol formation. Consistent with the notion that vitamin E remains essentially intact during atherosclerosis, available data from gas chromatography-mass spectrometry analysis suggest that only a fraction of the vitamin is oxidized (939). -Tocopherylquinone is the single major oxidation product, with maximal, albeit limited, -TOH oxidation observed at the earliest stage of atherogenesis, at a time when the extent of fatty acid oxidation is minimal and overall less than that of the vitamin. As the severity of the disease increases, the ratio of oxidized lipid to oxidized -TOH also increases (939). However, at all stages of atherosclerosis, the observed relative abundance of -tocopherylquinone over 2,3- and 5,6-epoxy- -tocopherylquinones resembles the situation when LDL is oxidized in vitro by 2e- rather than 1e-oxidants (939). These ndings are consistent with and further support the notion that 2e-oxidants are primarily involved in the oxidative events taking place in the artery wall and involving vitamin E. In the context of atherosclerosis, it may be important to note that vitamin E also has activities that may not be directly related to its involvement in lipid peroxidation (reviewed in Refs. 93, 475). Briey, vitamin E can enhance the bioactivity of NO (471), inhibits smooth muscle proliferation (73), and limits platelet aggregation (259). One common mechanism to account for these effects of vitamin E is the inhibition of protein kinase C stimulation (73). In the setting of atherosclerosis, inhibition of protein kinase C by vitamin E would be expected to maintain normal vascular homeostasis and thus reduce the clinical incidence of cardiovascular disease. II) Coenzyme Q10. To date, little information is available on the vessel content of coenzyme Q and the potential effect of atherosclerosis on this. Suarna et al. (915) reported comparable levels of total coenzyme Q10 in homogenates of healthy human arteries and carotid endarterectomy specimens, indicating that compared with cellular sources, lipoprotein-derived coenzyme Q10 is insignicant in diseased vessels. This interpretation is consistent with the observation that in apolipoprotein E / mice fed an atherogenic diet the aortic content of coenzyme Q also remains largely unchanged as lesions develop (541). However, supplementing these animals with large amounts of coenzyme Q, without and with
Physiol Rev VOL

additional vitamin E, decreases atherosclerosis (948, 1053), although supplements at therapeutic concentrations do not inhibit atherosclerosis in LDL receptor-decient rabbits (86), and even large amounts of coenzyme Q10 do not inhibit intimal hyperplasia in balloon-injured rabbits (152). It is presently not clear whether the vascular effects seen with coenzyme Q supplementation are related to antioxidant activity. What is known is that oral coenzyme Q10 supplementation increases the concentration of CoQ10H2 in human LDL (632) and in the blood vessels of animals used as models of cardiovascular disease (152, 1053), and this is associated with a decrease in the aortic content of oxidized lipids (152, 1053). In addition to this antioxidant activity, supplemental coenzyme Q10 has been reported to decrease integrin expression by monocytes in humans (962), suggestive of anti-inammatory activity. There is also some recent evidence that supplemental coenzyme Q10 may improve blood pressure (403) and endothelium-dependent vasodilation in type 2 diabetics (1022), although similar benecial effects were not observed in hyperlipidemic patients (751). E. Inhibition of LDL Oxidation Most studies of LDL lipid peroxidation in vitro utilize lipoproteins removed from native environments, although it is now recognized that such environs play an important role in the antioxidant function of vitamin E. For example, a number of endogenous reducing agents, termed coantioxidants, can impede the pro-oxidant activity of -TOH (79, 666, 949, 1059). As depicted in Figure 9, coantioxidants (denoted as XH) reduce the -TO and eliminate the radical character from the LDL particle, thereby inhibiting tocopherol-mediated peroxidation. Thus, for this model, a balance between the level of vitamin E and available coantioxidants determines whether LDL lipid peroxidation occurs. Vitamin C (ascorbic acid) and CoQ10H2 are examples of endogenous coantioxidants for -TOH in LDL. Both are lost easily during isolation of the lipoprotein. Despite the presence of apparently adequate levels of nonenzymatic antioxidants and coantioxidants, a signicant proportion of cholesteryllinoleate in advanced human lesions is nonetheless oxidized (915). As discussed above, so long as ascorbate and CoQ10H2 are present, tocopherol-mediated peroxidation of lipoprotein lipid is effectively prevented in vitro. An explanation for the coexistence of large amounts of oxidized lipid and ascorbate in advanced atherosclerosis is presently elusive. However, the above does not reect oxidized lipid and antioxidant levels at focal areas of lesions as whole tissue homogenates were used for analysis. Hence, it may be that oxidative damage occurs at sites remote from available antioxidants, for example, in the extracellular matrix

84 OCTOBER 2004



where LDL may become trapped and fuses to large vesicles (255). This rationale does not likely extend to the coantioxidant CoQ10H2, which associates with lipoproteins. However, there are no data available on the amount of CoQ10H2 in lesions (915). To address the above conundrum, that is, antioxidants and oxidized lipids apparently coexist in lesions, and the fact that the levels of reduced, lipophilic coantioxidants for -TOH in atherosclerosis is presently unknown, animal intervention studies employing coantioxidants have been carried out. As indicated above, the physiological levels of natural coantioxidants, in particular, ascorbate and CoQ10H2, can be manipulated by dietary supplementation. Thus coantioxidation is amenable as a potential antiatherogenic strategy. Importantly, results from intervention studies show that aortic lipoprotein lipid peroxidation can be effectively inhibited by lipophilic coantioxidants (152, 948, 1053, 1055, 1056). This is particularly striking in situations where coantioxidants were tested that are kinetically inferior peroxyl radical scavengers compared with -TOH (1055, 1056). Therefore, these results support the notion that inhibition of tocopherol-mediated peroxidation is a useful strategy to inhibit lipoprotein lipid oxidation in the vessel wall. F. Problems With the Oxidative Modication Hypothesis As reviewed in the preceding sections, a large body of evidence supports the view that oxidative modication of LDL contributes to atherogenesis, likely in a variety of different ways. Despite this however, and as we will see in the following, there is also literature evidence inconsistent with the oxidative modication hypothesis of atherosclerosis. 1. LDL oxidation versus atherosclerosis Over the last decade we have learned much about the chemistry underlying alterations in the redox status of antioxidants, lipids, amino acids, and proteins as well as the potential roles of ROS and RNS in cellular signaling, yet there remain lingering uncertainties about where, how, and to what extent LDL becomes oxidized in vivo, and how these processes directly relate to atherogenesis.

A common argument used to suggest that LDL oxidation must occur in the intima rather than plasma is that, relative to plasma, intima has a low antioxidant capacity. However, as we have seen (sect. IIID), the concentration of major extracellular antioxidants is surprisingly high in human atherosclerotic lesions. In fact, in the case of ascorbate, urate, and -TOH, the plaque concentrations approach those of human plasma (Table 10) so that the arguments put forward against the occurPhysiol Rev VOL

rence of oxidation of LDL in the circulation also hold true for the intimal space. It appears pertinent, therefore, that studies on LDL oxidation consider the presence of such antioxidants in general. This may be particularly true for -TOH, the major antioxidant associated with LDL. As mentioned earlier, a vast number of studies have established that in vitro, radical oxidants like copper ions or cells cultured in transition metal ion-containing medium can convert native LDL into oxidized or high uptake LDL. Such conversion requires drastic alterations to the lipoprotein particle, including the complete depletion of endogenous -TOH. This is in sharp contrast to the situation in vivo where, irrespective of the developmental stage of atherosclerosis, homogenates of diseased vessels or apolipoprotein B-100-containing lipoproteins isolated therefrom, are neither depleted of -TOH nor is the vitamin substantially oxidized, and a majority of lipoproteinassociated oxidized lipids are formed in the presence of -TOH (see sect. IIIB2A). This apparent discrepancy questions the general pathophysiological relevance of in vitro generated oxidized LDL and its potential proatherogenic activities (see sect. IIIB6) (Table 8). It also questions the pathophysiological relevance of minimally modied LDL (see sect. IIIC3). Thus minimally modied LDL is formed in vitro only after complete depletion of its antioxidants (58, 1019). Specically, formation of oxidized arachidonic acid products with chemotactic activity represents secondary lipid oxidation, a process largely prevented as long as -TOH is present. Therefore, depletion of the vitamin appears to be a prerequisite for formation of minimally modied LDL, and the extent of its oxidative modications is substantial when compared with the in vivo situation, although it is minimal when compared with LDL exposed to redox-active copper concentrations for prolonged periods. One way to overcome the above-described conundrum is to speculate that in the arterial wall LDL oxidation occurs in microenvironments where oxidants are produced excessively and/or where the antioxidant shield is no longer intact. The macrophage phagosome may represent such a microenvironment, although this would imply that oxidation of LDL takes place in the intracellular space, and it is not a prerequisite for lipoprotein uptake by macrophages, a notion itself inconsistent with the hypothesis that LDL oxidation causes foam cell formation. In vitro aggregation of LDL or its aggregation with proteoglycans does not appear to generate microenvironments from which coantioxidants like ascorbate are excluded, as the vitamin remains antioxidant active in such systems (967). An alternative way to overcome the conundrum is to speculate that in vivo LDL oxidation is mostly a consequence of reactions with 2e-oxidants rather than radicals. Indeed, there is ample and increasing evidence for the involvement of oxidants like HOCl and ONOO (see sect. IIIC1), although in this scenario too, one would

84 OCTOBER 2004



expect ascorbate to be protective at least in part, and it remains unclear whether the extent of such modications seen in vessels or LDL isolated from them are sufcient to explain foam cell formation. An attractive aspect of this interpretation is, however, that it could help explain the overall disappointing outcome of human interventions with antioxidant supplements (see sect. IIIF2), as the antioxidants tested to date are radical scavengers and, at least in the case of -TOH, offer little protection against LDL oxidation induced by 2e-oxidants. B) LDL OXIDATION: CAUSE OR CONSEQUENCE OF ATHEROSCLEROSIS. It is important to recognize that a large body of the support referred to in this review to substantiate the oxidative modication hypothesis of atherosclerosis provides indirect rather than direct evidence for a causative link between the two processes. This is perhaps not surprising given the difculties in experimental attempts to distinguish LDL oxidation as a cause rather than consequence of atherosclerosis. For example, associations such as the relative extent of LDL oxidation in the vessel wall and disease burden at best only strengthen the oxidative modication hypothesis; they do not prove the hypothesis. I) Correlation between lipid oxidation and atherosclerosis. As the formation of oxidized LDL in the vessel wall is thought to be an early event in atherogenesis and to contribute to on-going pathogenesis, it appears reasonable to assume that oxidized lipids are formed and accumulate early in disease and that their concentrations increase as lesions develop and decrease as lesions regress. Indeed, it has been reported that compared with C57Bl/6 mice, aortic concentrations of F2-isoprostanes are increased in apolipoprotein E / mice that spontaneously develop atherosclerosis and that have been reported to respond to vitamin E supplements by decreasing lesion size and tissue F2-isoprostanes (733). Similarly, the same group reported that hepatic gene transfer of apolipoprotein E decreases atherosclerosis and tissue concentrations of F2-isoprostanes in LDL receptor / mice fed an atherogenic diet (933) and that plasma levels of F2-isoprostanes directly correlate with lesion area in mice decient in apolipoprotein E and 12/15-lipoxygenase (175). A potential problem with these studies is, however, that tissue levels of F2-isoprostanes were not standardized for arachidonic acid (from which they are derived) so that the results reported do not distinguish differences in lipid load (i.e., disease) versus relative extent to which the lipids that have accumulated are oxidized. It is also noteworthy that others failed to observe that vitamin E supplements decrease arachidonic acid-standardized concentrations of aortic F2-isoprostanes in apolipoprotein E / mice (948). Furthermore, in human atherosclerotic lesions, F2-isoprostanes represent minor lipid oxidation products, and the functional relevance of F2-isoprostanes for atherosclerosis remains unclear (580, 1006).
Physiol Rev VOL

Compared with F2-isoprostanes, HETEs and HODEs in general, and their respective cholesterylesters in particular, are much more abundant in human lesions. In fact, these oxidized lipids can account for up to 1% of the corresponding parent lipids, yet the relationship between these oxidized lipids and atherosclerosis remains unclear (see sect. IIIB2A). Early studies reported the ratio of HODEs to linoleic acid in the abdominal aorta of men with chronic ischemic heart disease to increase slightly from stage I to III (507). Carpenter et al. (127) observed generally higher absolute concentrations of HODE in diseased than normal arteries. However, these authors (127) did not observe a disease stage-dependent increase in HODEs. Similarly, Waddington et al. (1006) reported comparable levels of HODEs in advanced lesions varying from type V to type VI. In addition, these authors failed to conrm an earlier study (580) reporting that increased HETEs and HODEs are associated with symptomatic atherosclerotic plaque in human carotid arteries (1006). Perhaps the most compelling evidence against a causative role for LDL oxidation in atherosclerosis comes from a recent study (966) reporting parent molecule-standardized concentrations of esteried HODEs in human aortas to increase signicantly only at late developmental stages of atherosclerosis. Similarly, antioxidant intervention studies have revealed situations where aortic concentrations of esteried HODEs do not correlate with disease burden (1054, 1055). Overall, it therefore appears that the levels of oxidized lipids correlate more weakly with lesion development than would be predicted by the oxidative modication hypothesis, despite the fact that established lesions contain increased concentrations of fatty acid oxidation products compared with healthy arteries. In addition, there is evidence that in human lesions oxidized lipids associated with LDL accumulate substantially only late in disease development, after accumulation of unoxidized cholesterol and cholesterol esters (966). Furthermore, lipoprotein lipid oxidation can be dissociated from disease in animal models of atherosclerosis (899, 1005, 1054, 1055). While these studies do not support a cornerstone of the oxidative modication hypothesis of atherosclerosis, namely, that LDL oxidation in the artery wall is an early event in the genesis of the disease and that it contributes to subsequent lipid accumulation, the data do not directly address the causal or temporal relationship between intracellular oxidative stress and disease progression. However, available literature such as the lack of clear disease stage-dependent increase in total HODEs (i.e., that include lipoprotein and cellular oxidized lipid) suggests that at least cellular lipid oxidation may not correlate with disease progression. II) Animal intervention studies with antioxidants. As we have seen in section IIIB8, several synthetic antioxidants inhibit lesion progression in animal models of

84 OCTOBER 2004



atherosclerosis. It is important to point out, however, that not all synthetic antioxidants offer protection against the disease in animals (reviewed in Ref. 894). This is particularly intriguing in situations where the antioxidants have been shown to decrease the extent of oxidation. For example, supplementation of a butter-based atherogenic diet with butylated hydroxytoluene and butylated hydroxyanisole (both phenolic lipid-soluble antioxidants that effectively inhibit LDL oxidation) do not prevent atherosclerosis in rabbits (1042). Also, compared with probucol, its structural analog bis(3,5-di-tert-butyl-4-hydroxy-phenylether)propane offers superior protection to LDL against in vitro oxidation, yet the analog is ineffective in inhibiting atherosclerosis in LDL receptor-decient rabbits (275). Perhaps even more striking, another structural analog of probucol, 3,3 -5,5 -tetra-tert-butyl-4,4 -bisphenol, prevents lipoprotein lipid oxidation in the vessel wall of LDL receptor-decient rabbits as effectively as probucol, yet unlike probucol, the analog does not protect against atherosclerosis (1055). Conversely, probucol inhibits atherosclerosis in the aortic arch and thoracic and abdominal aorta of apolipoprotein E / mice without inhibiting aortic lipoprotein oxidation (1054). These latter studies establish that at least in animals, the process of lipoprotein oxidation can be dissociated from atherosclerosis, a nding inconsistent with the oxidative modication hypothesis of atherosclerosis. In addition to the synthetic lipid-soluble antioxidants referred to above, vitamin E has been used repeatedly for intervention studies in a variety of experimental animal models (Table 11). This is not surprising, considering it is the most abundant endogenous antioxidant associated with LDL, although its role in protecting LDL lipids against oxidation is more complex, as we have seen in section IIIC4. As with the human clinical trials (see sect. IIIF2), a majority of the studies report a null effect of vitamin E supplementation on lesion formation in animals on a normal diet. Eleven of the 44 studies carried out over the last 50 years show vitamin E to attenuate disease. In 4 of these 11 studies, vitamin E supplements lowered plasma lipids so that this rather than an antioxidant function may have been responsible for the outcome. Thus an antiatherogenic effect independent of lipid lowering has in fact been observed in only seven studies (70, 177, 730,

733, 740, 921, 948). Notably, a similar number of investigations (n 5) have shown increased lesion formation with vitamin E supplements, particularly when given at high concentration (101, 311, 469, 643, 969). The overall marginal impact of -TOH on lesion formation is perhaps not so surprising given the lack of evidence for a deciency in this antioxidant (541). Similar to the situation with vitamin E, vitamin C supplements do not offer consistent benet against atherosclerosis in animals (reviewed in Refs. 468, 568). As indicated, interpretation of the early animal intervention studies is often complicated by a cholesterollowering effect of vitamin E (88, 730, 1030, 1042). Some, though not all, of the more recent studies of atherosclerosis in mouse models have reported vitamin E supplements to inhibit disease. An important point when comparing studies, however, is that many murine studies examine atherosclerosis only in the aortic root, a site that may be less sensitive to manipulation of oxidative stress than sites more distal in the aorta (41, 948). Also, the interpretation of animal studies that utilize nutrient vitamins is not entirely straightforward. Many of these studies lack standardization, as control diets among studies are not comparable. In particular, the tocopherol content of standard laboratory diets can vary considerably. This may have major implications on experimental ndings as reported previously by others (537, 1039). Interestingly in this context, studies that examine the effect of vitamin E supplements in otherwise vitamin E-decient animals appear to more frequently report inhibition of lesion formation (687, 704, 919, 1073) (Table 11). The relevance of this to human atherosclerosis is questionable, however, as deciency of vitamin E is rare. III) Studies with transgenic and knockout mice. Several recent studies utilizing transgenic and knockout mice have provided support for the oxidative modication hypothesis of atherosclerosis. Perhaps most strikingly, mice decient in scavenger receptors have been reported to show decreased atherosclerosis (243, 925) (see sect. IIIB7). As these receptors recognize oxidized LDL, it seems reasonable to attribute the observed protection to a decreased uptake of oxidatively modied LDL and hence a decrease in the progression of atherosclerosis. However, this mechanism has not been proven exper-

11. Vitamin E supplements and atherosclerotic disease in animals

Species Dose Hypolipidemic Effect

Effect on Disease

Inhibition (11) No effect (28) Increase (5) Inhibition (4) No effect (1)

Chicken, guinea pig, mouse, rabbit Chicken, hamster, mouse, rabbit, monkey Rabbit (Hamster, rat, rabbit)* (Hamster)*

50 mg/day, 2% 10 mg/day, 2% 25 mg/day, 1% 2260 mg kg 1 day 100 mg kg 1 day 1

4/11 6/21 0/2 1/3 0/1

* Studies in which the effect of vitamin E supplementation on atherosclerosis was examined in vitamin E-decient animals. Numbers in parentheses refer to number of studies. [Updated from that published in Upston et al. (963).] Physiol Rev VOL
84 OCTOBER 2004




imentally. Importantly, the extent of decrease in atherosclerosis observed was only modest, indicating that the scavenger receptors and uptake of oxidized LDL are not major contributors to atherosclerosis in these mice. Also, scavenger receptors have functions beyond the uptake of oxidized LDL (203b). For example, the scavenger receptor A also plays an important role in the adhesion of macrophages to extracellular matrix (799) and cells, thereby participating in proinammatory action providing for the recruitment of mononuclear phagocytes to and their retention in ligand-rich tissues such as in atherosclerotic lesion (256). In addition, and similar to the situation with antioxidant intervention studies, not all results from atherosclerosis experiments are in agreement (203b). For example, in APOE3Leiden mice, a deciency in the scavenger receptor A results in increased atherosclerosis (203a), and macrophage-specic overexpression of class A scavenger receptor decreases atherosclerosis in LDL receptor / mice (1032). Thus scavenger receptor class A is a multifunctional player in atherosclerosis, and the original observation by Suzuki et al. (925) does not provide direct evidence for a role of oxidized LDL in atherogenesis. As discussed in section IIIC1D, there is evidence for a role of lipoxygenases in atherosclerosis. However, not all data support a causal role for 15-lipoxygenase-induced oxidative events and atherosclerosis. For example, compared with controls, macrophage-specic overexpression of 15-lipoxygenase was reported to decrease atherosclerosis (838), whereas the reported marginal presence of 15-lipoxygenase-specic, oxidized lipids in human lesions (251) was not conrmed in studies by others, not even in lesions representing early developmental stages of the disease (967). In addition, it should be pointed out that lipoxygenases could conceivably affect atherosclerosis via their multiple effects on inammatory processes (218), and this could be unrelated to oxidative events. Therefore, present knowledge does not provide direct support for a contribution of lipoxygenases to oxidative events evoked by the oxidative modication hypothesis of atherosclerosis. C) OXIDIZED LDL VERSUS OTHER OXIDIZED TARGETS. As discussed in section IIIB, there is a large body of evidence for the presence of oxidized lipid and protein in human atherosclerotic lesions. However, in most of these studies, these oxidative changes were not directly linked to lesion LDL and, where this was done, the reports are conicting. For example, while one group reported LDL isolated from atherosclerotic lesions to possess properties that resemble those of LDL oxidized in vitro with copper ions (1089), other groups reported lesion LDL to be comparatively less substantially oxidized (672, 884). A complication with these latter studies is the argument that drastically oxidized LDL may be expected to be taken up rapidly by macrophages within the vessel wall
Physiol Rev VOL

and hence not available for extraction from lesion material. This argument is, however, not consistent with the ndings of Yla-Herttuala et al. (1089). It is also not immediately applicable to minimally modied LDL that is not recognized by scavenger receptors. There is evidence for the presence of the specic, biologically active oxidized phospholipids of minimally modied LDL in lesions of rabbits fed an atherogenic diet, as assessed by studies with the monoclonal antibody EO6 (1018). These oxidized lipids colocalize to foam cells (693) so that the simplest explanation is that they represent secondary lipid oxidation events taking place in cells rather than lesion lipoproteins. This interpretation is consistent with the preferred presence of other secondary lipid oxidation products, such as F2-isoprostanes (731) and malonyldialdehyde (1089) in vessel wall cells rather than the extracellular space. Irrespective of the precise origin however, these oxidized fatty acids have potential proinammatory activities that may contribute to atherosclerosis. The role of antioxidized LDL autoantibodies in the development of atherosclerosis also remains unclear (reviewed in Ref. 1086). In addition to supportive evidence (see sect. IIIB5), a large number of studies do not support the notion that the titer of autoantibodies to epitopes of oxidized LDL track with atherosclerosis (437, 954, 974), coronary heart disease (981a, 996), myocardial infarction (817), or restenosis (220). This and the fact that the overlap in autoantibody titer between control and patient groups is often considerable and shows wide standard deviations clearly limit the usefulness and clinical and prognostic value of measuring autoantibody titers (959). 2. Cardiovascular disease epidemiology and antioxidant intake In comparing populations with similar serum cholesterol values, rates of cardiovascular death and disease vary, and this relates to several dietary and nondietary factors. A consistent nding of the study of these populations is that consumption of diets rich in antioxidants offers benet for cardiovascular disease (301) and, furthermore, that plasma antioxidant levels reect such benet (770). Understandably, this has led to a large number of studies investigating the impact of dietary antioxidants in general and vitamin E in particular on cardiovascular disease. As with the animal studies, a benet with vitamin E supplements was anticipated. However, the overall outcome, particularly the results of the large, randomized controlled studies, has been disappointing and arguably provides the strongest evidence against the oxidative modication hypothesis of atherosclerosis. A) PROSPECTIVE COHORT STUDIES. Large population prospective cohort studies have examined the relationship bewww.prv.org

84 OCTOBER 2004



tween self-reported intakes of antioxidants and rates of cardiovascular disease. In the 87,000 population Nurses Health study (876) and the 40,000 population male Health Professionals Follow-up Study (771), benet was derived with 100 IU/day vitamin E supplement. However, lowdose or dietary vitamin E was ineffective. In contrast, a population study of 35,000 postmenopausal women showed signicant reduction in cardiovascular risk with a modest increase in dietary but not with supplemental vitamin E (513). Thus, while some self-reported studies seemingly suggest a role for vitamin E in diminishing cardiovascular disease risk, it appears that greater benet is attributable to small increases in dietary vitamin E rather than large doses of supplemental vitamin E. Similar to the situation with vitamin E, the evidence linking cardiovascular disease and vitamin C is inconsistent, as reviewed recently (131). Several prospective cohort studies reported high dietary vitamin C intake or supplementation to associate with reduced risk of cardiovascular disease. It is worth noting, however, that such studies tend to favor trends within the group of survivors (i.e., a survivor bias) that potentially skew the relative risk assessment. Nevertheless, different studies reported an association (n 8) or no signicant association (n 8) of dietary vitamin C with cardiovascular disease incidence (131). B) RANDOMIZED CONTROLLED STUDIES: PRIMARY PREVENTIONS. Clinical studies of antioxidant protection against cardiovascular disease have focused most attention on vitamin E, based on scientic studies describing lipid oxidation as a key determinant of atherosclerosis and also epidemiological studies showing signicant benet despite small differences in plasma concentrations between populations of low and high dietary antioxidant intake (301). The results of the major clinical trials to date designed to prevent cardiovascular disease at the primary level are summarized in Table 12. Two of these trials

investigated the effect of supplemental vitamin E on the traditional end points of myocardial infarction, cardiovascular disease, and stroke. For these two trials, vitamin E, equivalent to 50 or 448 IU/day vitamin E, or a placebo was administered. The population numbers varied from 4,500 to 29,000 and all subjects had risk factors. Follow-up was for 3.6 6.1 years before the relative risk for cardiovascular events was reported. In essence, neither study showed benet for cardiovascular risk with supplemental vitamin E. The Finnish Alpha-Tocopherol Beta Carotene Cancer Prevention (ATBC) study (943a) reported no effect of vitamin E on the incidence of fatal or nonfatal myocardial infarction. An increased risk of hemorrhagic stroke with vitamin E supplementation was observed in this study population but not in several secondary prevention studies (see below), and as such, the importance of this is unknown. The Collaborative Primary Prevention Project (PPP) similarly showed no effect on cardiovascular deaths by vitamin E, although this study was halted early as it conrmed a protective effect by aspirin seen in other trials (728). In addition to the traditional clinical end points (stroke, cardiovascular death, and myocardial infarction), carotid intima-to-media thickness has been used as a marker of on-going atherosclerotic disease. This marker is a useful surrogate for longitudinal studies, although it correlates only weakly with disease measured by angiography (5). The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study examined the effect of vitamin E or vitamin C. After a follow-up of 3 years, the rate of progression of intima-to-media thickness was not decreased by supplementation with either antioxidant (Table 12) (794). The Vitamin E Atherosclerosis Prevention Study (VEAPS) examined the effect of 400 IU/day D,L- -TOH on the progression of carotid artery intima-tomedia thickness in men and women with LDL cholesterol 3.37 mM (130 mg/dl) and no clinical signs or symptoms

12. Clinical studies of vitamin E supplementation and cardiovascular disease

Subjects History Follow-Up Vitamin E Outcomes Relative Risk


Primary prevention studies ATBC PPP ASAP VEAPS CHAOS ATBCsubgroup GISSI HOPE SPACE SECURE 29,133 4,495 260 353 2,002 1,862 11,324 9,541 196 732 M, smokers High risk for CVD M/F, chol 5 mM M/F, chol 3.4 mM CAD patients M, smokers Recent MI CVD Hemodialysis CVD 6.1 3.6 3.0 3.0 yr yr yr yr 50 mg (D,L- ) 300 mg (D,L- ) 91 mg (D- ) 268 (D,L- ) 800/400 (IU) 50 mg (D,L- ) 300 mg (D,L- ) 400 IU 800 IU 400 IU MI/fatal CHD CVD deaths IMT progression IMT progression CVD deaths Nonfatal MI Coronary events CVD deaths, nonfatal MI CVD deaths CVD, MI IMT progression 0.94 (0.701.25) 1.07 (0.741.56) 0.56 (0.231.36) 1.74* 1.18 (0.622.27) 0.23* (0.110.47) 0.97 (0.801.19) 1.00 (0.881.14) 1.05 (0.951.16) 0.46* (0.270.78) 1.03

Secondary prevention studies 1.4 yr 5.3 3.5 4.5 1.4 4.5 yr yr yr yr yr



CAD, coronary artery disease; chol, cholesterol; CVD, cardiovascular disease; F, female; IMT, intima to media; IU, international unit; D,L- , -tocopherol; M, male; MI, myocardial infarction. * Signicant effect. Condence interval not given. Physiol Rev VOL
84 OCTOBER 2004




of cardiovascular disease (404). Vitamin E supplements for 3 years did not reduce the progression of atherosclerosis compared with subjects randomized to placebo; rather, there was a borderline disease-promoting effect of -TOH supplements (404). Similarly, in a small, crossover study involving young patients with homozygous familial hypercholesterolemia, intima-to-media thickness increased with vitamin E supplements (400 mg/day) for 2 years, but decreased when subjects received statin therapy (744). Thus vitamin E supplementation fails to slow (or inhibit) the progression of intima-to-media thickness in healthy men and women at low risk for cardiovascular disease (Table 12).

To date, six secondary prevention clinical trials have been conducted to investigate the effect of vitamin E supplements in patients with preexisting cardiovascular disease (Table 12). Of these, two studies appear to show favorable effects with vitamin E. The Cambridge Heart Antioxidant Study (CHAOS) reported a major reduction in the risk of nonfatal acute myocardial infarction with vitamin E supplements, although this result was somewhat counterbalanced by the nding that vitamin E caused a nonsignicant increase in fatal myocardial infarction (887). Similarly, in a small group of hemodialysis patients (SPACE study), vitamin E supplements resulted in a signicant decrease in rates of acute myocardial infarction (68), raising the possibility that certain subjects, for example, those with renal failure and perhaps increased oxidative stress, may benet from supplemental vitamin E. The extent of benet on cardiovascular outcome in the CHAOS and SPACE study is considerable in light of the relatively short duration of follow-up of 1.4 yr. It is also inconsistent with other studies. Thus supplementation with vitamin E was found to exert no benet on cardiovascular events in the secondary prevention subgroup of the ATBC trial (762). In the large GISSI Prevenzione trial, the effect of supplemental vitamin E, n-3 polyunsaturated fatty acids, or both on cardiovascular death, nonfatal myocardial infarction and stroke was examined in 11,000 patients with a recent history of myocardial infarction (435). In this study, polyunsaturated fatty acid intake signicantly decreased cardiovascular event risk, whereas vitamin E produced only a nonsignicant trend. The combination of vitamin E and polyunsaturated fatty acids was neither additive nor interactive. This result is difcult to resolve with scientic studies supporting indirect evidence for the oxidation of polyunsaturated fatty acids in LDL in atherosclerosis. In this case, an adverse effect of polyunsaturated fatty acid supplementation would be expected as the susceptibility of LDL to oxidation increased and the antioxidant activity of vitamin E would be expected to be protective. In the Heart Outcomes Prevention Evaluation (HOPE) study, patients with cardiovascular disease or
Physiol Rev VOL

diabetes plus another risk factor were supplemented with vitamin E or ramipril (angiotensin-converting enzyme inhibitor) or a combination (1094, 1095). Vitamin E treatment did not affect any cardiovascular event, whereas ramipril signicantly reduced the risk of acute myocardial infarct, cardiovascular death, and stroke. The negative result with vitamin E is compellingly at odds with that in the CHAOS study despite similar supplementation usages and longer duration time (4.5 vs. 1.4 yr). The differences between the HOPE and CHAOS studies may lie in baseline medication (aspirin and calcium antagonists) usage and the study of a country-specic (CHAOS) versus multinational (HOPE) population. However, future secondary prevention strategies for cardiovascular disease will place importance on demonstrating that any benet from antioxidants, including vitamin E, is incremental to the commonly prescribed therapeutic agents. A substudy (SECURE) of the HOPE trial investigated the rate of intima-to-media thickness progression in secondary prevention (Table 12). Similar to the above, vitamin E realized no benet, whereas ramipril signicantly and dose-dependently reduced risk (565). Thus, hitherto, studies using intima-to-media thickness as a surrogate marker for atherosclerosis have returned a null effect of vitamin E on cardiovascular event risk. Consistent with the data reported above, a recent meta-analysis of randomized, controlled trials with vitamin E including a total of 81,788 patients concluded that vitamin E supplements do not reduce the risk of cardiovascular end points (1003). D) VITAMIN E IN COMBINATION WITH OTHER ANTIOXIDANTS. The effect of vitamin E on cardiovascular health has also been examined in combination supplementation studies with other antioxidants in both primary and secondary prevention trials (Table 13). In the ASAP study, the combination of vitamins E plus C was also tested, and this signicantly decreased the intima-to-media progression rates in men (794). In postmenopausal women with 1575% stenosis at baseline (WAVE), progression of coronary atherosclerosis worsened nonsignicantly with 800 IU vitamin E plus 1 g vitamin C daily for 2.8 yr compared with vitamin placebo (1016). The ATBC clinical study used a combination of vitamin E and -carotene in men as a secondary prevention strategy; however, no benet on major coronary events was established (762). The large MRC/BHF Heart Protection Study (HPS) for secondary prevention also examined the benet of antioxidant combination (vitamins E and C and -carotene). Although the supplementation regimen increased blood antioxidant levels substantially, no signicant reductions in the mortality from, or incidence of, any type of vascular disease, or other major outcome was found (380a). This was in contrast to the benecial effect observed with simvastatin (380b).

84 OCTOBER 2004



13. Clinical studies of antioxidant combination supplements and cardiovascular disease

Subjects History Follow-Up Antioxidant Combination (Dose/Day) Outcomes (95% Condence Interval)

Trial/Primary or Secondary Prevention

ASAP/primary WAVE/secondary

128 M, chol

5 mM

3.0 yr 2.8 yr

423 Postmenopausal F, 1575% stenosis 73 Coronary disease

Vitamin E (D- , 91 mg), vitamin C (250 mg) Vitamin E (800 IU), vitamin C (1 g)

50% Decrease in IMT progression* Nonsignicant progression of coronary atherosclerosis measured by angiogram Mean change in stenosis and occurrence of cardiovascular events not different in treated and placebo groups Major vascular events (0.941.06) Stroke (0.871.12)


3.5 yr


20,536 Coronary disease

5.5 yr

Vitamin E (800 IU), vitamin C (1 g), -carotene (25 mg), selenium (100 g) Vitamin E (600 mg), vitamin C (250 mg), -carotene (20 mg)

Denitions are as in Table 12. * No effect in women. Condence interval not given.

Two further studies have investigated antioxidant combination supplements together with lipid-lowering therapy. In the secondary prevention HDL Atherosclerosis Treatment study (HATS), subjects were randomized to simvastatin (lipid-lowering) plus niacin treatment, or antioxidants (vitamin C, -TOH, -carotene, and selenium) or a combination of both. Compared with no treatment, only simvastatin/niacin signicantly lowered stenosis progression rate and favorably altered plasma lipid proles (99). Antioxidant supplementation alone had no signicant effect on clinical end points but, notably, when used in combination with simvastatin/niacin, antioxidants negated the benet of the latter on plasma lipid prole and stenosis progression. The MRC/BHF Heart Protection Study (HPS) also examined antioxidant supplements in combination with simvastatin. While this combination did not counteract the favorable effect of simvastatin on mortality and cardiovascular events (in contrast to the previous study), it also did not benet any outcome including cardiovascular event risk (380a). In a recent small study involving 40 patients, the effect of vitamins C and E in addition to pravastatin on progression of cardiac transplant-associated arteriosclerosis was studied, with the change in average intimal index measured by intravascular ultrasound as the primary end point (242). Compared with control, antioxidant supplements reduced plaque growth independent of any change in endothelial function. In addition to the limitation associated with the small sample size of this study, it is worth noting that the underlying pathogenesis of transplant-associated arteriosclerosis is a broproliferative response to chronic allogenic immune activation, which differs from that of atherosclerosis. Also, the broproliferative response leading to restenosis after angioplasty has been reported to be inhibited signicantly by probucol, but not multivitamins (1,400 IU vitamin E, 1 g vitamin C, and 60,000 IU -carotene per day for 6 mo) (934). In summary, high dietary intake of vitamins E and C is associated with reduced risk of cardiovascular disease. However, trials in atherosclerosis-related cardiovascular
Physiol Rev VOL

disease indicate that supplements with vitamin E or vitamin C alone do not provide a general benet, as can be demonstrated with, e.g., statins. This is also the case for the combination of vitamin E with other antioxidants or with lipid-lowering therapy, which do not consistently convey cardiovascular benet, in either primary or secondary prevention. It is possible, however, that certain subpopulations of patients, such as those with endothelial dysfunction, benet from supplements with vitamin C (see sect. IVC3). IV. ROLE OF OXIDATIVE MODIFICATIONS OTHER THAN LOW-DENSITY LIPOPROTEIN OXIDATION AND CLINICAL MANIFESTATIONS OF CORONARY ARTERY DISEASE The oxidative modication hypothesis (Fig. 6) centers largely around the early events in atherosclerosis and the formation of lesions. However, there are oxidative events other than LDL oxidation that are involved in atherosclerosis and are thought to contribute to the clinical manifestations of the disease. For example, ROS and RNS have been implicated in smooth muscle cell proliferation, metalloproteinase activation, and endothelial function. A complete understanding of how oxidative events are involved in atherosclerosis will require some discussion of why atherosclerosis results in clinical events such as myocardial infarction and stroke. A. Concept of Disease Activity Traditionally, atherosclerosis was thought of as simply a problem of lesion growth into the arterial lumen. According to this paradigm, continual lesion expansion would progressively narrow the arterial lumen and eventually limit blood ow, thereby causing tissue ischemia. Inevitably, it was thought that arterial occlusion would result and necrosis of the target organ would ensue. It has

84 OCTOBER 2004



become clear in recent years that the scenario outlined above is not correct and that clinical manifestations of atherosclerosis are the consequence of abrupt lesion disruption and subsequent thrombosis. In addition, it is also clear these events often occur in the absence of critical luminal narrowing. The specic nature of these events is the subject to which we now direct our attention. A vexing problem in the cardiovascular literature is the prediction of patients that will experience a clinical event. To this end, angiographic studies have determined that more severely stenosed arteries frequently progress to coronary occlusion (10, 229). However, owing to their greater frequency, the less severe stenoses are the predominant source of coronary occlusions (10). Thus myocardial infarction most commonly arises from stenoses that are relatively mildly ( 50%) blocked. Thus clinical manifestations of atherosclerosis cannot be adequately predicted from angiographic images. The observations outlined above beg the question of how less severe atherosclerotic lesions give rise to clinical events. The short answer to this question is that traditional concepts of atherosclerosis and encroachment of the arterial lumen were incorrect. This realization stems, in large part, from the observations of Glagov et al. (306). In a series of pathological specimens, Glagov et al. (306) found that the development of early atherosclerotic lesions was characterized by compensatory enlargement of the artery such that luminal cross-sectional area was preserved and the bulk of early lesions are outside the arterial lumen. This information has subsequently been conrmed using imaging techniques such as intravascular ultrasound. If one examines early lesions using this technique, it is readily apparent that large atheroma can coexist with arteries that have preserved luminal architecture. Conventional angiography only images the lumen,

thereby underestimating the extent of atherosclerosis within the artery. This concept, along with the typical appearance of an atherosclerotic lesion, is contained in Figure 10. Thus a normal-appearing artery on angiography can harbor very bulky atherosclerotic lesions. Although the concept of compensatory arterial enlargement explains the coexistence of advanced atherosclerosis and normal arterial lumen, it does not explain how such lesions actually lead to luminal occlusion. DeWood et al. (204) provided considerable insight into this issue by performing immediate coronary angiography on patients suffering from acute myocardial infarction. They found that most myocardial infarctions involved total occlusion of the coronary artery that was principally due to thrombus. Thrombosis of the vessel appears to result from rupture of the atherosclerotic plaque and the exposure of its thrombogenic components to the bloodstream. This understanding is derived from pathological studies and investigations with both angioscopy and intravascular ultrasound. Thus plaque disruption and consequent thrombosis underlie most clinical atherosclerotic events. Based on the preceding paragraphs, one can appreciate that the development of atherosclerotic lesions simply sets the stage for clinical events such as myocardial infarction and stroke. Indeed, most atherosclerotic lesions are clinically silent and may exist for years without any meaningful sequelae. It is only when atherosclerotic plaques become active that clinical events ensue. As outlined above, the active component of atherosclerosis involves plaque rupture and a number of derivative events, including platelet adhesion, thrombosis, and vasospasm. We now consider these active components of atherosclerosis and how oxidative events contribute to this phase of atherosclerosis.

FIG. 10. Conceptual view of appearance and development of atherosclerotic lesions. According to the so-called Glagov hypothesis (306), the early stages of atherosclerotic lesion development are characterized by compensatory enlargement of the artery, such that the luminal diameter is preserved. It is only in later stages of atherosclerosis that the lumen becomes smaller. The result of this effect is that considerable atherosclerosis can exist before any detection of luminal narrowing is observed on angiography. [Adapted from Glagov et al. (306).]

Physiol Rev VOL

84 OCTOBER 2004


1438 B. Plaque Disruption


To understand this phenomenon, it is important to have a working knowledge of plaque anatomy. The classic mature atherosclerotic lesion (Fig. 10) involves a central core of foam cells with extracellular cholesterol arranged in so-called cholesterol clefts. Typically, there is also a considerable amount of necrotic debris, and overlying the central core is a brous cap comprised of extracellular matrix, smooth muscle cells, and collagen. Lesion activation is initiated by rupture of the atherosclerotic plaque such that the plaque contents are exposed to the luminal surface of the artery. This plaque rupture tends to involve a structural failure of the brous cap. 1. The brous cap Although rupture of the atherosclerotic plaque was proposed in the rst half of this century (528), it is only recently that autopsy studies have consistently identied morphological features associated with this phenomenon. These features include a large necrotic core of lipid and cellular debris and a thin brous cap that is often eccentric (187, 188), prompting concern about mechanical stresses on the brous cap. In particular, the presence of a large, soft lipid core focuses available forces on the brous cap (768) at its junction with more normal architecture, the so-called shoulder region (Fig. 10). This region of the plaque, coincidentally, is most often the site of plaque rupture based on autopsy studies (188). Thus it is not surprising that determinants of brous cap structural integrity have become the focus of considerable investigation, in part, to provide insight into the molecular events predisposing plaques to rupture. The extracellular matrix is a major component of the brous cap, and normally, matrix production and turn-

over are remarkably slow (831). In atherosclerosis, the environment of injury and inammation leads to an enhanced synthetic activity of matrix components such as elastin, collagen, and proteoglycans (557). For example, inammatory cells such as foam cells and monocytederived macrophages within the plaque produce an environment that is replete with the cytokines and growth factors that have important implications for matrix production. In particular, cytokines such as transforming growth factormay stimulate collagen synthesis, whereas others such as interferon- suppress it. Thus any propensity toward matrix degradation may have serious structural implications for the brous cap. A) MATRIX DEGRADATION. A wealth of information now indicates that matrix-degrading enzymes including serine proteases (tissue-type and urokinase-type) plasminogen activators and plasmin, the matrix metalloproteinases, and cysteine proteases can degrade the structural components of the brous cap. Table 14 lists selected matrixdegrading enzymes implicated in atherosclerosis along with their typical substrates. Considerable evidence indicates these matrix-degrading enzymes are active in atherosclerosis and that their production is enhanced in situations known to be relevant for atherosclerosis. For example, human lesions contain matrix metalloproteinases-3 and -1 (394), with the former demonstrating intense staining in the shoulder regions of atherosclerotic plaques (668). Cultured smooth muscle cells express little matrix metalloproteinase-1 activity required to cleave brillar collagen. However, the atherosclerotic plaque contains a milieu of cytokines and growth factors including tumor necrosis factor- and interleukin-1 that induce smooth muscle cells to produce enzymes capable of degrading structural collagen and other matrix components (284). In addition, macrophages from arterial lesions in rabbits


14. Selected matrix-degrading enzymes implicated in atherosclerosis

Type Examples Examples of Substrates

Serine protease Cysteine protease Matrix metalloproteinases

Plasmin, urokinase, cathepsin G, tissue plasminogen activator Cathepsins, B, D, H, L, N, and S Interstitial collagenase (MMP-1) Gelatinase A (MMP-2) Stromelysin-1 (MMP-3) PUMP-1 (MMP-7) Neutrophil collagenase (MMP-8) Gelatinase B (MMP-9) Stromelysin-2 (MMP-10) Stromelysin-3 (MMP-11) Metalloelastase (MMP-12) MT-MMP (MMP-14)

Fibrin, bronectin, laminin, and some proteoglycans Wide range, including collagen, proteglycans, and elastin Collagens I, II, III, VII, and X Collagens IV, V, VII, and X Collagens III, IV, V, and IX; laminin, bronectin, elastin, proteoglycans Gelatin, bronectin, laminin, collagen type IV, procollagenase, and proteoglycan core protein Collagens I, II, and III and proteoglycans Collagens IV, V, VII, and X Collagens III, IV, V, and IX; laminin, bronectin, elastin, proteoglycans Gelatin, bronectin, and proteoglycans Elastin Collagen IV, gelatin, and progelatinase A

All matrix metalloproteinases (MMP) listed are located in the extracellular space, except for MMP-14 which is located on the cell surface. Serine proteases are pericellular or extracellular, while the cysteine proteases are present mostly in the cytosol or within lysosomes. [Adapted from Lee and Libby (529).] Physiol Rev VOL
84 OCTOBER 2004




demonstrate production of matrix metalloproteinases-1 and -3, consistent with cell culture ndings (285). Thus the cellular environment of an atherosclerotic plaque contains a number of features that would be expected to promote degradation of the brous cap. A similar argument also applies to the oxidative events of atherosclerosis. Atherosclerosis is associated with an increased production of ROS and RNS that have implications for matrix metalloproteinase activity derived from smooth muscle cells. In particular, H2O2 increases smooth muscle cell gelatinase activity and ONOO activates matrix metalloproteinase-9 to generate collagenase activity (753). In transformed cells, the sustained production of H2O2 is associated with the activation of matrix metalloproteinases-2 through a tyrosine kinase-dependent mechanism. The production of HOCl is also associated with metalloproteinase activity, both directly and indirectly. With regard to the former, HOCl can fragment components of the extracellular matrix (1063), and there is evidence for this occurring in atherosclerotic plaques (1064). Matrix metalloproteinases are converted from a proenzyme to the activated form through amino-terminal cleavage (1029), a process that is facilitated by HOCl (278, 1025). Indirect activation of matrix metalloproteinases is related to a class of proteins known as the tissue inhibitors of metalloproteinases (192). ROS such as HOCl have been shown to inhibit the ability of these proteins to function (832), thereby removing inhibition of matrix metalloproteinase activity. Consistent with the notion that the cytokine and oxidant milieu of the brous plaque is important in determining plaque integrity, there is an inverse relation between plaque macrophage content and its mechanical strength (539). Indeed, macrophage inltration of the brous cap and its shoulder regions is a common nding in morphologically unstable lesions (635, 980). Thus the elaboration of cytokines and production of ROS within the atherosclerotic plaque have important implications for its structural integrity. Unregulated oxidant production has the potential to promote the elaboration and activation of matrix degrading enzymes in the brous cap of the plaque. This activity is one link between oxidative stress and cardiovascular disease activity that is independent of LDL oxidation. B) MATRIX PRODUCTION. The major source of matrix production within the brous cap is the smooth muscle cell. It is possible, therefore, that depopulation of the brous cap may also contribute to plaque weakening and the propensity to rupture (239). For example, brous caps that have ruptured tend to have many more macrophages than stable plaques with many fewer smooth muscle cells (239). Under such circumstances, one might expect a relative paucity of matrix production and an abundance of matrix degradation due to this imbalance in the ratio of smooth muscle cells to macrophages. There are considerable data to suggest this situation may arise from spePhysiol Rev VOL

cic cytokines produced within the plaque. For example, activated T lymphocytes are found within atherosclerotic plaques (359) and may represent 10 20% of the total cell population (454), particularly at sites prone to plaque rupture (980). Interferon- is a major product of lesional T cells (274) that is known to inhibit the proliferation of vascular smooth muscle cells (358) and sensitize these cells to apoptosis (53, 297). One could certainly envision a situation where inammation in specic areas of the atherosclerotic plaque may promote smooth muscle cell apoptosis and confer a defect in the synthetic capacity of the atherosclerotic plaque. This scenario could render the plaque susceptible to rupture in response to hemodynamic forces in the vessel. The local environment of ROS may also have implications for the population of smooth muscle cells in the brous cap. Although H2O2 stimulates the proliferation of smooth muscle cells (758), this response is highly dose dependent, as mentioned earlier. At low concentrations of H2O2, there is clearly a proliferative response (201). In fact, a number of smooth muscle cell mitogens actually require H2O2 production for a proliferative response (332, 923). However, higher concentrations of H2O2 are associated with smooth mucle cell apoptosis and necrosis (201), and the shoulder regions of atherosclerotic plaques appear to exhibit considerable levels of oxidant-generating enzymes and ROS (864). Similarly, atherosclerotic plaques exhibit evidence for HOCl generation and HOClmediated oxidation (368, 369), all the more important considering that HOCl induces growth arrest and apoptosis of vascular cells (997). Thus it is possible that the excess ambient oxidants contribute to the depopulation of the brous cap, thereby tilting the balance of matrix production and degradation in favor of the latter. In summary, development of the atherosclerotic lesion involves the generation of a brous cap overlying a lipid core. Stable lesions are characterized by a brous cap that remains thick and replete with collagen-producing smooth muscle cells that lend structural stability to the plaque. Under these circumstances, shear forces and mechanical stresses are not met with any structural failure, and the lipid core remains isolated from the circulation. However, under certain circumstances of cytokines and oxidative stress, shoulder regions of the atherosclerotic plaque become replete with matrix-degrading activity, and the population of smooth muscle cells is diminished. As a consequence, the plaque may become relatively acellular with less interstitial collagen. This sets the stage for structural failure and plaque rupture that we now understand is a critical event in the precipitation of cardiovascular disease events. Evidence for the contribution of oxidative events in the precipitation of cardiovascular events comes from studies showing that in patients with coronary artery disease low red blood cell peroxidase 1 activity (66) or increased plasma levels of myelowww.prv.org

84 OCTOBER 2004



peroxidase (91) are associated with increased risk of events. C. Vasomotor Function The precipitation of acute vascular events in atherosclerosis involves processes that go beyond plaque vulnerability and rupture. There is now a growing appreciation that local homeostatic processes in the arterial wall are also abnormal in those patients with frank atherosclerosis and risk factors for atherosclerosis. Among the more important components of vascular homeostasis is the endothelium, as it serves as the interface between the vascular wall and owing blood. Through the release of autocrine and paracrine factors, the endothelium regulates a number of important processes such as vascular tone, platelet adhesion, and leukocyte transit into tissues and the vascular wall. The principal factors released by the endothelium that regulate vascular homeostasis on a moment-by-moment basis are prostacyclin, leukotrienes, and NO. With regard to the latter, in 1980, Furchgott and Zawadzki (283) described an endothelium-derived factor responsible for arterial relaxation in response to acetylcholine that was later identied as NO (427). Endothelial production of NO is important in the regulation of vascular tone, arterial pressure, platelet adhesion, and leukocyte trafcking, as mice lacking eNOS exhibit spontaneous hypertension, defective vascular remodeling, enhanced vascular thrombosis, and leukocyte interactions (263, 417, 535, 788). The classic model of bioactivity of NO involves its binding to the heme group of guanylate cyclase in target cells (e.g., platelets, smooth muscle cells) to increase cellular cGMP and activate cGMP-dependent protein kinase, thereby affecting NO-mediated vasodilation and platelet inhibition (426). Under aerobic conditions, NO may also S-nitrosate protein cysteine thiols, and this mechanism has been implicated in NOmediated modulation of ion channels, protein kinases, caspase enzymes, and transcription factors (328). The endothelial isoform of NOS is a 135-kDa protein that consists of a carboxy-terminal reductase domain linked by a regulatory calmodulin-binding site to an amino-terminal oxygenase domain (Fig. 11, head-to-head apposition of eNOS). Normally, eNOS exists as a homodimer with the oxygenase domains of each protein linked together through a Zn-thiolate cluster (757). The spatial characteristics of eNOS are such that its catalytic action involves the avin-mediated transport of electrons from NADPH in the carboxy-terminal reductase domain of one monomer to the amino-terminal heme of the other monomer where O2 is reduced and incorporated into the guanidino nitrogen of L-arginine to form L-citrulline and NO. The regulation of eNOS-mediated NO production is
Physiol Rev VOL

FIG. 11. Model of head-to-head apposition of nitric oxide synthases (NOS). Shown is the typical structure of a NOS dimer where the electron ow (arrows) traverses the reductase domain of one monomer to enter the oxygenase domain of the other. In the case of endothelial NOS, a Zn-thiolate cluster stabilizes the dimer (546, 757). [From Stuehr et al. (913).]

present at the transcriptional level as well as through posttranslational regulation that includes substrate and cofactor availability, enzyme acylation, and targeting to Golgi membrane and plasma membrane caveolae, protein-protein interactions, and phosphorylation (for reviews, see Refs. 282, 946). 1. Endothelial dysfunction Endothelial dysfunction is a poorly dened term that we submit refers to a loss of normal homeostatic functions (e.g., vasodilatation, platelet inhibition). This condition often occurs early in the course of atherosclerosis with one important manifestation being a reduction in the bioactivity of endothelium-derived NO. Although the loss of NO bioactivity is not the only manifestation of endothelial dysfunction, it is an independent predictor of future cardiovascular events in patients with atherosclerosis (314). There are many potential reasons for impaired NO bioactivity. These range from inadequate NO production to NO degradation or an inadequate response to NO and include eNOS uncoupling. There is evidence to support defects in all facets of NO production and metabolism in the setting of vascular disease, but oxidative events gure prominently in many studies of impaired NO bioactivity. 2. Oxidative events and endothelial dysfunction
A) SUPEROXIDE ANION RADICAL. In models of vascular disease such as cholesterol-fed rabbits, blood vessels produce substantial amounts of nitrogen oxides (i.e., oxidation products of NO) despite the impairment in NOdependent vascular relaxation (628), suggesting that global NO production in vascular disease is not attenu-

84 OCTOBER 2004




ated. Rather, NO appears to become inactivated before reaching its cellular target, and one mechanism of NO inactivation considered initially involved O2 (340, 429, 785). Mugge et al. (645) observed later that treatment of cholesterol-fed rabbits with SOD conjugated to polyethylene glycol increased vascular SOD activity and improved NO-mediated arterial relaxation (645). It is now known that hypertension, hypercholesterolemia, diabetes, and atherosclerosis are associated with an increase in the steady-state ux of O2 in the vascular wall and O2 reacts with NO at near diffusion-controlled rates (see sect. IIC). Because the resulting ONOO inefciently activates the soluble isoform of guanylyl cyclase (936), its formation effectively decreases NO bioactivity in the vascular wall. The bimolecular combination of O2 and NO provides only a partial explanation for reduced NO bioactvity in the setting of vascular disease, as evident in later stages of atherosclerosis. For example, in older ( 24 mo) Watanabe heritable hyperlipidemic rabbits that lack a functional LDL receptor and develop chronic manifestations of atherosclerosis, NO bioactivity is impaired and is not restored by increasing endothelial SOD levels (623). This nding implies that other sources of O2 outside the endothelium must be considered or, alternatively, that other means of impaired NO bioactivity predominate in later stages of the disease, and we now direct our attention to this issue. B) LIPID PEROXYL RADICALS. In the presence of metal ions or NO, a ux of O2 can promote the formation of LOO (569) that have implications for NO bioactivity. Like O2 , LOO can combine with NO to form adducts (689, 787) and therefore may quench bioactive NO (677). Lipid peroxidation within the vascular wall may also lead to the formation of oxidized LDL that directly inactivates NO (149) and may reduce eNOS protein in endothelial cells (554). Indirect effects of lipid peroxidation are also potentially important. The transfer of oxidized phospholipids from oxidized LDL to the endothelial cell plasma membrane stimulates protein kinase C (681) and impairs G protein-coupled signal transduction leading to abnormal NO-mediated arterial relaxation in response to receptor-dependent NO agonists (505). It is important to realize that 1e-species such as O2 and LOO do not represent the sole source of reactive species that have implications for NO bioactivity and endothelial cell function. Indeed, there is now a growing appreciation that 2e-oxidants also play a role in the modication of endothelial function. C) PEROXYNITRITE AND N2O3. Although evidence outlined above plainly indicates that ONOO formation effectively limits NO bioactivity by quenching NO, other properties of ONOO appear to limit endothelial function as well. Peroxynitrite readily oxidizes tetrahydrobiopterin, thereby limiting the activity of eNOS and facilitating O2 production
Physiol Rev VOL

(524, 627) (see sect. IIC3). Atherosclerosis (985) and diabetes (843) are associated with reduced vascular levels of tetrahydrobiopterin, and ONOO -mediated oxidation of tetrahydrobiopterin has been proposed as a physiologically relevant mechanism of impaired NO bioactivity (400). Observations that uric acid, a scavenger of ONOO , improves endothelial NO bioactivity in atherosclerotic mice is consistent with this notion (524). Another plausible pathway of eNOS uncoupling involves RNS-mediated oxidation of the Zn-thiolate center, resulting in the conversion of active eNOS dimer to inactive eNOS monomers. Thus exposure of endothelial cells to low concentrations of ONOO has been reported to result in increasing uncoupling of eNOS activity, characterized by decreased NO production and increased O2 formation without apparent loss of tetrahydrobiopterin (1112). Such uncoupling, mediated by ONOO itself or NO2 derived from it (see sect. IIB2), likely involves the oxidation of one (or several) of the four cysteine residues coordinated to the Zn-atom present in the eNOS dimer (1112). As pointed out in section IIC3, NO reversibly inhibits eNOS activity via binding to the heme moiety of the protein. However, exposure of the isolated protein or endothelial cells to NO also causes monomerization of eNOS that is associated with loss of enzyme activity and release of zinc and that is prevented by thioredoxin plus thioredoxin reductase (763). These ndings have been rationalized by the binding of NO to eNOS proceeding in two steps: a rst, reversible one due to binding of NO to heme, followed by a second, irreversible step, caused by nitrosation of a critical thiol residue and resulting in the displacement of zinc and tetrahydrobiopterin, and loss of enzyme activity (763). Because NO itself is not an efcient nitrosating species, its autoxidation products, particularly the 2e-oxidant N2O3, need to be considered as the likely mediator of the proposed formation of nitrosothiols (see sect. IIC3). Such a mechanism may explain the apparent O2 -independent impairment of NO bioactivity in later stages of atherosclerosis. Thus, as lipids accumulate in the vessel wall, the local environment becomes increasingly hydrophobic. This will increase both the local concentration of molecular oxygen (that promotes autoxidation of NO) and the extent to which NO-derived N2O3 engages in nitrosation reactions (by decreasing N2O3 hydrolysis) (1045). Thus ONOO and N2O3 have multiple biologic activities that could lead to impaired NO bioactivity by limiting NO production. D) MYELOPEROXIDASE AND HYPOCHLOROUS ACID. As discussed in section II, myeloperoxidase exists in atherosclerotic lesions and vascular disease, and HOCl is the major product at physiological concentrations of chloride ions (362). Hypochlorous acid can oxidize a large variety of biological molecules, particularly proteins and amino acids (362), with the latter activity being particularly germane to endothelial function. For example, L-arginine reacts

84 OCTOBER 2004



with HOCl to form chlorinated derivatives that impair NO production from cultured endothelial cells and rat arterial segments (1102). Thus there is evidence to indicate that myeloperoxidase-derived products could contribute to endothelial dysfunction in the setting of atherosclerosis. The link between myeloperoxidase and NO bioactivity is not limited to HOCl. In particular, endothelial cells are known to transcytose myeloperoxidase leading to enzyme deposition in the subendothelial space and the facilitation of extracellular matrix protein tyrosine nitration (27). This may have important implications for NO bioactivity as myeloperoxidase can catalytically consume NO (4) even when the enzyme is localized to the subendothelial space (225). These ndings are consistent with human studies that circulating myeloperoxidase levels are an important determinant of endothelial NO bioactivity in the setting of coronary artery disease (999). Thus myeloperoxidase accumulation in the arterial wall represents another mechanism for impaired NO bioactivity through the catalytic consumption of NO. E) HYDROGEN PEROXIDE. Among 2e-oxidants produced in vivo, H2O2 is perhaps the most abundant. It freely diffuses through cell membranes and may travel several cell diameters before reacting with targets such as thiols and heme. Diseased vessels produce increased levels of H2O2 (333), and activated neutrophils at normal circulating concentrations can produce 200 400 M H2O2 over a 60-min period (562). Emerging evidence now also supports the notion that H2O2 may be involved in modulating NO bioactivity. Although H2O2 does not react with NO, it does produce arterial relaxation in an endothelium- and eNOS-dependent manner (945, 1100). Hydrogen peroxide treatment also promotes chronic increases in eNOS activity by upregulating transcription and enhancing mRNA stability (211) via a mechanism that involves activation of Ca2 /calmodulin kinase II and janus kinase 2 signaling pathways (117). Therefore, H2O2 may promote both acute and chronic increases in eNOS activity that could serve as a compensatory response to oxidative stress. Paradoxically, although treatment of endothelial cells with H2O2 promotes eNOS activity above basal levels, ambient levels of H2O2 can inhibit agonist-stimulated NO bioactivity (446, 586). For example, in cerebral arterioles, H2O2 impairs NO-mediated arterial relaxation in response to acetylcholine or authentic NO, an effect that appears to involve O2 as it is reversed by SOD (1024). Mice with a defect in H2O2 detoxication due to cellular glutathione peroxidase deciency have impaired endothelium-dependent vasodilator function (253). 3. Antioxidants and endothelial function

Given the overwhelming evidence linking oxidative stress to impaired NO bioactivity and endothelial function, it is not surprising that a number of investigators have utilized
Physiol Rev VOL

antioxidants as a strategy to improve endothelial cell phenotype. Many studies have reported a consistent benecial effect of acute and chronic ascorbate administration on the bioactivity of endothelium-derived NO in human subjects (for review, see Ref. 215). Both intraarterial infusion and oral supplementation of ascorbate results in improved endothelial-dependent vasodilation in human patients with vascular pathological conditions including atherosclerosis, diabetes, hypertension, and cigarette smoking (388, 542). The effect of ascorbate is both acute and is maintained over 30 days of supplementation (313). This is likely due to ascorbate increasing endothelial concentrations of tetrahydrobiopterin (392, 415) rather than scavenging of O2 (444). Indeed, clinical studies demonstrate that tetrahydrobiopterin supplementation improves endothelial function in human subjects with vascular disease (387, 911). Thus these data indicate that both ascorbate and tetrahydrobiopterin are limiting determinants of endothelial NO production. Glutathione is a major determinant of the intracellular redox environment and is present in millimolar concentrations. Studies have shown that patients treated with L-oxo-4-thiazolidine carboxylate, an agent that selectively increases intracellular glutathione concentrations, exhibit improved NO bioactivity in the brachial artery (1000). Likewise, intra-arterial glutathione infusion improves endothelium-dependent arterial relaxation in response to acetylcholine (506). The specic mechanisms responsible for these observations are not yet clear, as glutathione alone has limited activity in boosting endothelial NO production in culture (381, 415). However, it should be noted that thiols are excellent scavengers of 2e-oxidants such as H2O2 and HOCl, two species that have been implicated in endothelial dysfunction (see above). Taken together, studies with ascorbate, tetrahydrbiopterin, and glutathione indicate that intracellular redox environment is an important determinant of endothelial NO bioactivity. B) LIPID-SOLUBLE ANTIOXIDANTS. Vitamin E has also garnered considerable interest as an antioxidant with the potential to improve endothelial function. Similar to ascorbate, -TOH can scavenge O2 (k 5 103 M 1 s 1), but the reaction rate is unlikely to support effective competition with NO for O2 in vivo. Nevertheless, increasing vascular vitamin E levels have been shown to improve endothelial NO bioactivity in experimental animal models of vascular disease (470, 889), although this effect is not linked to the inhibition of lipoprotein lipid oxidation (469). Alternatively, increasing tissue vitamin E levels may act by inhibiting protein kinase C-dependent promotion of O2 production (471). Despite the consistent favorable effect of vitamin E on endothelial NO bioactivity in experimental animals, the situation in humans is contradictory. Vitamin E supplementation of hypercholesterolemic or coronary disease patients improves NO bioactivity in some studies

84 OCTOBER 2004



(390, 661) but not others (305, 610, 855). The discrepant ndings in animals and humans are not well explained but may reect differences in disease stages at the time the intervention is applied. Studies in experimental animals are typically early in the disease process, whereas human studies involve patients with established vascular disease. Thus although early atherosclerotic disease processes may be subject to modication by vitamin E, later stages may not. Probucol has been shown to inhibit atherosclerosis in multiple animal models (468, 594). In keeping with this vascular protective action of probucol, its use in animal models of vascular disease has demonstrated an improvement in NO bioactivity in atherosclerosis (434, 473, 854) and diabetes (940). This effect appears independent of its lipid-lowering properties and may be related to a reduction in the vascular O2 ux in cholesterol-fed rabbits (473). Limited studies within human subjects have provided mixed results, with one study demonstrating an additive effect with lipid lowering and another demonstrating no effect in forearm vessels (19, 610). Thus far, we have focused on endothelial vasomotor function as a prototypical vascular process that is subject to modulation by oxidative events. Some of this emphasis is driven by observations that endothelial vasomotor function is predictive of future cardiovascular events in patients (314, 315, 809). The link between oxidative events and endothelial function as it pertains to the process of atherosclerosis is further strengthened by observations that patients with oxidative stress-induced endothelial dysfunction are particularly prone to future cardiovascular events (389). Nevertheless, there are other events in the vascular wall that contribute to atherosclerosis that are also known to be sensitive to oxidative processes. We now turn our attention to this issue.

D. Adhesion Molecules Despite the long-standing appreciation that inammatory cells are involved in atherosclerosis (783), the specic mechanisms whereby vascular inammation is initiated remained elusive for many years. In 1991, Cybulsky and Gimbrone (172) made a seminal observation that early rabbit atherosclerosis was associated with induction of a leukocyte adhesion molecule on the endothelium that was homologous to human vascular cell adhesion molecule-1. We now know the recruitment of inammatory cells is dependent on cellular adhesion molecules. These are a diverse group of surface proteins that are divided, among others, into selectins, integrins, and immunoglobulin superfamily members (Table 15). Vascular inammation begins with leukocyte rolling on the endothelium that is facilitated by endothelial expression of P-selectin and its interaction with leukocyte P-selectin ligand-1 (59). Firm leukocyte adhesion requires interaction between leukocyte 1- and 2-integrins and endothelial immunoglobulin superfamily members such as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1, respectively (1111). Once rm adhesion is established, leukocytes may then transmigrate across the endothelium along a chemotactic gradient such as that produced by monocyte chemotactic protein-1 (171). Cellular adhesion molecules are an important component in atherosclerosis and the response to vascular injury. Histological studies demonstrate increased endothelial expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in developing and established atherosclerotic lesions (545, 727). Early atherosclerotic events and the initiation of lesion formation appear particularly dependent on vascular cell adhesion molecule-1 (173). Mice lacking intercellular adhesion mol-

15. Cellular adhesion molecules implicated in vascular injury

Cellular Expression Ligand or Counter-Receptor

Adhesion Molecule

Selectins L-selectin (CD62L) P-selectin (CD62P) E-selectin (CD62E) LFA-1 ( Mac-1 ( ; CD11 /CD18) 2: CD11b/CD18) PMN, eosinophils, monocytes, lymphocytes Endothelial cells, platelets Endothelial cells Integrins
L 2 M

CD34, GlyCAM-1 PSGL-1, Sialyl Lewis Sialyl Lewis ICAM-1, ICAM-2, ICAM-3 ICAM-1, FGN, C3bi, Factor X VCAM-1, FN, TSP FGN, vWF, VN, FN, TSP Collagens, laminin LFA-1, Mac-1 LFA-1 VLA-4

PMN, lymphocytes, monocytes PMN, monocytes, NK, T lymphocytes Eosinophils, lymphocytes, monocytes Platelets Platelets, endothelial cells, broblasts, epithelial cells Immunoglobulin superfamily Smooth muscle cells, endothelial cells Endothelial cells Endothelial cells

VLA-4 ( 4 1: CD49d/CD29) IIb/IIIa ( IIb 3: CD41/CD61) VLA-2 ( 2 1: CD49b/CD29) ICAM-1 ICAM-2 VCAM-1

FGN, brinogen; FN, bronectin; ICAM, intercellular adhesion molecule; PMN, polymorphonuclear leukocytes; PSGL, P-selectin glycoprotein ligand; TSP, thrombospondin; VCAM, vascular cell adhesion molecule; VN, vitronectin; vWF, von Willebrand factor. Physiol Rev VOL
84 OCTOBER 2004




ecule-1 (653), P-selectin (209, 452, 653), or 2-integrins (653) are protected against the full spectrum of atherosclerotic lesion development. Human studies have demonstrated that plasma levels of intercellular adhesion molecule-1 and E-selectin correlate with the clinical manifestations of coronary atherosclerosis (424, 769). Thus adhesion molecules modulate the biologic response to vascular injury, with atherosclerosis and plaque activation representing two prominent examples of vascular injury. The activity of adhesion molecules is regulated via distinct mechanisms. The immunoglobulin superfamily members, vascular cell adhesion molecule-1 and intercellular adhesion molecule-1, are predominantly regulated at the transcriptional level. In contrast, P-selectin activity is dependent on rapid mobilization to the surface from preexisting pools. Integrins are activated by G protein agonists (e.g., ADP), growth factors (e.g., platelet-derived growth factor), and cytokines (e.g., tumor necrosis factor), through a process known as inside-out signaling. Integrin activation is thought to reect conformational change(s) that increase ligand afnity of 1- (182), 2(773), and 3-integrins (162). Cross-linking of cell surface integrins by ligand occupancy triggers outside-in signals that induce cytoskeletal rearrangement, cell spreading, and, in leukocytes, respiratory burst (1080). The signaling pathways mediating integrin activation are incompletely dened but may involve altered intracellular pH, increased intracellular Ca2 , and/or activation of protein kinase C, phospholipase A2, phosphoinositol 3-kinase, and protein phosphatases (393, 1004). Oxidative events have been implicated in the regulation of endothelial cellular adhesion molecules. Cytokineinduced endothelial cell vascular cell adhesion molecule-1 expression is inhibited by the thiol N-acetylcysteine (592), the metal-chelator pyrrolidine dithiocarbamate (592), or a glutathione peroxidase mimic (181). Intracellular O2 generation appears critical to cytokine-induced upregulation of vascular cell adhesion molecule-1, as it is inhibited by cellular overexpression of SOD (145). Similarly, a O2 signal has been implicated in the upregulation of intercellular adhesion molecule-1 in endothelial cell by oscillatory shear stress (423). Cytokine-induced vascular cell adhesion molecule-1 expression is also enhanced by oxidized LDL or its oxidized fatty acids (480). Even in the absence of cytokines, human arterial endothelial cells exposed to oxidized LDL alone express intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin (14). Thus considerable data indicate that cellular oxidative events modulate the expression of adhesion molecules on the endothelium. The role of ROS in regulating cellular adhesion is not limited to the endothelium. Adhesion of neutrophils is associated with a ROS burst that is required for the activation of Src-family kinases that are important for outPhysiol Rev VOL

side-in signaling (1079). In fact, there appears to be considerable cross-talk between inammatory cells and the endothelium with regard to adhesion molecule regulation. For example, a respiratory burst from the leukocyte oxidase is necessary for tumor necrosis factor- -induced upregulation of intercellular adhesion molecule-1 on endothelial cells in vivo (240). When taken together, the paragraphs outlined above provide secure evidence that endothelial-leukocyte adhesion involves oxidative events within both cells involved. V. RECONCILING AVAILABLE DATA ON OXIDATIVE EVENTS AND ATHEROSCLEROSIS In the sections above, we have reviewed the data linking oxidative events to the pathogenesis of atherosclerosis. Without question, there is a wealth of data demonstrating that atherosclerosis and its resultant cardiovascular events are associated with a number of oxidative events ranging from LDL oxidation to the production of intracellular ROS and RNS. Despite abundant data, however, a fundamental problem with implicating oxidative stress as pathophysiologically important for atherosclerosis is the poor performance of antioxidant strategies in limiting either atherosclerosis or cardiovascular events from atherosclerosis. There remains today no consensus that antioxidant supplementation of patients at risk for atherosclerosis has any effect on the disease process (see sect. IIIF2). These observations have called into question the relation between oxidative events and atherosclerosis and provide a real challenge to designing strategies targeted at the oxidative stress associated with atherosclerosis. There are several potential explanations as to why antioxidant trials might have proven ineffective in the treatment of atherosclerosis and, as a consequence, reconcile available data. First and foremost, one must consider the possibility that oxidative events are not causally related to the process of atherosclerosis and clinical cardiovascular disease. For many, this represents an unattractive explanation given the wealth of associative data linking oxidative stress to atherosclerosis. Second, we may not have the requisite fundamental understanding of the relevant oxidants involved in atherosclerosis and thus have not tested the appropriate antioxidant treatment for atherosclerosis. In this regard, the distinction between 1eand 2e-oxidants is of particular importance since most antioxidant trials involved species that are solely effective against 1e-oxidation reactions. Finally, it is possible that oxidative events principally represent an injurious response to the process of atherosclerosis and are not causative. In this instance, any strategy aimed at minimizing oxidation reactions would be akin to treating the

84 OCTOBER 2004



symptoms of a disease rather than the disease itself. In the following paragraphs, we briey consider each of these potential explanations. A. Oxidative Events and Atherosclerosis Are Not Causally Linked Despite the fact that this interpretation of available data is, perhaps, the darkest, there are data to support this contention. Human (915) and animal atherosclerotic lesions (541, 1055) are characterized by the presence of oxidized lipids thought to result from LDL oxidation. The latter, of course, has been proposed to cause foam cell formation, a critical part of the initiation of atherosclerotic lesion formation. Nevertheless, atherosclerotic lesion formation can be dissociated from the occurrence of lipid peroxidation in the arterial wall (see sect. IIIF1B), suggesting lipid peroxidation is not necessary for foam cell formation. If one discounts lipid peroxidation as necessary for foam cell formation, an alternative means of macrophage cholesterol loading must be found. In this regard, the response-to-retention hypothesis of early atherogenesis is of particular interest. A number of studies indicate that arterial wall retention of lipoproteins has implications for atherogenesis (see sect. IB2). One interpretation of these and other studies (238, 819, 820) is that lesion-prone areas are characterized by enhanced retention of apolipoprotein B-containing lipoproteins, and this process is the inciting event for atherosclerosis rather than LDL oxidation. Entrapment of LDL in the arterial wall has important sequelae. For example, proteoglycan-bound LDL may be more susceptible to oxidation (422), and once oxidized, this species could obviously promote atherosclerosis as discussed above for oxidized LDL. Retained LDL is a substrate for sphingomyelinase (1074) that may generate ceramides that are known to promote apoptosis and mitogenesis (357, 455). Most importantly, however, and as pointed out earlier, aggregated LDL is avidly internalized by macrophages and smooth muscle cells (440), thereby supporting foam cell formation without the need for LDL oxidation (991). Such at least initially LDL oxidationindependent formation of foam cells could explain why in human aortic lesions nonoxidized lipids accumulate before oxidized lipids as disease progresses (966). Considering the totality of evidence, one can make a cogent argument that LDL aggregation is sufcient for the formation of foam cells and the generation of atherosclerotic lesions. It is entirely possible this process will also produce some LDL oxidation; however, this would not be causally linked to atherosclerotic lesion formation. More investigation will be needed to determine the relative roles of LDL oxidation versus LDL retention to the early aspects of atherosclerotic lesion formation.
Physiol Rev VOL

B. Incomplete Knowledge of Oxidants Involved in Atherosclerosis The initial link between oxidative stress and atherosclerosis was derived from studies of LDL oxidation and its prevention with antioxidants such as probucol, vitamin E, and butylated hydroxy toluene. Most of these antioxidant species were chosen because they had considerable activity to inhibit LDL oxidation in vitro in response to 1e-oxidants such as copper ions or radical-generating systems. As a consequence, almost all evidence on antioxidant treatment and atherosclerosis involves these traditional antioxidants that are only active against 1e-oxidant species. If, however, the putative oxidative stress of atherosclerosis were actually due to 2e-oxidants, many of the antioxidant species outlined above would be ineffective scavengers and thus expected to fail. Whether, and if so to what extent, this line of argument can be extended to ascorbate requires further investigation, as the vitamin offers near-complete protection against HOCl and chloramines, partial protection against ONOO , and its efcacy against N2O3, particularly within a lipid environment, is not known. As we have learned in section IIIC, there is considerable evidence that 2e-oxidants are involved in the process of atherosclerosis. With regard to LDL, 2e-oxidants like HOCl oxidize LDL by preferentially targeting apolipoprotein B-100 rather than lipids (372). Myeloperoxidase, the major source of HOCl, is present and active in human lesions (184, 368, 581), and leukocyte myeloperoxidase levels are positively associated with coronary artery disease (91, 1103). Lesions and lesion-derived LDL in humans and WHHL rabbits contain HOCl-modied epitopes (368, 369, 581, 582) and chemical markers for active myeloperoxidase and HOCl (277, 377, 391). Thus abundant data implicate the 2e-oxidant HOCl in the pathology of atherogenesis, and this component of oxidative stress would not be altered by classic antioxidants such as vitamin E that are active only against radicals. As discussed in section IIIC1C, this conclusion is not mitigated substantially by the observation that mice decient in myeloperoxidase have somewhat increased atherosclerosis (90). In addition to HOCl, H2O2 has become an important oxidant in atherosclerosis, in particular as a component of cell signaling (see sect. IIF) that mediates many maladaptive responses in the vasculature. Growth factors and cell proliferation have long been implicated in atherosclerosis (781), and these cellular responses are dependent, in large part, on intracellular generation of H2O2 (145, 923). As discussed above, reactions involving H2O2 are not subject to inhibition by classic antioxidants such as vitamin E. As a consequence, features of atherosclerosis due to unchecked H2O2 production would not be altered by most antioxidant interventions in both human and animal studies that have been published thus far.

84 OCTOBER 2004



This latter point raises a common problem with the pursuit of antioxidant strategies as a means to limit oxidative stress and ameliorate oxidant-mediated pathology. In particular, such strategies presuppose a detailed knowledge of the relevant oxidants involved in a disease process and the specic consequences of scavenging such oxidants. This problem is illustrated in Figure 12. As can be seen, the production of ROS has a number of potentially important consequences that have been implicated in the pathophysiology of vascular disease. Introducing specic antioxidant species has the potential to scavenge or metabolize some, but not all, of the relevant oxidizing species implicated in atherosclerosis. For example, the introduction of lipid-soluble antioxidants will limit lipid peroxidation but will have no effect on 2e-oxidants and thus no effect on protein modication by ONOO , cell signaling by H2O2, or HOCl-mediated oxidation reactions. Conversely, species that scavenge H2O2 will have a profound effect on HOCl-mediated oxidation but may also wipe out H2O2-mediated signaling, which may, under certain circumstances, be adaptive rather than maladaptive. This latter point is illustrated nicely with regard to NO production and the clinical syndrome of sepsis. Although excess NO production has been linked to the vascular leakage and hypotension of sepsis (for review, see Ref. 833), the use of general NOS inhibitors has met with uniform failure to improve outcome in this disease (159). Thus, whenever a physiological process goes awry in the setting of disease (e.g., ROS signaling), strategies that rely simply on scavenging the offending species must be employed with extreme caution lest physiological responses may well be interrupted and worsen the clinical situation. How can one resolve the aforementioned conundrum? A good starting point would be to develop a more complete understanding of the relevant oxidant sources and of what controls their production. With this information in hand, one could devise strategies to ameliorate the

unchecked production of oxidants while preserving physiological signaling by ROS and RNS. The advantages of this strategy are illustrated by the experiences with chronic myelogenous leukemia. For many years, this disease was treated with cytotoxic chemotherapeutic agents that produced brief palliation, yet the disease remained incurable. Subsequently, research determined that chronic myelogenous leukemia was characterized by chromosomal rearrangement (the so-called Philadelphia chromosome) resulting in a unique fusion gene known as BCR-ABL that encoded a dysregulated tyrosine kinase (845). With this knowledge, a specic inhibitor of this kinase was devised, and it proved to be extremely effective in treating the disease (210). Thus, by understanding the nature of dysregulation, specic therapeutic approaches can be developed that target the disease process rather than physiological signaling. Only through further understanding the mechanisms of dysregulated oxidant production can we hope to achieve a similar result with atherosclerosis. C. The Oxidative Response to Inammation Hypothesis of Atherosclerosis With the wealth of data indicating that LDL oxidation is a prominent feature of atherosclerosis, there has been considerable interest in linking atherosclerosis risk factors to the process of LDL oxidation and oxidative stress in general. Indeed, many studies indicate that oxidative stress is a feature of many atherosclerosis risk factors such as diabetes (319), hypertension (333), and smoking (641). The notion that oxidative stress is causally related to atherosclerosis was thought to be so compelling that some investigators have even proposed that all atherosclerosis risk factors act through the production of excess oxidative stress (Fig. 13A) (12). With regard to lipid peroxidation, this link with oxidative stress was recently

FIG. 12. Diversity of potential oxidants involved in atherosclerosis and inhibitors required counteracting the biological consequences of the different oxidants. As stated in the text, there is a plethora of sources for reactive oxygen species (ROS) in the vasculature with a number of secondary reactions that have been described. Any one scavenger strategy that tries to intercept the potentially damaging species is not likely to have a material effect on other potentially harmful reactions. As a consequence, identifying the signals and sources that lead to abnormal production of ROS and/or reactive nitrogen species (RNS) could prove more fruitful in limiting oxidative damage. MPO, myeloperoxidase; Mn , metal ions. [Adapted from Munzel and Keaney (649).]

Physiol Rev VOL

84 OCTOBER 2004




tested in the Framingham Study, the study that gave rise to the concept of atherosclerosis risk factors. This investigation found that lipid peroxidation was linked to some, but not all, risk factors for atherosclerosis (474). In fact, statistical modeling with established cardiovascular risk factors was only able to explain 15% of the observed evidence for lipid peroxidation. Thus lipid peroxidation is only modestly linked to atherosclerosis risk factors. Another process integral to atherosclerosis is inammation, and this concept is now rmly established (for review, see Refs. 683, 715). Some 25 years ago, Ross (781) observed that atherogenic diets produced inammatory cell adhesion to the arterial wall in a matter of days. As we have seen, this recruitment of inammatory cells is dependent on cellular adhesion molecules and requires an interaction between leukocyte 1- and 2-integrins and endothelial adhesion molecules such as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1, respectively (1111). Many studies have established that circulating markers of inammation are predictive of both atherosclerosis and the clinical events associated with atherosclerosis (424, 556, 577, 729, 769). With this information in mind, one needs to consider whether antioxidant strategies have been disappointing in atherosclerosis largely because oxidative events may be a consequence, rather than a cause, of the atherosclerotic process (Fig. 13B). In this scenario, the inammatory process produces oxidative events as a by-product, but these events are not strictly required for the progression of atherosclerosis. As a consequence, antioxidant strategies that lead to scavenging of oxidants and limiting markers of oxidative stress would not be predicted to have a major impact on the disease process, as the link between inammation and atherosclerosis would not be altered. Thus the scheme depicted in Figure 13B provides an explanation for both the occurrence of oxidative events with atherosclerosis and the disappointing results that have been achieved with antioxidant supplementation trials. It is reasonable to ask if there is evidence to support such a contention. To address this issue, let us contrast the relation between atherosclerosis risk factors and the processes of oxidative stress and inammation. With regard to the former, there is only a loose relationship as

outlined above (474). Of the established risk factors, only smoking and diabetes are predictive of increased urinary levels of F2-isoprostanes (474). In comparison, the relation between atherosclerosis risk factors and inammation is quite rm. Epidemiological studies using circulating inammatory markers such as soluble intercellular adhesion molecule-1 (777) or C-reactive protein (558) have found that all established cardiovascular disease risk factors (i.e., smoking, hypertension, diabetes, hypercholesterolemia, age, and obesity) are predictive of circulating inammation markers. In addition, there is now evidence that hypercholesterolemia promotes atherosclerosis lesion development by activating macrophage innate immunity signaling pathways (63), thereby directly linking elevated serum lipids to a pro-inammatory signaling cascade. Taken together, these ndings tend to support the notion that inammation is a primary process in atherosclerosis, and oxidative stress is secondary. Additional studies will be needed to substantiate this notion or otherwise. In particular, it will be important to distinguish atherosclerosis, inammation, and oxidative stress to extend the measures of oxidative stress to lipid oxidation markers other than urinary F2-isoprostanes, and to include markers of protein oxidation. Concerning the latter, a recent case-control study showed plasma 3-nitrotyrosine levels to be higher in patients with established coronary artery disease than controls, and preliminary results suggested this to be independent of inammation (844). The notion that oxidative stress is an important secondary consequence of inammation is well established (658). The inammatory process is modulated by the activities of several families of enzymes including cyclooxgenases, lipoxygenases, NADPH oxidases, nitric oxide synthases, and peroxidases that all possess the catalytic capacity to produce ROS and RNS. The roles of these reactive species in host defense and antimicrobial activity are well documented as impaired ROS or RNS production results in susceptibility to bacterial (25) or parasitic infection (651). The specic role that reactive species play in the inammation of vascular disease, however, is not yet clear. We would submit that ROS- and RNS-mediated oxidative events are most important for modulating the healing response to inammation. As a consequence, we

FIG. 13. Conceptual views of oxidative stress as a cause (A) or consequence (B) of atherogenesis. In scheme B, one can see that scavenging ROS/RNS and preventing markers of oxidative stress will not have any material impact on the course of atherosclerosis.

Physiol Rev VOL

84 OCTOBER 2004




propose the oxidative response to inammation hypothesis as a means to reconcile available evidence concerning oxidative events and vascular disease. According to our proposal (Fig. 14), the injurious response to cardiovascular risk factors is manifest as an inammatory response in the vascular wall subsequent to lipoprotein retention and vascular injury. This response is characterized by the production of ROS and RNS, not as a means to mediate atherosclerosis, but as a by-product of the inammatory process. In this scheme, the production of ROS is, however, involved in promoting tissue reorganization and the regenerative response to injury. The model depicted in Figure 14 lends itself to several predictions about atherosclerosis. For example, this model would predict that modication of atherosclerotic risk factors should be manifest as a reduction in vascular inammation. In large part, this prediction has already been fullled as lipid-lowering (7), smoking cessation (698), weight loss (1109) and improved glucose control (775) have all been associated with a reduction in circulating markers of inammation. Another prediction from the oxidative response to inammation hypothesis is that any state of heightened inammation should be associated with a greater degree of atherosclerosis. Considerable data support such a contention as many conditions known to activate the immune system have now been linked to the activity of atherosclerosis. For example, periodontal disease (639) and prior infection (608) have been associated with more advanced or active atherosclerosis. The converse is also true, in that agents known to

increase circulating markers of inammation would be expected to exacerbate atherosclerotic vascular disease. With regard to this latter point, hormone replacement therapy increases circulating C-reactive protein levels (559), and clinical trials thus far have demonstrated its promotion of atherosclerotic cardiovascular events (329). Thus the oxidative response to inammation model of atherosclerosis is consistent with available clinical and epidemiological evidence on the link between inammation and atherosclerosis. The oxidative response to inammation model is also consistent with available data on tissue injury, and this has implications for vascular remodeling. For example, the migration and proliferation of smooth muscle cells is a common response to vascular injury (818). The smooth muscle cell response to growth factors is now known to be dependent on the intracellular generation of H2O2 (26, 923). This putative role for ROS in the response to tissue injury is consistent with a recent report in which Nox2decient mice demonstrate an impaired proliferative response to vascular injury (146a). Teleologically, one can rationalize the relation between ROS and the response to tissue injury. If high levels of ROS and RNS are common sequelae of host invasion and tissue injury, and one considers that the concentration of these reactive species falls as a cubed function of the distance from tissue injury, it makes sense that at low levels (at the fringes of injured tissue) ROS and RNS serve as an initiating signal for tissue remodeling. A similar scenario exists for NO whereby low levels are associated with normal vascular homeostasis and high levels of NO accompany overwhelming tissue invasion and sepsis. The specic means, however, by which ROS and RNS modulate tissue remodeling will require considerable further study. D. Conclusions There is a wealth of data linking oxidative events to the pathogenesis of atherosclerosis and its resultant cardiovascular events. These include unambiguous evidence for the occurrence of oxidative modications in atherosclerotic lesions, proatherogenic activities of oxidized LDL, successful outcome of some antioxidant intervention studies in animal models of atherosclerosis, the increased production of intracellular ROS and RNS during disease, and the role of oxidative processes in vasomotor function and plaque disruption. Despite this, the causative relationship between oxidative events and atherosclerosis in general and the pathophysiological importance of LDL oxidation in particular have been challenged by the overall poor performance of antioxidant strategies in limiting atherosclerosis and its cardiovascular events, the overall lack of clear disease stage dependency in the vessel wall contents of oxidized molecules and antioxiwww.prv.org

FIG. 14. Conceptual view for the oxidative response to inammation hypothesis of atherosclerosis. In this scheme, the presence of cardiovascular risk factors promotes the extent of arterial retention of lipoproteins that leads to the vascular endothelium adopting an injury phenotpe. This event stimulates inammatory cell recruitment into the arterial wall and, as a consequence, vascular inammation. The inammatory process is central to lesion development but also leads to the production of ROS/RNS. The latter may amplify vascular inammation, and they cause the oxidation of biomolecules (i.e., oxidative stress) that is important for promoting tissue remodeling and has a modulatory inuence on the characteristic of atherosclerotic lesions, but does not directly cause atherosclerosis.

Physiol Rev VOL

84 OCTOBER 2004



dants, and by the reported dissociation of atherosclerosis and lipoprotein oxidation in the vessel wall of animals. As discussed, the poor outcome of antioxidant trials may be explained by the lack of appreciation of the importance of oxidative events caused by 2e-oxidants combined with the inappropriate focus on classic antioxidants effective only against 1e-oxidation reactions. It will be important in this context to provide experimental evidence that scavengers of 2e-oxidants can offer protection against disease in suitable animal models of atherosclerosis. Perhaps just as important, the relation between atherosclerosis and cellular redox processes such as the role of ROS and RNS in cell signaling require experimental testing employing targeted strategies. Finally, the real challenge will be to distinguish oxidative events as a cause rather than an injurious response to the process of atherosclerosis. In this context, it will perhaps be particularly important to experimentally examine whether oxidative modications in the vessel wall occur as a process secondary to inammation, as is implied by the oxidative response to inammation hypothesis presented here.
We thank Drs. Proctor and Mamo for their original drawing (736) of Figure 5. The work in R. Stockers laboratory is supported by National Health & Medical Research Council of Australia (NH&MRC) Programme Grant 222722 and by grants from the Heart Foundation of Australia. R. Stocker also acknowledges the support he receives as a recipient of a NH&MRC Senior Principal Research Fellowship. The work in J. F. Keaneys laboratory is supported by National Institutes of Health Grants DK-55656, HL-60886, HL-67206, and HL-68758. J. F. Keaney is an Established Investigator of the American Heart Association. Address for reprint requests and other correspondence: R. Stocker, Centre for Vascular Research, Univ. of New South Wales, and Dept. of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia (E-mail: r.stocker@unsw. edu.au).













1. Abe J, Takahashi M, Ishida M, Lee JD, and Berk BC. c-Src is required for oxidative stress-mediated activation of big mitogenactivated protein kinase 1. J Biol Chem 272: 20389 20394, 1997. 2. Abid MR, Kachra Z, Spokes KC, and Aird WC. NADPH oxidase activity is required for endothelial cell proliferation and migration. FEBS Lett 486: 252256, 2000. 3. Abrahamsson T, Brandt U, Marklund SL, and Sjoqvist PO. Vascular bound recombinant extracellular superoxide dismutase type C protects against the detrimental effects of superoxide radicals on endothelium-dependent arterial relaxation. Circ Res 70: 264 271, 1992. 4. Abu-Soud HM and Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 275: 37524 37532, 2000. 4a.Adachi T, Pimentel DR, Heibeck T, Hou X, Lee YJ, Jiang B, Ido Y, and Cohen RA. S-glutathiolation of Ras mediates redoxsensitive signaling by angiotensin II in vascular smooth muscle cells. J Biol Chem 279: 2985729862, 2004. 5. Adams MR, Nakagomi A, Keech A, Robinson J, McCredie R, Bailey BP, Freedman SB, and Celermajer DS. Carotid intimaPhysiol Rev VOL





media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 92: 21272134, 1995. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, and Iida M. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109: 227233, 2004. Albert MA, Danielson E, Rifai N, and Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64 70, 2001. Albrich JM, McCarthy CA, and Hurst JK. Biological reactivity of hypochlorous acid: implications for microbicidal mechanisms of leukocyte myeloperoxidase. Proc Natl Acad Sci USA 78: 210 214, 1981. Alcain FJ, Buron MI, Villalba JM, and Navas P. Ascorbate is regenerated by HL-60 cells through the transplasmalemma redox system. Biochim Biophys Acta 1073: 380 385, 1991. Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa JA, and Bourassa MG. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol 22: 11411154, 1993. Alderton WK, Cooper CE, and Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593 615, 2001. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inammatory response: a new perspective. Hypertension 25: 155161, 1995. Allentoff AJ, Bolton JL, Wilks A, Thompson JA, and Ortiz de Montellano PR. Heterolytic versus homolytic peroxide bond cleavage by sperm whale myoglobin and myoglobin mutants. J Am Chem Soc 114: 9744 9749, 1992. Amberger A, Maczek C, Jurgens G, Michaelis D, Schett G, Trieb K, Eberl T, Jindal S, Xu Q, and Wick G. Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones 2: 94 103, 1997. Ambrosio G, Golino P, Pascucci I, Rosolowsky M, Campbell WB, DeClerck F, Tritto I, and Chiariello M. Modulation of platelet function by reactive oxygen metabolites. Am J Physiol Heart Circ Physiol 267: H308 H318, 1994. Ames BN, Cathcart R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defence in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78: 6858 6862, 1981. Anderson MM, Hazen SL, Hsu FF, and Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glyceraldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive -hydroxy and , -unsaturaed aldehydes by phagocytes at sites of inammation. J Clin Invest 99: 424 432, 1997. Anderson MM, Requena JR, Crowley JR, Thorpe SR, and Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon- (carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inammation. J Clin Invest 104: 103113, 1999. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, and Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488 493, 1995. Applegate LA, Luscher P, and Tyrrell RM. Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res 51: 974 978, 1991. Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, Petros JA, and Lambeth JD. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA 98: 5550 5555, 2001. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. ature. Evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin. J Biol Chem 273: 1350213508, 1998. Becker BF, Reinholz N, Ozcelik T, Leipert B, and Gerlach E. Uric acid as radical scavenger and antioxidant in the heart. Pugers Arch 415: 127135, 1989. Beckman JS, Beckman TW, Chen J, Marshall PA, and Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620 1624, 1990. Beckman JS, Chen J, Ischiropoulos H, and Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol 233: 229 240, 1994. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol Cell Physiol 271: C1424 C1437, 1996. Beckman JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, and White CR. Extensive nitration of protein tyrosine in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe-Seyler 375: 81 88, 1994. Bedwell S, Dean RT, and Jessup W. The action of dened oxygen-centered free radicals on human low-density lipoproteins. Biochem J 262: 707712, 1989. Beinert H and Kennedy MC. Aconitase, a two-faced protein: enzyme and iron regulatory factor. FASEB J 7: 14421449, 1993. Belkner J, Wiesner R, Kuhn H, and Lankin VZ. The oxygenation of cholesterol esters by the reticulocyte lipoxygenase. FEBS Lett 279: 110 114, 1991. Belkner J, Wiesner R, Rathman J, Barnett J, Sigal E, and Kuhn H. Oxygenation of lipoproteins by mammalian lipoxygen ases. Eur J Biochem 213: 251261, 1993. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 3: 20 26, 2002. Bennett MR, Evan GI, and Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 95: 2266 2274, 1995. Benz DJ, Mol M, Ezaki M, Mori-Ito N, Zelan I, Miyanohara A, Friedmann T, Parthasarathy S, Steinberg D, and Witztum JL. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine broblast expressing high levels of human 15-lipoxygenase. J Biol Chem 270: 51915197, 1995. Berger TM, Polidori MC, Dabbagh A, Evans PJ, Halliwell B, Morrow JD, Roberts LJ II, and Frei B. Antioxidant activity of vitamin C in iron-overloaded human plasma. J Biol Chem 272: 15656 15660, 1997. Bergmark C, Wu R, de Faire U, Lefvert AK, and Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15: 441 445, 1995. Berliner JA and Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20: 707727, 1996. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, and Fogelman AM. Minimally modied low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85: 1260 1266, 1990. Bevilacqua MP and Nelson RM. Selectins. J Clin Invest 91: 379 387, 1993. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 12: 647 656, 1992. Bird DA, Tangirala RK, Fruebis J, Steinberg D, Witztum JL, and Palinski W. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor decient mice. J Lipid Res 39: 1079 1090, 1998. Bisby RH and Parker AW. Reactions of the -tocopheroxyl radical in micellar solutions studied by nanosecond laser ash photolysis. FEBS Lett 290: 205208, 1991. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, and Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10: 416 421, 2004. Bjorkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, and Henriksson P. The antioxidant butylated www.prv.org

22. Arroyo A, Navarro F, Gomez-Diaz C, Crane FL, Alcain FJ, Navas P, and Villalba JM. Interactions between ascorbyl free radical and coenzyme Q at the plasma membrane. J Bioenerg Biomembr 32: 199 210, 2000. 23. Azuma H, Ishikawa M, and Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 88: 411 415, 1986. 24. Baas AS and Berk BC. Differential activation of mitogen-activated protein kinases by H2O2 and O2 in vascular smooth muscle cells. Circ Res 77: 29 36, 1995. 25. Babior BM, Lambeth JD, and Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys 397: 342344, 2002. 26. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, and Rhee SG. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 272: 217221, 1997. 27. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White CR, Bullard DC, Brennan ML, Lusis AJ, Moore KP, and Freeman BA. Endothelial transcytosis of myeloperoxidase confers specicity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 108: 1759 1770, 2001. 28. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, and Vercellotti GM. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 267: 18148 18153, 1992. 29. Balla G, Jacob HS, Eaton JW, Belcher JD, and Vercellotti GM. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb 11: 1700 1711, 1991. 30. Ballinger SW, Patterson C, Knight-Lozano CA, Burow DL, Conklin CA, Hu Z, Reuf J, Horaist C, Lebovitz R, Hunter GC, McIntyre K, and Runge MS. Mitochondrial integrity and function in atherogenesis. Circulation 106: 544 549, 2002. 31. Ballou DP, Zhao Y, Brandish PE, and Marletta MA. Revisiting the kinetics of nitric oxide (NO) binding to soluble guanylate cyclase: the simple NO-binding model is incorrect. Proc Natl Acad Sci USA 99: 1209712101, 2002. 32. Baranano DE, Rao M, Ferris CD, and Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99: 1609316098, 2002. 33. Barclay LR, Baskin KA, Locke SJ, and Vinqvist MR. Absolute rate constants for lipid peroxidation and inhibition in model biomembranes. Can J Chem 67: 1366 1369, 1989. 34. Barclay LRC, Locke SJ, and MacNeil JM. Autoxidation in micelles. Synergism of vitamin C with lipid-soluble vitamin E and water-soluble Trolox. Can J Chem 63: 366 374, 1985. 35. Barford D, Jia Z, and Tonks NK. Protein tyrosine phosphatases take off. Nat Struct Biol 2: 10431053, 1995. 36. Barnard ML, Muller-Eberhard U, and Turrens JF. Protective role of hemopexin on heme-dependent lung oxidative stress. Biochem Biophys Res Commun 192: 82 87, 1993. 37. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, ORourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, and Hare JM. Nitric oxide regulates the heart by spatial connement of nitric oxide synthase isoforms. Nature 416: 337339, 2002. 38. Barrett WC, DeGnore JP, Keng YF, Zhang ZY, Yim MB, and Chock PB. Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B. J Biol Chem 274: 3454334546, 1999. 39. Barrett WC, DeGnore JP, Konig S, Fales HM, Keng YF, Zhang ZY, Yim MB, and Chock PB. Regulation of PTP1B via glutathionylation of the active site cysteine 215. Biochemistry 38: 6699 6705, 1999. 40. Barrett-Connor E and Bush TL. Estrogen and coronary heart disease in women. JAMA 265: 18611867, 1991. 41. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, and Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE( / ) mice. J Clin Invest 108: 15131522, 2001. 42. Bec N, Gorren AC, Voelker C, Mayer B, and Lange R. Reaction of neuronal nitric-oxide synthase with oxygen at low temperPhysiol Rev VOL







49. 50.


52. 53.




57. 58.

59. 60. 61.




84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 11: 1522, 1991. Bjornstedt M, Hamberg M, Kumar S, Xue J, and Holmgren A. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem 270: 11761 11764, 1995. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, and Lackner KJ. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349: 16051613, 2003. Blouin E, Halbwachs-Mecarelli L, and Rieu P. Redox regulation of 2-integrin CD11b/CD18 activation. Eur J Immunol 29: 3419 3431, 1999. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, and Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebocontrolled trial. Lancet 356: 12131218, 2000. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, and Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22: 347551, 1999. Boger RH, Bode-Boger SM, Phivthong-ngam L, Brandes RP, Schwedhelm E, Mugge A, Bohme M, Tsikas D, and Frolich JC. Dietary L-arginine and -tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis 141: 31 43, 1998. Boren J, Olin K, Lee I, Chait A, Wight TN, and Innerarity TL. Identication of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 101: 2658 2664, 1998. Boring L, Gosling J, Cleary M, and Charo IF. Decreased lesion formation in CCR2 / mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894 897, 1998. Boscoboinik D, Szewczyk A, Hensey C, and Azzi A. Inhibition of cell proliferation by -tocopherol. Role of protein kinase C. J Biol Chem 266: 6188 6194, 1991. Bourcier T, Sukhova G, and Libby P. The nuclear factor -B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 272: 1581715824, 1997. Bouton C, Raveau M, and Drapier JC. Modulation of iron regulatory protein functions. Further insights into the role of nitrogen- and oxygen-derived reactive species. J Biol Chem 271: 2300 2306, 1996. Boveris A, Alvarez S, Bustamante J, and Valdez L. Measurement of superoxide radical and hydrogen peroxide production in isolated cells and subcellular organelles. Methods Enzymol 349: 280 287, 2002. Bowry VW and Ingold KU. The unexpected role of vitamin E ( -tocopherol) in the peroxidation of human low-density lipoprotein. Acc Chem Res 32: 2734, 1999. Bowry VW, Ingold KU, and Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 288: 341344, 1992. Bowry VW, Mohr D, Cleary J, and Stocker R. Prevention of tocopherol-mediated peroxidation of ubiquinol-10-free human low density lipoprotein. J Biol Chem 270: 5756 5763, 1995. Bowry VW, Stanley KK, and Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in fasted human plasma. Proc Natl Acad Sci USA 89: 10316 10320, 1992. Bowry VW and Stocker R. Tocopherol-mediated peroxidation. The pro-oxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein. J Am Chem Soc 115: 6029 6044, 1993. Boyd HC, Gown AM, Wolfbauer G, and Chait A. Direct evidence for a protein recognized by a monoclonal antibody against Physiol Rev VOL










87. 88.


89. 90.






93. 94.







97. 98.








101. 102.


oxidatively modied LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 135: 815 825, 1989. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, and Neumeier D. Activated transcription nuclear factor-kappa B is present in atherosclerotic lesion. J Clin Invest 97: 17151722, 1996. Brandwein HJ, Lewicki JA, and Murad F. Reversible inactivation of guanylate cyclase by mixed disulde formation. J Biol Chem 256: 2958 2962, 1981. Brasen JH, Hakkinen T, Malle E, Beisiegel U, and Yla-Hert tuala S. Patterns of oxidized epitopes, but not NF-kappaB expression, change during atherogenesis in WHHL rabbits. Atherosclerosis 166: 1321, 2003. Brasen JH, Koenig K, Bach H, Kontush A, Heinle H, Witting PK, Yla-Herttuala S, Stocker R, and Beisiegel U. Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. Atherosclerosis 163: 249 259, 2002. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274: 23679 23682, 1999. Brattsand R. Actions of vitamins A and E and some nicotinic acid derivatives on plasma lipids and on lipid inltration of aorta in cholesterol-fed rabbits. Atherosclerosis 22: 47 61, 1975. Bray TM and Taylor CG. Tissue glutathione, nutrition, and oxidative stress. Can J Physiol Pharmacol 71: 746 751, 1993. Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, Mehta AC, Lim LL, Shi W, Hazen SL, Jacob JS, Crowley JR, Heinecke JW, and Lusis AJ. Increased atherosclerosis in myeloperoxidase-decient mice. J Clin Invest 107: 419 430, 2001. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, and Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349: 15951604, 2003. Bressler NM, Broekman MJ, and Marcus AJ. Concurrent studies of oxygen consumption and aggregation in stimulated human platelets. Blood 53: 167178, 1979. Brigelius-Flohe R and Traber MG. Vitamin E: function and metabolism. FASEB J 13: 11451155, 1999. Brooks CJW, Harland WA, Steel G, and Gilbert JD. Lipids of human atheroma: isolation of hydroxyoctadecadienoic acids from advanced aortal lesions. Biochim Biophys Acta 202: 563566, 1970. Brooks CJW, Steel G, Gilbert JD, and Harland WA. Lipids in human atheroma. Part 4. Characterisation of a new group of polar sterol esters from human atherosclerotic plaques. Atherosclerosis 13: 223237, 1971. Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, and Soares MP. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 192: 10151026, 2000. Brown AJ and Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 142: 128, 1999. Brown AJ, Leong S, Dean RT, and Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J Lipid Res 38: 1730 1745, 1997. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, and Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 15831592, 2001. Brown MR, Miller FJ Jr, Li WG, Ellingson AN, Mozena JD, Chatterjee P, Engelhardt JF, Zwacka RM, Oberley LW, Fang X, Spector AA, and Weintraub NL. Overexpression of human catalase inhibits proliferation and promotes apoptosis in vascular smooth muscle cells. Circ Res 85: 524 533, 1999. Bruger M. Experimental atherosclerosis. VII. Effect of vitamin E. Proc Soc Exp Biol Med 59: 56 57, 1945. Brune B and Ullrich V. 12-Hydroperoxyeicosatetraenoic acid inhibits main platelet functions by activation of soluble guanylate cyclase. Mol Pharmacol 39: 671 678, 1991. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. 123. Cardillo C, Kilcoyne CM, Cannon RO, 3rd Quyyumi AA, and Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 30: 57 63, 1997. 124. Carew TE, Pittman RC, Marchand ER, and Steinberg D. Measurement in vivo of irreversible degradation of low density lipoprotein in the rabbit aorta. Predominance of intimal degradation. Arteriosclerosis 4: 214 224, 1984. 125. Carew TE, Schwenke DC, and Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84: 7725 7729, 1987. 126. Carpenter KL, Cheeseman KH, van der Veen C, Taylor SE, Walker MK, and Mitchinson MJ. Depletion of alpha-tocopherol in human atherosclerotic lesions. Free Radic Res 23: 549 558, 1995. 127. Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, and Mitchinson MJ. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta 1256: 141150, 1995. 128. Carpenter KLH, Taylor SE, Ballantine JA, Fussell B, Halliwell B, and Mitchinson MJ. Lipids and oxidised lipids in human atheroma and normal aorta. Biochim Biophys Acta 1167: 121130, 1993. 129. Carr A and Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J 13: 10071024, 1999. 130. Carr AC and Frei B. Human neutrophils oxidize low-density lipoprotein by a hypochlorous acid-dependent mechanism: the role of vitamin C. Biol Chem 383: 627 636, 2002. 131. Carr AC and Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 69: 1086 1107, 1999. 132. Carr AC, McCall MR, and Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20: 1716 1723, 2000. 133. Carr AC, Myzak MC, Stocker R, McCall MR, and Frei B. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett 487: 176 180, 2000. 134. Carr AC, Tijerina T, and Frei B. Vitamin C protects against and reverses specic hypochlorous acid- and chloramine-dependent modications of low-density lipoprotein. Biochem J 346: 491 499, 2000. 135. Carr AC, Zhu BZ, and Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res 87: 349 354, 2000. 136. Caselli A, Marzocchini R, Camici G, Manao G, Moneti G, Pieraccini G, and Ramponi G. The inactivation mechanism of low molecular weight phosphotyrosine-protein phosphatase by H2O2. J Biol Chem 273: 32554 32560, 1998. 137. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 24: 2328, 2004. 138. Cathcart MK, McNally AK, Morel DW, and Chisolm GM. Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. J Immunol 142: 19631969, 1989. 139. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, and Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269 6279, 1996. 140. Chae HZ, Chung SJ, and Rhee SG. Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem 269: 27670 27678, 1994. 141. Chai YC, Ashraf SS, Rokutan K, Johnston RB Jr, and Thomas JA. S-Thiolation of individual human neutrophil proteins including actin by stimulation of the respiratory burst: evidence against a role for glutathione disulde. Arch Biochem Biophys 310: 273 281, 1994. 142. Chamulitrat W and Mason RP. Lipid peroxyl radical intermediates in the peroxidation of polyunsaturated fatty acids by lipoxywww.prv.org

103. Budanov AV, Sablina AA, Feinstein E, Koonin EV, and Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304: 596 600, 2004. 104. Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 300: 535543, 1993. 105. Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, Breall JA, and Rackley CE. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J 131: 663 667, 1996. 106. Burch JW and Burch PT. Glutathione disulde production during arachidonic acid oxygenation in human platelets. Prostaglandins 39: 123134, 1990. 107. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 18: 775794, 1995. 108. Burk RF, and Hill KE. Selenoprotein P. A selenium-rich extracellular glycoprotein. J Nutr 124: 18911897, 1994. 109. Burke TM and Wolin MS. Hydrogen peroxide elicits pulmonary arterial soluble relaxation and guanylate cyclase activation. Am J Physiol Heart Circ Physiol 252: H721H732, 1987. 110. Burton GW and Ingold KU. Autoxidation of biological molecules. 1. The antioxidant activity of vitamin E and related chainbreaking phenolic antioxidants in vitro. J Am Chem Soc 103: 6472 6477, 1981. 111. Burton GW and Ingold KU. -Carotene: an unusual type of lipid antioxidant. Science 224: 569 573, 1984. 112. Burton GW and Ingold KU. Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. Acc Chem Res 19: 194 201, 1986. 113. Burton GW, Wronska U, Stone L, Foster DO, and Ingold KU. Biokinetics of dietary RRR- -tocopherol in the male guinea pig at three dietary levels of vitamin C and two levels of vitamin E. Evidence that vitmain C does not spare vitamin E in vivo. Lipids 25: 199 210, 1990. 114. Buttery LD, Springall DR, Chester AH, Evans TJ, Standeld EN, Parums DV, Yacoub MH, and Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 75: 77 85, 1996. 115. Byun J, Mueller DM, Fabjan JS, and Heinecke JW. Nitrogen dioxide radical generated by the myeloperoxidase-hydrogen peroxide-nitrite system promotes lipid peroxidation of low density lipoprotein. FEBS Lett 455: 243246, 1999. 116. Cadwgan TM and Benjamin N. Evidence for altered platelet nitric oxide synthesis in essential hypertension. J Hypertens 11: 417 420, 1993. 117. Cai H, Davis ME, Drummond GR, and Harrison DG. Induction of endothelial NO synthase by hydrogen peroxide via a Ca2 / calmodulin-dependent protein kinase II/janus kinase 2-dependent pathway. Arterioscler Thromb Vasc Biol 21: 15711576, 2001. 118. Camejo G, Fager G, Rosengren B, Hurt-Camejo E, and Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem 268: 1413114137, 1993. 119. Camejo G, Halberg C, Manschik-Lundin A, Hurt-Camejo E, Rosengren B, Olsson H, Hansson GI, Forsberg GB, and Ylhen B. Hemin binding and oxidation of lipoproteins in serum: mechanisms and effect on the interaction of LDL with human macrophages. J Lipid Res 39: 755766, 1998. 120. Camejo G, Hurt E, Wiklund O, Rosengren B, Lopez F, and Bondjers G. Modications of low-density lipoprotein induced by arterial proteoglycans and chondroitin-6-sulfate. Biochim Biophys Acta 1096: 253261, 1991. 121. Camejo G, Hurt-Camejo E, Rosengren B, Wiklund O, Lopez F, and Bondjers G. Modication of copper-catalyzed oxidation of low density lipoprotein by proteoglycans and glycosaminoglycans. J Lipid Res 32: 19831991, 1991. 122. Campbell DL, Stamler JS, and Strauss HC. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 108: 277293, 1996. Physiol Rev VOL

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS genase. Direct electron spin resonance investigations. J Biol Chem 264: 20968 20973, 1989. 143. Chance B, Sies H, and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59: 527 605, 1979. 144. Chang L and Karin M. Mammalian MAP kinase signalling cascades. Nature 410: 37 40, 2001. 145. Chen K, Thomas SR, and Keaney JF Jr. Beyond LDL oxidation: ROS in vascular signal transduction. Free Radic Biol Med 35: 117132, 2003. 146. Chen K, Vita JA, Berk BC, and Keaney JF Jr. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation. J Biol Chem 276: 1604516050, 2001. 146a.Chen Z, Keaney JF Jr, Schulz E, Levison B, Shan L, Sakuma M, Zhang X, Shi C, Hazen SL, and Simon SI. Decreased neointimal formation in Nox2-decient mice reveals a direct role for NADPH oxidase in the response to arterial injury. Proc Natl Acad Sci USA. In press. 147. Cheng G, Cao Z, Xu X, van Meir EG, and Lambeth JD. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 269: 131140, 2001. 148. Cherry PD and Wolin MS. Ascorbate activates soluble guanylate cyclase via H2O2-metabolism by catalase. Free Radic Biol Med 7: 485 490, 1989. 149. Chin JH, Azhar S, and Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 89: 10 18, 1992. 150. Chisolm GM III, Hazen SL, Fox PL, and Cathcart MK. The oxidation of lipoproteins by monocytes-macrophages. Biochemical and biological mechanisms. J Biol Chem 274: 25959 25962, 1999. 151. Chisolm GM, Ma G, Irwin KC, Martin LL, Gunderson KG, Linberg LF, Morel DW, and DiCorleto PE. 7 -Hydroperoxycholest-5-en-3 -ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc Natl Acad Sci USA 91: 1145211456, 1994. 152. Choy KJ, Deng YM, Hou JY, Wu B, Lau AK, Witting PK, and Stocker R. Coenzyme Q10 supplementation inhibits aortic lipid oxidation but fails to attenuate intimal thickening in ballooninjured New Zealand White rabbits. Free Radic Biol Med 35: 300 309, 2003. 153. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, and Ames BN. -Tocopherol traps mutagenic electrophiles such as NO(X) and complements -tocopherol: physiological implications. Proc Natl Acad Sci USA 94: 32173222, 1997. 154. Christison JK, Karjalainen A, Brauman J, Bygrave F, and Stocker R. Rapid reduction and removal of HDL- but not LDLassociated cholesterylester hydroperoxides by in situ perfused rat liver. Biochem J 314: 739 742, 1996. 155. Cirino G, Fiorucci S, and Sessa WC. Endothelial nitric oxide synthase: the Cinderella of inammation? Trends Pharmacol Sci 24: 9195, 2003. 156. Claiborne A, Miller H, Parsonage D, and Ross RP. Proteinsulfenic acid stabilization and function in enzyme catalysis and gene regulation. FASEB J 7: 14831490, 1993. 157. Cleary J, Mohr D, Adams MR, Celermajer DS, and Stocker R. Plasma and LDL levels of major lipophilic antioxidants are similar in patients with advanced atherosclerosis and healthy controls. Free Radic Res 26: 175182, 1997. 158. Cleeter MW, Cooper JM, Darley-Usmar VM, Moncada S, and Schapira AH. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett 345: 50 54, 1994. 159. Cobb JP. Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red. Crit Care Med 27: 855 856, 1999. 160. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, and Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277: 31013108, 2002. Physiol Rev VOL


161. Collaboration AT. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308: 81106, 1994. 162. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 76: 101108, 1985. 163. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, and Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF- B and cytokine-inducible enhancers. FASEB J 9: 899 909, 1995. 164. Collison MW and Thomas JA. S-thiolation of cytoplasmic cardiac creatine kinase in heart cells treated with diamide. Biochim Biophys Acta 928: 121129, 1987. 165. Cowie CC, Rust KF, Byrd-Holt D, Eberhardt MS, Saydah S, Geiss LS, Engelgan MM, Ford ES, and Gregg EW. Prevalence of diabetes and impaired fasting glucose in adultsUnited States, 1999 2000. MMWR 52: 833 837, 2003. 166. Cooney RV, Franke AA, Harwood PJ, Hatch-Pigott V, Custer LJ, and Mordan LJ. -Tocopherol detoxication of nitrogen dioxide: superiority to -tocopherol. Proc Natl Acad Sci USA 90: 17711775, 1993. 167. Coxon A, Rieu P, Barkalow FJ, Askari S, Sharpe AH, von Andrian UH, Arnaout MA, and Mayadas TN. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inammation. Immunity 5: 653 666, 1996. 168. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 20: 591598, 2001. 169. Culbertson SM, Vinqvist MR, Barclay LR, and Porter NA. Minimizing tocopherol-mediated radical phase transfer in lowdensity lipoprotein oxidation with an amphiphilic unsymmetrical azo initiator. J Am Chem Soc 123: 8951 8960, 2001. 170. Culleton BF, Larson MG, Kannel WB, and Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131: 713, 1999. 171. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, and Fogelman AM. Minimally modied low density lipoprotein induces monocyte chemotactic protein (MCP-1) in human endothelial and smooth muscle cells. Proc Natl Acad Sci USA 87: 5134 5138, 1990. 172. Cybulsky MI and Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251: 788 791, 1991. 173. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, and Milstone DS. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107: 12551262, 2001. 174. Cynshi O, Kawabe Y, Suzuki T, Takashima Y, Kaise H, Nakamura M, Ohba Y, Kato Y, Tamura K, Hayasaka A, Higashida A, Sakaguchi H, Takeya M, Takahashi K, Inoue K, Noguchi N, Niki E, and Kodama T. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc Natl Acad Sci USA 95: 1012310128, 1998. 175. Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, and Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-decient mice. Circulation 103: 22772282, 2001. 176. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, and Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-decient mice. J Clin Invest 103: 15971604, 1999. 177. Cyrus T, Yao Y, Rokach J, Tang LX, and Pratico D. Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-decient mice with established vascular lesions. Circulation 107: 521523, 2003. 178. Dabbagh AJ and Frei B. Human suction blister interstitial uid prevents metal ion-dependent oxidation of low density lipoprotein by macrophages and in cell-free systems. J Clin Invest 96: 1958 1966, 1995. 179. Dabbagh AJ, Shwaery GT, Keaney JF Jr, and Frei B. Effect of iron overload and iron deciency on atherosclerosis in the hyperwww.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. cholesterolemic rabbit. Arterioscler Thromb Vasc Biol 17: 2638 2645, 1997. Dafre AL, Sies H, and Akerboom T. Protein S-thiolation and regulation of microsomal glutathione transferase activity by the glutathione redox couple. Arch Biochem Biophys 332: 288 294, 1996. dAlessio P, Moutet M, Coudrier E, Darquenne S, and Chaudiere J. ICAM-1 and VCAM-1 expression induced by TNFalpha are inhibited by a glutathione peroxidase mimic. Free Radic Biol Med 24: 979 987, 1998. Danilov YN and Juliano RL. Phorbol ester modulation of integrin-mediated cell adhesion: a postreceptor event. J Cell Biol 108: 19251933, 1989. Das SK, White AC, and Fanburg BL. Modulation of transforming growth factor- 1 antiproliferative effects on endothelial cells by cysteine, cystine, and N-acetylcysteine. J Clin Invest 90: 1649 1656, 1992. Daugherty A, Dunn JL, Rateri DL, and Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437 444, 1994. Davies KJA, Sevanian A, Muakkassah-Kelly SF, and Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235: 747754, 1986. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 82: II38 II46, 1990. Davies MJ, Bland JM, Hangartner JR, Angelini A, and Thomas AC. Factors inuencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 10: 203208, 1989. Davies MJ and Thomas AC. Plaque ssuringthe cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 53: 363373, 1985. Davis M, Hatzubai A, Andersen JS, Ben-Shushan E, Fisher GZ, Yaron A, Bauskin A, Mercurio F, Mann M, and BenNeriah Y. Pseudosubstrate regulation of the SCF( -TrCP) ubiquitin ligase by hnRNP-U. Genes Dev 16: 439 451, 2002. Dean RT, Fu S, Stocker R, and Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 324: 118, 1997. De Clerck YA, Darville MI, Eeckhout Y, and Rousseau GG. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 139: 185 191, 1994. Del Boccio G, Lapenna D, Porreca E, Pennelli A, Savini F, Feliciani P, Ricci G, and Cuccurullo F. Aortic antioxidant defence mechanisms: time-related changes in cholesterol-fed rabbits. Atherosclerosis 81: 127135, 1990. Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, and Stevenson DK. Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med 19: 395 404, 1995. Dennery PA, Spitz DR, Yang G, Tatarov A, Lee CS, Shegog ML, and Poss KD. Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2. J Clin Invest 101: 1001 1011, 1998. Dennery PA, Sridhar KJ, Lee CS, Wong HE, Shokoohi V, Rodgers PA, and Spitz DR. Heme oxygenase-mediated resistance to oxygen toxicity in hamster broblasts. J Biol Chem 272: 1493714942, 1997. Denu JM and Tanner KG. Specic and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37: 56335642, 1998. Deora AA, Hajjar DP, and Lander HM. Recruitment and activation of Raf-1 kinase by nitric oxide-activated Ras. Biochemistry 39: 99019908, 2000. Deora AA, Win T, Vanhaesebroeck B, and Lander HM. A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 3 -kinase to Ras by redox stress. J Biol Chem 273: 2992329928, 1998. Deshpande NN, Sorescu D, Seshiah P, Ushio-Fukai M, Akers M, Yin Q, and Griendling KK. Mechanism of hydrogen peroxidePhysiol Rev VOL induced cell cycle arrest in vascular smooth muscle. Antioxid Redox Signal 4: 845 854, 2002. 202. Deterding LJ, Barr DP, Mason RP, and Tomer KB. Characterization of cytochrome c free radical reactions with peptides by mass spectrometry. J Biol Chem 273: 1286312869, 1998. 203. Devary Y, Gottlieb RA, Smeal T, and Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 71: 10811091, 1992. 203a.De Winther MP, Gijbels MJ, van Dijk KW, van Gorp PJ, suzuki H, Kodama T, Frants RR, Havekes LM, and Hofker MH. Scavenger receptor deciency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice. Atherosclerosis 144: 315321, 1999. 203b.De Winther MP, van Dijk KW, Havekes LM, and Hofker MH. Macrophage scavenger receptor class A: a multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 20: 290 297, 2000. 204. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, and Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303: 897902, 1980. 205. Didion SP, Ryan MJ, Didion LA, Fegan PE, Sigmund CD, and Faraci FM. Increased superoxide and vascular dysfunction in CuZnSOD-decient mice. Circ Res 91: 938 944, 2002. 206. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, and Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci USA 98: 34040 33409, 2001. 207. Djousse L, Levy D, Cupples LA, Evans JC, DAgostino RB, and Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 87: 1196 1200, 2001. 208. Doll R and Hill AB. Lung cancer and other causes of death in relation to smoking: a second report on the mortality of British doctors. Br Med J 2: 10711081, 1956. 209. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, and Wagner DD. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 102: 145152, 1998. 210. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, and Talpaz M. Activity of a specic inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038 1042, 2001. 211. Drummond GR, Cai H, Davis ME, Ramasamy S, and Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res 86: 347354, 2000. 212. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, and Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97: 1222212226, 2000. 213. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Webb RC, Lee ME, Nable GJ, and Nabel EG. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 7: 693 698, 2001. 214. Duffy SJ, Keaney JF Jr, Holbrook M, Gokce N, Swerdloff PL, Frei B, and Vita JA. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104: 151156, 2001. 215. Duffy SJ, Vita JA, and Keaney JF Jr. Antioxidants and endothelial function. Heart Failure 15: 135152, 1999. 216. Dupont GP, Huecksteadt TP, Marshall BC, Ryan US, Michael JR, and Hoidal JR. Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial cells. J Clin Invest 89: 197202, 1992. 217. Durner J, Gow AJ, Stamler JS, and Glazebrook J. Ancient origins of nitric oxide signaling in biological systems. Proc Natl Acad Sci USA 96: 14206 14207, 1999. www.prv.org







186. 187.













84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS 218. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, and Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350: 29 37, 2004. 219. Eaton P, Wright N, Hearse DJ, and Shattock MJ. Glyceraldehyde phosphate dehydrogenase oxidation during cardiac ischemia and reperfusion. J Mol Cell Cardiol 34: 1549 1560, 2002. 220. Eber B, Schumacher M, Tatzber F, Kaufmann P, Luha O, Esterbauer H, and Klein W. Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty. Cardiology 84: 310 315, 1994. 221. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, and Becker AE. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103: 19551960, 2001. 222. Ehara S, Ueda M, Naruko T, Haze K, Matsuo T, Ogami M, Ikura Y, Itabe H, Komatsu R, Yoshiyama M, Takeuchi K, and Yoshikawa J. Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases. J Diabetes Complications 16: 60 64, 2002. 223. Ehrenwald E, Chisolm GM, and Fox PL. Intact human ceruloplasmin oxidatively modies low density lipoprotein. J Clin Invest 93: 14931501, 1994. 224. Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 20: 627 662, 2000. 225. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, and Freeman BA. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296: 23912394, 2002. 226. Eiserich JP, Cross CE, Jones AD, Halliwell B, and van der Vliet A. Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid. A novel mechanism for nitric oxide-mediated protein modication. J Biol Chem 271: 19199 19208, 1996. 227. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, and van der Vliet A. Formation of nitric oxidederived inammatory oxidants by myeloperoxidase in neutrophils. Nature 391: 393397, 1998. 228. Eling TE, Curtis JF, Harman LS, and Mason RP. Oxidation of glutathione to its free radical metabolite by prostaglandin H synthase. A potential endogenous substrate for the hydroperoxidase. J Biol Chem 261: 50235028, 1986. 229. Ellis S, Alderman E, Cain K, Fisher L, Sanders W, and Bourassa M. Prediction of risk of anterior myocardial infarction by lesion severity and measurement method of stenoses in the left anterior descending coronary distribution: a CASS Registry Study. J Am Coll Cardiol 11: 908 916, 1988. 230. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, and Haber DA. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 10: 9951005, 2002. 231. English JP, Willius FA, and Berksa NJ. Tobacco and coronary disease. JAMA 115: 13271329, 1940. 232. Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, and Yla Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20: 204 209, 2000. 233. Ernster L and Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271: 195204, 1995. 234. Esterbauer H, Gebicki J, Puhl H, and Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modication of LDL. Free Radic Biol Med 13: 341390, 1992. 235. Esterbauer H, Jurgens G, Quehenberger O, and Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 28: 495509, 1987. Physiol Rev VOL


236. Esterbauer H, Striegl G, Puhl H, and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6: 6775, 1989. 237. Ezaki M, Witztum JL, and Steinberg D. Lipoperoxides in LDL incubated with broblasts that overexpress 15-lipoxygenase. J Lipid Res 36: 1996 2004, 1995. 238. Falcone DJ, Hajjar DP, and Minick CR. Lipoprotein and albumin accumulation in reendothelialized and deendothelialized aorta. Am J Pathol 114: 112120, 1984. 239. Falk E. Why do plaques rupture? Circulation 86: III30 III42, 1992. 240. Fan J, Frey RS, Rahman A, and Malik AB. Role of neutrophil NADPH oxidase in the mechanism of tumor necrosis factor- induced NF- B activation and intercellular adhesion molecule-1 expression in endothelial cells. J Biol Chem 277: 3404 3411, 2002. 241. Fang J and Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971 1992. National Health and Nutrition Examination Survey. JAMA 283: 2404 2410, 2000. 242. Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, Suh J, Frei B, Mudge GH, Selwyn AP, and Ganz P. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 359: 1108 1113, 2002. 243. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, and Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105: 1049 1056, 2000. 244. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM Jr, Hajjar DP, and Nicholson AC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res 41: 688 696, 2000. 245. Fennell JP, Brosnan MJ, Frater AJ, Hamilton CA, Alexander MY, Nicklin SA, Heistad DD, Baker AH, and Dominiczak AF. Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension. Gene Ther 9: 110 117, 2002. 246. Fernandez AZ, Lopez F, Tablante A, Romano E, Hurt-Ca mejo E, Camejo G, and Apitz-Castro R. Intravascular hemolysis increases atherogenicity of diet-induced hypercholesterolemia in rabbits in spite of heme oxygenase-1 gene and protein induction. Atherosclerosis 158: 103111, 2001. 247. Fiers W, Beyaert R, Declercq W, and Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18: 7719 7730, 1999. 248. Fleming I and Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284: R1R12, 2003. 249. Flohe L. Die Glutathionperoxidase: Enzymologie und biologische Aspekte. Klin Wschr 49: 669 683, 1971. 250. Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP, and Boren J. Identication of the proteoglycan binding site in apolipoprotein B48. J Biol Chem 277: 32228 32233, 2002. 251. Folcik VA, Nivar-Aristy RA, Krajewski LP, and Cathcart MK. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest 96: 504 510, 1995. 252. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, Goldschmidt-Clermont PJ, and Loscalzo J. Heterozygous cellular glutathione peroxidase deciency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation 106: 1154 1158, 2002. 253. Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, and Loscalzo J. Cellular glutathione peroxidase deciency and endothelial dysfunction. Am J Physiol Heart Circ Physiol 282: H1255H1261, 2002. 254. Forsmark-Andree P, Dallner G, and Ernster L. Endogenous ubiquinol prevents protein modication accompanying lipid peroxidation in beef heart submitochondrial particles. Free Radic Biol Med 19: 749 757, 1995. 255. Frank JS and Fogelman AM. Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching. J Lipid Res 30: 967978, 1989. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. 278. Fu X, Kassim SY, Parks WC, and Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276: 41279 41287, 2001. 279. Fu X, Mueller DM, and Heinecke JW. Generation of intramolecular and intermolecular sulfenamides, sulnamides, and sulfonamides by hypochlorous acid: a potential pathway for oxidative cross-linking of low-density lipoprotein by myeloperoxidase. Biochemistry 41: 12931301, 2002. 280. Fujii J and Ikeda Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7: 123130, 2002. 281. Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, and Harrison DG. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ Res 85: 2328, 1999. 282. Fulton D, Gratton JP, and Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isnt calcium/calmodulin enough? J Pharmacol Exp Ther 299: 818 824, 2001. 283. Furchgott RF and Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373376, 1980. 284. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, and Libby P. Cytokinestimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75: 181189, 1994. 285. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, and Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 92: 402 406, 1995. 286. Gardner PR. Superoxide-driven aconitase FE-S center cycling. Biosci Rep 17: 33 42, 1997. 287. Gardner PR and Fridovich I. Inactivation-reactivation of aconitase in Escherichia coli. A sensitive measure of superoxide radical. J Biol Chem 267: 8757 8763, 1992. 288. Gardner PR and Fridovich I. Superoxide sensitivity of the Escherichia coli aconitase. J Biol Chem 266: 19328 19333, 1991. 289. Garner B, Dean RT, and Jessup W. Human macrophage-mediated oxidation of low density lipoprotein is delayed and independent of superoxide production. Biochem J 301: 421 428, 1994. 290. Garner B and Jessup W. Cell-mediated oxidation of low-density lipoprotein: the elusive mechanism(s). Redox Report 2: 97104, 1996. 291. Garner B, van Reyk D, Dean RT, and Jessup W. Direct copper reduction by macrophages. Its role in low density lipoprotein oxidation. J Biol Chem 272: 6927 6935, 1997. 292. Garner B, Waldeck AR, Witting PK, Rye KA, and Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of HDL lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273: 6088 6095, 1998. 293. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, and Stocker R. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that correlates with lipid peroxidation and can be enhanced by -tocopherol. J Biol Chem 273: 6080 6087, 1998. 294. Gaston B, Reilly J, Drazen JM, Fackler J, Ramdev P, Arnelle D, Mullins ME, Sugarbaker DJ, Chee C, Singel DJ, Loscalzo J, and Stamler JS. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci USA 90: 1095710961, 1993. 295. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, and Heinecke JW. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest 109: 13111319, 2002. 296. Gaziano JM. Epidemiology of risk factor reduction. In: Vascular Medicine, edited by Loscalzo J, Creagher M, and Dzau V. Boston, MA: Little Brown, 1996, p. 569 586. 297. Geng YJ, Wu Q, Muszynski M, Hansson GK, and Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, www.prv.org

256. Fraser I, Hughes D, and Gordon S. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature 364: 343346, 1993. 257. Fredrikson GN, Hedblad B, Berglund G, Alm R, Ares M, Cercek B, Chyu KY, Shah PK, and Nilsson J. Identication of immune responses against aldehyde-modied peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 23: 872 878, 2003. 258. Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, and Nilsson J. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 23: 879 884, 2003. 259. Freedman JE, Farhat JH, Loscalzo J, and Keaney JF Jr. -Tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 94: 2434 2440, 1996. 260. Freedman JE and Keaney JF Jr. Nitric oxide and superoxide detection in human platelets. Methods Enzymol 301: 6170, 1999. 261. Freedman JE, Li L, Sauter R, and Keaney JF Jr. -Tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release. FASEB J 14: 23772379, 2000. 262. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, and Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350 356, 1997. 263. Freedman JE, Sauter R, Battinelli EM, Ault K, Knowles C, Huang PL, and Loscalzo J. Decient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res 84: 1416 1421, 1999. 264. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, and Vita JA. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 98: 1481 1486, 1998. 265. Frei B. Ascorbic acid protects lipids in human plasma and lowdensity lipoprotein against oxidative damage. Am J Clin Nutr 54: 1113S1118S, 1991. 266. Frei B. Natural Antioxidants in Human Health and Disease. San Diego, CA: Academic, 1994. 267. Frei B, England L, and Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86: 6377 6381, 1989. 268. Frei B, Kim M, and Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA 87: 4879 4883, 1990. 269. Frei B, Stocker R, and Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 85: 9748 9752, 1988. 270. Frei B, Stocker R, England L, and Ames BN. Ascorbate: the most effective antioxidant in human blood plasma. Adv Exp Med Biol 264: 155163, 1990. 271. Freyschuss A, Stiko-Rahm A, Swedenborg J, Henriksson P, Bjorkhem I, Berglund L, and Nilsson J. Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 91: 12821288, 1993. 272. Friebe A and Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93: 96 105, 2003. 273. Frisch SM and Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 13: 555562, 2001. 274. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, and Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145: 33 43, 1999. 275. Fruebis J, Steinberg D, Dresel HA, and Carew TA. A comparison of the antiatherogenic effects of probucol and a structural analogue of probucol in low density lipoprotein receptor-decient rabbits. J Clin Invest 94: 392398, 1994. 276. Fu S, Davies MJ, Stocker R, and Dean RT. Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. Biochem J 333: 519 525, 1998. 277. Fu S, Wang H, Davies M, and Dean R. Reactions of hypochlorous acid with tyrosine and peptidyl-tyrosyl residues give dichlorinated and aldehydic products in addition to 3-chlorotyrosine. J Biol Chem 275: 1085110858, 2000. Physiol Rev VOL

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS and interleukin-1 beta. Arterioscler Thromb Vasc Biol 16: 19 27, 1996. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, and Harats D. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-decient mice. Circulation 104: 1646 1650, 2001. George J, Harats D, Bakshi E, Adler Y, Levy Y, Gilburd B, and Shoenfeld Y. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 68: 263266, 1999. Gerschman R, Gilbert D, Nye SW, Dwyer P, and Fenn WO. Oxygen poisoning and X-irradiation: a mechanism in common. Science 119: 623 626, 1954. Gey KF, Puska P, Jordan P, and Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 53: 326S 334S, 1991. Ghosh S and Karin M. Missing pieces in the NF- B puzzle. Cell 109 Suppl: S81S96, 2002. Gilbert HF. Redox control of enzyme activities by thiol/disulde exchange. Methods Enzymol 107: 330 351, 1984. Gilbert JD, Harland WA, Steel G, and Brooks CJW. The isolation and identication of 5 -cholestan-3 -ol from the human atheromatous aorta. Biochim Biophys Acta 187: 453 456, 1969. Gilligan DM, Sack MN, Guetta V, Casino PR, Quyyumi AA, Rader DJ, Panza JA, and Cannon RO III. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 24: 16111617, 1994. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, and Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316: 13711375, 1987. Glavind J, Hartmann S, Clemmesen J, Jessen KE, and Dam H. Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathol Microbiol Scand 30: 1 6, 1952. Gniwotta C, Morrow JD, Roberts LJI, and Kuhn H. Prosta glandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17: 3236 3241, 1997. Go YM, Gipp JJ, Mulcahy RT, and Jones DP. H2O2-dependent activation of GCLC-ARE4 reporter occurs by mitogen-activated protein kinase pathways without oxidation of cellular glutathione or thioredoxin-1. J Biol Chem 279: 58375845, 2004. Go YM, Patel RP, Maland MC, Park H, Beckman JS, DarleyUsmar VM, and Jo H. Evidence for peroxynitrite as a signaling molecule in ow-dependent activation of c-Jun NH(2)-terminal kinase. Am J Physiol Heart Circ Physiol 277: H1647H1653, 1999. Godfried SL, Combs GF, Saroka JM, and Dillingham LA. Potentiation of atherosclerotic lesions in rabbits by high dietary level of vitamin E. Br J Nutr 61: 607 617, 1989. Godin DV, Garnett ME, Cheng KM, and Nichols CR. Sexrelated alterations in antioxidant status and susceptibility to atherosclerosis in Japanese quail. Can J Cardiol 11: 945951, 1995. Gokce N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, and Vita JA. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 99: 3234 3240, 1999. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, and Vita JA. Risk stratication for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 105: 15671572, 2002. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, and Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41: 1769 1775, 2003. Goldstein JL and Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 46: 897930, 1977. Physiol Rev VOL






302. 303. 304.













317. Goldstein JL, Ho YK, Basu SK, and Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76: 333337, 1979. 318. Goossens V, Grooten J, De Vos K, and Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 92: 8115 8119, 1995. 319. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, and Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 368: 225229, 1995. 320. Gordon T, Castelli WP, Hjortland MC, Kannel WB, and Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707714, 1977. 321. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, and Busse R. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)containing NADPH oxidase. Circ Res 89: 4754, 2001. 322. Gorren AC, Schrammel A, Riethmuller C, Schmidt K, Koesling D, Werner ER, and Mayer B. Nitric oxide-induced autoinhibition of neuronal nitric oxide synthase in the presence of the autoxidation-resistant pteridine 5-methyltetrahydrobiopterin. Biochem J 347: 475 484, 2000. 323. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, and Charo IF. MCP-1 deciency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103: 773778, 1999. 324. Gotoh Y and Cooper JA. Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J Biol Chem 273: 1747717482, 1998. 325. Gotto AM Jr and Farmer JA. Risk factors for coronary artery disease. In: Heart Disease: A Textbook of Cardiovascular Medicine, edited by Braunwald E. Philadelphia, PA: Saunders, 1988, p. 11531190. 326. Gotto AM Jr and Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data. Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation 99: E1E7, 1999. 327. Gow A, Duran D, Thom SR, and Ischiropoulos H. Carbon dioxide enhancement of peroxynitrite-mediated protein tyrosine nitration. Arch Biochem Biophys 333: 42 48, 1996. 328. Gow AJ, Chen Q, Hess DT, Day BJ, Ischiropoulos H, and Stamler JS. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem 277: 96379640, 2002. 329. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, and Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 49 57, 2002. 330. Graham A, Hogg N, Kalyanaraman B, OLeary V, DarleyUsmar V, and Moncada S. Peroxynitrite modication of lowdensity lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 330: 181185, 1993. 331. Grant CM, Quinn KA, and Dawes IW. Differential protein Sthiolation of glyceraldehyde-3-phosphate dehydrogenase isoenzymes inuences sensitivity to oxidative stress. Mol Cell Biol 19: 2650 2656, 1999. 332. Griendling KK, Sorescu D, Lassegue B, and Ushio-Fukai M. ` Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 21752183, 2000. 333. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494 501, 2000. 334. Grifth RL, Virella GT, Stevenson HC, and Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. activated with low density lipoprotein immune complexes A possible mechanism of foam cell formation. J Exp Med 168: 1041 1059, 1988. Griscavage JM, Fukuto JM, Komori Y, and Ignarro LJ. Nitric oxide inhibits neuronal nitric oxide synthase by interacting with the heme prosthetic group. Role of tetrahydrobiopterin in modulating the inhibitory action of nitric oxide. J Biol Chem 269: 21644 21649, 1994. Gruetter DY, Gruetter CA, Barry BK, Baricos WH, Hyman AL, Kadowitz PJ, and Ignarro LJ. Activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside, and nitrosoguanidineinhibition by calcium, lanthanum, and other cations, enhancement by thiols. Biochem Pharmacol 29: 29432950, 1980. Gryglewski RJ, Palmer RM, and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320: 454 456, 1986. Gunther MR, Hsi LC, Curtis JF, Gierse JK, Marnett LJ, Eling TE, and Mason RP. Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation. J Biol Chem 272: 17086 17090, 1997. Gupta S, Campbell D, Derijard B, and Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389 393, 1995. Guthikonda S, Sinkey C, Barenz T, and Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 107: 416 421, 2003. Gutteridge JMC. The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta 917: 219 223, 1987. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, and Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656 1662, 2002. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, and Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 86: E85E90, 2000. Haberland ME, Fogelman AM, and Edwards PA. Specicity of receptor-mediated recognition of malonydialdehyde-modied low density lipoproteins. Proc Natl Acad Sci USA 79: 17121716, 1982. Haberland ME, Fong D, and Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe Heritable Hyperlipidemic rabbits. Science 241: 215218, 1988. Haberland ME, Olch CL, and Fogelman AM. Role of lysines in mediating interaction of modied low density lipoproteins with the scavenger receptor of human monocyte macrophages. J Biol Chem 259: 1130511311, 1984. Hakala JK, Oksjoki R, Laine P, Du H, Grabowski GA, Kovanen PT, and Pentikainen MO. Lysosomal enzymes are re leased from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 23: 1430 1436, 2003. Halliwell B. Vitamin C: antioxidant or pro-oxidant in vivo? Free Radic Res 25: 439 454, 1996. Halliwell B and Gutteridge JMC. The antioxidants of human extracellular uids. Arch Biochem Biophys 280: 1 8, 1990. Halliwell B and Gutteridge JMC. Free Radicals in Biology and Medicine. New York: Oxford Univ. Press, 1999. Hamilton IM, Gilmore WS, and Strain JJ. Marginal copper deciency and atherosclerosis. Biol Trace Elem Res 78: 179 189, 2000. Hammond EC and Horn D. Smoking and death rates: report on forty-four months of follow-up of 187,783 men. 2. Death rates by cause. J Am Med Assoc 166: 1294 1308, 1958. Handin RI, Karabin R, and Boxer GJ. Enhancement of platelet function by superoxide anion. J Clin Invest 59: 959 965, 1977. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269: 31253128, 1994. Hansson GK, Hellstrand M, Rymo L, Rubbia L, and Gabbiani G. Interferon inhibits both proliferation and expression of difPhysiol Rev VOL ferentiation-specic -smooth muscle actin in arterial smooth muscle cells. J Exp Med 170: 15951608, 1989. Hansson GK, Holm J, and Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135: 169 175, 1989. Harland WA, Gilbert JD, and Brooks CJW. Lipids of human atheroma. VIII. Oxidised derivatives of cholesteryl linoleate. Biochim Biophys Acta 316: 378 385, 1973. Harland WA, Gilbert JD, Steel G, and Brooks CJW. Lipids of human atheroma. Part 5. The occurrence of a new group of polar sterol esters in various stages of human atherosclerosis. Atherosclerosis 13: 239 246, 1971. Harrison JE and Schultz J. Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 251: 13711374, 1976. Hathaway CA, Heistad DD, Piegors DJ, and Miller FJ Jr. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 90: 277283, 2002. Hausladen A, Privalle CT, Keng T, DeAngelo J, and Stamler JS. Nitrosative stress: activation of the transcription factor OxyR. Cell 86: 719 729, 1996. Hawkins CL and Davies MJ. Hypochlorite-induced oxidation of proteins in plasma: formation of chloramines and nitrogen-centred radicals and their role in protein fragmentation. Biochem J 340: 539 548, 1999. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, and Kikugawa K. Evidence that reactive oxygen species do not mediate NF- B activation. EMBO J 22: 3356 3366, 2003. Hayes JD and Strange RC. Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic Res 22: 193207, 1995. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, and Stocker R. Presence of hypochlorite-modied proteins in human atherosclerotic lesions. J Clin Invest 97: 15351544, 1996. Hazell LJ, Baernthaler G, and Stocker R. Correlation between intima-to-media ratio, apolipoprotein B-100, myeloperoxidase and hypochlorite-oxidized proteins in human atherosclerosis. Free Radic Biol Med 31: 1254 1262, 2001. Hazell LJ, Davies MJ, and Stocker R. Secondary radicals derived from chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of low-density lipoproteins. Biochem J 339: 489 495, 1999. Hazell LJ and Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J 290: 165172, 1993. Hazell LJ and Stocker R. -Tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett 414: 541544, 1997. Hazell LJ, van den Berg JJM, and Stocker R. Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modication of lysine residues rather than lipid oxidation. Biochem J 302: 297304, 1994. Hazen SL, Fu Hsu F, and Heinecke JW. p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes. A chlorine-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. J Biol Chem 271: 18611867, 1996. Hazen SL, Gaut JP, Crowley JR, Hsu FF, and Heinecke JW. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. Biochem J 352: 693 699, 2000. Hazen SL, Gaut JP, Hsu FF, Crowley JR, dAvignon A, and Heinecke JW. p-Hydroxyphenylacetaldehyde, the major product of L-tyrosine oxidation by myeloperoxidase-H2O2-chloride system of phagocytes, covalently modies -amino groups of protein lysine residues. J Biol Chem 272: 16990 16998, 1997. Hazen SL and Heinecke JW. 3-Chlorotyrosine, a specic marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99: 20752081, 1997. Hazen SL, Heller J, Hsu FF, dAvignon A, and Heinecke JW. Synthesis, isolation, and characterization of the adduct formed in www.prv.org






362. 363.























351. 352. 353. 354.




356. 357. 358.



84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS the reaction of p-hydroxyphenylacetaldehyde with the amino headgroup of phosphatidylethanolamine and phosphatidylserine. Chem Res Toxicol 12: 19 27, 1999. 379. Hazen SL, Hsu FF, dAvignon A, and Heinecke JW. Human neutrophils employ myeloperoxidase to convert alpha-amino acids to a battery of reactive aldehydes: a pathway for aldehyde generation at sites of inammation. Biochemistry 37: 6864 6873, 1998. 380. He J and Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 138: 211219, 1999. 380a.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 2333, 2002. 380b.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 722, 2002. 381. Hecker M, Siegle I, Macarthur H, Sessa WC, and Vane JR. Role of intracellular thiols in release of EDRF from cultured endothelial cells. Am J Physiol Heart Circ Physiol 262: H888 H896, 1992. 382. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, and Prescott SM. Oxidatively modied LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 96: 23222330, 1995. 383. Heikkila RE, Cabbat FS, and Cohen G. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. J Biol Chem 251: 21822185, 1976. 384. Heinecke JW. Mass spectrometric quantication of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. FASEB J 13: 1113 1120, 1999. 385. Heinecke JW, Li W, Francis GA, and Goldstein JA. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest 91: 2866 2872, 1993. 386. Heinecke JW, Li W, Mueller DM, Bohrer A, and Turk J. Cholesterol chlorohydrin synthesis by the myeloperoxidase-hydrogen peroxide-chloride system: potential markers for lipoproteins oxidatively damaged by phagocytes. Biochemistry 33: 1012710136, 1994. 387. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, and Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 86: E36 E41, 2000. 388. Heitzer T, Just H, and Munzel T. Antioxidant vitamin C im proves endothelial dysfunction in chronic smokers. Circulation 94: 6 9, 1996. 389. Heitzer T, Schlinzig T, Krohn K, Meinertz T, and Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104: 26732678, 2001. 390. Heitzer T, Yla-Herttuala S, Wild E, Luoma J, and Drexler H. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol 33: 499 505, 1999. 391. Heller JI, Crowley JR, Hazen SL, Salvay DM, Wagner P, Pennathur S, and Heinecke JW. p-Hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima. J Biol Chem 275: 99579962, 2000. 392. Heller R, Unbehaun A, Schellenberg B, Mayer B, WernerFelmayer G, and Werner ER. L-Ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276: 40 47, 2001. 393. Hemler ME, Weitzman JB, Pasqualini R, Kawaguchi S, and Kassner PD. Structure, biochemical properties, and biological functions of integrin cytoplasmic domains. In: Integrins: the BiPhysiol Rev VOL


ological Problem, edited by Takada Y. Ann Arbor, MI: CRC, 1994, p. 135. 394. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, and Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 88: 8154 8158, 1991. 395. Henriksen T, Mahoney EM, and Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 78: 6499 6503, 1981. 396. Heydeck D, Upston JM, Viita H, Yla-Herttuala S, and Stocker R. Oxidation of low-density lipoprotein by rabbit and human 15-lipoxygenase: prevalence of non-enzymatic reactions. J Lipid Res 42: 10821088, 2001. 397. Heyworth PG, Bohl BP, Bokoch GM, and Curnutte JT. Rac translocates independently of the neutrophil NADPH oxidase components p47phox and p67phox. Evidence for its interaction with avocytochrome b558. J Biol Chem 269: 30749 30752, 1994. 398. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, and Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 677 683, 2004. 399. Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, Harrison DG, and Fukai T. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 22: 14021408, 2002. 400. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, and Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14 E22, 2001. 401. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF- B. J Biol Chem 274: 2789127897, 1999. 402. Hodgson EK and Fridovich I. The interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide: inactivation of the enzyme. Biochemistry 14: 5294 5299, 1975. 403. Hodgson JM, Watts GF, Playford DA, Burke V, and Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 56: 11371142, 2002. 404. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, Liu CH, Hwang J, Selzer RH, and Azen SP. Alpha-tocopherol supplementation in healthy individuals reduces lowdensity lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 106: 14531459, 2002. 405. Hogg N. Biological chemistry and clinical potential of S-nitrosothiols. Free Radic Biol Med 28: 1478 1486, 2000. 406. Holland JA, Meyer JW, Chang MM, ODonnell RW, Johnson DK, and Ziegler LM. Thrombin stimulated reactive oxygen species production in cultured human endothelial cells. Endothelium 6: 113121, 1998. 407. Holland JA, Pritchard KA, Pappolla MA, Wolin MS, Rogers NJ, and Stemerman MB. Bradykinin induces superoxide anion release from human endothelial cells. J Cell Physiol 143: 2125, 1990. 408. Holmgren A. Thioredoxin and glutaredoxin. J Biol Chem 264: 1396313966, 1989. 409. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2: 811 820, 2000. 409a.Holvoet P, Collen D, and Van de Werf F. Malondialdehydemodied LDL as a marker of acute coronary syndromes. JAMA 281: 1718 1721, 1999. 409b.Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, and Collen D. Malondialdehyde-modied low-density lipoprotein in patients with atherosclerotic disease. J Clin Invest 95: 26112619, 1995. 409c.Holvoet P, Stassen JM, Van Cleemput J, Collen D, and Vanhaecke J. Oxidized low density lipoprotein in patients with transwww.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. 426. Ignarro LJ. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol 67: 17, 1990. 427. Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84: 9265 9269, 1987. 428. Ignarro LJ, Burke TM, Wood KS, Wolin MS, and Kadowitz PJ. Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. J Pharmacol Exp Ther 228: 682 690, 1984. 429. Ignarro LJ, Byrns RE, Buga GM, Wood KS, and Chaudhuri G. Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. J Pharmacol Exp Ther 244: 181189, 1988. 430. Ignarro LJ, Edwards JC, Gruetter DY, Barry BK, and Gruetter CA. Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett 110: 275 278, 1980. 431. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, and Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 218: 739 749, 1981. 432. Ignarro LJ, Napoli C, and Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90: 2128, 2002. 433. Ingold KU, Bowry VW, Stocker R, and Walling C. Autoxidation of lipids and antioxidation by -tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids. The unrecognized consequences of lipid particle size as exemplied by the oxidation of human low density lipoprotein. Proc Natl Acad Sci USA 90: 45 49, 1993. 434. Inoue N, Ohara Y, Fukai T, Harrison DG, and Nishida K. Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits. Am J Med Sci 315: 242247, 1998. 435. Investigators GP. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354: 447 455, 1999. 436. Irani K, Pham Y, Coleman LD, Roos C, Cooke GE, Miodovnik A, Karim N, Wilhide CC, Bray PF, and Goldschmidt-Clermont PJ. Priming of platelet IIb 3 by oxidants is associated with tyrosine phosphorylation of 3. Arterioscler Thromb Vasc Biol 18: 1698 1706, 1998. 437. Iribarren C, Folsom AR, Jacobs DR Jr, Gross MD, Belcher JD, and Eckfeldt JH. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 17: 11711177, 1997. 438. Ishikawa K, Sugawara D, Goto J, Watanabe Y, Kawamura K, Shiomi M, Itabe H, and Maruyama Y. Heme oxygenase-1 inhibits atherogenesis in Watanabe Heritable hyperlipidemic rabbits. Circulation 104: 18311836, 2001. 439. Ishikawa K, Sugawara D, Wang X, Suzuki K, Itabe H, Maruyama Y, and Lusis AJ. Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res 88: 506 512, 2001. 440. Ismail NA, Alavi MZ, and Moore S. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells. Atherosclerosis 105: 79 87, 1994. 441. Itabe H, Yamamoto H, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A, Imanaka T, and Takano T. Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem 271: 33208 33217, 1996. 442. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of www.prv.org

plant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 18: 100 107, 1998. 409d.Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, and Collen D. Oxidized LDL and malondialdehyde-modied LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98: 14871494, 1998. 410. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, and Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16: 250 255, 1996. 411. Hori R, Kashiba M, Toma T, Yachie A, Goda N, Makino N, Soejima A, Nagasawa T, Nakabayashi K, and Suematsu M. Gene transfection of H25A mutant heme oxygenase-1 protects cells against hydroperoxide-induced cytotoxicity. J Biol Chem 277: 1071210718, 2002. 412. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbana gounder G, Berliner JA, Friedman P, Dennis EA, Curtiss LK, Palinski W, and Witztum JL. Monoclonal autoantibodies specic for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103: 117128, 1999. 413. Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, and Finkel T. Vascular effects following homozygous disruption of p47phox: an essential component of NADPH oxidase. Circulation 101: 1234 1236, 2000. 414. Hu ML, Louie S, Cross CE, Motchnik P, and Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121: 257262, 1993. 415. Huang A, Vita JA, Venema RC, and Keaney JF Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 275: 17399 17406, 2000. 416. Huang HY, Appel LJ, Croft KD, Miller ER, Mori TA III, and Puddey IB. Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial. Am J Clin Nutr 76: 549 555, 2002. 417. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, and Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377: 239 242, 1995. 418. Huhmer AF, Nishida CR, OrtizdeMontellano PR, and Scho neich C. Inactivation of the inducible nitric oxide synthase by peroxynitrite. Chem Res Toxicol 10: 618 626, 1997. 419. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, and Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605 613, 1998. 420. Hunt NH and Stocker R. Oxidative stress and the redox status of malaria-infected erythrocytes. Blood Cells 16: 499 526, 1990. 421. Hurst R, Bao Y, Jemth P, Mannervik B, and Williamson G. Phospholipid hydroperoxide glutathione peroxidase activity of human glutathione transferases. Biochem J 332: 97100, 1998. 422. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Ahlstrom C, Fager G, and Bondjers G. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb 12: 569 583, 1992. 423. Hwang J, Saha A, Boo YC, Sorescu GP, McNally JS, Holland SM, Dikalov S, Giddens DP, Griendling KK, Harrison DG, and Jo H. Oscillatory shear stress stimulates endothelial production of O2 from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem 278: 47291 47298, 2003. 424. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, and Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96: 4219 4225, 1997. 425. Ichiki K, Ikeda H, Haramaki N, Ueno T, and Imaizumi T. Long-term smoking impairs platelet-derived nitric oxide release. Circulation 94: 3109 3114, 1996. Physiol Rev VOL

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76 86, 1999. Iwatsuki M, Niki E, Stone D, and Darley-Usmar VM. -Tocopherol mediated peroxidation in the copper (II) and met myoglobin induced oxidation of human low density lipoprotein: the inuence of lipid hydroperoxides. FEBS Lett 360: 271276, 1995. Jackson TS, Xu A, Vita JA, and Keaney JF Jr. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res 83: 916 922, 1998. Jahngen-Hodge J, Obin MS, Gong X, Shang F, Nowell TR Jr, Gong J, Abasi H, Blumberg J, and Taylor A. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem 272: 28218 28226, 1997. Jaimes EA, Sweeney C, and Raij L. Effects of the reactive oxygen species hydrogen peroxide and hypochlorite on endothelial nitric oxide production. Hypertension 38: 877 883, 2001. Jarasch ED, Grund C, Bruder G, Heid HW, Keenan TW, and Franke WW. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 25: 67 82, 1981. Jessup W, Simpson JA, and Dean RT. Does superoxide radical have a role in macrophage-mediated oxidative modication of LDL? Atherosclerosis 99: 107120, 1993. Jiang Q and Ames BN. -Tocopherol, but not -tocopherol, decreases proinammatory eicosanoids and inammation damage in rats. FASEB J 17: 816 822, 2003. Jiang XM, Fitzgerald M, Grant CM, and Hogg PJ. Redox control of exofacial protein thiols/disuldes by protein disulde isomerase. J Biol Chem 274: 2416 2423, 1999. Johansson C, Lillig CH, and Holmgren A. Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high afnity accepting electrons from either glutathione or thioredoxin reductase. J Biol Chem 279: 75377543, 2004. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, Hynes RO, Schaefer EJ, and Wagner DD. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 99: 10371043, 1997. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, and Finkel T. Reactive oxygen species are downstream mediators of p53dependent apoptosis. Proc Natl Acad Sci USA 93: 11848 11852, 1996. Jonasson L, Holm J, Skall O, Bondjers G, and Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6: 131138, 1986. Joseph CK, Wright SD, Bornmann WG, Randolph JT, Kumar ER, Bittman R, Liu J, and Kolesnick RN. Bacterial lipopolysaccharide has structural similarity to ceramide and stimulates ceramide-activated protein kinase in myeloid cells. J Biol Chem 269: 17606 17610, 1994. Jourdheuil D, Jourdheuil FL, and Feelisch M. Oxidation and nitrosation of thiols at low micromolar exposure to nitric oxide. Evidence for a free radical mechanism. J Biol Chem 278: 15720 15726, 2003. Juan SH, Lee TS, Tseng KW, Liou JY, Shyue SK, Wu KK, and Chau LY. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein Edecient mice. Circulation 104: 1519 1525, 2001. Jung CH and Thomas JA. S-glutathiolated hepatocyte proteins and insulin disuldes as substrates for reduction by glutaredoxin, thioredoxin, protein disulde isomerase, and glutathione. Arch Biochem Biophys 335: 6172, 1996. Jung O, Marklund SL, Geiger H, Pedrazzini T, Busse R, and Brandes RP. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-decient mice. Circ Res 93: 622 629, 2003. Juul K, Nielsen LB, Munkholm K, Stender S, and Nordestgaard BG. Oxidation of plasma low-density lipoprotein accelerates its accumulation and degradation in the arterial wall in vivo. Circulation 94: 1698 1704, 1996. Kagan VE, Serbinova EA, Koynova GM, Kitanova SA, Tyurin VA, Stoytchev TS, Quinn PJ, and Packer L. Antioxidant action Physiol Rev VOL







































of ubiquinol homologues with different isoprenoid chain length in biomembranes. Free Radic Biol Med 9: 117126, 1990. Kagan VE, Serbinova EA, and Packer L. Recycling and antioxidant activity of tocopherol homologs of differing hydrocarbon chain lengths in liver micrososmes. Arch Biochem Biophys 282: 221225, 1990. Kalinina N, Agrotis A, Tararak E, Antropova Y, Kanellakis P, Ilyinskaya O, Quinn MT, Smirnov V, and Bobik A. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 22: 20372043, 2002. Kanayama A, Inoue J, Sugita-Konishi Y, Shimizu M, and Miyamoto Y. Oxidation of I B at methionine 45 is one cause of taurine chloramine-induced inhibition of NF- B activation. J Biol Chem 277: 24049 24056, 2002. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, and Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 273: 6297 6302, 1998. Kawamura M, Heinecke JW, and Chait A. Increased uptake of alpha-hydroxy aldehyde-modied low density lipoprotein by macrophage scavenger receptors. J Lipid Res 41: 1054 1059, 2000. Kayden HJ and Traber MG. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res 34: 343358, 1993. Keaney JF Jr. Antioxidants and atherosclerosis: animal studies. In: Oxidative Stress and Vascular Disease, edited by Keaney JF Jr. Boston, MA: Kluwer Academic, 2000, p. 195211. Keaney JF Jr, Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, Loscalzo J, and Vita JA. Low-dose -tocopherol improves and high-dose -tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 93: 844 851, 1994. Keaney JF Jr, Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, Loscalzo J, and Vita JA. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterolfed rabbits. Proc Natl Acad Sci USA 90: 11880 11884, 1993. Keaney JF Jr, Guo Y, Cunningham D, Shwaery GT, Xu A, and Vita JA. Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest 98: 386 394, 1996. Keaney JF Jr, Simon DI, Stamler JS, Jaraki O, Scharfstein J, Vita JA, and Loscalzo J. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 91: 15821589, 1993. Keaney JF Jr, Xu A, Cunningham D, Jackson T, Frei B, and Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest 95: 2520 2529, 1995. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, and Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23: 434 439, 2003. Keaney JF Jr, Simon DI, and Freedman JE. Vitamin E and vascular homeostasis: implications for atherosclerosis. FASEB J 13: 965975, 1999. Kenar JA, Havrilla CM, Porter NA, Guyton JR, Brown SA, Klemp KF, and Selinger E. Identication and quantication of the regioisomeric cholesteryl linoleate hydroperoxides in oxidized human low density lipoprotein and high density lipoprotein. Chem Res Toxicol 9: 737744, 1996. Kennedy MC, Emptage MH, Dreyer JL, and Beinert H. The role of iron in the activation-inactivation of aconitase. J Biol Chem 258: 11098 11105, 1983. Kettle AJ, Clark BM, and Winterbourn CC. Superoxide converts indigo carmine to isatin sulfonic acid: implications for the hypothesis that neutrophils produce ozone. J Biol Chem 279: 1852118525, 2004. Kettle AJ, van Dalen CJ, and Winterbourn CC. Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Redox Report 3: 257258, 1997. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. 499. Kopprasch S, Leonhardt W, Pietzsch J, and Kuhne H. Hypo chlorite-modied low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells. Atherosclerosis 136: 315324, 1998. 500. Krieger M. The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol 8: 275280, 1997. 501. Krieger M, Acton S, Ashkenas J, Pearson A, Penman M, and Resnick D. Molecular ypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors. J Biol Chem 268: 4569 4572, 1993. 502. Kritchevsky D, Kim HK, and Tepper SA. Inuence of 4,4 (isopropylidenedithio)bis(2,6-di-t-butylphenol) (DH-581) on experimental atherosclerosis in rabbits. Proc Soc Exp Biol Med 136: 1216 1221, 1971. 503. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, and Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100: 917924, 2002. 504. Kubes P, Suzuki M, and Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88: 4651 4655, 1991. 505. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, and Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modied low-density lipoprotein. Nature 344: 160 162, 1990. 506. Kugiyama K, Ohgushi M, Motoyama T, Hirashima O, Soejima H, Misumi K, Yoshimura M, Ogawa H, Sugiyama S, and Yasue H. Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation. Circulation 97: 2299 2301, 1998. 507. Kuhn H, Belkner J, Wiesner R, Schewe T, Lankin VZ, and Tikhaze AK. Structure elucidation of oxygenated lipids in human atherosclerotic lesions. Eicosanoids 5: 1722, 1992. 508. Kuhn H, Belkner J, Zaiss S, Fahrenklemper T, and Wohlfeil S. Involvement of 15-lipoxygenase in early stages of atherogenesis. J Exp Med 179: 19031911, 1994. 509. Kullik I, Toledano MB, Tartaglia LA, and Storz G. Mutational analysis of the redox-sensitive transcriptional regulator OxyR: regions important for oxidation and transcriptional activation. J Bacteriol 177: 12751284, 1995. 510. Kumar S, Mishra N, Raina D, Saxena S, and Kufe D. Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. Mol Pharmacol 63: 276 282, 2003. 511. Kume N and Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 93: 907911, 1994. 512. Kurz CR, Kissner R, Nauser T, Perrin D, and Koppenol WH. Rapid scavenging of peroxynitrous acid by monohydroascorbate. Free Radic Biol Med 35: 1529 1537, 2003. 513. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, and Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 334: 1156 1162, 1996. 514. Lagendijk J, Ubbink JB, Delport R, Vermaak WJ, and Human JA. Ubiquinol/ubiquinone ratio as marker of oxidative stress in coronary artery disease. Res Commun Mol Pathol Pharmacol 95: 1120, 1997. 515. Lamb DJ, Mitchinson MJ, and Leake DS. Transition metal ions within human atherosclerotic lesions can catalyse the oxidation of low density lipoprotein by macrophages. FEBS Lett 374: 1216, 1995. 516. Lamb DJ, Reeves GL, Taylor A, and Ferns GA. Dietary copper supplementation reduces atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 146: 33 43, 1999. 517. Lander HM, Milbank AJ, Tauras JM, Hajjar DP, Hempstead BL, Schwartz GD, Kraemer RT, Mirza UA, Chait BT, Burk SC, and Quilliam LA. Redox regulation of cell signalling. Nature 381: 380 381, 1996. 518. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, and Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated www.prv.org

480. Khan BV, Parthasarathy SS, Alexander RW, and Medford RM. Modied low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 95: 12621270, 1995. 481. Kikinis Z, Eisenstein RS, Bettany AJ, and Munro HN. Role of RNA secondary structure of the iron-responsive element in translational regulation of ferritin synthesis. Nucleic Acids Res 23: 4190 4195, 1995. 482. Kim K, Kim IH, Lee KY, Rhee SG, and Stadtman ER. The isolation and purication of a specic protector protein which inhibits enzyme inactivation by a thiol/Fe(III)/O2 mixed-function oxidation system. J Biol Chem 263: 4704 4711, 1988. 483. Kim SO, Merchant K, Nudelman R, Beyer WF Jr, Keng T, DeAngelo J, Hausladen A, and Stamler JS. OxyR: a molecular code for redox-related signaling. Cell 109: 383396, 2002. 484. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, and LeBoeuf RC. Impaired superoxide production due to a deciency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 20: 1529 1535, 2000. 485. Kirk EA, Heinecke JW, and LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-decient mice. J Clin Invest 107: 15451553, 2001. 486. Kirsch M, Korth HG, Sustmann R, and de Groot H. The pathobiochemistry of nitrogen dioxide. Biol Chem 383: 389 399, 2002. 487. Kirsch M, Korth HG, Wensing A, Sustmann R, and de Groot H. Product formation and kinetic simulations in the pH range 114 account for a free-radical mechanism of peroxynitrite decomposition. Arch Biochem Biophys 418: 133150, 2003. 488. Kissner R, Nauser T, Bugnon P, Lye PG, and Koppenol WH. Formation and properties of peroxynitrite as studied by laser ash photolysis, high-pressure stopped-ow technique, and pulse radiolysis. Chem Res Toxicol 10: 12851292, 1997. 489. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, and Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84: 5928 5931, 1987. 490. Klatt P and Lamas S. Regulation of protein function by Sglutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 267: 4928 4944, 2000. 491. Klatt P, Molina EP, De Lacoba MG, Padilla CA, MartinezGalesteo E, Barcena JA, and Lamas S. Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J 13: 14811490, 1999. 492. Klimov AN, Denisenko AD, Popov AV, Nagornev VA, Pleskov VM, Vinogradov AG, Denisenko TV, Magracheva E, Kheifes GM, and Kuznetzov AS. Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation. Atherosclerosis 58: 115, 1985. 493. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, and Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 343: 531535, 1990. 494. Kohlmeier L and Hastings SB. Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention. Am J Clin Nutr 62: 1370S1376S, 1995. 495. Kol A, Bourcier T, Lichtman AH, and Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103: 571577, 1999. 496. Kontush A, Finckh B, Karten B, Kohlschutter A, and Beisie gel U. Antioxidant and prooxidant activity of -tocopherol in human plasma and low density lipoprotein. J Lipid Res 37: 1436 1448, 1996. 497. Kontush A, Meyer S, Finckh B, Kohlschutter A, and Beisie gel U. -Tocopherol as a reductant for Cu(II) in human lipoproteins. Triggering role in the initiation of lipoprotein oxidation. J Biol Chem 271: 11106 11112, 1996. 498. Koppenol WH. The basic chemistry of nitrogen monoxide and peroxynitrite. Free Radic Biol Med 25: 385391, 1998. Physiol Rev VOL

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810 17814, 1997. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, and Harrison DG. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40: 511515, 2002. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, and Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 12011209, 2003. Lapenna D, de Gioia S, Ciofani G, Mezzetti A, Ucchino S, Calaore AM, Napolitano AM, Di Ilio C, and Cuccurullo F. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 97: 1930 1934, 1998. Lapenna D, Pierdomenico SD, Ciofani G, Giamberardino MA, and Cuccurullo F. Aortic glutathione metabolic status: time-dependent alterations in fat-fed rabbits. Atherosclerosis 173: 19 25, 2004. Laurindo FR, Pedro Mde A, Barbeiro HV, Pileggi F, Carvalho MH, Augusto O, and da Luz PL. Vascular free radical release. Ex vivo and in vivo evidence for a ow-dependent endothelial mechanism. Circ Res 74: 700 709, 1994. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, and Harrison DG. Endothelial regulation of vasomotion in apoE-decient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103: 12821288, 2001. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, and Oram JF. The Tangier disease gene product ABC1 controls the cellular apolipoproteinmediated lipid removal pathway. J Clin Invest 104: R25R31, 1999. Lawson JA, Rokach J, and FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 274: 2444124444, 1999. Leake DS. Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions? Atherosclerosis 129: 149 157, 1997. Leary T. Coronary spasm as a possible factor in producing sudden death. Am Heart J 10: 338 344, 1934. Lee RT and Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 17: 1859 1867, 1997. Lee SL, Wang WW, and Fanburg BL. Superoxide as an intermediate signal for serotonin-induced mitogenesis. Free Radic Biol Med 24: 855 858, 1998. Lee SL, Wang WW, Finlay GA, and Fanburg BL. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol Lung Cell Mol Physiol 277: L282L291, 1999. Lee SR, Kwon KS, Kim SR, and Rhee SG. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem 273: 15366 15372, 1998. Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P, Oh-ishi S, Steinbrecher UP, and Heinecke JW. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 272: 14331436, 1997. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, and Heinecke JW. Mass spectrometric quantication of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 272: 3520 3526, 1997. Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL, and Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-decient mice. Am J Physiol Heart Circ Physiol 276: H1943H1950, 1999. Lehr HA, Frei B, Olofsson AM, Carew TE, and Arfors KE. Protection from oxidized LDL-induced leukocyte adhesion to microvascular and macrovascular endothelium in vivo by vitamin C but not by vitamin E. Circulation 91: 15251532, 1995. Lehr HA, Vajkoczy P, Menger MD, and Arfors KE. Do vitamin E supplements in diets for laboratory animals jeopardize ndings Physiol Rev VOL













543. 544.







528. 529. 530.


549. 550.











556. 557. 558.



in animal models of disease? Free Radic Biol Med 26: 472 481, 1999. Lehr HA, Weyrich AS, Saetzler RK, Jurek A, Arfors KE, Zimmerman GA, Prescott SM, and McIntyre TM. Vitamin C blocks inammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest 99: 2358 2364, 1997. Lendon CL, Davies MJ, Born GV, and Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 87: 8790, 1991. Leopold JA, Zhang YY, Scribner AW, Stanton RC, and Loscalzo J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol 23: 411 417, 2003. Letters JM, Witting PK, Christison JK, Westin Eriksson A, Pettersson K, and Stocker R. Changes to lipids and antioxidants in plasma and aortae of apoE-decient mice. J Lipid Res 40: 1104 1112, 1999. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, and Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93: 11071113, 1996. Levinson SS. Relationship between bilirubin, apolipoprotein B, and coronary artery disease. Ann Clin Lab Sci 27: 185192, 1997. Li AE, Ito H, Rovira II, Kim KS, Takeda K, Yu ZY, Ferrans VJ, and Finkel T. A role for reactive oxygen species in endothelial cell anoikis. Circ Res 85: 304 310, 1999. Li H, Cybulsky MI, Gimbrone MA Jr, and Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 13: 197204, 1993. Li H, Raman CS, Glaser CB, Blasko E, Young TA, Parkinson JF, Whitlow M, and Poulos TL. Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J Biol Chem 274: 21276 21284, 1999. Li JM and Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 277: 1995219960, 2002. Li JM and Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 278: 12094 12100, 2003. Li N and Karin M. Is NF- B the sensor of oxidative stress? FASEB J 13: 11371143, 1999. Li PF, Dietz R, and von Harsdorf R. Reactive oxygen species induce apoptosis of vascular smooth muscle cell. FEBS Lett 404: 249 252, 1997. Li PF, Dietz R, and von Harsdorf R. Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-beta1 in cardiac broblasts. FEBS Lett 448: 206 210, 1999. Liao F, Andalibi A, deBeer FC, Fogelman AM, and Lusis AJ. Genetic control of inammatory gene induction and NF- B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 91: 25722579, 1993. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, and Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 94: 877 884, 1994. Liao JK, Shin WS, Lee WY, and Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 270: 319 324, 1995. Liao L, Aw TY, Kvietys PR, and Granger DN. Oxidized LDLinduced microvascular dysfunction. Dependence on oxidation procedure. Arterioscler Thromb Vasc Biol 15: 23052311, 1995. Libby P. Inammation in atherosclerosis. Nature 420: 868 874, 2002. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91: 2844 2850, 1995. Libby P and Ridker PM. Inammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116 Suppl 6A: 9S16S, 2004. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358: 971976, 2001. Malinski T, Mesaros S, Patton SR, and Mesarosova A. Direct measurement of nitric oxide in the cardiovascular system. Physiol Res 45: 279 284, 1996. Malinski T, Radomski MW, Taha Z, and Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun 194: 960 965, 1993. Mallat Z, Nakamura T, Ohan J, Leseche G, Tedgui A, Maclouf J, and Murphy RC. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 103: 421 427, 1999. Malle E, Waeg G, Schreiber R, Grone EF, Sattler W, and Grone HJ. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modied proteins. Eur J Biochem 267: 4495 4503, 2000. Malle E, Wag G, Thiery J, Sattler W, and Grone HJ. Hypo chlorite-modied (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem Biophys Res Commun 289: 894 900, 2001. Mao SJ, Yates MT, Parker RA, Chi EM, and Jackson RL. Attenuation of atherosclerosis in a modied strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol. Arterioscler Thromb 11: 1266 1275, 1991. Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, Collins JA, van Dam M, Molhuizen HO, Loubster O, Ouellette BF, Sensen CW, Fichter K, Mott S, Denis M, Boucher B, Pimstone S, Genest J Jr, Kastelein JJ, and Hayden MR. Mutations in the ABC1 gene in familial HDL deciency with defective cholesterol efux. Lancet 354: 13411346, 1999. Marcus AJ, Silk ST, Saer LB, and Ullman HL. Superoxide production and reducing activity in human platelets. J Clin Invest 59: 149 158, 1977. Marczin N, Ryan US, and Catravas JD. Effects of oxidant stress on endothelium-derived relaxing factor-induced and nitrovasodilator-induced cGMP accumulation in vascular cells in culture. Circ Res 70: 326 340, 1992. Marklund SL. Extracellular superoxide dismutase in human tissues and human cell lines. J Clin Invest 74: 1398 1403, 1984. Marklund SL. Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci USA 79: 7634 7638, 1982. Marsche G, Zimmermann R, Horiuchi S, Tandon NN, Sattler W, and Malle E. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modied low density lipoprotein. J Biol Chem 278: 47562 47570, 2003. Marshall FN. Pharmacology and toxicology of probucol. Artery 10: 721, 1982. Martin A and Frei B. Both intracellular and extracellular vitamin C inhibit atherogenic modication of LDL by human vascular endothelial cells. Arterioscler Thromb Vasc Biol 17: 15831590, 1997. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, and Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 92: 1866 1874, 1993. Marumo T, Schini-Kerth VB, Fisslthaler B, and Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 96: 23612367, 1997. Mashima R, Witting PK, and Stocker R. Oxidants and antioxidants in atherosclerosis. Curr Opin Lipidol 12: 411 418, 2001. Mashima R, Yamamoto Y, and Yoshimura S. Reduction of phosphatidylcholine hydroperoxide by apolipoprotein A-I: purication of the hydroperoxide-reducing proteins from human blood plasma. J Lipid Res 39: 11331140, 1998. www.prv.org

559. Libby P, Ridker PM, and Maseri A. Inammation and atherosclerosis. Circulation 105: 11351143, 2002. 560. Liebler DC, Kaysen KL, and Burr JA. Peroxyl radical trapping and autoxidation reactions of -tocopherol in lipid bilayers. Chem Res Toxicol 4: 89 93, 1991. 561. Lincoln TM, Komalavilas P, and Cornwell TL. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension 23: 11411147, 1994. 562. Liu X and Zweier JL. A real-time electrochemical technique for measurement of cellular hydrogen peroxide generation and consumption: evaluation in human polymorphonuclear leukocytes. Free Radic Biol Med 31: 894 901, 2001. 563. Liu XM, Chapman GB, Wang H, and Durante W. Adenovirusmediated heme oxygenase-1 gene expression stimulates apoptosis in vascular smooth muscle cells. Circulation 105: 79 84, 2002. 564. Lohse DL, Denu JM, Santoro N, and Dixon JE. Roles of aspartic acid-181 and serine-222 in intermediate formation and hydrolysis of the mammalian protein-tyrosine-phosphatase PTP1. Biochemistry 36: 4568 4575, 1997. 565. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, MooreCox A, Bosch J, Riley WA, and Teo KK. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103: 919 925, 2001. 566. Lougheed M and Steinbrecher UP. Mechanism of uptake of copper-oxidized low density lipoprotein in macrophages is dependent on its extent of oxidation. J Biol Chem 271: 11798 11805, 1996. 567. Luoma JS, Stralin P, Marklund SL, Hiltunen TP, Sarkioja T, and Yla-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modied proteins. Arterioscler Thromb Vasc Biol 18: 157167, 1998. 568. Lynch SM and Frei B. Antioxidants as antiatherogens: animal studies. In: Natural Antioxidants in Human Health and Disease, edited by Frei B. New York: Academic, 1994, p. 353385. 569. Lynch SM, Frei B, Morrow JD, Roberts LJ II, Xu A, Jackson T, Reyna R, Klevay LM, Vita JA, and Keaney JF Jr. Vascular superoxide dismutase deciency impairs endothelial vasodilator function through direct inactivation of nitric oxide and increased lipid peroxidation. Arterioscler Thromb Vasc Biol 17: 29752981, 1997. 570. Lynch SM, Morrow JD, Roberts LJ II, and Frei B. Formation of noncyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low-density lipoprotein exposed to oxidative stress in vitro. J Clin Invest 93: 998 1004, 1994. 571. Mackness MI, Arrol S, Abbott C, and Durrington PN. Protection of low-density lipoprotein against oxidative modication by high-density lipoprotein associated paraoxonase. Atherosclerosis 104: 129 135, 1993. 572. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, and Durrington PN. Presence of paraoxonase in human interstitial uid. FEBS Lett 416: 377380, 1997. 573. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, and Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765774, 1990. 574. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, and Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14: 18921899, 1994. 575. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 2: 25572568, 1988. 576. Maiorino M, Thomas JP, Girotti AW, and Ursini F. Reactivity of phospholipid hydroperoxide glutathione peroxidase with membrane and lipoprotein lipid hydroperoxides. Free Radic Res Commun 1213: 131135, 1991. 577. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A, and Haskard D. Soluble adhesion Physiol Rev VOL










587. 588.


590. 591.



594. 595.

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS 596. Mashima R, Yoshimura S, and Yamamoto Y. Reduction of lipid hydroperoxides by apolipoprotein B-100. Biochem Biophys Res Commun 259: 185189, 1999. 597. Mathews CE, McGraw RA, Dean R, and Berdanier CD. Inheritance of a mitochondrial DNA defect and impaired glucose tolerance in BHE/Cdb rats. Diabetologia 42: 35 40, 1999. 598. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, and Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 106: 15211530, 2000. 599. Matsubara T and Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol 137: 32953298, 1986. 600. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, and Hay RT. Thioredoxin regulates the DNA binding activity of NF- B by reduction of a disulphide bond involving cysteine 62. Nucleic Acid Res 20: 38213830, 1992. 601. Matthews N. Anti-tumour cytotoxin produced by human monocytes: studies on its mode of action. Br J Cancer 48: 405 410, 1983. 602. Mattsson Hulten LM, Lindmark H, Diczfalusy U, Bjorkhem I, Ottosson M, Liu Y, Bondjers G, and Wiklund O. Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J Clin Invest 97: 461 468, 1996. 603. May JM. How does ascorbic acid prevent endothelial dysfunction? Free Radic Biol Med 28: 14211429, 2000. 604. May JM, Cobb CE, Mendiratta S, Hill KE, and Burk RF. Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase. J Biol Chem 273: 23039 23045, 1998. 605. May JM, Mendiratta S, Hill KE, and Burk RF. Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J Biol Chem 272: 2260722610, 1997. 606. May JM, Qu ZC, and Mendiratta S. Protection and recycling of -tocopherol in human erythrocytes by intracellular ascorbic acid. Arch Biochem Biophys 349: 281289, 1998. 607. Mayer B, Klatt P, Werner ER, and Schmidt K. Kinetics and mechanism of tetrahydrobiopterin-induced oxidation of nitric oxide. J Biol Chem 270: 655 659, 1995. 608. Mayr M, Kiechl S, Willeit J, Wick G, and Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 102: 833 839, 2000. 609. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312: 159 163, 1985. 610. McDowell IF, Brennan GM, McEneny J, Young IS, Nicholls DP, McVeigh GE, Bruce I, Trimble ER, and Johnston GD. The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. Eur J Clin Invest 24: 759 765, 1994. 611. McMurray HF, Parthasarathy S, and Steinberg D. Oxidatively modied low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 92: 1004 1008, 1993. 612. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, and Harrison DG. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285: H2290 H2297, 2003. 613. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ, and Shih W. Identication of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91: 120 126, 2002. 614. Mehrabian M, Wong J, Wang X, Jiang Z, Shi W, Fogelman AM, and Lusis AJ. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res 89: 125130, 2001. 615. Mehta JL, Chen LY, Kone BC, Mehta P, and Turner P. Identication of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 125: 370 377, 1995. 616. Meier B, Radeke HH, Selle S, Habermehl GG, Resch K, and Sies H. Human broblasts release low amounts of reactive oxygen species in response to the potent phagocyte stimulants, sePhysiol Rev VOL



















634. 635.


rum-treated zymosan, N-formyl-methionyl-leucyl-phenylalanine, leukotriene B4 or 12-O-tetradecanoylphorbol 13-acetate. Biol Chem Hoppe Seyler 371: 10211025, 1990. Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, and Habermehl GG. Human broblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor- . Biochem J 263: 539 545, 1989. Mellion BT, Ignarro LJ, Myers CB, Ohlstein EH, Ballot BA, Hyman AL, and Kadowitz PJ. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol 23: 653 664, 1983. Mendelsohn ME, ONeill S, George D, and Loscalzo J. Inhibition of brinogen binding to human platelets by S-nitroso-Nacetylcysteine. J Biol Chem 265: 19028 19034, 1990. Mendiratta S, Qu ZC, and May JM. Enzyme-dependent ascorbate recycling in human erythrocytes: role of thioredoxin reductase. Free Radic Biol Med 25: 221228, 1998. Meng TC, Fukada T, and Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9: 387399, 2002. Mietus-Snyder M, Friera A, Glass CK, and Pitas RE. Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C: a role for oxidative stress. Arterioscler Thromb Vasc Biol 17: 969 978, 1997. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, and Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298 1305, 1998. Miller M and Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 272: 231233, 1994. Miller YI, Felikman Y, and Shaklai N. Hemoglobin induced apolipoprotein B crosslinking in low-density lipoprotein peroxidation. Arch Biochem Biophys 326: 252260, 1996. Miller YI, Smith A, Morgan WT, and Shaklai N. Role of hemopexin in protection of low-density lipoprotein against hemoglobin-induced oxidation. Biochemistry 35: 1311213117, 1996. Milstien S and Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 263: 681 684, 1999. Minor RL Jr, Myers PR, Guerra R Jr, Bates JN, and Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 86: 2109 2116, 1990. Minuz P, Andrioli G, Degan M, Gaino S, Ortolani R, Tommasoli R, Zuliani V, Lechi A, and Lechi C. The F2-isoprostane 8-epiprostaglandin F2 increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 18: 1248 1256, 1998. Moghadasian MH, McManus BM, Godin DV, Rodrigues B, and Frohlich JJ. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-decient mice: possible mechanisms of action. Circulation 99: 17331739, 1999. Mohazzab KM and Wolin MS. Sites of superoxide anion production detected by lucigenin in calf pulmonary artery smooth muscle. Am J Physiol Lung Cell Mol Physiol 267: L815L822, 1994. Mohr D, Bowry VW, and Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 1126: 247254, 1992. Mohr D, Umeda Y, Redgrave TG, and Stocker R. Antioxidant defenses in rat intestine and mesenteric lymph. Redox Report 4: 79 87, 1999. Monod J, Wyman J, and Changeux JP. On the nature of allosteric transitions: a plausible model. J Mol Biol 12: 88 118, 1965. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, and Fallon JT. Macrophage inltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90: 775778, 1992. Morin CL, Allen KG, and Mathias MM. Thromboxane production in copper-decient and marginal platelets: inuence of superoxide dismutase and lipid hydroperoxides. Proc Soc Exp Biol Med 202: 167173, 1993. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. 656. Nakamura K, Hori T, Sato N, Sugie K, Kawakami T, and Yodoi J. Redox regulation of a src family protein tyrosine kinase p56lck in T cells. Oncogene 8: 31333139, 1993. 657. Nardai G, Braun L, Csala M, Mile V, Csermely P, Benedetti A, Mandl J, and Banhegyi G. Protein-disulde isomerase- and pro tein thiol-dependent dehydroascorbate reduction and ascorbate accumulation in the lumen of the endoplasmic reticulum. J Biol Chem 276: 8825 8828, 2001. 658. Nathan C. Points of control in inammation. Nature 420: 846 852, 2002. 659. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, and Fogelman AM. Monocyte transmigration induced by modication of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88: 2039 2046, 1991. 660. Neale ML, Fiera RA, and Matthews N. Involvement of phospholipase A2 activation in tumour cell killing by tumour necrosis factor. Immunology 64: 81 85, 1988. 661. Neunteu T, Kostner K, Katzenschlager R, Zehetgruber M, Maurer G, and Weidinger F. Additional benet of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol 32: 711716, 1998. 662. Neuzil J and Stocker R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett 331: 281284, 1993. 663. Neuzil J and Stocker R. Free and albumin-bound bilirubin is an efcient co-antioxidant for -tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 269: 1671216719, 1994. 664. Neuzil J, Thomas SR, and Stocker R. Requirement for, promotion, or inhibition by -tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radic Biol Med 22: 5771, 1997. 665. Neuzil J, Upston JM, Witting PK, Scott K, and Stocker R. Secretory phospholipase A2 and lipoprotein lipase enhance 15lipoxygenase-induced enzymic and non-enzymic lipid peroxidation in low-density lipoproteins. Biochemistry 37: 92039210, 1998. 666. Neuzil J, Witting PK, and Stocker R. -Tocopheryl hydroquinone is an efcient multifunctional inhibitor of radical-initiated oxidation of low-density lipoprotein lipids. Proc Natl Acad Sci USA 94: 78857890, 1997. 667. Nievelstein PFEM, Fogelman AM, Mottino G, and Frank JS. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue. Arterioscl Thromb 11: 17951805, 1991. 668. Nikkari ST, OBrien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, and Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 92: 13931398, 1995. 669. Nimnual AS, Taylor LJ, and Bar-Sagi D. Redox-dependent downregulation of Rho by Rac. Nat Cell Biol 5: 236 241, 2003. 670. Nishigaki I, Hagihara M, Tsunekawa H, Maseki M, and Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med 25: 373378, 1981. 671. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787790, 2000. 672. Niu X, Zammit V, Upston JM, Dean RT, and Stocker R. Co-existence of oxidized lipids and -tocopherol in all lipoprotein fractions isolated from advanced human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 19: 1708 1718, 1999. 673. Noguchi N, Okimoto Y, Tsuchiya J, Cynshi O, Kodama T, and Niki E. Inhibition of oxidation of low-density lipoprotein by a novel antioxidant, BO-653, prepared by theoretical design. Arch Biochem Biophys 347: 141147, 1997. 674. Nohl H and Jordan W. The mitochondrial site of superoxide formation. Biochem Biophys Res Commun 138: 533539, 1986. www.prv.org

637. Moro MA, Darley-Usmar V, Goodwin DA, Read NG, ZamoraPino R, Feelisch M, Radomski MW, and Moncada S. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci USA 91: 6702 6706, 1994. 638. Moro MA, Darley-Usmar VM, Lizasoain I, Su Y, Knowles RG, Radomski MW, and Moncada S. The formation of nitric oxide donors from peroxynitrite. Br J Pharmacol 116: 1999 2004, 1995. 639. Morrison HI, Ellison LF, and Taylor GW. Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases. J Cardiovasc Risk 6: 711, 1999. 640. Morrow JD, Awad JA, Boss HJ, Blair IA, and Roberts LJ II. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 89: 1072110725, 1992. 641. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, and Roberts LJ II. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332: 1198 1203, 1995. 642. Morrow JD and Roberts LJ. Quantication of noncyclooxygenase derived prostanoids as a marker of oxidative stress. Free Radic Biol Med 10: 195200, 1991. 643. Moses C, Rhodes GL, and Levinson JP. The effect of alphatocopherol on experimental aptherosclerosis. Angiology 3: 397 407, 1952. 644. Mueller S, Pantopoulos K, Hubner CA, Stremmel W, and Hentze MW. IRP1 activation by extracellular oxidative stress in the perfused rat liver. J Biol Chem 276: 2319223196, 2001. 645. Mugge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, and Harrison DG. Chronic treatment with polyethyleneglycolated superoxide dismutase partially restores endotheliumdependent vascular relaxations in cholesterol-fed rabbits. Circ Res 69: 12931300, 1991. 646. Mukai K, Itoh S, and Morimoto H. Stopped-ow kinetic study of vitamin E regeneration reaction with biological hydroquinones (reduced forms of ubiquinone, vitamin K, and tocopherolquinone) in solution. J Biol Chem 267: 2227722281, 1992. 647. Mukai K, Kikuchi S, and Urano S. Stopped-ow kinetic study of the regeneration reaction of tocopheroxyl radical by reduced ubiquinone-10 in solution. Biochim Biophys Acta 1035: 77 82, 1990. 648. Mukhopadhyay CK, Ehrenwald E, and Fox PL. Ceruloplasmin enhances smooth muscle cell- and endothelial cell-mediated low density lipoprotein oxidation by a superoxide-dependent mechanism. J Biol Chem 271: 1477314778, 1996. 649. Munzel T and Keaney JF Jr. Are ACE inhibitors a magic bullet against oxidative stress? Circulation 104: 15711574, 2001. 650. Murphy HS, Shayman JA, Till GO, Mahrougui M, Owens CB, Ryan US, and Ward PA. Superoxide responses of endothelial cells to C5a and TNF- : divergent signal transduction pathways. Am J Physiol Lung Cell Mol Physiol 263: L51L59, 1992. 651. Murray HW and Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 189: 741746, 1999. 652. Murray JJ and Brash AR. Rabbit reticulocyte lipoxygenase catalyses specic 12(S) and 15(S) oxygenation of arachidonoylphosphatidylcholine. Arch Biochem Biophys 265: 514 523, 1988. 653. Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, and Beaudet AL. Deciency of inammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 17: 15171520, 1997. 654. Nakajima T, Kitajima I, Shin H, Takasaki I, Shigeta K, Abeyama K, Yamashita Y, Tokioka T, Soejima Y, and Maruyama I. Involvement of NF- B activation in thrombin-induced human vascular smooth muscle cell proliferation. Biochem Biophys Res Commun 204: 950 958, 1994. 655. Nakamura H, Vaage J, Valne G, Padilla CA, Bjornstedt M, and Holmgren A. Measurement of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic Biol Med 24: 1176 1186, 1998. Physiol Rev VOL

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS 675. Nonaka H, Tsujino T, Watari Y, Emoto N, and Yokoyama M. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine: amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation 104: 11651170, 2001. 676. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, Nakata A, Ishigami M, Miyagawa J, and Kameda-Takemura K. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-decient subjects. J Clin Invest 96: 1859 1865, 1995. 677. ODonnell VB, Chumley PH, Hogg N, Bloodsworth A, DarleyUsmar VM, and Freeman BA. Nitric oxide inhibition of lipid peroxidation: kinetics of reaction with lipid peroxyl radicals and comparison with -tocopherol. Biochemistry 36: 15216 15223, 1997. 678. ODonnell-Tormey J, DeBoer CJ, and Nathan CF. Resistance of human tumor cells in vitro to oxidative cytolysis. J Clin Invest 76: 80 86, 1985. 679. Offermann MK and Medford RM. Antioxidants and atherosclerosis: a molecular perspective. Heart Dis Stroke 3: 5257, 1994. 680. Ohara Y, Peterson TE, and Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546 2551, 1993. 681. Ohgushi M, Kugiyama K, Fukunaga K, Murohara T, Sugiyama S, Miyamoto E, and Yasue H. Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modied LDL. Arterioscler Thromb 13: 15251532, 1993. 682. Oram JF. Tangier disease and ABCA1. Biochim Biophys Acta 1529: 321330, 2000. 683. sterud B and Bjrklid E. Role of monocytes in atherogenesis. Physiol Rev 83: 1069 1112, 2003. 684. Otterbein LE, Soares MP, Yamashita K, and Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 24: 449 455, 2003. 685. Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AM, and Soares MP. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med 9: 183190, 2003. 686. Oury TD, Day BJ, and Crapo JD. Extracellular superoxide dismutase in vessels and airways of humans and baboons. Free Radic Biol Med 20: 957965, 1996. 687. Ozer NK, Sirikci O, Taha S, San T, Moser U, and Azzi A. Effect of vitamin E and probucol on dietary cholesterol-induced atherosclerosis in rabbits. Free Radic Biol Med 24: 226 233, 1998. 688. Packer JE, Slater TF, and Willson RL. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 278: 737738, 1979. 689. Padmaja S and Huie RE. The reaction of nitric oxide with organic peroxyl radicals. Biochem Biophys Res Commun 195: 539 544, 1993. 690. Paganga G, Rice-Evans C, Rule R, and Leake D. The interaction between ruptured erythrocytes and low-density lipoproteins. FEBS Lett 303: 154 158, 1992. 691. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, and Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 94: 14483 14488, 1997. 692. Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI, and Cohen RA. An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol Heart Circ Physiol 268: H2274 H2280, 1995. 693. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, and Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-decient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 98: 800 814, 1996. 694. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, and Witztum JL. AopE-decient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specic Physiol Rev VOL





















epitopes in lesions and high titres of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 14: 605 616, 1994. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, and Witztum JL. Low density lipoprotein undergoes oxidative modication in vivo. Proc Natl Acad Sci USA 86: 1372 1376, 1989. Palinski W, Tangirala RK, Miller E, Young SG, and Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-decient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 15: 1569 1576, 1995. Palinski W and Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 247: 371380, 2000. Palmer RM, Stapleton JA, Sutherland G, Coward PY, Wilson RF, and Scott DA. Effect of nicotine replacement and quitting smoking on circulating adhesion molecule proles (sICAM-1, sCD44v5, sCD44v6). Eur J Clin Invest 32: 852 857, 2002. Panasenko OM, Briviba K, Klotz LO, and Sies H. Oxidative modication and nitration of human low-density lipoproteins by the reaction of hypochlorous acid with nitrite. Arch Biochem Biophys 343: 254 259, 1997. Pantopoulos K and Hentze MW. Activation of iron regulatory protein-1 by oxidative stress in vitro. Proc Natl Acad Sci USA 95: 10559 10563, 1998. Pantopoulos K and Hentze MW. Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J 14: 29172924, 1995. Paravicini TM, Chrissobolis S, Drummond GR, and Sobey CG. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke 35: 584 589, 2004. Park JB and Levine M. Purication, cloning and expression of dehydroascorbic acid-reducing activity from human neutrophils: identication as glutaredoxin. Biochem J 315: 931938, 1996. Parker RA, Sabrah T, Cap M, and Gill BT. Relation of vascular oxidative stress, -tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler Thromb Vasc Biol 15: 349 358, 1995. Parkinson SJ, Jovanovic A, Jovanovic S, Wagner F, Terzic A, and Waldman SA. Regulation of nitric oxide-responsive recombinant soluble guanylyl cyclase by calcium. Biochemistry 38: 6441 6448, 1999. Parkos CA, Allen RA, Cochrane CG, and Jesaitis AJ. Puried cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000. J Clin Invest 80: 732742, 1987. Parthasarathy S, Printz DJ, Boyd D, Joy L, and Steinberg D. Macrophage oxidation of low density lipoprotein generates a modied form recognized by the scavenger receptor. Arteriosclerosis 6: 505510, 1986. Parthasarathy S, Wieland E, and Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modication of low-density lipoprotein. Proc Natl Acad Sci USA 86: 1046 1050, 1989. Parthasarathy S, Young SG, Witztum JL, Pittman RC, and Steinberg D. Probucol inhibits oxidative modication of low density lipoprotein. J Clin Invest 77: 641 644, 1986. Parums DV, Brown DL, and Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 114: 383387, 1990. Patel KB, Stratford MR, Wardman P, and Everett SA. Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med 32: 203211, 2002. Patrono C and FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17: 2309 2315, 1997. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, and Runge MS. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. this oxidase in vitro and in vivo. J Biol Chem 274: 19814 19822, 1999. Pattison DI and Davies MJ. Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. Chem Res Toxicol 14: 14531464, 2001. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, and Vinicor F. Markers of inammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499 511, 2003. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, and Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107: 853 860, 2001. Petersen SV, Oury TD, Ostergaard L, Valnickova Z, Wegrzyn J, Thgersen IB, Jacobsen C, Bowler RP, Fattman CL, Crapo JD, and Enghild JJ. Extracellular superoxide dismutase (ECSOD) binds to type I collagen and protects against oxidative fragmentation. J Biol Chem 279: 1370513710, 2004. Petersen SV, Oury TD, Valnickova Z, Thgersen IB, Hjrup P, Crapo JD, and Enghild JJ. The dual nature of human extracellular superoxide dismutase: one sequence and two structures. Proc Natl Acad Sci USA 100: 1387513880, 2003. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, and Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 91: 484 490, 1998. Podrez EA, Abu-Soud HM, and Hazen SL. Myeloperoxidasegenerated oxidants and atherosclerosis. Free Radic Biol Med 28: 17171725, 2000. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Febbraio M, Hajjar DP, Silverstein RL, Hoff HF, Salomon RG, and Hazen SL. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 277: 3851738523, 2002. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, and Hazen SL. Identication of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 277: 3850338516, 2002. Podrez EA, Schmitt D, Hoff HF, and Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103: 15471560, 1999. Polyak K, Xia Y, Zweier JL, Kinzler KW, and Vogelstein B. A model for p53-induced apoptosis. Nature 389: 300 305, 1997. Porter NA, Weber BA, Weenen H, and Khan JA. Autoxidation of polyunsaturated lipids. Factors controlling the stereochemistry of product hydroperoxides. J Am Chem Soc 102: 55975601, 1980. Poss KD and Tonegawa S. Reduced stress defense in heme oxygenase 1-decient cells. Proc Natl Acad Sci USA 94: 10925 10930, 1997. Poston RN, Haskard DO, Coucher JR, Gall NP, and JohnsonTidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 140: 665 673, 1992. (PPP) Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357: 89 95, 2001. Pradhan AD, Rifai N, and Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 106: 820 825, 2002. Prasad K and Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 125: 958 973, 1993. Pratico D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Maclouf J, Violi F, and FitzGerald GA. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100: 2028 2034, 1997. Physiol Rev VOL 732. Pratico D, Tangirala RK, Horkko S, Witztum JL, Palinski W, and FitzGerald GA. Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F(2alpha)-VI levels and the extent of atherosclerosis in ApoE-decient mice: modulation by vitamin E. Blood 97: 459 464, 2001. 733. Pratico D, Tangirala RK, Radar D, Rokach J, and FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-decient mice. Nat Med 4: 1189 1192, 1998. 734. Pressure JNCoDoHB. The fth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 153: 154 183, 1993. 735. Pritchard KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, and Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 77: 510 518, 1995. 736. Proctor SD, Vine DF, and Mamo JC. Arterial retention of apolipoprotein B48- and B100-containing lipoproteins in atherogenesis. Curr Opin Lipidol 13: 461 470, 2002. 737. Pryor WA, Cornicelli JA, Devall LJ, Tait B, Trivedi BK, Witiak DT, and Wu M. A rapid screening test to determine the antioxidant potencies of natural and synthetic antioxidants. J Org Chem 58: 35213532, 1993. 738. Puig JG and Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 17: 869 872, 1999. 739. Pyorala K, Laakso M, and Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3: 463524, 1987. 740. Qiao Y, Yokoyama M, Kameyama K, and Asano G. Effect of vitamin E on vascular integrity in cholesterol-fed guinea pigs. Arterioscl Thromb 13: 18851892, 1993. 741. Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J, and Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem 272: 21388 21395, 1997. 742. Quinn MT, Parthasarathy S, Fong LG, and Steinberg D. Oxidatively modied low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 84: 29952998, 1987. 743. Quinn MT, Parthasarathy S, and Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modied forms of low density lipoprotein. Proc Natl Acad Sci USA 82: 5949 5953, 1985. 744. Raal FJ, Pilcher GJ, Veller MG, Kotze MJ, and Joffe BI. Efcacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol 84: 1344 1346, 1999. 745. Radi R. Reactions of nitric oxide with metalloproteins. Chem Res Toxicol 9: 828 835, 1996. 746. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 101: 4003 4008, 2004. 747. Radi R, Rodriguez M, Castro L, and Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 308: 89 95, 1994. 748. Radomski MW, Palmer RM, and Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 10571058, 1987. 749. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, and OHalloran TV. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284: 805 808, 1999. 750. Raftery MJ, Yang Z, Valenzuela SM, and Geczy CL. Novel intra- and inter-molecular sulnamide bonds in S100A8 produced by hypochlorite oxidation. J Biol Chem 276: 3339333401, 2001. 751. Raitakari OT, McCredie RJ, Witting P, Grifths KA, Letters J, Sullivan D, Stocker R, and Celermajer DS. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med 28: 1100 1105, 2000. 752. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via www.prv.org











724. 725.







84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916 1923, 1996. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, and Galis ZS. Reactive oxygen species produced by macrophagederived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98: 25722579, 1996. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, and Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modied low-density lipoproteins. Nature 344: 254 257, 1990. Ramachandran A, Levonen AL, Brookes PS, Ceaser E, Shiva S, Barone MC, and Darley-Usmar V. Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radic Biol Med 33: 1465 1474, 2002. Ramachandran N, Root P, Jiang XM, Hogg PJ, and Mutus B. Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by cell-surface protein disulde isomerase. Proc Natl Acad Sci USA 98: 9539 9544, 2001. Raman CS, Li H, Martasek P, Kral V, Masters BS, and Poulos TL. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell 95: 939 950, 1998. Rao GN and Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 70: 593599, 1992. Rao GN, Corson MA, and Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266: 8604 8608, 1991. Rao GN, Katki KA, Madamanchi NR, Wu Y, and Birrer MJ. JunB forms the majority of the AP-1 complex and is a target for redox regulation by receptor tyrosine kinase and G protein-coupled receptor agonists in smooth muscle cells. J Biol Chem 274: 6003 6010, 1999. Rao GN, Lassegue B, Griendling KK, and Alexander RW. Hydrogen peroxide stimulates transcription of c-jun in vascular smooth muscle cells: role of arachidonic acid. Oncogene 8: 2759 2764, 1993. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, and Heinonen OP. Randomised trial of -tocopherol and -carotene supplements on incidence of major coronary events in men with previous myocardial infraction. Lancet 349: 17151720, 1997. Ravi K, Brennan LA, Levic S, Ross PA, and Black SM. Snitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc Natl Acad Sci USA 101: 2619 2624, 2004. Ravichandran V, Seres T, Moriguchi T, Thomas JA, and Johnston RB Jr. S-thiolation of glyceraldehyde-3-phosphate dehydrogenase induced by the phagocytosis-associated respiratory burst in blood monocytes. J Biol Chem 269: 25010 25015, 1994. Ravid T, Sweeney C, Gee P, Carraway KL III, and Goldkorn T. Epidermal growth factor receptor activation under oxidative stress fails to promote c-Cbl mediated down-regulation. J Biol Chem 277: 31214 31219, 2002. Rey FE and Pagano PJ. The reactive adventitia: broblast oxidase in vascular function. Arterioscler Thromb Vasc Biol 22: 19621971, 2002. Rhee SG, Chang TS, Bae YS, Lee SR, and Kang SW. Cellular regulation by hydrogen peroxide. J Am Soc Nephrol 14: S211 S215, 2003. Richardson PD, Davies MJ, and Born GV. Inuence of plaque conguration and stress distribution on ssuring of coronary atherosclerotic plaques. Lancet 2: 941944, 1989. Ridker PM, Hennekens CH, Roitman Johnson-B, Stampfer MJ, and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351: 88 92, 1998. Riemersma RA, Wood DA, Macintyre CC, Elton RA, Gey KF, and Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 337: 15, 1991. Physiol Rev VOL




















771. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, and Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328: 1450 1456, 1993. 772. Roberts LJ II and Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta 1345: 121135, 1997. 773. Robinson MK, Andrew D, Rosen H, Brown D, Ortlepp S, Stephens P, and Butcher EC. Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events. J Immunol 148: 1080 1085, 1989. 774. Rodriguez J, Maloney RE, Rassaf T, Bryan NS, and Feelisch M. Chemical nature of nitric oxide storage forms in rat vascular tissue. Proc Natl Acad Sci USA 100: 336 341, 2003. 775. Rodriguez-Moran M and Guerrero-Romero F. Elevated concentrations of C-reactive protein in subjects with type 2 diabetes mellitus are moderately inuenced by glycemic control. J Endocrinol Invest 26: 216 221, 2003. 776. Rodvien R, Lindon JN, and Levine P. Physiology and ultrastructure of the blood platelet following exposure to hydrogen peroxide. Br J Haematol 33: 19 24, 1976. 777. Rohde LE, Hennekens CH, and Ridker PM. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol 19: 15951599, 1999. 778. Rokitansky C. A Manual of Pathological Anatomy. London: Sydenham Society, 1852. 779. Roman LJ, Martasek P, and Masters BS. Intrinsic and extrinsic modulation of nitric oxide synthase activity. Chem Rev 102: 1179 1190, 2002. 780. Romano M and Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 17: 1986 1695, 2003. 781. Ross R. Atherosclerosisan inammatory disease. N Engl J Med 340: 115126, 1999. 782. Ross R and Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180: 13321339, 1973. 783. Ross R and Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 295: 369 377, 1976. 784. Ross R and Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 295: 420 425, 1976. 785. Rubanyi GM and Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol Heart Circ Physiol 250: H822H827, 1986. 786. Rubartelli A, Bajetto A, Allavena G, Wollman E, and Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 267: 2416124164, 1992. 787. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, and Freeman BA. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 269: 26066 26075, 1994. 788. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, and Sessa WC. Direct evidence for the importance of endotheliumderived nitric oxide in vascular remodeling. J Clin Invest 101: 731736, 1998. 789. Ruiz-Stewart I, Kazerounian S, Pitari GM, Schulz S, and Waldman SA. Soluble guanylate cyclase is allosterically inhibited by direct interaction with 2-substituted adenine nucleotides. Eur J Biochem 269: 2186 2193, 2002. 790. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denee P, and Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22: 352 355, 1999. 791. Saito Y, Hayashi T, Tanaka A, Watanabe Y, Suzuki M, Saito E, and Takahashi K. Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic characterization of human selenoprotein P. J Biol Chem 274: 2866 2871, 1999. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. 811. Schewe T. 15-Lipoxygenase-1: a prooxidant enzyme. Biol Chem 383: 365374, 2002. 812. Schinina ME, Carlini P, Polticelli F, Zappacosta F, Bossa F, and Calabrese L. Amino acid sequence of chicken Cu,Zn-containing superoxide dismutase and identication of glutathionyl adducts at exposed cysteine residues. Eur J Biochem 237: 433 439, 1996. 813. Schissel SL, Jiang X, Tweedie-Hardman J, Jeong T, Camejo EH, Najib J, Rapp JH, Williams KJ, and Tabas I. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 273: 2738 2746, 1998. 814. Schmidt P, Youhnovski N, Daiber A, Balan A, Arsic M, Bachschmid M, Przybylski M, and Ullrich V. Specic nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J Biol Chem 278: 1281312819, 2003. 815. Schneider C, Tallman KA, Porter NA, and Brash AR. Two distinct pathways of formation of 4-hydroxynonenal. Mechanisms of nonenzymatic transformation of the 9- and 13-hydroperoxides of linoleic acid to 4-hydroxyalkenals. J Biol Chem 276: 20831 20838, 2001. 816. Schreck R, Rieber P, and Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 10: 22472258, 1991. 817. Schumacher M, Eber B, Tatzber F, Kaufmann P, Halwachs G, Fruhwald FM, Zweiker R, Esterbauer H, and Klein W. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med 18: 1087 1091, 1995. 818. Schwartz SM and Ross R. Cellular proliferation in atherosclerosis and hypertension. Prog Cardiovasc Dis 26: 355372, 1984. 819. Schwenke DC and Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis 9: 895907, 1989. 820. Schwenke DC and Carew TE. Initiation of atherosclerotic lesison in cholesterol-fed rabbits. II. Selective retention of LDL vs selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 9: 908 918, 1989. 821. Schwenke DC and Zilversmit DB. The arterial barrier to lipoprotein inux in the hypercholesterolemic rabbit. 1. Studies during the rst two days after mild aortic injury. Atheroscleorsis 77: 91103, 1989. 822. Schwertner HA and Fischer JR Jr. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis 150: 381387, 2000. 823. Schwertner HA, Jackson WG, and Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40: 18 23, 1994. 824. Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, Colbry N, Dyer RD, Feinmark SJ, and Daugherty A. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking signicant antioxidant properties. Br J Pharmacol 120: 1199 1206, 1997. 825. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S, Hirata KI, Kawashima S, Tawa R, Imajoh-Ohmi S, Sakurai H, and Yokoyama M. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 103: 399 409, 2001. 826. Sentman ML, Brannstrom T, Westerlund S, Laukkanen MO, Yla-Herttuala S, Basu S, and Marklund SL. Extracellular su peroxide dismutase deciency and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 21: 14771482, 2001. 828. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, and Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91: 406 413, 2002. 829. Sesso HD, Buring JE, Norkus EP, and Gaziano JM. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. Am J Clin Nutr 79: 4753, 2004. 830. Sevanian A, Hwang J, Hodis H, Cazzolato G, Avogaro P, and Bittolo-Bon G. Contribution of an in vivo oxidized LDL to LDL www.prv.org

792. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596 2606, 1998. 793. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, and Barford D. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423: 769 773, 2003. 794. Salonen JT, Nyyssonen K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Lakka TA, Rissanen T, Leskinen L, Tuomainen TP, Valkonen VP, Ristonmaa U, and Poulsen HE. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 248: 377386, 2000. 795. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, and Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339: 883 887, 1992. 796. Salvemini D, de Nucci G, Sneddon JM, and Vane JR. Superoxide anions enhance platelet adhesion and aggregation. Br J Pharmacol 97: 11451150, 1989. 797. Samokyszyn VM and Marnett LJ. Hydroperoxide-dependent cooxidation of 13-cis-retinoic acid by prostaglandin H synthase. J Biol Chem 262: 14119 14133, 1987. 798. Sankarapandi S and Zweier JL. Bicarbonate is required for the peroxidase function of Cu,Zn-superoxide dismutase at physiological pH. J Biol Chem 274: 1226 1232, 1999. 799. Santiago-Garca J, Kodama T, and Pitas RE. The class A scavenger receptor binds to proteoglycans and mediates adhesion of macrophages to the extracellular matrix. J Biol Chem 278: 6942 6946, 2003. 800. Sasahara M, Raines EW, Chait A, Carew TE, Steinberg D, Wahl PW, and Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 94: 155164, 1994. 801. Sase K and Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 57: 2049 2055, 1995. 802. Sato K, Niki E, and Shimasaki H. Free radical-mediated chain oxidation of low density lipoprotein and its synergistic inhibition by vitamin E and vitamin C. Arch Biochem Biophys 279: 402 405, 1990. 803. Sattler W, Christison JK, and Stocker R. Cholesterylester hydroperoxide reducing activity associated with isolated highand low-density lipoproteins. Free Radic Biol Med 18: 421 429, 1995. 804. Sattler W, Maiorino M, and Stocker R. Reduction of HDL- and LDL-associated cholesterylester- and phospholipid hydroperoxides by phospholipid hydroperoxide glutathione peroxidase and Ebselen (PZ 51). Arch Biochem Biophys 309: 214 221, 1994. 805. Sattler W, Mohr D, and Stocker R. Rapid isolation of lipoproteins and assessment of their peroxidation by HPLC postcolumn chemiluminescence. Methods Enzymol 233: 469 489, 1994. 806. Savenkova ML, Mueller DM, and Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 269: 20394 20400, 1994. 807. Savitsky PA and Finkel T. Redox regulation of Cdc25C. J Biol Chem 277: 2053520540, 2002. 808. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, and Hayashi J. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39: 610 616, 2002. 809. Schachinger V, Britten MB, and Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899 1906, 2000. 810. Schafer M, Schafer C, Ewald N, Piper HM, and Noll T. Role of redox signaling in the autonomous proliferative response of endothelial cells to hypoxia. Circ Res 92: 1010 1015, 2003. Physiol Rev VOL

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 16: 784 793, 1996. Seyer J and Kang A. Connective tissues of the subendothelium. In: Vascular Medicine, edited by Loscalzo J, Craeger MA, and Dzao VJ. Boston: Little Brown, 1992, p. 4778. Shabani F, McNeil J, and Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. Free Radic Res 28: 115123, 1998. Shah NS and Billiar TR. Role of nitric oxide in inammation and tissue injury during endotoxemia and hemorrhagic shock. Environ Health Perspect 106 Suppl 5: 1139 1143, 1998. Shaish A, Daugherty A, OSullivan F, Schonfeld G, and Heinecke JW. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest 96: 20752082, 1995. Sharma MK and Buettner GR. Interaction of vitamin C and vitamin E during free radical stress in plasma: an ESR study. Free Radic Biol Med 14: 649 653, 1993. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 64: 749 774, 2002. Shaulian E and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131E136, 2002. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, Guevara NV, and Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 98: 22012208, 1996. Shen W, Hintze TH, and Wolin MS. Nitric oxide: an important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation 92: 35053512, 1995. Shi Y, Evans JE, and Rock KL. Molecular identication of a danger signal that alerts the immune system to dying cells. Nature 425: 516 521, 2003. Shibanuma M, Kuroki T, and Nose K. Stimulation by hydrogen peroxide of DNA synthesis, competence family gene expression and phosphorylation of a specic protein in quiescent Balb/3T3 cells. Oncogene 5: 10251032, 1990. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, and Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284 287, 1998. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, Masada M, Toda N, Kikkawa R, and Kashiwagi A. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulinresistant rats. Circ Res 87: 566 573, 2000. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, and Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289: 16751680, 2003. Shtivelman E, Lifshitz B, Gale RP, and Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315: 550 554, 1985. Shwaery GT, Samii JM, Frei B, and Keaney JF Jr. Determination of phospholipid oxidation in cultured cells. Methods Enzymol 300: 5157, 1999. Sies H. Oxidative stress: introductory remarks. In: Oxidative Stress, edited by Sies H. New York: Academic, 1985, p. 1 8. Sies H. Oxidative Stress: Oxidants and Antioxidants. London: Academic, 1991. Sies H. What is oxidative stress? In: Oxidative Stress and Vascular Disease, edited by Keaney JF Jr. Boston: Kluwer Academic, 2000, p. 1 8. Sigalov AB and Stern LJ. Enzymatic repair of oxidative damage to human apolipoprotein A-I. FEBS Lett 433: 196 200, 1998. Silva JP, Kohler M, Graff C, Oldfors A, Magnuson MA, Berggren PO, and Larsson NG. Impaired insulin secretion and betacell loss in tissue-specic knockout mice with mitochondrial diabetes. Nat Genet 26: 336 340, 2000. Simionescu M and Simionescu N. Proatherosclerotic events: pathobiochemical changes occurring in the arterial wall before monocyte migration. FASEB J 7: 1359 1366, 1993. Physiol Rev VOL







836. 837. 838.









847. 848. 849.

850. 851.


853. Simon AR, Rai U, Fanburg BL, and Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol Cell Physiol 275: C1640 C1652, 1998. 854. Simon BC, Haudenschild CC, and Cohen RA. Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol. J Cardiovasc Pharmacol 21: 893901, 1993. 855. Simons LA, von Konigsmark M, Simons J, Stocker R, and Celermajer DS. Vitamin E ingestion does not improve arterial endothelial dysfunction on older subjects. Atherosclerosis 143: 193199, 1999. 856. Singh D, Greenwald JE, Bianchine J, Metz EN, and Sagone AL Jr. Evidence for the generation of hydroxyl radical during arachidonic acid metabolism by human platelets. Am J Hematol 11: 233240, 1981. 857. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, and Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417: 750 754, 2002. 858. Skinner KA, White CR, Patel R, Tan S, Barnes S, Kirk M, Darley-Usmar V, and Parks DA. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem 273: 2449124497, 1998. 859. Smith C, Mitchinson MJ, Aruoma OI, and Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J 286: 901905, 1992. 860. Smith EB. The relationship between plasma and tissue lipids in human atherosclerosis. Adv Lipid Res 12: 1 49, 1974. 861. Smith LL and Van Lier JE. Sterol metabolism. 9. 26-Hydroxycholesterol levels in the human aorta. Atherosclerosis 12: 114, 1970. 862. Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, Grey ST, Colvin RB, Choi AM, Poss KD, and Bach FH. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 4: 10731077, 1998. 863. Soares MP, Usheva A, Brouard S, Berberat PO, Gunther L, Tobiasch E, and Bach FH. Modulation of endothelial cell apoptosis by heme oxygenase-1-derived carbon monoxide. Antioxid Redox Signal 4: 321329, 2002. 864. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, and Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429 1435, 2002. 865. Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, and Chao YS. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N -diphenyl-phenylenediamine. J Clin Invest 89: 18851891, 1992. 866. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschlager N, Hornig B, Drexler H, and Harrison DG. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 107: 13831389, 2003. 867. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, and Pryor WA. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376: 333337, 2000. 868. Squadrito GL and Pryor WA. The nature of reactive species in systems that produce peroxynitrite. Chem Res Toxicol 11: 718 719, 1998. 869. Squadrito GL and Pryor WA. Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med 25: 392 403, 1998. 870. Stadler N, Lindner RA, and Davies MJ. Direct detection and quantication of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24: 949 954, 2004. 871. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, and Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 89: 7674 7677, 1992. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. 889. Stewart-Lee AL, Forster LA, Nourooz-Zadeh J, Ferns GAA, and Anggard EE. Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol-fed rabbits. Arterioscl Thromb 14: 494 499, 1994. 890. Stiko-Rahm A, Hultgardh-Nilsson A, Regnstrom J, Hamsten A, and Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb 12: 1099 1109, 1992. 891. Stocker R. Induction of haem oxygenase as a defence against oxidative stress. Free Radic Res Commun 9: 101112, 1990. 892. Stocker R. Antioxidant defenses in the vascular wall. In: Oxidative Stress and Vascular Disease, edited by Keaney JF Jr. Boston: Kluwer Academic, 1999, p. 27 47. 893. Stocker R. The ambivalence of vitamin E in atherogenesis. Trends Biochem Sci 24: 219 223, 1999. 894. Stocker R. Dietary and pharmacological antioxidants in atherosclerosis. Curr Opin Lipidol 10: 589 597, 1999. 895. Stocker R. Antioxidant defenses in the vascular wall. In: Oxidative Stress and Vascular Disease, edited by Keaney JF Jr. Boston: Kluwer Academic, 2000, p. 27 47. 896. Stocker R, Bowry VW, and Frei B. Ubiquinol-10 protects human low density lipoprotein more efciently against lipid peroxidation than does -tocopherol. Proc Natl Acad Sci USA 88: 1646 1650, 1991. 897. Stocker R and Frei B. Endogenous antioxidant defenses in human blood plasma. In: Oxidative Stress: Oxidants and Antioxidants, edited by Sies H. London: Academic, 1991, p. 213243. 898. Stocker R, Hunt NH, Weidemann MJ, and Clark IA. Protection of vitamin E from oxidation by increased ascorbic acid content within Plasmodium vinckei-infected erythrocytes. Biochim Biophys Acta 876: 294 299, 1986. 899. Stocker R and OHalloran RA. Dealcoholized red wine decreases atherosclerosis in apolipoprotein E gene-decient mice independently of inhibition of lipid peroxidation in the artery wall. Am J Clin Nutr 79: 123130, 2004. 900. Stocker R and Upston JM. Anti-oxidants and co-antioxidation in lipoproteins and the intima. In: Atheroscleorosis, edited by Dean RT and Kelly D. Oxford: Oxford Univ. Press, 2000, p. 326 347. 901. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, and Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 235: 10431046, 1987. 902. Stokes KY, Clanton EC, Russell JM, Ross CR, and Granger DN. NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circ Res 88: 499 505, 2001. 903. Stone JR and Collins T. Rapid phosphorylation of heterogeneous nuclear ribonucleoprotein C1/C2 in response to physiologic levels of hydrogen peroxide in human endothelial cells. J Biol Chem 277: 1562115628, 2002. 904. Stone JR and Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 9: 231238, 2002. 905. Stoyanovsky DA, Osipov AN, Quinn PJ, and Kagan VE. Ubiquinone-dependent recycling of vitamin E radicals by superoxide. Arch Biochem Biophys 323: 343351, 1995. 906. Stralin P, Jacobsson H, and Marklund SL. Oxidative stress, NO* and smooth muscle cell extracellular superoxide dismutase expression. Biochim Biophys Acta 1619: 1 8, 2003. 907. Stralin P, Karlsson K, Johansson BO, and Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 15: 20322036, 1995. 908. Stralin P and Marklund SL. Multiple cytokines regulate the expression of extracellular superoxide dismutase in human vascular smooth muscle cells. Atherosclerosis 151: 433 441, 2000. 909. Stralin P and Marklund SL. Effects of oxidative stress on expression of extracellular superoxide dismutase, CuZn-superoxide dismutase and Mn-superoxide dismutase in human dermal broblasts. Biochem J 298: 347352, 1994. 910. Strange RC, Spiteri MA, Ramachandran S, and Fryer AA. Glutathione-S-transferase family of enzymes. Mutat Res 482: 21 26, 2001. www.prv.org

872. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, Gernert K, and Piantadosi CA. Blood ow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 276: 2034 2037, 1997. 873. Stamler JS, Lamas S, and Fang FC. Nitrosylation: the prototypic redox-based signaling mechanism. Cell 106: 675 683, 2001. 874. Stamler JS, Simon DI, Jaraki O, Osborne JA, Francis S, Mullins M, Singel D, and Loscalzo J. S-nitrosylation of tissuetype plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme. Proc Natl Acad Sci USA 89: 8087 8091, 1992. 875. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ, and Loscalzo J. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 89: 444 448, 1992. 876. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, and Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328: 1444 1449, 1993. 877. Stary HC. Evolution of atherosclerotic plaques in the coronary arteries of young adults. Arteriosclerosis 3: 417A 421A, 1983. 878. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull WJ, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, and Wissler MD. A denition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 12: 120 134, 1992. 879. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull WJ, Rosenfeld ME, Schwartz CJ, Wagner WD, and Wissler RW. A denition of advanced types of atherosclerotic lesions and a histological classication of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 15: 15121531, 1995. 880. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, and Wissler RW. A denition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Arterioscler Thromb 14: 840 856, 1994. 881. Steinberg D. Oxidized low density lipoproteinan extreme example of lipoprotein heterogeneity. Isr J Med Sci 32: 469 472, 1996. 882. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, and Witztum JL. Beyond cholesterol: modications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915924, 1989. 883. Steinbrecher UP. Role of superoxide in endothelial-cell modication of low-density lipoproteins. Biochim Biophys Acta 959: 20 30, 1988. 884. Steinbrecher UP and Lougheed M. Scavenger receptor-independent stimulation of cholesterol esterication in macrophages by low density lipoprotein extracted from human aortic intima. Arterioscler Thromb 12: 608 625, 1992. 885. Steinbrecher UP, Lougheed M, Kwan WC, and Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 264: 15216 15223, 1989. 886. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, and Steinberg D. Modication of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81: 38833887, 1984. 887. Stephens NG, Parsons A, Schoeld PM, Kelly F, Cheeseman K, Mitchinson MJ, and Brown MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781786, 1996. 888. Stewart D, Killeen E, Naquin R, Alam S, and Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J Biol Chem 278: 2396 2402, 2003. Physiol Rev VOL

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS 911. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, and Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 99: 41 46, 1997. 912. Stuart MJ and Holmsen H. Hydrogen peroxide, an inhibitor of platelet function: effect on adenine nucleotide metabolism, and the release reaction. Am J Hematol 2: 53 63, 1977. 913. Stuehr D, Pou S, and Rosen GM. Oxygen reduction by nitricoxide synthases. J Biol Chem 276: 1453314536, 2001. 914. Sturgeon BE, Sipe HJ Jr, Barr DP, Corbett JT, Martinez JG, and Mason RP. The fate of the oxidizing tyrosyl radical in the presence of glutathione and ascorbate. Implications for the radical sink hypothesis. J Biol Chem 273: 30116 30121, 1998. 915. Suarna C, Dean RT, May J, and Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of -tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 15: 1616 1624, 1995. 916. Suarna C, Dean RT, Southwell-Keely P, Moore DE, and Stocker R. Separation and characterization of cholesteryl oxoand hydroxy-linoleate in human atheroclerotic plaque. Free Radic Res 27: 397 408, 1997. 917. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, and Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158: 879 891, 2001. 918. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, and Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox1. Nature 401: 79 82, 1999. 919. Sulkin NM and Sulkin DF. Intimal lesions in arteries of vitamin E decient rats. Proc Soc Exp Biol Med 103: 111115, 1960. 920. Sumbayev VV. S-nitrosylation of thioredoxin mediates activation of apoptosis signal-regulating kinase 1. Arch Biochem Biophys 415: 133136, 2003. 921. Sun J, Giraud DW, Moxley RA, and Driskell JA. -Carotene and -tocopherol inhibit the development of atherosclerotic lesions in hypercholesterolemic rabbits. Int J Vitam Nutr Res 67: 155163, 1997. 922. Sun J, Xin C, Eu JP, Stamler JS, and Meissner G. Cysteine3635 is responsible for skeletal muscle ryanodine receptor modulation by NO. Proc Natl Acad Sci USA 98: 11158 11162, 2001. 923. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, and Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270: 296 299, 1995. 924. Sundqvist T. Bovine aortic endothelial cells release hydrogen peroxide. J Cell Physiol 148: 152156, 1991. 925. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Horiuchi S, Takahashi K, Kruijt JK, van Berkel TJC, Steinbrecher UP, Ishibashi S, Maeda N, Gordon S, and Kodama T. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386: 292296, 1997. 927. Tai LK, Okuda M, Abe J, Yan C, and Berk BC. Fluid shear stress activates proline-rich tyrosine kinase via reactive oxygen species-dependent pathway. Arterioscler Thromb Vasc Biol 22: 1790 1796, 2002. 928. Takahashi K, Avissar N, Within J, and Cohen HJ. Purication and characterization of human plasma glutathione peroxidase: a selenoglycoprotein distinct from the known cellular enzyme. Arch Biochem Biophys 256: 677 686, 1987. 929. Takeya R, Ueno N, Kami K, Taura M, Kohjima M, Izaki T, Nunoi H, and Sumimoto H. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem 278: 25234 25246, 2003. 930. Tamba M and ONeill P. Redox reactions of thiol free radicals with the anti-oxidants ascorbate and chlorpromazine: role in radioprotection. J Chem Soc Perkin Trans 2: 16811685, 1991. Physiol Rev VOL


931. Tamminen M, Mottino G, Qiao JH, Breslow JL, and Frank JS. Ultrastructure of early lipid accumulation in ApoE-decient mice. Arterioscler Thromb Vasc Biol 19: 847 853, 1999. 932. Tangirala RK, Casanada F, Miller E, Witztum JL, Steinberg D, and Palinski W. Effect of the antioxidant N,N -diphenyl 1,4phenylenediamine (DPPD) on atherosclerosis in apoE-decient mice. J Lipid Res 15: 16251630, 1995. 933. Tangirala RK, Pratico D, FitzGerald GA, Chun S, Tsukamoto K, Maugeais C, Usher DC, Pure E, and Rader DJ. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem 276: 261266, 2001. 934. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, and de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 337: 365372, 1997. 935. Tardif JC, Gregoire J, Schwartz L, Title L, Laramee L, Reeves F, Lesperance J, Bourassa MG, LAllier PL, Glass M, Lambert J, and Guertin MC. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 107: 552 558, 2003. 936. Tarpey MM, Beckman JS, Ischiropoulos H, Gore JZ, and Brock TA. Peroxynitrite stimulates vascular smooth muscle cell cyclic GMP synthesis. FEBS Lett 364: 314 318, 1995. 937. Tawara K, Ishihara M, Ogawa H, and Tomikawa M. Effect of probucol, pantethine and their combinations on serum lipoprotein metabolism and on the incidence of atheromatous lesions in the rabbit. Jpn J Pharmacol 41: 211222, 1986. 938. Teng JI, and Smith LL. Sterol metabolism. XXXVI. Hydroxycholesterol esters of the human aorta. Texas Reports Biol Med 33: 293301, 1975. 939. Terentis AC, Thomas SR, Burr JA, Liebler DC, and Stocker R. Vitamin E oxidation in human atherosclerotic lesions. Circ Res 90: 333339, 2002. 940. Tesfamariam B and Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol Heart Circ Physiol 263: H321H326, 1992. 941. Thannickal VJ, Aldweib KD, and Fanburg BL. Tyrosine phosphorylation regulates H2O2 production in lung broblasts stimulated by transforming growth factor 1. J Biol Chem 273: 23611 23615, 1998. 942. Thannickal VJ and Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung broblasts by transforming growth factor 1. J Biol Chem 270: 30334 30338, 1995. 943. Thannickal VJ, Hassoun PM, White AC, and Fanburg BL. Enhanced rate of H2O2 release from bovine pulmonary artery endothelial cells induced by TGF- 1. Am J Physiol Lung Cell Mol Physiol 265: L622L626, 1993. 943a.The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029 1035, 1994. 943b.T Hoen PAC, Van der Lans CAC, Van Eck M, Bijsterbosch MK, Van Berkel TJC, and Twisk J. Aorta of ApoE-decient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res 93: 262269, 2003. 944. Thomas JP, Maiorino M, Ursini F, and Girotti AW. Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. J Biol Chem 265: 454 461, 1990. 945. Thomas SR, Chen K, and Keaney JF Jr. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. J Biol Chem 277: 6017 6024, 2002. 946. Thomas SR, Chen K, and Keaney JF Jr. Oxidative stress and endothelial nitric oxide bioactivity. Antioxid Redox Signal 5: 181194, 2003. 947. Thomas SR, Davies MJ, and Stocker R. Oxidation and antioxidation of human low-density lipoprotein and plasma exposed to 3-morpholinosydnonimine and reagent peroxynitrite. Chem Res Toxicol 11: 484 494, 1998. www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. 966. Upston JM, Niu X, Brown AJ, Mashima R, Wang H, Senthilmohan R, Kettle AJ, Dean RT, and Stocker R. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am J Pathol 160: 701710, 2002. 967. Upston JM, Terentis AC, Morris K, Keaney JF Jr, and Stocker R. Oxidized lipid accumulates in the presence of -tocopherol in atherosclerosis. Biochem J 363: 753760, 2002. 968. Upston JM, Terentis AC, and Stocker R. Tocopherol-mediated peroxidation (TMP) of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J 13: 977994, 1999. 969. Upston JM, Witting PK, Brown AJ, Stocker R, and Keaney JF Jr. Effect of vitamin E on aortic lipid oxidation and intimal proliferation after vascular injury in cholesterol-fed rabbits. Free Radic Biol Med 31: 12451253, 2001. 970. Ushio-Fukai M, Alexander RW, Akers M, and Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 273: 1502215029, 1998. 971. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, and Griendling KK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 274: 22699 22704, 1999. 972. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, and Alexander RW. Novel role of gp91phox-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 91: 1160 1167, 2002. 973. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, and Griendling KK. p22phox is a critical component of the superoxidegenerating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271: 2331723321, 1996. 974. Uusitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, and Yla-Herttuala S. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16: 1236 1242, 1996. 975. Valen G, Yan ZQ, and Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38: 307314, 2001. 976. Van Berkel TJ, De Rijke YB, and Kruijt JK. Different fate in vivo of oxidatively modied low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem 266: 22822289, 1991. 978. Van den Berg JJM, Winterbourn CC, and Kuypers FA. Hypochlorous acid-mediated modication of cholesterol and phopsholipids: analysis of reaction products by gas chromatography-mass spectrosmetry. J Lipid Res 34: 20052012, 1993. 979. Van der Vliet A, Eiserich JP, Halliwell B, and Cross CE. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem 272: 76177625, 1997. 980. Van der Wal AC, Becker AE, van der Loos CM, and Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inammatory process irrespective of the dominant plaque morphology. Circulation 89: 36 44, 1994. 981. Van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, and Becker AE. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 61: 166 170, 1989. 981a.Van de Vijver LP, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, and Princen HM. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122: 245253, 1996. 982. Van Hinsburg VWM, Scheffer M, Havekes L, and Kempen HJM. Role of endothelial cells and their products in the modication of low-density lipoproteins. Biochim Biophys Acta 878: 49 64, 1986. www.prv.org

948. Thomas SR, Leichtweis SB, Pettersson K, Croft KD, Mori TA, Brown AJ, and Stocker R. Dietary co-supplementation with vitamin E and coenzyme Q10 inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol 21: 585593, 2001. 949. Thomas SR, Witting PK, and Stocker R. 3-Hydroxyanthranilic acid is an efcient, cell-derived co-antioxidant for -tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation. J Biol Chem 271: 32714 32721, 1996. 950. Thukkani AK, Albert CJ, Wildsmith KR, Messner MC, Martinson BD, Hsu FF, and Ford DA. Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein. J Biol Chem 278: 36365 36372, 2003. 951. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, Brock TA, and Williamson JR. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 99: 21922202, 1997. 952. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T, and Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2: 222228, 2001. 953. Togane Y, Morita T, Suematsu M, Ishimura Y, Yamazaki JI, and Katayama S. Protective roles of endogenous carbon monoxide in neointimal development elicited by arterial injury. Am J Physiol Heart Circ Physiol 278: H623H632, 2000. 954. Tornvall P, Waeg G, Nilsson J, Hamsten A, and Regnstrom J. Autoantibodies against modied low-density lipoproteins in coronary artery disease. Atherosclerosis 167: 347353, 2003. 955. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, and Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 90: 12051213, 2002. 956. Touyz RM and Schiffrin EL. ANG II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 34: 976 982, 1999. 957. Traber MG and Sies H. Vitamin E in humans: demand and delivery. Annu Rev Nutr 16: 321347, 1996. 958. Tribble DL, Gong EL, Leeuwenburgh C, Heinecke JW, Carlson EL, Verstuyft JG, and Epstein CJ. Fatty streak formation in fat-fed mice expressing human copper-zinc superoxide dismutase. Arterioscler Thromb Vasc Biol 17: 1734 1740, 1997. 959. Tsimikas S and Witztum JL. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 103: 1930 1932, 2001. 960. Tsimikas S and Witztum JL. The oxidative modication hypothesis of atherosclerosis. In: Oxidative Stress and Vascular Disease, edited by Keaney JF. Boston: Kluwer, 2000, p. 49 74. 961. Tsukahara T, Kominami E, and Katunuma N. Formation of mixed disulde of cystatin-beta in cultured macrophages treated with various oxidants. J Biochem 101: 14471456, 1987. 962. Turunen M, Wehlin L, Sjoberg M, Lundahl J, Dallner G, Brismar K, and Sindelar PJ. 2-Integrin and lipid modications indicate a non-antioxidant mechanism for the anti-atherogenic effect of dietary coenzyme Q10. Biochem Biophys Res Commun 296: 255260, 2002. 962a.United States Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. Report Surgeon General DHSS CDC 89 8411, 1989. 963. Upston JM, Kritharides L, and Stocker R. The role of vitamin E in atherosclerosis. Prog Lipid Res 42: 405 422, 2003. 964. Upston JM, Neuzil J, and Stocker R. Oxidation of LDL by recombinant human 15-lipoxygenase: evidence for -tocopherol dependent oxidation of esteried core and surface lipids. J Lipid Res 37: 2650 2661, 1996. 965. Upston JM, Neuzil J, Witting PK, Alleva R, and Stocker R. 15-Lipoxygenase-induced enzymic oxidation of low density lipoprotein associated free fatty acids stimulates nonenzymic, -tocopherol-mediated peroxidation of cholesteryl esters. J Biol Chem 272: 3006730074, 1997. Physiol Rev VOL

84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS 983. Van Marwijk Kooy M, Borghuis L, van Prooijen HC, AartsRiemens MI, and Akkerman JW. Irradiation of platelets with UV-B light exposes brinogen binding sites via an intracellular mechanism. Br J Haematol 76: 531536, 1990. 984. Van Wart HE and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87: 5578 5582, 1990. 985. Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, and Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol 22: 16551661, 2002. 986. Vasquez-Vivar J, Hogg N, Martasek P, Karoui H, Pritchard KA Jr, and Kalyanaraman B. Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase. J Biol Chem 274: 26736 26742, 1999. 987. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, and Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the inuence of cofactors. Proc Natl Acad Sci USA 95: 9220 9225, 1998. 989. Vasquez-Vivar J, Whitsett J, Martasek P, Hogg N, and Kaly anaraman B. Reaction of tetrahydrobiopterin with superoxide: EPR-kinetic analysis and characterization of the pteridine radical. Free Radic Biol Med 31: 975985, 2001. 990. Veniant MM, Pierotti V, Newland D, Cham CM, Sanan DA, Walzem RL, and Young SG. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 100: 180 188, 1997. 991. Vijayagopal P, Srinivasan SR, Radhakrishnamurthy B, and Berenson GS. Lipoprotein-proteoglycan complexes from atherosclerotic lesions promote cholesteryl ester accumulation in human monocytes/macrophages. Arterioscl Thromb 12: 237249, 1992. 992. Vile GF, Basu-Modak S, Waltner C, and Tyrrell RM. Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin broblasts. Proc Natl Acad Sci USA 91: 26072610, 1994. 993. Vile GF and Tyrrell RM. Oxidative stress resulting from ultraviolet A irradiation of human skin broblasts leads to a heme oxygenase-dependent increase in ferritin. J Biol Chem 268: 14678 14681, 1993. 994. Viner RI, Ferrington DA, Williams TD, Bigelow DJ, and Schoneich C. Protein modication during biological aging: selec tive tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2 -ATPase in skeletal muscle. Biochem J 340: 657 669, 1999. 995. Virchow R. Cellular pathology. As based upon physiological and pathological history. Lecture XVIAtheromatous effection of arteries 1852. Nutr Rev 47: 2325, 1989. 996. Virella G, Virella I, Leman RB, Pryor MB, and Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 23: 95101, 1993. 997. Vissers MC, Pullar JM, and Hampton MB. Hypochlorous acid causes caspase activation and apoptosis or growth arrest in human endothelial cells. Biochem J 344: 443 449, 1999. 998. Vissers MC, Stern A, Kuypers F, vandenBerg J, and Winterbourn CC. Membrane changes associated with lysis of red blood cells by hypochlorous acid. Free Radic Biol Med 16: 703712, 1994. 999. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, and Hazen SL. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. In press. 1000. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, and Keaney JF Jr. L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Invest 101: 1408 1414, 1998. 1001. Vita JA, Keaney JF Jr, Raby KE, Morrow JD, Freedman JE, Lynch S, Koulouris SN, Hankin BR, and Frei B. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome. J Am Coll Cardiol 31: 980 986, 1998. Physiol Rev VOL


1002. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotny L, and Kotal P. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160: 449 456, 2002. 1003. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, and Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361: 2017 2023, 2003. 1004. Vlahos CJ, Matter WF, Brown RF, Traynor-Kaplan AE, Heyworth PG, Prossnitz ER, Ye RD, Marder P, Schelm JA, Rothfuss KJ, Serlin BS, and Simpson PJ. Investigation of neutrophil signal transduction using a specic inhibitor of phosphatidylinositol 3-kinase. J Immunol 154: 24132422, 1995. 1005. Waddington E, Puddey IB, and Croft KD. Red wine polyphenolic compounds inhibit atherosclerosis in apolipoprotein E-decient mice independently of effects on lipid peroxidation. Am J Clin Nutr 79: 54 61, 2004. 1006. Waddington EI, Croft KD, Sienuarine K, Latham B, and Puddey IB. Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates. Atherosclerosis 167: 111120, 2003. 1007. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, Kensler TW, and Talalay P. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modied by inducers. Proc Natl Acad Sci USA 101: 2040 2045, 2004. 1008. Wakabayashi Y, Fujita H, Morita I, Kawaguchi H, and Murota S. Conversion of xanthine dehydrogenase to xanthine oxidase in bovine carotid artery endothelial cells induced by activated neutrophils: involvement of adhesion molecules. Biochim Biophys Acta 1265: 103109, 1995. 1009. Waldman SA and Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 39: 163196, 1987. 1010. Walldius G, U E, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, and Nilsson S. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 74: 875 883, 1994. 1011. Wang GR, Zhu Y, Halushka PV, Lincoln TM, and Mendelsohn ME. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 95: 4888 4893, 1998. 1012. Wang LJ, Lee TS, Lee FY, Pai RC, and Chau LY. Expression of heme oxygenase-1 in atherosclerotic lesions. Am J Pathol 152: 711720, 1998. 1013. Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, Lerner CP, and Paigen B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem 278: 25179 25190, 2003. 1014. Wardman P. Reactions of thyil radicals. In: Biothiols in Health and Disease, edited by Packer L and Cadenas E. New York: Dekker, 1995, p. 119. 1015. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, and Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the reninangiotensin system. Circulation 99: 20272033, 1999. 1016. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, and Verter JI. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288: 24322440, 2002. 1017. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, and Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96: 28822891, 1995. 1018. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, www.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. Subbanagounder G, Fogelman AM, and Berliner JA. Structural identication by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 272: 1359713607, 1997. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, and Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95: 774 782, 1995. Watson AD, Subbanagounder G, Welsbie DS, Faull KF, Navab M, Jung ME, Fogelman AM, and Berliner JA. Structural identication of a novel pro-inammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J Biol Chem 274: 2478724798, 1999. Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, and Jones DP. Redox potential of human thioredoxin 1 and identication of a second dithiol/disulde motif. J Biol Chem 278: 33408 33415, 2003. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, and Burke V. Coenzyme Q10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 45: 420 426, 2002. Wayner DDM, Burton GM, Ingold KU, Barclay LRC, and Locke SJ. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim Biophys Acta 924: 408 419, 1987. Wei EP, Kontos HA, Christman CW, DeWitt DS, and Povlishock JT. Superoxide generation and reversal of acetylcholineinduced cerebral arteriolar dilation after acute hypertension. Circ Res 57: 781787, 1985. Weiss SJ, Peppin G, Ortiz X, Ragsdale C, and Test ST. Oxidative autoactivation of latent collagenase by human neutrophils. Science 227: 747749, 1985. Wells WW, Xy DP, Yang Y, and Rocque PA. Mammalian thioltransferase (glutaredoxin) and protein disulde isomerase have dehydroascorbate reductase acitivity. J Biol Chem 265: 15361 15364, 1990. Wendel A. Measurement of in vivo lipid peroxidation and toxicological signicance. Free Radic Biol Med 3: 355358, 1987. Wentworth P Jr, Nieva J, Takeuchi C, Galve R, Wentworth AD, Dilley RB, DeLaria GA, Saven A, Babior BM, Janda KD, Eschenmoser A, and Lerner RA. Evidence for ozone formation in human atherosclerotic arteries. Science 302: 10531056, 2003. Werb Z, Mainardi CL, Vater CA, and Harris ED Jr. Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 296: 10171023, 1977. Westrope KL, Miller RA, and Wilson RB. Vitamin E in a rabbit model of endogenous hypercholesterolemia and atherosclerosis. Nutr Rep Int 25: 83 88, 1982. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, and Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 93: 8745 8749, 1996. Whitman SC, Rateri DL, Szilvassy SJ, Cornicelli JA, and Daugherty A. Macrophage-specic expression of class A scavenger receptors in LDL receptor ( / ) mice decreases atherosclerosis and changes spleen morphology. J Lipid Res 43: 12011208, 2002. Wilcox JN, Smith KM, Schwartz SM, and Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86: 2839 2843, 1989. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, and Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem 267: 13284 13292, 1992. Williams KJ, Petrie KA, Brocia RW, and Swenson TL. Lipoprotein lipase modulates net secretory output of apolipoprotein Physiol Rev VOL B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia. J Clin Invest 88: 1300 1306, 1991. Williams KJ and Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15: 551 561, 1995. Williams KJ and Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9: 471 474, 1998. Willis GC and Fishman S. Ascorbic acid content of human arterial tissue. Can Med Assoc J 72: 500 503, 1955. Willy C, Thiery J, Menger M, Messmer K, Arfors KE, and Lehr HA. Impact of vitamin E supplement in standard laboratory animal diet on microvascular manifestation of ischemia/reperfusion injury. Free Radic Biol Med 19: 919 926, 1995. Wilson PW, DAgostino RB, Levy D, Belanger AM, Silbershatz H, and Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97: 18371847, 1998. Wilson PW, Kannel WB, Silbershatz H, and DAgostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159: 1104 1109, 1999. Wilson RB, Middleton CC, and Sun GY. Vitamin E, antioxidants and lipid peroxidation in experimental atherosclerosis of rabbits. J Nutr 108: 1858 1867, 1978. Wingler K, Muller C, Schmehl K, Florian S, and Brigelius Flohe R. Gastrointestinal glutathione peroxidase prevents trans port of lipid hydroperoxides in CaCo-2 cells. Gastroenterology 119: 420 430, 2000. Wink DA, Cook JA, Kim SY, Vodovotz Y, Pacelli R, Krishna MC, Russo A, Mitchell JB, Jourdheuil D, Miles AM, and Grisham MB. Superoxide modulates the oxidation and nitrosation of thiols by nitric oxide-derived reactive intermediates. Chemical aspects involved in the balance between oxidative and nitrosative stress. J Biol Chem 272: 1114711151, 1997. Wink DA and Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 25: 434 456, 1998. Winterbourn CC. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim Biophys Acta 840: 204 210, 1985. Winterbourn CC and Brennan SO. Characterization of the oxidation products of the reaction between reduced glutathione and hypochlorous acid. Biochem J 326: 8792, 1997. Winterbourn CC and Kettle AJ. Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic Biol Med 29: 403 409, 2000. Winterbourn CC, van den Berg JJM, Roitman E, and Kuypers FA. Chlorohydrin formation from unsaturated fatty acids reacted with hypochlorous acid. Arch Biochem Biophys 296: 547555, 1992. Wissler RW and Vesselinovitch D. Combined effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkey aortas. Appl Pathol 1: 89 96, 1983. Witting PK, Bowry VW, and Stocker R. Inverse deuterium kinetic isotope effect for peroxidation in human low-density lipoprotein (LDL): a simple test for tocopherol-mediated peroxidation of LDL lipids. FEBS Lett 375: 45 49, 1995. Witting PK, Douglas DJ, and Mauk AG. Reaction of human myoglobin and H2O2. Involvement of a thiyl radical produced at cysteine 110. J Biol Chem 275: 2039120398, 2000. Witting PK, Pettersson K, Letters J, and Stocker R. Antiatherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice. Free Radic Biol Med 29: 295305, 2000. Witting PK, Pettersson K, Letters J, and Stocker R. Sitespecic anti-atherogenic effect of probucol in apolipoprotein E decient mice. Arterioscler Thromb Vasc Biol 20: e26 e33, 2000. Witting PK, Pettersson K, Ostlund-Lindqvist AM, Westerlund C, Wagberg M, and Stocker R. Dissociation of atherogen esis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 104: 213 220, 1999. Witting PK, Pettersson K, Ostlund-Lindqvist AM, Westerlund C, Westin Eriksson A, and Stocker R. Inhibition by a co-antioxidant of aortic lipoprotein lipid peroxidation and atherowww.prv.org



1037. 1038. 1039.















1027. 1028.


















84 OCTOBER 2004

ROLE OF OXIDATIVE MODIFICATIONS IN ATHEROSCLEROSIS sclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice. FASEB J 13: 667 675, 1999. Witting PK, Upston JM, and Stocker R. The molecular action of -tocopherol in lipoprotein lipid peroxidation: pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions. In: Subcellular Biochemistry: Fat-Soluble Vitamins, edited by Quinn P and Kagan V. London: Plenum, 1998, p. 345390. Witting PK, Upston JM, and Stocker R. The role of -tocopheroxyl radical in the initiation of lipid peroxidation in human low density lipoprotein exposed to horse radish peroxidase. Biochemistry 36: 12511258, 1997. Witting PK, Westerlund C, and Stocker R. A rapid and simple screening test for potential inhibitors of tocopherol-mediated peroxidation of LDL lipids. J Lipid Res 37: 853 867, 1996. Witting PK, Willhite CA, Davies MJ, and Stocker R. Lipid oxidation in human low density lipoprotein induced by metmyoglobin/H2O2: involvement of -tocopheroxyl and phosphatidylcholine alkoxyl radicals. Chem Res Toxicol 12: 11731181, 1999. Woenckhaus C, Kaufmann A, Bussfeld D, Gemsa D, Sprenger H, and Grone HJ. Hypochlorite-modied LDL: chemotactic potential and chemokine induction in human monocytes. Clin Immunol Immunopathol 86: 2733, 1998. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, Kim K, and Rhee SG. Reversing the inactivation of peroxiredoxins caused by cysteine sulnic acid formation. Science 300: 653 656, 2003. Woods AA and Davies MJ. Fragmentation of extracellular matrix by hypochlorous acid. Biochem J 376: 219 227, 2003. Woods AA, Linton SM, and Davies MJ. Detection of HOClmediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem J 370: 729 735, 2003. Woollard KJ, Loryman CJ, Meredith E, Bevan R, Shaw JA, Lunec J, and Grifths HR. Effects of oral vitamin C on monocyte: endothelial cell adhesion in healthy subjects. Biochem Biophys Res Commun 294: 11611168, 2002. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, and Lefvert AK. Antibodies against cardiolipin and oxidatively modied LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 17: 3159 3163, 1997. Wu TW, Carey D, Wu J, and Sugiyama H. The cytoprotective effects of bilirubin and biliverdin on rat hepatocytes and human erythrocytes and the impact of albumin. Biochem Cell Biol 69: 828 834, 1991. Wu TW, Wu J, Li RK, Mickle D, and Carey D. Albumin-bound bilirubins protect human ventricular myocytes against oxyradical damage. Biochem Cell Biol 69: 683 688, 1991. Wu XB, Brune B, von Appen F, and Ullrich V. Reversible activation of soluble guanylate cyclase by oxidizing agents. Arch Biochem Biophys 294: 75 82, 1992. Xanthoudakis S, Miao G, Wang F, Pan YCE, and Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J 11: 33233335, 1992. Xia Y, Tsai AL, Berka V, and Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2 /calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 273: 25804 25808, 1998. Xing X, Bafc J, and Sparrow CP. LDL oxidation by activated monocytes: characterization of the oxidized LDL and requirement for transition metal ions. J Lipid Res 39: 22012208, 1998. Xu R, Yokoyama WH, Irving D, Rein D, Walzem RL, and German JB. Effect of dietary catechin and vitamin E on aortic fatty streak accumulation in hypercholesterolemic hamsters. Atherosclerosis 137: 29 36, 1998. Xu XX and Tabas I. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J Biol Chem 266: 24849 24858, 1991. Yamamoto Y, Brodsky MH, Baker JC, and Ames BN. Detection and characterization of lipid hydroperoxides at picomole levels by high-performance liquid chromatography. Anal Biochem 160: 713, 1987. Yamashita H, Nakamura A, Noguchi N, Niki E, and Kuhn H. Oxidation of low density lipoprotein and plasma by 15-lipoxygenase and free radicals. FEBS Lett 445: 287290, 1999. Physiol Rev VOL








1063. 1064.













1077. Yamawaki H, Haendeler J, and Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res 93: 1029 1033, 2003. 1078. Yan LJ, Lodge JK, Traber MG, Matsugo S, and Packer L. Comparison between copper-mediated and hypochlorite-mediated modications of human low density lipoproteins evaluated by protein carbonyl formation. J Lipid Res 38: 9921001, 1997. 1079. Yan SR and Berton G. Regulation of Src family tyrosine kinase activities in adherent human neutrophils. Evidence that reactive oxygen intermediates produced by adherent neutrophils increase the activity of the p58c-fgr and p53/56lyn tyrosine kinases. J Biol Chem 271: 23464 23471, 1996. 1080. Yan SR and Berton G. Antibody-induced engagement of 2 integrins in human neutrophils causes a rapid redistribution of cytoskeletal proteins, Src-family tyrosine kinases, and p72syk that precedes de novo actin polymerization. J Leukoc Biol 64: 401 408, 1998. 1081. Yang CY, Gu ZW, Yang M, Lin SN, Garcia-Prats AJ, Rogers LK, Welty SE, and Smith CV. Selective modication of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro. J Lipid Res 40: 686 698, 1999. 1082. Yang KS, Kang SW, Woo HA, Hwang SC, Chae HZ, Kim K, and Rhee SG. Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulnic acid. J Biol Chem 277: 38029 38036, 2002. 1083. Yao Y, Yin D, Jas GS, Kuczer K, Williams TD, Schoneich C, and Squier TC. Oxidative modication of a carboxyl-terminal vicinal methionine in calmodulin by hydrogen peroxide inhibits calmodulin-dependent activation of the plasma membrane CaATPase. Biochemistry 35: 27672787, 1996. 1084. Yin H, Havrilla CM, Gao L, Morrow JD, and Porter NA. Mechanisms for the formation of isoprostane endoperoxides from arachidonic acid. Dioxetane intermediate versus -fragmentation of peroxyl radicals. J Biol Chem 278: 16720 16725, 2003. 1085. Yla-Herttuala S. Biochemistry of the arterial wall in developing atherosclerosis. Ann NY Acad Sci 623: 40 59, 1991. 1086. Yla-Herttuala S. Is oxidized low-density lipoprotein present in vivo? Curr Opin Lipidol 9: 337344, 1998. 1087. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yo shimura T, Leonard EJ, Witztum JL, and Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophagerich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88: 52525256, 1991. 1088. Yla-Herttuala S, Luoma J, Viita H, Hiltunen T, Sisto T, and Nikkari T. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specic lipid-protein adducts characteristic of oxidized low density lipoprotein. J Clin Invest 95: 26922698, 1995. 1089. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, and Steinberg D. Evidence for the presence of oxidatively modied low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086 1095, 1989. 1090. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, and Steinberg D. Colocalization of 15lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA 87: 6959 6963, 1990. 1091. Yla-Herttuala S, Solakivi T, Hirvonen J, Laaksonen H, Mot tonen M, Pesonen E, Raekallio J, Akerblom HK, and Nikkari T. Glycosaminoglycans and apolipoproteins B and A-I in human aortas. Chemical and immunological analysis of lesion-free aortas from children and adults. Arteriosclerosis 7: 333340, 1987. 1092. Yuan XM, Anders WL, Olsson AG, and Brunk UT. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 124: 6173, 1996. 1093. Yuan XM, Brunk UT, and Olsson AG. Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL. Arterioscler Thromb Vasc Biol 15: 13451351, 1995. 1094. Yusuf S, Dagenais G, Pogue J, Bosch J, and Sleight P. Vitamin E supplementation and cardiovascular events in high-risk pawww.prv.org

84 OCTOBER 2004


ROLAND STOCKER AND JOHN F. KEANEY JR. tients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 154 160, 2000. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145153, 2000. Zabel U, Kleinschnitz C, Oh P, Nedvetsky P, Smolenski A, Muller H, Kronich P, Kugler P, Walter U, Schnitzer JE, and Schmidt HH. Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat Cell Biol 4: 307311, 2002. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, and Griendling KK. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 32: 488 495, 1998. Zai A, Rudd MA, Scribner AW, and Loscalzo J. Cell-surface protein disulde isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. J Clin Invest 103: 393399, 1999. Zakhary R, Gaine SP, Dinerman JL, Ruat M, Flavahan NA, and Snyder SH. Heme oxygenase 2: endothelial and neuronal localization and role in endothelium-dependent relaxation. Proc Natl Acad Sci USA 93: 795798, 1996. Zembowicz A, Hatchett RJ, Jakubowski AM, and Gryglewski RJ. Involvement of nitric oxide in the endothelium-dependent relaxation induced by hydrogen peroxide in the rabbit aorta. Br J Pharmacol 110: 151158, 1993. Zhang B, Hirahashi J, Cullere X, and Mayadas TN. Elucidation of molecular events leading to neutrophil apoptosis following phagocytosis: cross-talk between caspase 8, reactive oxygen species, and MAPK/ERK activation. J Biol Chem 278: 2844328454, 2003. Zhang C, Reiter C, Eiserich JP, Boersma B, Parks DA, Beckman JS, Barnes S, Kirk M, Baldus S, Darley-Usmar VM, and White CR. L-Arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem 276: 27159 27165, 2001. 1103. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, and Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286: 2136 2142, 2001. 1104. Zhang SH, Reddick RL, Avdievich E, Surles LK, Jones RG, Reynolds JB, Quarfordt SH, and Maeda N. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-decient mice. J Clin Invest 99: 2858 2866, 1997. 1105. Zhang ZY and Dixon JE. Active site labeling of the Yersinia protein tyrosine phosphatase: the determination of the pKa of the active site cysteine and the function of the conserved histidine 402. Biochemistry 32: 9340 9345, 1993. 1106. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, and Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39: 10848 10854, 2000. 1107. Zheng M and Storz G. Activation of the OxyR transcription factor by reversible disulde bond formation. Science 279: 1718 1721, 1998. 1108. Zhu H, Takahashi Y, Xu W, Kawajiri H, Murakami T, Yamamoto M, Iseki S, Iwasaki T, Hattori H, and Yoshimoto T. Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages. J Biol Chem 278: 13350 13355, 2003. 1109. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Ciof M, DAndrea F, Molinari AM, and Giugliano D. Reduction of inammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105: 804 809, 2002. 1110. Zilversmit DB. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res 33: 633 638, 1973. 1111. Zimmerman GA, Prescott SM, and McIntyre TM. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today 13: 93100, 1992. 1112. Zou MH, Shi C, and Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109: 817 826, 2002.









Physiol Rev VOL

84 OCTOBER 2004